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Preface 
PSEUDOXANTHOMA ELASTICUM:  
History of a triad disorder                        o                                                                                                                                                                      
 
“Nous dirons avec  lui  [M. Chambard] que ce qu’il  faut  trouver 
maintenant,  c’est  la  cause  première,  le moteur  du  processus 
xanthélasmique.  C’est  la  ce  qu’il faut connaître avant de 
pouvoir classer le xanthélasma.” 
 
Felix Balzer, 1884 
    From ancient mythology to present catholic believes, triads have always been a symbol 
for the mysterious, stirring ones imagination. The Ptah-Sekhmet-Nefertem Memphis triad, the 
resistance movement against Chinese Manchu emperors, the Divine Trinity and so many other 
examples all reflect how they intrigued mankind throughout the centuries. Often, it was or is not 
clear why three apparently different entities were joined, if not that they could perform different, 
yet related functions contributing to a purpose akin. 
 In many ways, pseudoxanthoma elasticum (PXE) – a classic example of a triad disease – 
reflects the mystery and ambiguous character of the ancient and modern triads. Perhaps this is 
the reason why it has fascinated researchers throughout the world and stimulated them to try and 
unravel the enigmas that PXE lays in front of them. And although some puzzles of PXE have 
been solved, many more remain subject of intensive exploration.   
 
As H.B. Stowe already said, the past, the present and the future are really one: they are 
today. So, before looking at the present and taking a glance at the future, allow me to elaborate 
on the history of PXE. Although probably as old as mankind, the first descriptions of PXE by Rigal 
and Balzer date from 1881 and 1884 respectively [1, 2]. D. Rigal is credited with the first 
description of the skin lesions, while Felix Balzer provided the first autopsy report and grouped 
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the disorder with the xanthomatoses. The disorder was however given its current name by Jean-
Ferdinand Darier, who in 1896 described the histological changes of the elastic fibres, which 
remain to date the hallmark of PXE [3]. As such, Darier was the first to perceive PXE as a 
separate, non-xanthomatous entity. 
 In 1929, 48 years after the initial description by Rigal, a Swedish ophthalmologist, Ester 
Grönblad and her colleague James Strandberg, a dermatologist made the first unequivocal 
connection between the skin and eye manifestations of PXE [4, 5]. As descriptive medical 
science in the late nineteenth and early twentieth century tended to name new discoveries after 
their discoverers, the Grönblad-Strandberg syndrome was born. Angioid streaks, the most 
prominent feature of the PXE retinopathy, were however already described in 1889 by Robert W. 
Doyne,  an  English  ophthalmologist,  while  the  term  “streaks”  was  coined  by  a  German  born 
American ophthalmologist, Herman J. Knapp, in 1892. 
 The full triad of PXE was completed in the 1940s, when René Touraine and collegues 
studied the cardiovascular aspects of PXE. It has remained essentially unchanged ever since [6, 
7].   
  
 PXE has for a long time been thought of as a primary disorder of elastic fibres, which was 
reflected by the screening of numerous candidate genes (elastin, fibrillin-1, fibrillin-2) encoding 
structural components of these fibres or related enzymes [8]. The mapping of the PXE gene to 
chromosome 16p13.1 was followed by the surprising finding that the causal gene for PXE codes 
for a transporter protein which had no apparent connection to the extracellular matrix [9-15]. This 
finding was intriguing, as it raised novel, exciting pathophysiological hypotheses and changed our 
view on PXE as a connective tissue disorder towards a metabolic disease with important 
implications for connective tissue homeostasis.    
 
In 1884, Balzer already emphasized the importance of unravelling the pathophysiological 
mechanisms,  “the motor”, which drives this complex disorder. Today, over one hundred years 
later, this quest remains more up to date than ever and represents the motor for this PhD thesis. 
While attempting to contribute to the better understanding of the mechanisms leading to PXE, it is 
however in first instance a humble tribute to the genius and magnificence of human (molecular) 
biology. 
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Chapter 1 
Introduction                                               o                                                                    
  
“My scientific studies have afforded me great gratification; and I 
am convinced that it will not be long before the whole world 
acknowledges the results of my work. ”    
        
         Gregor Mendel, 1865 
 
1.1 Fundamentals of human genetics 
 
Genetics is the dynamic science dealing with the mechanisms of hereditary transmission 
and the variation of hereditary characteristics – either physiological or pathological – among 
(similar or related) organisms. Although considered to be a relatively young branch of medicine 
and biology, it is primarily based on principles which were already published in 1866 by Gregor 
Mendel. This Austrian monk was the first to describe the basic principles of heredity by his 
experiments with pea plant characteristics. Only a few basic principles on patterns of 
transmission, terminology and molecular defects – necessary to fully understand this thesis –  will 
be briefly touched.  
 
1.1.1 Clinical genetics 
 
1.1.1.1 Modes of inheritance 
 
The three basic patterns of inheritance of Mendelian disorders are autosomal dominant, 
autosomal recessive and X-linked. Y-linked inheritance is rare and only mentioned for the sake of 
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completeness. Non-Mendelian inheritance patterns are beyond the subject of this thesis and will 
not be discussed. 
 
1/ autosomal dominant inheritance occurs when one mutated gene copy (or allele) is 
sufficient to develop clinical disease. As the patient passes on one of both alleles to his 
offspring, children have a 50% risk of being affected. As a result, each generation of 
the family usually has affected individuals, unless it concerns a novel mutation 
occurring for the first time in the patient.  
 
2/ autosomal recessive inheritance requires both alleles to be mutated before disease 
can occur. As the patient has received one mutated allele from each of his parents, 
both parents are obligate carriers (or heterozygotes) of one mutation. Conversely, as 
one allele  is passed on  to  the patients’ offspring,  they also are obligate carriers. The 
risk for offspring to develop clinical disease is limited, unless there is consanguinity. 
Consanguinity increases the likelihood of both partners being heterozygous for the 
same mutation, hence increasing the risk that their children will inherit two mutated 
alleles. Typically, the two alleles will then carry the same mutation (homozygosity). 
The term pseudodominant refers to the situation where an affected individual of an 
autosomal recessive disease has children with a heterozygous carrier. The pedigree of 
these families mimics autosomal dominant inheritance.   
 
3/ X-linked inheritance involves disorders caused by mutations in a gene located on 
the X chromosome. These disorders can be either dominant or recessive. As males 
have only one X chromosome, next to a Y chromosome and females have two X-
chromosomes, the X-linked recessive disorders are mostly seen in males with little or 
no symptoms in females. Exceptions to this rule can occur due to skewed X inactivation 
or lyonisation.  X-linked dominant disorders can occur both in females and males, with 
a ratio of 2 to 1, reflecting the ratio of X chromosomes. The latter are also often lethal in 
males. 
 
4/ Y-linked inheritance is extremely rare because of the few genes on the Y-
chromosome; only male to male transmission occurs. 
 
1.1.1.2 Terminology 
 
While the human genome, our complete DNA sequence containing the entire genetic 
information of an individual, has not yet revealed its last secret, we have been confronted with its 
huge complexity. As often in science, genetics added to this complexity by creating its own 
terminology – by  outsiders  often  considered  as  “magical”  or  “witch  craft”  – of which the most 
common terms, which are used throughout this thesis, are explained below.    
 
A gene is a sequence of DNA, necessary for the production of a functional product. It is in fact 
the “unit of heredity”. The human genome contains approximately 30.000 genes,  located on 23 
pairs of chromosomes. Each of these genes occurs twice in the genome; these copies, which are 
identical and positioned in the same location (or locus) are called alleles. Transcription involves 
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the synthesis of a single-stranded RNA molecule from a DNA template in the cell nucleus, while 
translation is the synthesis of a polypeptide from this mRNA template.   
 
A phenotype comprises the observed biochemical, physiological and morphological 
characteristics of an individual or, in a more limited sense, the abnormalities resulting from a 
particular mutant gene. 
 
A phenocopy is a mimic of a phenotype that is usually determined by a specific genotype, 
produced instead by the interaction of some environmental factor with a normal genotype. 
 
A genotype is the genetic constitution of an individual or, more specifically, the two alleles  
present at one locus. 
 
Pleiotropism of a gene reflects to the contributions of apparently unrelated phenotypical features 
resulting from mutations in a single gene.  
 
1.1.2 Molecular genetics 
 
The elementary techniques in molecular genetics – gene detection techniques, DNA 
amplification and sequencing – have as common goal the detection of one or two causal 
mutations (or genotype), responsible for the combined clinical signs and symptoms of a patient 
(or phenotype). While the technical details of these procedures will be explained in chapter two, 
we will here briefly review the different types of genetic defects which can lead to disease. 
 
1/ A missense mutation is a single DNA base substitution resulting in a codon (or group 
of three base pairs) specifying an amino acid different from the wild type sequence. 
 
2/ A nonsense mutation is a single base pair change resulting in a stop codon, ending 
transcription prematurely. Most often, the shortened transcript will be degraded in a 
process called nonsense-mediated decay (NMD). 
 
3/ A splice site mutation interferes with the physiological removal of introns in the 
generation of mature mRNA (or splicing) by changing the binding site for enzymes 
necessary for splicing. 
 
4/ A deletion or loss of one or more basepairs. 
 
5/ An insertion or addition of one or more basepairs to the DNA sequence. 
 
6/ A frameshift mutation involves a deletion or insertion that is not an exact multiple of 3 
basepairs, changing the reading frame of the gene. All coding regions 3’ of the mutation 
will be read completely different, usually soon encountering a stop codon. 
 
 Besides the above mentioned types of mutations, certain base pair variations in the 
genetic code are considered as physiologic alternatives or polymorphisms. Although such a 
polymorphism cannot be attributed to cause a disease by itself, many of these have been shown 
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to have an effect on the expression and regulation of the gene they occur in and as such have 
relevance in human (patho)physiology.  
  
1.2 Connective tissue disorders 
 
1.2.1 The connective tissue 
 
The connective tissue, as the name implies, is a basic type of tissue providing structural 
and metabolic support for other tissues and organs throughout the body. Beside the loose 
connective tissue, also bone, cartilage and blood are considered part of this supportive tissue.  
 The uniqueness of connective tissue, compared to the other tissues of the body, lies in its 
composition of a diverse set of constituents – cells, fibres, blood vessels – scattered around in an 
extracellular matrix (ECM – Figure 1). Four types of macromolecules can be distinguished in the 
ECM: collagen, elastin, glycoproteins and proteoglycans. Each of these are produced by cell 
types specific for the various tissues. Among those, the fibroblast is the most important to 
maintain structural integrity of the ECM. It is however thought that over 2500 proteins are involved 
in ECM composition. 
 Although its presumed composition and historical function as biological packing material 
between cells and other tissues makes believe that the connective tissue is a static structure, it 
has become clear in recent years that this perception could not be further away from the truth. 
Indeed, as its complexity becomes more apparent, evidence is emerging that the ECM is a 
dynamic structure, playing a crucial role in the physiology of cells and tissues and influencing – 
through various signal transduction pathways – several biological processes such as cell growth, 
differentiation, migration, development and survival.  
 
 
Figure 1 
Simplified overview of the major components of the connective tissue 
Adopted from McGraw-Hill Encyclopaedia of Science and Technology 
 
1.2.1.1 Elastin and elastic fibres 
 
The elastic fibre system forms a network responsible for the resilience and elasticity of 
various tissues. It consists of interconnecting fibres of varying diameter, containing two distinct 
components: elastin, a well-characterized connective tissue protein and elastin-associated 
microfibrils, the components of which include fibrillin, a microfibril-associated glycoprotein. The 
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biology of elastic fibres is complex because of its multiple associated molecules (Table 1), tightly 
regulated developmental pattern of deposition, multi-step assembly, unique elastomeric 
properties and influence on cell phenotype. Hence, what follows is only a brief summary of 
knowledge on elastic fibre biology, with abstraction of different facets of its complexity.  
 
Molecule Function 
Fibrillin-1 Architectural function in EC microfibrils 
Fibrillin-2 Architectural function in EC microfibrils 
Fibrillin-3 Architectural function in EC microfibrils 
MAGP-1 Unknown 
MAGP-2 Unknown 
LTBP-1 Structural component of TGF- β1 
LTBP-2 Production and degradation of ECM 
LTBP-3 Production and degradation of ECM 
LTBP-4 Production and degradation of ECM 
Decorin Cell cycle regulation 
Biglycan Unknown 
Versican Unknown 
MFAP-1 Cell division 
MFAP-3 Unknown 
MFAP-4 (MAGP-36) Unknown 
Tropoelastin Initial translation product of ELN 
Lysyl oxidase (LOX) Elastic fibre cross-linking 
LOXL Cross-linking enzyme 
LOXL2 Cross-linking enzyme 
LOXL3 Cross-linking enzyme 
BigH3 (keratoepithelin) Corneal adhesion protein 
Fibulin-1 Organogenesis 
Fibulin-2 
Fibulin 4 
ECM constituent 
Elastic fibre formation 
Fibulin-5 Vascular development and remodelling 
Emilin-1 Inhibitor of TGF-β signalling 
Emilin-2 Unknown 
Elastin-binding protein Elastin chaperone protein 
Vitronectin Cytolysis, blood coagulation 
Amyloid  
Collagen VIII Component of Descemet membrane 
Collagen XVI ECM interactions 
Endostatin Angiogenesis inhibitor 
Collagen VI Anchoring function 
Table 1 
Reported microfibril and elastic fibre associated molecules 
Adopted from Kielty et al. [16] 
 
  a/ elastic fibre organisation 
 
 Ultrastructural studies have provided insights into the organisation of the microfibrils and 
elastic fibre core, which will be briefly presented.  
 
1/ The microfibrillar component of elastic fibres consists of fibrillin-rich microfibrils 
which show a 56 nm beaded periodicity (Figure 2). Calcium plays a key role in microfibril 
organisation through its influence on this beaded periodicity. Characteristic for this 
organisation is the octagonal structure of up to eight fibrillin molecules.  
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Figure 2 
Atomic force microscopic image of microfibril, illustrating bead-to-bead periodicity 
Adopted from Kielty et al. [16] 
 
Fibrillins are highly homologous glycoproteins, of which 5 isoforms have been described 
with the same overall arrangement of repetitive domains. The expression pattern of 
fibrillins is distinct but overlapping [17]. Time of expression varies from early development 
to adult life, reflecting different functions in elastic fibre formation and/or maintenance 
[18].  
 
Apart from fibrillins, microfibril-associated glycoprotein 1 (MAGP-1) is associated with 
virtually all microfibrils and may be important for structural integrity. In contrast, MAGP-2 
may have a function related to cell signalling during microfibril assembly and 
elastinogenesis. Besides the latent TGFB-binding proteins (LTBP), important for TGF-β 
targeting, several other microfibril-associated proteins and proteoglycans have been 
identified, many of which have an as yet unknown function (Table 1).      
 
2/ The elastic fibre core has been shown not to be amorphous – in contrast to early 
descriptions – but instead to consist of laterally packed, thin ordered filaments [19].  
 
  b/ elastic fibre assembly 
 
1/ Microfibrils assemble close to the cell surface in a process which is not fully 
understood but leads to linear assembly. The current assembly model predicts that 
fibrillins, which are initially aligned head-to-tail, maturate to a one-third stagger alignment 
by folding at the termini and proline-rich regions. In tissues, assembled and matured 
microfibrils form loosely packed parallel bundles.    
 
Several proteins such as fibronectin, α5β1 integrins and heparin sulphate proteoglycans 
are proposed to have a role in this assembly. As different extracellular microfibril 
populations have been identified, the extracellular environment might play a major role in 
regulating microfibril fate after assembly.  
 
2/ Tropoelastin (TE), the precursor of elastin is a linear polypeptide of ~70 kDa, encoded 
by the elastin gene (ELN, chromosome 7q11.1-7q21.1) and is then secreted to the 
plasmamembrane via secretory vesicles. Its amino acid composition is rich in 
hydrophobic residues (Gly, Val, Pro, Ala), with glycine making out one-third of the total 
number of amino acids. Interactions between these hydrophobic domains play a crucial 
role in a process called coacervation. This process reflects the formation of aggregates of 
TE – which is soluble in a cold (< 20°C) aqueous solution – when temperature rises 
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towards the physiological range. Coacervation is an important step in fibrillogenesis of 
elastic fibres prior to crosslinking.  
Next to hydrophobic domains, hydrophilic residues, including Lys and Ala, build up the 
crosslinking domains, allowing formation of covalent lysyl-derived desmosine crosslinks 
by an enzyme called lysyl oxidase [20].  
 
Molecular events leading to assembly of microfibrils and TE into an elastic fibre are 
poorly understood, although several models have been proposed. It has been demonstrated that 
microfibril formation is followed by an accumulation of TE, gradually obscuring the microfibrils. 
This lead to the hypothesis that microfibrils form a scaffold on which TE molecules align and, 
throughout maturation, become predominant. As such, mircofibrils play a critical role in early 
fibrillogenesis, while the physiological properties of the elastic fibres are attributable to the 
matured elastin. Indeed, the alternating presence of hydrophobic and cross-link domains is likely 
to cause the elasticity of these fibres. When stretched, the hydrophobic domains are exposed to 
the surrounding aqueous milieu, and the energy for contraction of the fibres is derived from the 
return of these hydrophobic groups to the non-aqueous environment. 
 
 
Figure 3 
Schematic representation of microfibril and elastic fibre formation. (1) Transport and organization of tropoelastin into 
aggregates, cross-linked by LOX. (2) increase of  aggregates size by newly secreted elastin. (3) Transfer of  aggregates 
to extracellular microfibrils. (4) Elastin aggregates on the microfibril coalesce into larger structures. (5) Elastin aggregates 
are further cross-linked by LOX to form the complete elastic fiber. 
Adopted from Wagenseil et al. 
 
The distribution and concentration of elastic fibres varies in different tissues, being the 
highest in the arterial vascular tissues and the lungs, both characterized by a vast need of 
elasticity for their function. In other tissues, such as skin or liver, the concentration of elastin is 
rather low. Also the architecture of elastic fibres is highly tissue specific, reflecting tissue-specific 
functions. In the medial layer of blood vessels, the fibres form concentric fenestrated lamellae 
separated by smooth muscle cell layers. In the lung, elastic fibres are thin and highly branched 
while in the dermis they have a variable diameter and are horizontally or perpendicularly 
arranged. 
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 The metabolic turnover of elastin – with a continuous degradation and replacement by 
newly formed fibres – is remarkably slow compared to other proteins. In pathologic conditions 
however, degradation is rapidly increased. The process of degrading elastic fibres is executed by 
a set of elastolytic enzymes, of which elastase is best known. First discovered in the pancreas, 
elastolytic enzymes have been detected in various cell types including polymorphonuclear 
leukocytes, monocyte/macrophages and platelets.  
  
To allow maintenance of an optimal level of functional elastic fibres in tissues, the 
pathways involved in fibrillogenesis and degradation of fibres must be carefully controlled. If the 
balance in the rate of any of these processes is disturbed, the steady-state level of the fibres 
could be altered, manifesting as a pathological disease.  
 
1.2.1.2 Other constituents of the ECM 
 
Besides the elastic fibres, several other proteins are known to have an important 
structural and/or functional role in the dynamic function of the connective tissues. These 
compounds are altered in PXE but have no known central role in its pathophysiology and will 
therefore be discussed only briefly. 
  
a/ collagen fibres 
 
Collagen is a major component of the extracellular matrix and the most abundant protein 
in the body, accounting for about 25 to 30% of the total protein mass. Collagens are triple helical 
proteins formed when three polypeptide chains, called alpha chains, wind around each other to 
form a collagen molecule. The alpha chains are rich in the amino acids proline and glycine, which 
are important for the helical conformation. Because of its ring structure, proline stabilizes the 
helix. Glycine, the smallest of the amino acids, is spaced at every third position such that it 
occupies the tightly spaced inside portions of the triple helix [21]. 
Posttranslational modifications, including hydroxylation of specific proline and lysine 
residues, occur during the processing of the procollagen molecules and are important in 
stabilizing the collagen structure and in forming interchain and intrachain cross-links [21]. 
The collagens can be divided into different groups by structure and function. Fibrillar 
collagen molecules (collagen types I, II, III, V, and XI) are packed in a staggered and ordered 
fashion to form a collagen fibril, which in turn will be packed together to form fibres.  Fibril 
formation occurs outside the cell after the N-terminal and C-terminal propeptides present on 
procollagen molecules are proteolytically removed to form mature collagen. Further cross-linking 
of collagen fibrils strengthens the structure. These rather stiff, rope-like structures provide the 
tensile strength for connective tissues. The fibril-associated collagens (collagen types IX, XII, XIV) 
help to form and stabilize the collagen fibrils. Unlike the fibrillar collagens, this group of collagens 
contains regions where the triple helical structure is interrupted, which can result in a bend in the 
collagen molecule, thus the name fibril-associated collagens with interrupted triple helixes. Type 
IV collagen is the classic basement-membrane collagen that forms in aggregates to provide 
structural support to the basement membrane [21]. 
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b/ proteoglycans 
 
Proteoglycans are build out of a protein core to which short oligosaccharides and longer 
chains of glycosaminoglycans (GAGs) are covalently attached. There is a large variety of 
proteoglycans based on the types and lengths of GAGs as well as the sequence and length of the 
protein core. Chondroitin sulfate, keratan sulfate, heparin sulfate, and dermatan sulfate are four 
different forms of GAGs that consist of repeating disaccharide units. The sulfates present on the 
GAGs create a highly negatively charged environment that is hydrophilic. Thus, connective 
tissues that contain large amounts of proteoglycans will also contain relatively large amounts of 
water bound to the proteoglycans. In addition to water, proteoglycans bind cationic proteins, 
which in some cases include growth factors, resulting in a mechanism by which tissues can store 
growth factors in the matrix. 
The size of these proteoglycans can vary significantly. Aggrecan, predominantly found in 
cartilage is a very large protein (molecular weight of more than 200,000 kDa), while decorin, 
biglycan, fibromodulin, and lumican are small proteoglycans (30 to 60 kDa). The latter interact 
with collagen and function to regulate the formation of collagen fibrils and help stabilize the 
collagen network. Although their functions are not completely understood, they likely have other 
roles based on their ability to bind other matrix molecules such as elastin and fibronectin and on 
their affinity for growth factors. 
 
c/ glycoproteins 
 
Along with the proteoglycans, the many other noncollagenous matrix glycoproteins 
found in connective tissues form much of what is sometimes described in histological terms as 
the "ground substance". This rather inert-sounding description should in no way be taken to 
suggest that these matrix components simply fill in or hold the tissue together. Rather these 
proteins participate actively in creating the information-rich environment described earlier. 
Proteins in this group include fibronectin, vitronectin, osteopontin, laminin, and thrombospondin. 
Fibronectin is found in most connective tissues throughout the body. Laminin is particularly 
prominent in basement membranes, and osteopontin is found in greater amounts in cartilage and 
bone. All of these proteins bind to cells through specific cell-surface receptors to promote 
attachment of cells to the matrix. The proteins also interact with the other matrix proteins to 
further integrate the cells with the extracellular matrix. Through these interactions, they function in 
regulating tissue morphogenesis as well as tissue repair and remodelling. They also appear to 
play a role in other diverse processes, including tumour growth and metastasis. 
 
1.2.2 Connective tissue disorders (CTD) 
  
Heritable disorders that involve connective tissue are among the most common genetic 
diseases in humans. The first comprehensive effort to classify these diseases was made by 
Victor McKusick in a series of reports and then in the monograph Heritable Disorders of 
Connective Tissue. Based on pattern of inheritance, the cluster of signs and symptoms, the 
histological changes in tissues and limited information about the molecular defects involved, he 
drew the first classification of CTD. In the advent of molecular genetics, some limitations of 
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McKusick’s categories became apparent.   One  is  the phenotypic variability within and between 
families which characterises several of these disorders. Classification also tends to 
overemphasize the etiologic differences between severe genetic disorders that are apparent in 
infants or young children and the more common diseases that appear later in life. Yet these late-
onset diseases, such as osteoporosis, aneurysms, osteoarthritis and stroke can be caused or 
influenced by single-gene variants. The debate on whether these patients should be classified as 
having a mild form of the CTD which is linked to the defective gene remains ongoing and will 
probably never be solved. These individuals have however made it clear that the class of 
“disorders of the connective tissue” needs to be expanded.  
 
Because of the wide distribution of connective tissues within the human body, diseases 
that affect connective tissue cells or extracellular matrix proteins often have systemic effects. 
Based on the two major constituents of the connective tissue, collagen and elastin, these 
disorders  can  be  divided  into  ‘collagenopathies’ and  ‘elastinopathies’. The most common 
collagenopathies include the a.o. Ehlers-Danlos syndromes, osteogenesis imperfecta, Alport 
syndrome and the chondrodysplasias. Elastinopathies include a.o. Marfan syndrome and the 
cutis laxa syndromes. However, one of the most intriguing examples of an elastinopathy – 
although this label does not meet the complexity of the disease –, is pseudoxanthoma elasticum.   
 
1.3 Pseudoxanthoma elasticum 
 
Pseudoxanthoma elasticum occupies a unique position within the connective tissue 
disorders, because of its molecular and etiopathological characteristics. PXE is found in all 
populations, with a higher prevalence in the Afrikaner population of South Africa due to a founder 
effect [22, 23]. Its world-wide prevalence has been estimated at 1:25000, with a predominance of 
female patients (female to male ratio of 2:1) when ascertainment from the skin changes is made 
[23, 24]. Although it has been previously suggested that there may be an estrogen effect, based 
on the aggravation of cardinal features during pregnancy, it is far more probable that sex 
predilection may be due to cosmetic concerns [25].  
 
A classification of PXE into clinical subtypes has been previously proposed by Pope et 
al. and revised by Lebwohl et al. [26-28]  Pope, in 1974, suggested that two autosomal recessive 
and two dominant forms existed, describing several clinical differences between them [26, 27]. In 
the years to come, several authors refuted this initial classification as it became clear that most – 
if not all - cases were autosomal recessive with a marked variability in expression [22, 29-34]. 
The few pedigrees which were truly suggestive for autosomal dominant inheritance, were up until 
now all shown to be due to pseudodominance.   
 
Recent findings have changed our perspective on the disorder from a strict CTD to a 
metabolic disease with secondary connective tissue implications [35]. A summary of the current 
knowledge is presented against a background of physiological facts, necessary for the 
comprehension of this thesis.  
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1.3.1 Pathology 
 
The primary histological alteration in PXE is degeneration of elastic fibres that undergo 
progressive mineralization and fragmentation, resulting in a histological image called 
“elastorrhexis” (Figure 4) [36, 37]. These alterations can be observed through light and electron 
microscopy in the main organs affected by PXE (skin, retina, blood vessels), but also in other 
tissues which contain elastin. The latter include the urinary system (kidney, bladder), the gastro-
intestinal tract (oesophagus, intestines) and the pulmonary system (trachea, lung) [36]. The 
alterations in these systems, although often widespread and associated with collagen 
abnormalities, are however usually very small which could account for their lack of clinical 
significance [36]. 
 
  
Figure 4 
Histological alterations in PXE. Panel A shows the normal thin elastic fibres (insert) and a lightmicroscopical Von Kossa 
stain revealing elastorrhexis (x400). Panel B shows an electron microscopical image of calcifications (arrowed) throughout 
the core of an elastic fibre (Bar = 1μm). Panel C illustrates the presence of collagen flowers (arrowed) (Bar = 1μm).  
Panel B and C adopted from [36] 
 
 Although subtle but distinct differences can be noted in the histological findings in the 
different affected tissues, the chain of degenerative events is always alike. One of the intriguing 
questions in the chain of events – similar to the chicken or the egg dilemma –was whether the 
primum movens was the calcification or the fragmentation [38]. Both are theoretically possible as 
calcified fibres are prone to degradation, while fragmented fibres become more easily calcified. 
Several EM studies have however reported calcification in elastic fibres that appear normal as the 
first pathological sign in young individuals, allowing to put forward a pathological cascade as 
follows [38-40].  Initially, mineralization of the elastic fibre is seen as a central core of electron 
density on EM, with core density increasing as mineralization continues. Prior to fragmentation, 
the elastic fibres will develop holes, where the central portion of the core disappears or 
spontaneously fades. Finally, the fibres become maximally calcified, followed by fragmentation.    
 Two main kinds of calcification have been described: one composed of hydroxyapatite 
and the other of CaHPO4 [41]. Other mineral precipitates, such as iron, phosphate and carbonate 
have also been identified in altered elastic PXE fibres [42-45].  
 A series of studies have described abnormalities of other ECM components, such as 
collagens and proteoglycans. Collagen flowers, a sign of abnormal collagen fibrillogenesis, are – 
although commonly found in PXE – also highly aspecific. Abnormal amounts of proteoglycans 
are localized nearby and within mineralized elastic fibres and abnormal amounts of GAGs, as well 
as alterations in their synthesis and deposition have been detected in PXE patients [46-49].  
Moreover, PXE cells have been shown to produce proteoglycan species with altered properties, 
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such as stronger polyanion properties, increased hydrodynamic size, abnormal hydrophobic 
actions and different content and distribution of heparan sulphate, indicating an abnormal 
proteoglycan metabolism [49, 50]. In urine of PXE patients and carriers, both decreased and 
increased concentration of GAGs has been observed [51, 52]. Although no straightforward 
explanation exists for these discrepant findings, Maccari et al. found three distinguishing 
differences of urinary GAGs in PXE: the chondroitin sulphate/heparin sulphate ratio (which is 
lower), the 4-sulphated/6-sulphated chrondroitin sulphate ratio (which is lower) and the high 
degree of chrondroitin sulphate sulfation [52].      
Baccarani-Contri et al. showed that elastic fibres have enhanced expression of normal 
constitutive proteins (e.g. vitronectine), but also accumulated aberrant matrix proteins known for 
their high affinity for calcium and involvement in mineralisation processes (e.g. alkaline 
phosphatase, bone sialoprotein, osteonectin) [48].  
 
Several histological stains can be applied to reveal the mentioned pathological features 
of PXE. Aberrant clumped and fragmented elastic fibres are demonstrated by hematoxylin-eosin-
safran staining or by the use of specific elastin stains (orcein, Verhoeff-Van Giesson). Ectopic 
mineralization can be shown by a Von Kossa stain, which colours calcium black. The presence of 
proteoglycans in the vicinity of the increased amount of abnormal elastin fibres can be 
demonstrated by alcian blue or colloidal iron stain. 
 
1.3.1.1 Calcium homeostasis 
 
Physiological mineralization is a crucial metabolic function which is restricted to specific 
sites in skeletal tissues, including growth plate cartilage, bones and teeth. Uncontrolled or 
pathological calcification can occur in every tissue, although articular cartilage, cardiovascular 
tissues and the kidney are particularly prone. The regulation of physiological mineralization 
encompasses a complex network of metabolic pathways. Being cell-mediated, it involves the 
coordinated expression of and interactions between stimulatory and inhibitory factors. 
 
 a/ matrix vesicle-mediated mineralization 
 
Matrix vesicles initiate the mineralization process in growth plate cartilage and bone. 
These vesicles are released from the plasma membrane of mineralization-competent cells into 
the ECM. Channel proteins mediate the influx of calcium ions and inorganic phosphate into the 
vesicles, in which a calcium-inorganic phosphate-phospholipid complex is formed when being 
released from the plasma membrane. This complex serves as a nucleus for the formation of the 
first intravesicular mineral phase. Once the mineral has reached a certain size, it ruptures the 
vesicle membrane and grows into the ECM [53].  
 
  b/ mineralization propagators and inhibitors 
 
 To propagate extravesicular  crystal growth, an appropriate  “calcifiable” matrix needs  to 
be present. It has been shown that both collagen type I, II and X are required for ectopic 
mineralization. Interaction of type II and type X collagen with annexin V, a channel protein for 
calcium, leads to a rapid influx of calcium into the vesicle [54].  
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 A second important protein group implicated in regulation of mineralization are the Gla-
proteins (Figure 5). Named after the glutamic acid (gla) residues which they contain, they all 
have a similar metabolic processing comprising transcription and translation to an inactive 
protein, followed by post-translational modification. This post-translational modification consists of 
the carboxylation of one or more gla-residues by a gamma-carboxylase enzyme.  
 The γ-carboxylase (GGCX) is one of two enzymes within the vitamin K-cycle, together 
with the vitamin K epoxide reductase (VKOR; Figure 5). For these enzymatic processes, vitamin 
K acts as an essential co-factor, which needs recycling due to the limited amount of vitamin K in 
the diet. Several vitamin K-dependent (or Gla-) proteins have been discovered, which undergo 
processing via this metabolic cycle. These include coagulation factors II (prothrombin), VII, IX 
and X, protein S and protein C but also several inhibitors of calcification, such as matrix gla 
protein (MGP) and osteocalcin (OC), and four integral membrane proteins of unknown function. 
The carboxylase enzyme itself is negatively regulated by a protein called calumenin. 
 
 
Figure 5 
The vitamin K cycle. Reduced vitamin K acts as a co-factor of the γ-carboxylase GGCX, activating hypofunctional 
proteins. The vitamin K, which becomes oxidized during this modification, is reduced by VKOR.  
F2-7-9-10: vitamin K dependent clotting factors; PROC: protein C; PROS: protein S; PROZ: protein Z; MGP: matrix gla 
protein; BGLAP: bone gla protein (or osteocalcin); GAS6: growth arrest-specific gene 6; CALU: calumenin. 
 
 MGP is expressed in vascular smooth muscle cells and chondrocytes but not in 
osteoblasts, whereas OC is expressed in osteoblasts, odontoblasts and terminally differentiated 
chondrocytes. Whereas OC-deficient mice show no alteration in ECM mineralization, Mgp-/- mice 
show extensive vascular and cartilaginous mineralization, leading to early death due to arterial 
rupture [55, 56]. The human correlate is Keutel syndrome, an autosomal dominant disorder 
characterized by extensive cartilage calcifications which, in contrast to the animal model, is 
however not lethal [57]. The presence of MGP has been demonstrated in association with the 
ECM and specifically the elastic laminae in the human arterial vessel wall [58]. In areas of 
vascular calcification, colocalization of MGP and the elastic laminae is lost and MGP is found at 
the borders of vascular mineralization. It has been shown that absence of MGP promotes 
atherosclerosis and plays an important role in ectopic calcification seen in terminal renal 
insufficiency patients in need of dialysis [59, 60].  
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Other negative regulators of uncontrolled mineralization are osteopontin (OPN) and 
pyrophosphate. OPN, a phosphoprotein expressed in the growth plate cartilage and bone, can 
act as in inhibitor or activator of mineralization, depending on the phosphorylation degree [61]. 
Recently, it has been shown that OPN is upregulated in Mgp-/- mice, pointing towards a possible 
secondary effect of absent MGP. Pyrophosphate is an inhibitory protein which itself is regulated 
by interactions of glycoprotein-1 – generating pyrophosphate –, ANK – a cell-membrane 
associated protein transporting pyrophospate to the ECM –, and TNAP – hydrolysing organic 
phosphor compounds – although the latter may be particularly important in removing the inhibitor 
from the mineralization site [62]. The Ank-/- mouse, similarly to Mgp-/- mice, features extensive 
soft tissue mineralization [62]. 
 
Fetuin A (α2-Heremans-Schmidt glycoprotein) is a systemic calcification inhibitor 
synthesized by the liver. The fetuin A deficient mice (Ahsg-/-) developed severe calcification of 
various organs, while calcium and phosphate homeostasis remained unchanged [63]. Further 
extensive genetic evidence for the inhibitory role of fetuin A was given by ultrastructural and 
biophysical data demonstrating that inhibition of calcium precipitation by fetuin A is caused by 
formation of soluble, colloidal spheres containing fetuin A, MGP, calcium and phosphate [64, 65]. 
These  “calciprotein  particles”  are  more  soluble  than  calcium  and  phosphate  alone  but  may 
become progressively more crystalline and insoluble in a time- and temperature-dependent 
manner. 
 
Finally, the BMP-pathway has been implicated in mineralization homeostasis. Bone 
morphogenetic proteins or BMPs are a group of growth factors and cytokines known for their 
ability to induce formation of bone and cartilage [66]. In total, 16 BMPs have been described, six 
of  which  belong  to  the  TGFβ-superfamily of proteins. BMPs interact with specific cell surface 
receptors, through a signalling pathway involving members of the SMAD protein family. Of the 
BMPs involved in mineralization, BMP-2 acts as a disulfide-linked homodimer, inducing bone and 
cartilage formation. It also has a crucial role in osteoblast differentiation, similar to BMP-7. In 
addition, BMP-3 and BMP-8a are involved in bone and/or cartilage development [66]. The BMP 
pathway is regulated by several activators and inhibitors. A well-known example of the latter is 
MGP, which has been shown to inhibit the function of BMP-2 [67].  
 
1.3.1.2 Ectopic calcification 
 
Deposition of calcium crystals or true bone formation in non-osseous soft tissue (or 
ectopic calcification/ossification) may occur by one of three mechanisms:  
 
1/ metastatic calcification due to a supranormal calcium x phosphate concentration 
product in extracellular fluid 
 
2/ dystrophic calcification due to mineral deposition into metabolically impaired or dead 
tissue despite normal serum levels of calcium and phosphate 
 
3/ ectopic ossification or true bone formation 
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 Disorders that may cause extraskeletal calcification or ossification are listed in table 2. 
Despite the abnormal calcium x phosphorus product, several disorders in which metastatic 
calcification occurs, such as renal failure and hemodialysis, have been shown to also present 
abnormalities of the physiological inhibitors of calcification, including MGP.  As such, abnormal 
ionic serum levels probably do not fully account for the pathological features.  A severe and 
aggressive disease is fibrodysplasia ossificans progressiva or FOP, in which a deficiency of the 
BMP pathway of mineralization inhibitors finally leads to widespread ectopic ossification, often 
leading to premature death due to respiratory failure. Because of the normal values of calcium 
and phosphate, the mineralization in PXE is defined as dystrophic calcification. In rare cases, 
ectopic ossification has been reported, as described further. 
 
Metastatic calcification Dystrophic calcification Ectopic ossification 
Primary hyperparathyroidism Scleroderma Myositis ossificans 
Sarcoidosis 
Vitamin D intoxication 
Dermatomyositis 
Systemic lupus erythematosus 
Fibrodysplasia ossificans 
progressiva 
Milk-alkali syndrome Pseudoxanthoma elasticum  
Tumoral calcinosis   
Secondary hyperparathyroidism   
Pseudohypoparathyroidism   
Renal failure   
Hemodialysis   
Tumor lysis syndrome   
Therapy with vitamin D & 
phosphate 
  
Table 2 
Diseases and conditions associated with ectopic calcification and ossification 
 
1.3.2 Clinical findings 
 
PXE is characterized by a marked clinical variability, even between siblings [22-24]. While 
the organ systems affected – skin, eye and cardiovascular system – are the same in all patients, 
the age of onset, severity of organ system involvement and natural course display a remarkable 
variability.  
 
1.3.2.1 Skin and mucosal membranes 
 
a/ basic anatomy 
 
 The skin forms the continuous external surface or integument of the body and is as such 
considered to be our largest organ. Four types of skin can be recognized, based on the region of 
their occurrence, which all have a similar histological structure consisting of 3 main layers: 
 
1/ the epidermis, the external surface of the skin consisting of a keratinised squamous 
epithelium. the epidermis is build out of 5 distinct layers reflecting the maturation of 
epidermal cells formed by mitosis in the inner or germinal layer. 
  
2/ the dermis, a thick layer of dense, fibro-elastic tissue, supporting and nourishing the    
epidermis. This highly vascularised layer is divided into the superficial papillary dermis    
– a loose network of bloodvessels and fine interlacing collagen fibres – and the larger so-
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called reticular layer of the derm, because of the reticular arrangement of the collagen 
fibres.  
  
3/ the hypodermis or subcutaneous layer which contains variable amounts of adipose 
tissue.  
 
 
Figure 6 
Schematic structure of the skin 
Adopted from Virtual Science fair 
 
Elastic fibres are important constituents of both layers of the dermis, forming a fine 
interlacing network of fibres in the papillary dermis, whereas in the reticular layer long thick fibres 
which follow the path of the coarse interlacing collagen bundles. The cells of the dermis are 
mainly fibroblasts, responsible for production of collagen, elastin and the ground substance. 
   
  b/ histopathology of the mid-dermis 
   
 Elastic fibres in the mid-dermis are typically polymorphous, mineralized and fragmented, 
while those in the papillary dermis and deep dermal layers have normal morphology. By EM, two 
types of mineralization can be noted: fine deposits in the center of the fibre and bulky 
precipitates deforming and breaking the fibres [36, 68, 69]. In these dermal mineralized areas, 
deposits of thread-like material, collagen flowers and collagen fibrils of irregular diameter are 
present in most patients. Fibroblasts are often numerous, with hypertrophy and dilatation of the 
endoplasmatic reticulum [36]. Near the mineralized areas, macrophages are abundant. 
Interestingly, ultrastructural elastic tissue alterations can be observed in both lesional and 
clinically non-involved skin, while the other ECM changes are only seen in clinically involved skin 
in vicinity of aberrant elastic fibres [23]. In rare cases, the dermal calcification can lead to 
ossification [70]. Interestingly, this has always been noted in those patients with significant cutis 
laxa. Of note, the dermal EM alterations are certainly not specific for PXE; they can also be seen 
in other inherited diseases of the ECM and normal skin aging [23]. Therefore, light microscopy 
evaluation remains essential for the diagnosis of PXE.  
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  c/ clinical symptoms and evaluation 
 
 The skin features of PXE – resulting from clumping of the mineralized and fragmented 
elastic fibres in the mid-dermis – are characterized by a significant heterogeneity both in clinical 
severity and type of lesions. Although the skin manifestations are usually the first to appear, they 
are often not recognized as such, thus postponing the diagnosis [22]. During puberty, yellowish 
discoloured small 2-5 mm papules surrounded by normal skin can emerge, usually in the neck. 
Often referred to as cobblestone-like, Moroccan leather or plucked chicken skin texture, they are 
very characteristic for the disorder and, although they may enlarge and coalesce into larger 
plaques, they usually remain confined to the flexural areas of the body (neck, axillae, antecubital 
fossae, groins, popliteal spaces) and around the umbilicus [22, 23]. Although the face is ordinarily 
not markedly involved, Lebwohl et al. recently showed that horizontal and oblique mental creases 
have a high specificity for the diagnosis of PXE before the age of 30 [71]. 
In some patients, anogenital, gastric and mouth mucosae (most typically the inner lower 
lip) are affected, with a yellowish reticular pattern or – more rarely – small mucosal papules. 
 
 
Figure 7 
Skin features in PXE including papular lesions in the neck region and elbow (A-B-C), coalesced plaques of papules (D), 
cutaneous peau d’orange (E),  increased axillary skin laxity (F) and mucosal involvement with yellowish reticular pattern of 
lower lip (G) 
 
 Long-term cutaneous changes may comprise loss of elasticity of the skin, resulting in 
redundant skin folds, particularly in the axillae. Some case reports described patients with a 
systemic cutis laxa-like PXE [70, 72, 73]. In rare cases, facial involvement can lead to a “hound-
dog look”. These long-term effects can be a significant esthetical and psychological burden. Only 
in very rare instances, spontaneous resolution of PXE skin changes has been noted; yet, in at 
least two cases it concerned acquired and hence pseudo-PXE [37, 74, 75]. 
 
 More rare skin presentations which can be observed in PXE patients include Miescher 
elastoma [76, 77], elastofibroma [78], acne-like lesions on the neck or trunk, featuring comedones 
or inflammatory papules [79-81], elastosis perforans serpiginosa – a reactive perforating 
dermatosis characterized by elimination of abnormal elastic fibres from the upper dermis through 
 20 
the epidermis – [82-89] a reticulate pigmented rash [90], or milia en plaque [91]. 
Keratoacanthomas – a benign cutaneous neoplasm – have been described located specifically 
on PXE skin lesions [92]. Bahadir et al. described irregular purple plaques in a patient, the 
histology of which was characteristic for PXE [70]. Nanda Kumar et al. reported a patient with 
multiple confluent atrophic plaques with peripheral hyperpigmentation, the histology of which was 
fully compatible with PXE [93]. Calcinosis cutis has rarely been reported in PXE patients but was 
always found in association with disorders of calcium and phosphate metabolism [94-97].  
  
1.3.2.2 Eye symptoms 
 
a/ basic anatomy 
 
 The human eye, although underrating its complexity, can be described as a cup-shaped 
photocamera (Figure 8). It is primarily designed to translate light into electrical impulses, which 
are then led to the visual cortex of the hindbrain through a complex network of intracranial visual 
pathways. For this purpose, light or images are projected onto the retina after appropriate 
focussing by the compound lens system formed by the cornea and the crystalline lens.    
 
 
Figure 8 
Schematic structure of the human eye 
Adopted from Virtual Science Fair 
 
 The retina, approximately 500 micron thick, forms the innermost lining of the eyeball, and 
consists histologically of 10 layers, containing neural and/or supportive cells. It is bordered by the 
choroid, a highly vascularised layer and the sclera, the external coat of the eye. The most outer 
layer of the retina, a monolayer of cuboidal epithelial cells, is called the retinal pigment epithelium 
(RPE), which interacts with the photoreceptor layer of the retina and is separated from the 
choroid by Bruch membrane (BrM) (Figure 9). This elastin- and collagen-rich acellular 
membrane acts as an attachment site for the RPE cells and has a role in the vital bidirectional 
transport of oxygen and nutrients between the RPE and the choroid. Due to numerous 
interactions, the photoreceptors form one functional complex with the RPE cells and the ECM 
structure of BrM. This complex has a high level of metabolic activity and depends almost entirely 
on oxygen and nutrients derived from the choroid. 
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Figure 9 
Transverse section through the posterior wall of the eye, showing BrM in between the retina and the bloodvessels of the 
choroid. Adopted from the American Health Assistance Foundation 
 
 Histologically, BrM consists of 5 layers: 
 
 1/    the RPE basal lamina 
 
 2/    the inner collagenous zone, consisting of collagens type I, III and VI 
 
3/    the middle elastic zone, which forms a unique interlacing network with the inner and 
outer collagen fibrils, differing from elastin structures in the skin and bloodvessels. This 
maze-like structure is considered to play a role in the integration of the various ECM 
components into one functional unit. 
  
4/    an outer collagenous zone 
  
5/    the basement membrane of the endothelial cells of the choroid 
 
In addition to the collagenous and elastic components, BrM contains a variety of 
proteoglycans (heparin, dermatan, chondroitin sulphate), which may be involved in the structural 
and functional properties of BrM, as they are suggested to make up anionic sites acting as charge 
barriers [98-100].  
 
  b/ histopathology of Bruch membrane 
 
 The changes in BrM are apparently identical to those seen in the middermis, with similar 
calcium deposits onto and clumping of fragmented elastic fibres. As a result, the barrier 
membrane will no longer have a smooth surface, but will start to exhibit breaks (Figure 10), 
making it possible for choroid vessels to grow towards the inner retina. The start of this 
degradation is characterized by discontinuities in the middle elastic layer and loss of RPE 
pigment granules. In a next stage, full thickness breaks in combination with atrophy of the 
overlying RPE and photoreceptor cells are observed plus ruptures of the underlying choroid. In 
some cases, herniation of choroidal fibrillar collagen tissue and choriocapillaris in to the breaks in 
BrM can be seen, separating this membrane. Surprisingly, no histological data on peau d’orange 
or comet tails (see paragraph ‘d’) could be found.   
 
 22 
 
Figure 10 
Graphic representation of BrM degradation (crack formation) and  
subsequent growth of bloodvessels through the breaks 
 
 
  c/ clinical evaluation 
 
 As light needs to be projected onto the retina, both the lens system of the eye as well as 
the vitreous liquid which fills the eye ball, are fully transparent. For this reason, the retina can be 
easily evaluated using a fundoscope (ophthalmoscope) and/or fundus camera. 
 Fundoscopically, the retina can be divided into the macula or yellow spot, of which the 
center or fovea is the region of highest visual acuity, and the retinal periphery responsible for the 
peripheral visual field (figure 11). The posterior pole, seen when the patient looks straight into the 
fundoscope, comprises the optic disk, macula and retinal midperiphery. In addition, a network of 
arteries, arterioles and veins can be seen in the superficial layers of the retina, supplying the 
inner cell layers of the retina.  
 
 
Figure 11 
Normal fundus image of the right eye showing optic disc, macula (outer circle), fovea (inner circle), retinal midperiphery as 
well as retinal vasculature 
 
Retinal fundus photographs will document the appearance of a retinopathy and serve 
as a baseline for future observations. In addition, retinal fluorescein and indocyanine green 
angiography may enhance recognition of retinopathy features [101-109].  
 Novel emerging fundus imaging techniques, such as autofluorescence, infra-red and red-
free imaging – the mechanisms of which are explained in chapter 2 – have so far had no or 
limited use in PXE [110-113].  
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  d/ clinical signs and symptoms 
  
The five major components of the PXE retinopathy are (Figure 12): 
 
1/ Ocular peau d’orange (Pd’O), a diffuse mottled hyperpigmentation of the fundus which 
is probably the first ocular sign of PXE [22, 23, 114, 115]. It consists of fine, relatively 
symmetrical flat lesions in the RPE. As it does not give rise to any symptoms, its exact 
time of origin is unknown and discovery is often postponed to a later age. Located in the 
retinal periphery, most prominent temporal to the fovea, approximately 28 to 73% of 
patients are presumed to have this aberration [116, 117]. The peau d’orange is however 
known to regress with age, significantly reducing the prevalence in elder PXE patients. 
When readily identifiable in one individual, siblings should be investigated for the 
presence of Pd’O, even in the absence of angioid streaks. 
 
2/ Angioid streaks (AS) represent the breaks in Bruch membrane due to elastorrhexis. 
In fundo, they are seen as irregular, often jagged pigmented red-brown lines, radiating 
out from the optic disk, resembling normal retinal or choroidal vasculature at first glance, 
hence their name [25]. Sometimes, connecting streaks encircling the optic disk can be 
observed. AS are typically bilateral and variable in their number and extent. While in 
many patients there is a slow increase in number and length/width of streaks, they are 
asymptomatic and, although their mean age of onset is in the second decade, detection 
often only occurs when they are complicated by retinal haemorrhages. It is considered 
that all PXE patients will develop AS sooner or later and, if taken together with the other 
characteristics of the retinopathy, they have a high specificity for PXE [24, 25]. 
Occasionally, AS are found in isolation, but they have also been seen in younger 
individuals with PXE who had no cutaneous manifestations of the disease but developed 
them later. Therefore, when AS are identified in a patient, a systemic disorder as PXE 
must always be suspected and the patient should remain under surveillance. 
 
3/ Peripapillary atrophy, can be observed in different forms (varying from helicoid to 
cuboid) and can be so extensive around the disk and in the macula that AS are no longer 
visible [24]. Generalized atrophy of the RPE and choroid, as well as reactive hyperplasia 
of the RPE with less marked AS have been described [23, 118].  
 
4/ Subretinal neovascularisation, haemorrhages and macular degeneration, are 
regarded as complications of AS and were, in the past, often the first sign leading to the 
diagnosis of PXE. Neovascularisation engages from the choroid through the breaks in 
BrM, possibly triggered by Vascular Endothelial Growth Factor (VEGF). The novel vessel 
will push against the outer retinal layers, deforming the otherwise tightly stretched retina. 
Due to a lack of tight junctions in the neovessels, an exsudative reaction – leakage 
through the vessel wall – occurs. As a result, patients can experience metamorphopsia, a 
distortion of their vision, with straight lines becoming curved. As these neovessels also 
have brittle walls, rupture – either spontaneous or traumatic – can occur easily, resulting 
in a haemorrhage and subsequent (partial) vision loss (scotoma), depending on the size 
and location of the haemorrhage in fundo. When the macula is affected, patients lose 
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their central sight. It is however unusual for PXE patients to become completely blind; in 
most cases, peripheral vision is retained.  
Subsequent neovascularisations and haemorrhages may lead to macular degeneration 
(so-called disciform process), the irreversible end-stage of the PXE retinopathy. 
 
5/ Comets and/or comet tails are nodular white punched-out fundus lesions, 
representing crystalline bodies in the retinal midperiphery and juxta-papillary area with a 
variable degree of retinal pigment epithelium (RPE) atrophy. These white dots may 
extend to the sclera with a slightly depigmented tail in the RPE (hence comet tail). Gass, 
who coined the term comets, described these lesions as being the only fundus feature 
pathognomonic for PXE [119]. When found in isolated cases, they must be differentiated 
from the lesions seen in presumed ocular histoplasmosis (POHS), a fungus infection in 
which white dot lesions are however brighter and lack a tail [24] .  
 
 
Figure 12 
PXE retinopathy features with peau d’orange (A, circle) , angioid streaks (B , arrows), retinal haemorrhage and macular 
degeneration (C) and comets (D, arrows) 
 
Other funduscopical findings include drusen of the optic nerve head (Figure 13) [120, 
121], salmon patches (which typically represent a healing subretinal haemorrhage) [115], “black 
dots”  (as  a  result  of  metaplasia  of  the  RPE  following  focal  haemorrhage)  and  chorioretinal 
arteriovenous communications [122]. Although the latter occur with significant higher prevalence 
in PXE, these features are less specific for the disorder. Historical references to chorioiditis or 
chorioretinitis in PXE are probably based on misinterpretations of the disciform process. Similarly, 
early case reports of blue sclerae and vulnerability to global rupture represent probably 
misdiagnosis of osteogenesis imperfecta [123].   
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Figure 13 
Fundoscopic image of optic disc drusen (A) and salmon spot (B, arrowed) 
 
1.3.2.3 Cardiovascular symptoms 
 
a/ basic anatomy 
 
 The cardiovascular manifestations of PXE are due to degradation of elastic fibres in the 
endocardium and arteries. ECM alterations in the latter are also responsible for the gastro-
intestinal symptoms [124].  
 Histologically, arteries are divided up based on their location (peripheral or central 
arteries), size (small, medium-sized or large) or main histological component (elastic, muscular or 
musculo-elastic). In PXE, mostly peripheral, medium-sized muscular vessels are affected. The 
wall of these bloodvessel consists out of three layers: 
   
1/ the tunica adventitia, an outer layer of connective tissue, supporting the nervi and 
vasa vasorum 
 
 2/ the tunica media, a middle layer of smooth muscle cells 
 
3/ the tunica intima, made up of a single layer of endothelial cells and underlying 
connective tissue 
 
These primary layers are separated from each other by two thin membranes which 
consist of elastic fibres and are therefore called the internal (between intima and media) and 
external (between media and adventitia) elastic laminae. 
  
 
Figure 14 
Transverse and horizontal section of a bloodvessel 
Adopted from Stevens and Lowe, Basic Histology 
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 The histological structure of the heart is very similar to that of bloodvessels, albeit that the 
terminology is different. Three basic layers can be distinguished: 
 
1/ the endocardium – the innermost layer of the heart – is the equivalent of the tunica 
intima and consists of a single lining of endothelial cells and its supportive, collagenous 
tissue. Beneath the collagen lays a robust fibro-elastic layer, allowing movement of the 
myocardium without damage to the endothelium.  
 
2/ the tunica media of the heart is called the myocardium and is made up of cardiac 
muscle.  
 
3/ the epicardium, the tunica adventitia of the heart, consists of a single cell layer, the 
mesothelium, which is supported by a thin fibro-elastic layer. 
  
  b/ histopathology 
  
 Both the myocardium and pericardium show elastic fibre mineralization and collagen 
flowers, resembling the mid-dermal alterations [36]. Similar findings can be observed in nearly all 
small and medium-sized bloodvessels, including intestinal vessels, although it has been observed 
that alterations are not homogeneously distributed in the vessel wall. Alterations are most 
prominent close to the adventitia [36].  
In contrast to the dermis and retina, vascular elastic fibres tend to form aggregates of 
thin strands of amorphous elastin which replaces the internal elastic lamina, e.g. in the aorta. 
These degenerative changes may be accompanied by various degrees of intima thickening due 
to a patchy proliferation pattern of the fibroelastic components [125]. These vascular changes 
show great comparison with Mönckeberg-type arteriosclerosis and the idiopathic type of 
generalized arterial calcification in infancy (IACA). The former is a type of focal calcific 
arteriosclerosis in the elderly, while IACA is a dramatic variant of arterial myoelastic degenerative 
tissue calcifications, caused by mutations in the ENPP gene and leading to intrauterine death or 
lethality within the first months of life.  
Also the venous system, more specifically the vena cava, can be affected at the 
ultrastructural level in PXE [36].  
   
c/ clinical signs and symptoms 
  
Vascular morphological changes result in peripheral (PAD) and coronary (CAD) artery 
disease of various severity. Microangiopathy has been illustrated by capillaroscopy but deemed 
aspecific [126]. The most frequent symptoms and signs of PAD include: 
 
1/ hypertension which has been reported in 8 to 22% of PXE patients; in some 
childhood cases, hypertension was the presenting manifestation of the disorder [125, 
127-136]. 
 
2/ intermittent claudication (IC) of the lower extremities is described as the most fre-
quent vascular complaint, occurring in ~30% of patients [137, 138]. Usually starting from 
the third decade on, it has been described in childhood in rare cases. Absence of 
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peripheral pulsations should be seen as an alarm symptom. Although in literature the 
term  “accelerated  atherosclerosis”  is mentioned,  the  peripheral  artery  calcifications are 
usually patchy so that the resulting ischemia progresses slow enough to allow for the 
development of collateral circulation. As such, severe complications of IC, such as 
gangrene and total loss of an extremity are rare. 
 
3/ abdominal angina resulting from celiac artery stenosis is, next to gastro-intestinal 
bleeding, the most common abdominal complaint in patients [77, 130].  
  
4/ stroke has traditionally been considered a rare complication of PXE and mostly due to 
small vessel disease [139]. Childhood cases have been described [140]. Anecdotal case 
reports describe involvement of the cerebral or basilar arteries [93]. An association of 
PXE with intracranial aneurysms has been deemed unlikely, although no large case 
series are available to support this hypothesis [139].  
 
5/ increased compressibility of the arterial wall, particularly of the carotid arteries, has 
been demonstrated in PXE patients, possibly because of the observed accumulation of 
proteoglycans in vessel walls [141, 142]. Large proteoglycans are considered key 
components for maintaining shape and sustaining compression generated by pulsatile 
forces and, by interacting with macromolecules entering the vascular wall (such as 
oxidized LDL), may favour atherosclerosis [143].    
 
Cardiac involvement is uncommon in PXE, although a higher prevalence of diastolic 
dysfunction has been reported [144]. Previously described associations with valvular disease, in 
particular mitral valve prolapse, remain to be determined using stringent diagnostic criteria [145-
148]. Restrictive cardiomyopathy in relation to diffuse endocardial fibroelastosis seems to be very 
specific for PXE but is also very rare [149]. Most common CAD manifestations in PXE patients 
are: 
 
1/ angina pectoris or silent coronary insufficiency [150], which in two large clinical series 
occurred in 13 to 53% of patients [6, 37]. 
 
2/ myocardial infarction has not been reported frequently in association with PXE, 
although examples of very young patients are at hand [135, 151-158]. Thus, PXE should 
be considered in young individuals with precocious coronary artery disease and no 
cardiovascular risk factors[159].   
 
Sudden death has only been described in four cases and may be due to fatal arrhythmias 
subsequent to large or small vessel coronary stenosis with ischaemia, conducting system and 
endocardial disruption [160, 161]. 
 
 A serious vascular complication of PXE is gastro-intestinal haemorrhage, usually 
originating from the stomach, which has been reported in 8 to 19% of patients, and probably 
results from similar morphological changes in the submucosal gastric arteries as in peripheral 
arteries which – in contrast to PAD - lead to arterial fragility and haemorrhage [162-164]. Some 
authors have proposed that bleeding may be related to defective submucosal vasoconstriction 
[165]. Other etiological factors, such as increased gastric acidity with mucosal erosions and 
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damage of submucosal arteries have been suggested to play a role, although this has never been 
proven.  
 
1.3.2.4 Other clinical manifestations  
 
Although no patients with respiratory complaints have been described, pulmonary 
opacities in the lungparenchyma have been described in rare cases [166-169]. As the lung is 
very rich in elastic fibres, it remains unclear why this organ seems protected from clinically 
significant ECM degeneration.  
Calcifications can be observed on mammograms in female PXE patients, which might 
be of diagnostic value in women, as breast tumour calcifications are usually easily ruled out [170, 
171]. One case report demonstrated similar ectopic calcifications in the testicles of a 14-year 
old patient [172].  
Several auto-immune diseases, including chronic cutaneous lupus erythematosus 
[173], rheumatoid arthritis and Hashimoto's thyroiditis have been described in association with 
PXE [174-179]. In most – if not all – cases hitherto reported, it is most likely to concern 
coincidental findings rather than a true pathogenetic association. 
Most women with PXE have normal pregnancies and deliveries [180]. In the past, case 
reports have undoubtfully overemphasized the risk for gastric bleeding during the pregnancy as 
well as complications such as chorio-amnionitis, intra-uterine growth retardation or thrombo-
embolic events [181-192]. Although the placenta may show more necrotic changes and 
mineralization compared to normal women, these are unlikely to provoke growth restriction or 
miscarriage [193]. A recent large case series concluded that there is no basis for advising women 
with PXE to avoid becoming pregnant and that most pregnancies in PXE are without 
complications [180].  Most effects of pregnancy directly on PXE relate to aggravation of the skin 
lesions [188, 189, 191]. Epidural anaesthesia can be established if necessary [194, 195]. It has 
been suggested that ophthalmological monitoring is important during labour to prevent retinal 
haemorrhages, while some authors advise delivery through caesarean section to avoid visual 
complications [196].   
 
1.3.2.5 Phenotype in heterozygous carriers 
 
Individuals carrying one mutated allele of an autosomal recessive disorder have 
traditionally  been  considered  as  “healthy  carriers”,  which  do  not  develop  any  disease 
manifestations. In several disorders, this has been proven incorrect, as carriers were shown to 
have at least a partial phenotype. In PXE, the issue on whether or not the carriers of one ABCC6 
mutation have a clinically relevant (partial) phenotype has long been ongoing. It is certainly true 
that one ABCC6 mutation is sufficient to modify dermal elastic fibres and – by extrapolation – 
fibres in BrM and blood vessels [197, 198]. Martin et al. identified three histological phenotypes of 
the skin elastic fibre system depending on the ABCC6 genotype (patient vs. carrier vs. wild type), 
in which severity of disruption in carriers was between patients and unaffected individuals with 
short, thick and sometimes fragmented fibres, staining mildly for bone sialoprotein compared to 
patients [198].  
In addition to the histological aberrations, several authors described one or more clinical 
manifestations in heterozygotes. Sherer et al. have reported on mild ophthalmological and/or 
cutaneous involvement in heterozygous carriers, but they did not indicate the frequency of this 
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phenomenon in their cohort of patients [199]. Additionally, no other reports of oculocutaneous 
involvement in carriers have been issued. More convincing are the reports emphasizing the 
carriage of one ABCC6 mutation to be a risk factor for cardiovascular disease; the p.R1141X 
mutation has, in heterozygous state, been observed as an independent risk factor for coronary 
heart disease in young people [200, 201]. It seems probable that the course of disease in carriers 
is different – probably more beneficial – than in PXE patients. However, these findings emphasize 
the importance of screening other – apparently healthy – individuals in a PXE family for 
carriership of an ABCC6 mutation. Depending on their confirmation in other cohorts, these 
observations may represent considerable concerns for PXE families and public health in general.  
 
1.3.3 Molecular genetics 
 
The molecular era for PXE was launched in 2001 – four years after the first mapping of a 
chromosomal region on 16p13.1 – with the identification of causal mutations in the ABCC6 gene 
[12, 14, 202]. Prior to its characterization, the initial 16p locus was refined to a region of about 
500 kb, containing 5 genes (ABCC1, ABCC6, pM5, and two copies of the NPIP gene) [9, 11, 
203], direct sequencing of which identified the pathogenic gene. The involvement of ABCC6 was 
unexpected, as its protein, an ATP-dependent transporter, had no apparent relation with ECM 
proteins or homeostasis. Although our understanding of the domain structure has increased 
significantly, ABCC6 still harbours several unclarities and apparent contradictions.  
 
1.3.3.1 The ABC transporter superfamily 
 
The ATP-binding cassette (ABC) superfamily involves 48 human functionally diverse 
active transmembrane transporters. Strongly conserved in different species, they play a 
fundamental role in the inter- and intracellular membrane transport of a.o. amino acids, lipids, 
lipopolysaccharids, anorganic ions, peptides, saccharids, metals, drugs and proteins. They are 
implicated in signal transduction, drug resistance, protein secretion and antigen production. 
Although most often directly involved in substrate transport based on ATP hydrolysis, some 
appear to be part of ion channels where ATP hydrolysis regulates opening and closing. Most 
transporters function unidirectional, although for some members, bidirectional transport capacities 
have been described.  
 
The typical ABC-transporter (so-called full-transporter) consists of two transmembrane 
domains (TMD), responsible for substrate specificity and containing 6-11 transmembranary 
helices, and two highly conserved hydrophilic nucleotide bindings folds (NBF), build up of two 
sequence motifs (Walker A & B) and a consensus sequence (C-motif), critical for ATP binding. 
Half-transporters have only one TM and NBF and need coupling to become active (Figure 15). 
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Figure 15 
Characteristics of the human ABC transporters 
 
ABC transporters are divided into 7 subclasses (A through G), based on phylogenetic 
analysis. Fourteen out of the 48 transporters have been implicated in 13 genetic disorders, the 
most common of which are cystic fibrosis (ABCC7), Stargardt disease (ABCA4), 
adrenoleukodystrophy and Tangier disease. The ABCC subfamily contains 12 full transporters 
with a diverse functional spectrum (Table 3). 
 
Transporter name Function Disease OMIM# 
ABCC1 (MRP1) Drug resistance 
Bile acid transport 
Unknown  
ABCC2 (CMOAT) Dubin-Johnson syndrome 237500 
ABCC3 Drug resistance Unknown  
ABCC4 Nucleoside transport Unknown  
ABCC5 Drug resistance Unknown  
ABCC6 Unknown Pseudoxanthoma elasticum 264800 
ABCC7 (CFTR) Chloride ion channel Cystic fibrosis 219700 
ABCC8 Sulfonylurea receptor FPHH, DM type II 256450/600509 
ABCC9 K(ATP) channel regulator Dilated CMP with VT 608569 
ABCC10 Unknown Unknown  
ABCC11 Unknown PKC* 128200 
ABCC12 Unknown ICPC* 602066 
Table 3 
Members of the ABCC subfamily, their function and associated diseases 
(*) Candidate gene; FPHH: Familial Persistent Hyperinsulinemic Hypoglycemia (nesidioblastosis), DM: Diabetes Mellitus; 
CMP: Cardiomyopathy; VT: Ventricular Tachycardia; PKC: Paroxysmal Kinesigenic Choreoathetosis; ICPC: Infantile 
Convulsions with Paroxysmal Choreoathetosis 
Adopted from Stefkova et al. [203] 
 
With the ABCC6 transporter, previously referred to as MRP6 (multidrug resistance protein 
6), implicated in PXE, a fairly unknown member of the ABC superfamily came to attention. It is 
composed of three hydrophobic membrane segments comprising five, six and six transmembrane 
spanning domains, respectively, and two nucleotide bindings folds (Figure 15). ABCC6 was 
classified as an MRP, because of its homology with MRP1, reaching 45% identity. While MRP1 is 
a well characterized transporter of amphipathic anionic conjugates, glucuronidated and sulphated 
compounds, the transport capacities of ABCC6 remain unclear [205].  
In vitro, ABCC6 was demonstrated to have ATP-dependent transport capacities of at 
least two anionic glutathione conjugates (leukotriene C, N-ethyl maleimide S-glutathione [NEM-
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SG]), comparable to ABCC1 and 2 [206, 207]; organic anions known to interfere with glutathione 
conjugate transport inhibited NEM-SG in a specific manner, indicating ABCC6 to have a unique 
substrate specificity. It also confers low levels of resistance to several agents such as etoposide, 
teniposide, doxorubicine and daunorubicin [206]. The affinity of ABCC6 for these compounds is 
however very low, excluding them as plausible physiological substrates.  
Using several polyclonal antibodies, ABCC6 was localised to the basolateral side of 
human hepatocytes and to the basolateral membrane of kidney proximal tubules [208]. This 
subcellular localisation suggests that the transporter extrudes into the blood specific substrates 
from liver and kidney. However, the search for the genuine physiological transport substrate of 
ABCC6 and hence its physiological function currently still continues. 
 
1.3.3.2 The ABCC6 gene 
 
The ABCC6 gene, located on chromosome 16p13.1, comprises 31 exons spanning ~73 
kb of genomic DNA. The transcribed messenger RNA is 6 kb, with a coding region of ~4.5 kb, 
leading to translation of a protein of 1503 aminoacids [14].  
Closely mapped to ABCC6, two pseudogenes (ABCC6-φ1 and ABCC6-φ2) were 
identified with high homology of the promoter region as well as exon 1 through 9 and exon 1 
through 4 respectively [209]. 
Surprisingly, the highest ABCC6 expression is observed in the kidneys and liver, while 
tissues involved in PXE (skin, retina, blood vessels) only revealed low expression levels [12, 206, 
210]. A series of other tissues – including brain, tongue, stomach and small intestine – 
demonstrate very low levels of ABCC6 expression [211, 212]. Based on this remarkable 
expression profile and the subcellular localization of the ABCC6 protein, PXE has recently been 
considered a metabolic disease, in which a so far unknown metabolite – or lack of it – is 
responsible for the connective tissue alterations. 
 
The regulation of ABCC6 expression and activity is not yet completely understood and 
– based on current knowledge – is deemed highly complex, involving regulatory proteins, DNA 
methylation determining tissue-specificity, liver and erythroid-specific enhancers and pro-
inflammatory cytokines. The high hepatic expression suggested that transcriptional cis-elements 
confer high liver-specific expression of the gene. This was confirmed by promoter-reporter gene 
constructs in HepG2 cells [213]. Subsequently, a NF-κβ-like segment (the promoter segment –
249 and -176) was discovered, functioning as a liver-specific element which binds HepG2 cell 
nuclear proteins in a specific manner. Other sequences for liver-enriched transcription factors 
could not be detected, suggesting that this cis-element is responsible for the high hepatic 
expression of ABCC6 [213]. The complexity of transcriptional regulation was further unravelled by 
the identification of at least four eukaryotic transcription factors (activator protein-2, USF-1, NF-κβ 
and epidermal growth factor) to the -2631 to +30 promotor region [213]. Arányi et al. described 
both activator and repressor sequences in the proximal ABCC6 promotor region; the most potent 
activator sequence consisted of conserved elements protected by DNA methylation in non-
expressing cells [214]. In murine abcc6 gene regulation, the importance of the proximal promotor 
was also stressed by identifying HNF4α (Hepatocyte Nuclear Factor 4 alpha) and NF-E2 (Nuclear 
Factor Erythroid 2) as transcriptional regulators, enhancing the promotor activity of abcc6. 
Recently, two members of the PLAG family of cell cycle progression-related DNA-binding 
proteins, PLAG 1 and PLAGL1, were identified as transcriptional regulators of the human ABCC6 
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gene [215]. This interaction is suggested to be direct and mediated by a single response element 
(PLAG binding site) in the ABCC6 proximal promotor. The events occurring upstream from the 
PLAG proteins remain however unclear [215].  
ABCC6 promotor activity can also be modulated by several cytokines, including 
transforming growth factor β (TGF-β), tumour necrosis factor α (TNF-α) and interferon γ (IFN-γ). 
In particular, TGF-β,  a  profibrotic  cytokine  from  the  liver,  significantly  upregulated  promoter 
activity [213, 216]. For TGF- β  responsiveness, an upstream Sp1 (Specificity protein 1) binding 
site at -58 to -49 was shown to be critical as was already suggested by other investigators for 
other genes [213, 217, 218].  
 
Currently, more than 150 mutations have been described in nearly all exons of ABCC6, 
albeit with a predominance of mutations at the 3’ end of the gene [12-15, 23, 33, 155, 197, 202, 
219-239]. All types of mutations have been described, although the majority are missense. Of 
these, about half are located in exons 15 through 19 and 26 through 31, encoding the two NBF’s, 
replacing critical aminoacids and thus projected to compromise ATP hydrolysis. Functional 
experiments on these missense mutations are scarce, but findings on three missense mutations 
in NBF2 confirm the hypothesis of abolished transport function [207]. As several missense 
variants are located in intracellular domains outside NBF 1 and 2, this suggests that other 
domains may be functionally important, e.g. for substrate recognition. 
Although most mutations are confined to a limited number of families, two recurrent 
mutations have been described. The p.R1141X (c.3421C>T) nonsense mutation is the most 
frequent mutation in a European population, although frequencies differ between different 
countries [232]. For the South-African population as well as for the French and Italian 
populations, a founder effect was described for p.R1141X [229, 235, 237, 240]. In the United 
States, a multi-exon deletion spanning exon 23 though 29 is most frequent, accounting for 28% of 
detected mutants [224].  
Reported mutation detection rates vary from 55 to 80%. Lack of one or both mutations 
can be due to middle-sized insertions or deletions – often missed with direct sequencing –, 
mutations in gene regulatory sequences or molecular analysis of patients with a PXE phenocopy. 
The argument of locus heterogeneity of PXE, although unlikely, cannot be ruled based on these 
detection rates. 
 
To date, no correlation has been established between the phenotype and the nature or 
position of the mutations. There is no significant association of mutations leading to a premature 
stopcodon with a more severe phenotype. Several studies are however hampered by relatively 
small patient groups and/or ill-defined phenotypes. The high intrafamilial variability is suggestive 
of other factors, both environmental and genetic modifiers, to influence the PXE phenotype.  
 
Recently, polymorphisms in three genes – SPP1, XYLT-1 and XYLT-2 – have been 
suggested as modifiers of the PXE phenotype [241]. The SPP1 gene encodes osteopontin, 
known to be involved in mineralization. XYLT-1 and XYLT-2 encode the xylosyltransferase 1 and 
2 enzyme respectively. Both Golgi-resident enzymes catalyze the transfer of xylose from UDP-
xylose to serine residues in the proteoglycan core protein and have been identified as risk factors 
for a.o. diabetic nephropathy and osteoarthritis [242].   
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1.3.3.3 Other phenotypes associated with 
ABCC6 
 
Only a few authors have attempted a candidate gene approach using ABCC6 for other – 
often more common – disorders than PXE. Most studies – including cohorts of cerebral and 
abdominal aneurysm patients or cervical artery dissections - turned out negative, although the 
patient group investigated was usually quite small [239, 240]. 
Naouri et al. looked at ABCC6 mutations in patients with elastofibroma (EF), a 
subcutaneous fibroelastic pseudotumour, usually presenting in adulthood at the lower end of the 
subcapsular space [243]. As in PXE, dystrophic elastic fibres can be observed albeit without 
mineralization or elastorrhexis. PXE and EF have also been reported once in the same patient 
[78]. No ABCC6 mutations were however found in the 3 patients examined. 
 
1.3.4 Pathomechanisms of PXE 
 
Although the pathophysiology of PXE remains largely unknown, two major hypothesis, 
the  “cell hypothesis” and  the  “metabolic hypothesis” have been proposed  to shed  light onto 
the processes leading to ectopic elastic fibre mineralization.  
 
1.3.4.1 The PXE cell hypothesis 
 
In  the  “PXE  cell  hypothesis”,  it  is  postulated  that  absent  expression  of  ABCC6 in 
fibroblasts or smooth muscle cells, may result in local mineralization as a result of cellular 
perturbation. The hypothesis is based on experiments on fibroblast cultures established from skin 
lesions of PXE patients. These cells have been suggested to display abnormalities in cell-cell and 
cell-matrix adhesion properties, in the proliferative capacity of the cells harbouring the mutations 
and in the rate of synthesis of connective tissue compounds, such as elastin, collagen and 
proteoglycans [244]. The cells have been shown to suffer from mild chronic oxidative stress and 
to demonstrate increased degradative potential as reflected by elevated MMP-2 expression [245, 
246]. Question remains whether the observed mild oxidative stress is an important primary 
pathogenetic mechanism or merely a secondary end-stage result of ECM degradation in PXE. 
  
1.3.4.2 The PXE metabolic hypothesis 
 
The metabolic hypothesis is based on the clinical observation that PXE is a slowly 
progressing disorder, caused by a transporter, predominantly expressed in the liver and kidney, 
which apparently has transport capacities from intracellular towards the blood stream. Hence, it 
has been postulated that in the absence of functional ABCC6, the levels of certain metabolic 
compounds in the circulation are altered. The perturbed levels of such compounds may affect the 
connective tissue directly, may have an indirect effect through pathways involved in ECM 
homeostasis or may alter the biosynthetic capacity of resident cells, thus leading to pathologic 
mineralization and degradation. The findings in Abcc6 knockout mouse models, described below, 
support the hypothesis that PXE is a metabolic disease with secondary connective tissue 
manifestations [247]. 
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Le Saux et al. addressed this hypothesis by incubating cultured fibroblasts from the skin 
of patients and age-matched, unaffected individuals in medium supplemented with normal human 
serum or serum from patients with PXE [248]. Results indicated that in the presence of normal 
human serum, PXE fibroblasts displayed increased synthesis of elastic fibres in comparison with 
normal fibroblasts, but the fibres were structurally normal. When maintained in the presence of 
serum from PXE patients, both PXE and normal fibroblasts deposited abnormal aggregates of 
elastic fibres. It can be concluded that certain metabolites in the PXE serum interfered with 
normal elastic fibre assembly in vitro [248]. Although no data are available of the effects of sera 
on the mineralization process, these experiments also support the metabolic hypothesis. 
 
1.3.5 Diagnosis 
 
The consensus for the diagnosis of PXE is based on a clinical and histological 
evaluation. Minimum criteria were said to be the presence of middermal elastorrhexis, 
associated with angioid streaks. In the advent of molecular testing, this consensus – although 
generally true, particularly in older patients – has been questioned by occasional reports of 
patients with molecularly confirmed PXE who were missing either skin or ocular involvement 
[249]. In addition, in children with PXE the ocular phenotype is often non-existing at the time of 
onset of the skin features. In this respect, molecular analysis of the ABCC6 gene has been 
suggested as an alternative diagnostic tool in patients with features of PXE. The cost and labour 
intensiveness of these analyses being one of the major concerns, several authors have 
suggested a two- or multi-step approach for ABCC6 analysis to become more efficient [219, 234]. 
So far however, such strategies have been of little help in the screening of ABCC6 outside the 
specific study-populations of these reports. Hence, no guidelines are available, neither on the 
position of molecular analysis in the diagnostic work-up of a novel PXE patient nor on its relation 
towards a skin biopsy. 
 
1.3.6 Differential diagnosis 
 
The differential diagnosis of classic PXE is usually not that difficult, although several other 
disorders may present with some symptoms considered typical for PXE. Although the skin lesions 
are characteristic in their appearance and location and can be confirmed through skin biopsy, 
table 4 lists the most important diseases, both hereditary and acquired, in which the skin features 
are highly similar to PXE. Interestingly, treatment with D-Penicillamin  (DPA)  for  e.g. Wilson’s 
disease causes a pseudo-PXE, possibly through interference with elastin cross-linking (by 
inhibiting lysyl oxidase) or by formation of complexes with the cross-linked precursors, impairing a 
normal maturation of elastic fibres [250]. Skin biopsy however will not show the characteristic 
elastorrhexis.  
Conversely, several disorders such as localized acquired cutaneous PXE (LAC-PXE or 
periumbilical perforating PXE) or Saltpeter contact may show a histological PXE-like appearance 
but have only limited clinical resemblance [251, 252]. LAC-PXE is an acquired disorder, most 
frequently found in obese, multiparous middle-aged women. The main clinical feature is a 
yellowish, reticulated or cobblestone plaque with papules in the periumbilical region. Patients 
should be reassured that, although no treatment is available, the disorder is benign and limited to 
the skin [253-257]. 
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Disorder Main clinical and/or histological difference(s) Ref. 
White papulosis of the neck & Flesh-colored papules that occur in the neck but also 
in nonflexural sites 
[255, 256]  
PXE-like papillary dermal elastolysis [257-259]  
Hyperphosphatemic tumoral calcinosis (MIM#211900) Identical skin features, however without elastorrhexis [258] 
Familial hypoalphalipoproteinemia (MIM#107680) Infiltrative xanthomas confined to neck and elbows [259] 
Buschke-Ollendorf syndrome (MIM#166700) Identical skin features, often on trunk, buttocks & feet [260] 
D-Penicillamin treatment Isolated elastic fibre degradation without calcification [250] 
Elastosis perforans serpiginosa Clumped elastic fibres extruded through epidermis [83] 
Perforating peri-umbilical PXE Identical skin features, isolated around umbilicus [253, 254, 
261-265] 
Table 4 
Dermatological differential diagnosis for PXE 
 
 Of the ophthalmological features, AS are not pathognomonic for PXE, with over 20 other 
disorders in which they have been observed. The most important ones are listed in table 5.  
 
Disorders featuring angioid streaks 
Sickle cell anaemia 
Beta-thalassaemia 
Paget’s disease of the bone 
Pituitary disorders (acromegaly) 
Familial hyperphosphatemia 
Table 5 
Disorders associated with angioid streaks 
 
A puzzling finding is that patients with inherited haemoglobinopathies, most often beta-
thalassaemia but also sickle cell disease, may have elastic tissue changes and clinical features 
closely resembling – if not identical to – PXE. The skin, eye and cardiovascular symptoms are 
indeed indistinguishable from PXE – except for their age of onset which is usually later in life – 
despite that none of these patients carry ABCC6 mutations [266-275]. These clinical findings are 
not anecdotal in haemoglobinopathy patients: out of a cohort of 100 patients with major or 
intermediate beta-thalassaemia, 26 patients had angioid streaks and/or skin lesions [272]. While 
one hypothesis might be that this is related to the pathophysiology of the primary 
haemoglobinopathy (and as such “acquired”), the identical histological findings in these patients 
suggest that either a pathway is involved which is independent of ABCC6 or that the largely 
unknown ABCC6 pathway is affected more downstream. 
 
 Besides the haemoglobinopathy phenocopy, there have recently been two reports of 
unclassified autosomal dominant conditions in large families, resembling PXE, in which 
involvement of the ABCC6 gene was excluded by linkage analysis. In one three generation 
family, affected individuals had mottled fundi, angioid streaks and drusen in various combinations, 
but no skin involvement suggestive for PXE [276]. Robert et al. described a four generation 
pedigree in which patients had typical skin involvement with papules and skin laxity as well as 
angioid streaks in fundo. Interestingly, only one patient showed mid-dermal elastorrhexis on skin 
biopsy, while the other affected individuals had a normal mid-dermis [277]. Both disorders, of 
which the molecular background remains currently unknown, might be examples of the clinical 
spectrum which we call PXE.  
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1.3.7 Animal models 
 
An animal model for PXE has been long considered to be useful in pursuing a better 
understanding of the pathophysiology, not only because of the unclear etiological role of ABCC6 
but also because of the difficulty of tissue availability for functional analysis. Indeed, besides skin, 
the other frequently affected organs (eye and cardiovascular system) are more difficult to obtain 
because of debilitating biopsy effects (eye) or lack of need for surgery in PXE (CVD). The same is 
true for the organs – liver and kidney – which most significantly express ABCC6. As all of the 
human ABC genes have mouse homologues, besides ABCC11 (which may have risen as a 
recent duplication of ABCC12), the mouse presents an excellent animal model system to study 
ABC genes. 
Towards the development of an animal model for PXE, Uitto et al. generated a targeted 
mutant mouse in which both alleles of the Abcc6 gene were inactivated by targeted ablation 
[278]. The histological phenotype of these mice revealed mineralization in various connective 
tissues, although with distinct differences compared to humans. The accumulation of calcium in 
the middermis is very focal compared to humans. Mineralization was particularly dense at the 
periphery of the fibres, while in PXE patients the calcifications are located in the elastic fibre core. 
Remarkably, severe calcification of the collagen fibres was also observed. Abnormal collagen 
fibrillogenesis, leading to cauliflowers has been observed in PXE tissues; however, these fibres 
do not tend to be mineralized. A striking feature was the mineralization of the connective tissue 
capsule surrounding the bulb of the vibrissae, which is detectable at 5-6 weeks and progressively 
increases. Although this has been suggested as an early biomarker of the pathologic 
mineralization process, its relevance for human PXE remains debatable. Immunohistochemical 
characterization of the mice demonstrate direct association of fetuin A, MGP, Ank and APase 
activity with the mineralization process of the calcified vibrissae [278]. 
 
A second mouse model, created by targeted disruption of Abcc6, results in extensive 
mineralization of soft tissue – including the skin, retina and blood vessels, in homozygous mice, 
whereas the heterozygous animals are indistinguishable from wild type mice [279]. 
 
From a clinical perspective, no convincing skin lesions could be seen besides very small 
and largely dispersed papules. Similarly, no data on features of the retinopathy in Abcc6 -/- mice 
are available, despite calcification in BrM. These findings suggest that, although present mouse 
models may serve as a model for ectopic mineralization, one must remain critical and careful in 
extrapolating findings to human PXE. 
 
Recently, Abcc6 has been identified as the major causal gene for dystrophic cardiac 
calcification (DCC) in mice [280-282]. Using a mouse model, the Dyscalc1 locus was fine-
mapped and by integrating genetic segregation and expression array analysis, a single candidate 
gene, Abcc6, was identified. It was demonstrated that in the DCC model, the expression of Abcc6 
is highly correlated with the local mineralization-regulatory system and the BMP2-Wnt signalling 
known to be involved in the systemic regulation of calcification [280]. Although myocardial 
calcification has not yet been reported as a phenotypic feature in human PXE, nor in the Abcc6-/- 
models, these findings might suggest potential pathways for the action of ABCC6. 
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1.3.8 Prognosis and treatment 
 
1.3.8.1 Prognosis 
 
Data on the natural course of the skin, eye and cardiovascular features are limited. 
Hence, any prediction on the prognosis of PXE is based on a limited number of observations 
reported in literature. The absence of genotype-phenotype correlations makes it currently 
impossible to individualise prognostic counselling, while recently identified potential modifiers 
await further study to evaluate reproducibility before they can be used in the clinic. It must be 
noted however that the prognosis of PXE in terms of life expectancy and life quality strongly 
depends on the age of diagnosis. When diagnosed at a young age, preventive measures and 
current therapeutic options may assure that the life span of a PXE patient is equal to the general 
population and that quality of life is maintained at a high level.   
 
1.3.8.2 Treatment 
 
At present,  there  is no  treatment  to “cure” PXE. Management focuses on prevention of 
complications and – if necessary – early intervention when they do occur. Unfortunately, no 
standard guidelines are available for the care of PXE families.  
 
a/ prevention 
 
Prevention of subretinal haemorrhages comprises avoiding ball and contact sports, to 
reduce  the  risk  of  facial  trauma.  Similarly,  isometric  activities  (weight  lifting,  …)  are 
contraindicated. All patients are advised to perform a regular self-examination to detect 
metamorphopsia using an Amsler grid (Figure 16). If the straight lines of this grid are seen as 
undulating lines, patients are asked to come into the hospital immediately for treatment. Practical 
alternatives to the Amsler grid are the tiles in kitchen or bathroom and the subtitles on television.    
 
 
Figure 16 
Amsler grid as observed by a normal individual (A) and as observed by a PXE patient with metamorphopsias (B) 
 
Cardiovascular prevention focuses on classic risk factors such as hypertension, 
hypercholesterolaemia, diabetes, obesity and smoking. Aspirin and non-steroidal anti-
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inflammatory drugs should be avoided because of the risk for mucosal bleeding. Particularly in 
patients who suffered an ischemic stroke, this can cause a significant therapeutic dilemma, for 
which no optimal solution presently exists. 
A single study has addressed the role of calcium restriction in the diet and found it to 
have a beneficiary influence on the evolution of PXE by reducing the extent of mineralization. 
However, the poor methodology of this study resulted in many authors refuting these findings. As 
such, there is presently no evidence that dietary measurements have any efficacy in PXE 
prevention.   
 
b/ treatment 
 
Surgical reduction of excessive and redundant skin for cosmetic improvement has been 
applied in some patients. The long term outcome is however highly variable and cases are mostly 
anecdotal. Several difficulties, such as delayed wound healing and scarring, should be taken into 
account, as well as the re-occurrence of skin folds [283]. The efficacy of collagen or autologous 
fat injections in the mental creases has not been established [284]. Preliminary studies with 
aluminium hydroxide, an oral phosphate binder, have suggested a significant clinical 
improvement of skin lesions and absence of ophthalmological deterioration [285]. The study 
cohort was however quite small (6 patients) and the follow-up period limited (1 year). Hence, 
these observations should be confirmed in a larger patient group before clinical use.  
Several approaches have been used in the past to stop vessel proliferation. Laser 
therapy was effective in some patients with submacular neovessels, but causes retinal burns and 
subsequent scotomata [286]. Also, a recurrence rate of 50% has been noted [286]. Surgical 
procedures, such as macular translocation for subfoveal choroidal neovascularisation, have 
occasionally been undertaken [287]. Because of the resemblance of the PXE retinopathy with 
age-related macular degeneration, photodynamic therapy and – more recently – anti-angiogenic 
drug therapy have been attempted. The former consist of a peripheral injection of verteporfine, a 
drug known to undergo a conformational change when targeted with deep red light, forming a 
clot. When targeting specifically the neovessels, clotting will induce anoxia and shrinking of the 
vessel thus preventing subretinal haemorrhage. Results of this approach are variable between 
patients – from significant improvement of visual acuity to stabilisation of decreased vision – and  
patients must avoid direct exposure to sunlight [288-290]. Red light is present in sunlight and, as 
the verteporfin – with a half-life of 72 hours – is present throughout the body after infusion, could 
induce vessel clotting throughout the body. The latter consist of intra-ocular injection of anti-
VEGF antibodies (Bevacizumab or Avastin®, Pegaptanib Sodium or Macugen®, Ranibizumab or 
Lucentis®), which block the trigger inducing the formation of neovessels, leading to shrinkage. 
Current results show good outcome – preservation of normal visual acuity – in patients with 
metamorphopsia but without haemorrhage [291, 292]. When haemorrhage has occurred, an 
improvement of vision can be envisaged. Recent reports of possible systemic side-effects 
emphasized the necessity of performing this treatment under well-controlled circumstances and 
the need for larger clinical trials.    
Despite the occurrence of gastro-intestinal bleeding, it is noteworthy that no vascular 
brittleness exists in PXE. As such, cardiovascular complications can be treated by standard 
surgical or interventional radiological neovascularisation procedures if indicated. For coronary 
surgery, controversy exists on whether the left internal mammary artery, which may be involved in 
PXE is suitable for bypass grafting [293-295].  
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Chapter 2 
Patients, materials and methods             o                                
      
“Chaque jour, à dix heures, mon médécin vient me prendre ma 
température et m’en donne une nouvelle.” 
    
                  Erik Satie 
 
The Center for Medical Genetics of the Ghent University has developed a specific 
expertise in the study of hereditary CTD, which is unique in Belgium and Europe. At the clinical 
level, a multidisciplinary setting was created for patients with hereditary CTD. In addition, a 
laboratory for biochemical and molecular research into the genetic defects in connective tissue 
proteins, such as the collagens and elastin is present. From its position as a health care service, 
a unique opportunity has been created to expand the research in this domain and to implement 
new developments in the clinic. By elucidating the genetic basis of this complex group of 
disorders, it is attempted to offer better diagnostics, prevention and new perspectives for 
treatment. 
 
2.1 Patient population 
 
PXE patients and family members were gathered from our own PXE clinic, from several 
European countries and from the registry of PXE International, a large patient support group 
offering a DNA- and tissue databank of over 3000 patients. Clinical data were gathered either 
through detailed clinical checklists – filled out by the referring physician – or by personal physical 
examination.  
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In our PXE clinic, all patients are submitted to a clinical protocol consisting of: 
 
1/ a skin biopsy, which is taken either in a skin lesion or at the lateral side of the neck 
when no lesion is clinically apparent. Histological confirmation of PXE is obtained with 
haematoxylin & eosin, Van Giesson and von Kossa stains. 
In some of these patients, part of the biopsy was processed for electron microscopy 
evaluation and/or immunohistochemical experiments. 
 
2/ a thorough macroscopic skin evaluation. To establish potential genotype-phenotype 
correlations, dermatological manifestations are scored as follows: S0: No typical skin 
lesions; S1: Yellow papules; S2: Plaques of coalesced papules; S3: Laxity and 
redundancy of skin.  
 
3/ measurement of best-corrected visual acuity, combined with dilated fundoscopy and 
fundus photography to evaluate the PXE retinopathy. The ocular manifestations are 
scored  as  following:  E0:  No  fundus  abnormalities;  E1:  Peau  d’orange;  E2:  Angioid 
streaks; E3: Subretinal neovascularisation with retinal haemorrhages; E4: Macular 
degeneration with scarring. 
 
4/ with respect to the cardiovascular history, information on intermittent claudication, 
vascular occlusion requiring surgery, angor pectoris or myocardial infarction is obtained. 
Physical exam specifically screens for presence of weak or absent pulses and 
hypertension. Echocardiography looks for the presence of mitral valve prolapse and mild 
or severe valvular regurgitation. Finally, Doppler examinations of the carotid and femoral 
arteries are performed. 
 
5/ an ultrasonographical examination, detailed below, to evaluate calcium precipitation 
in the abdominal organs (in particular liver, spleen and kidneys) and the testicles. 
 
6/ a blood sample of EDTA (for DNA extraction), serum (for routine liver and kidney 
tests, ionogram and ELISA tests) and/or citrate (for clotting factor analysis and ELISA 
tests).  
 
A nearly identical examination protocol, aside from the skin biopsy, is always proposed for family 
members in whom molecular analysis confirmed carriership of 1 ABCC6 mutation. 
 
The scores for skin and ocular manifestations were delineated from the Phenodex, a 
scoring system developed by PXE International ( see publication 2). Unfortunately, such a scoring 
method is always artificial, as multiple signs and symptoms within one category – skin, eyes or 
cardiovascular system – can occur at the same time in one patient. This is particularly true for the 
cardiovascular complications, which is the reason why I did not use such a scoring system for the 
cardiovascular history. Due to these shortcomings, the Phenodex has limited use as a descriptive 
tool for the PXE phenotype. However, it does provide sufficient simplification to perform statistical 
analysis for phenotype-genotype correlations.  
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2.2 Methods 
 
2.2.1  Clinical methods and techniques 
 
 Besides the clinical examination, as described above, the clinical techniques most 
frequently used in this thesis are ultrasonography, visual electrophysiological examinations and 
auto-fluorescence imaging of the fundus.  
 
 2.2.1.1 Ultrasonography 
 
 Ultrasound is the form of mechanical vibrations in which the vibration has a frequency in 
excess of that to which the human ear is sensitive (20-200.000 MHz). It is produced by a 
transducer made from a piezoelectric material, capable of both transmitting and receiving waves. 
The generated ultrasonic waves are reflected from naturally occurring bounderies between 
different tissues within the body, a fraction of the energy being reflected if there is impedance at 
such boundary. Energy that is not reflected travels onwards, with the depth to which it can 
penetrate being limited by the attenuation of the wave. 
 
 In an A-scan (or amplitude mode), the transducer is pulsed and the echoes received 
from each tissue interface are displayed as spikes on an oscilloscope screen. The distances 
between spikes are a measure of the separation debt of the reflecting tissues whereas spike 
heights indicate echo amplitudes. In a TM-scan (time and motion), the spikes are registered as 
moving dots in a line on the screen. Motions can be detected by software and correlated with the 
echoes, locating their origin and assembling the data to form a two-dimensional gray-scale image 
or B-scan. Doppler imaging, based on the Doppler principle by which a perceived shift in 
frequency occurs when a sound-producing object passes an observer, is used to measure the 
motion of blood or other fluids through a vessel.  
 
 2.2.1.2 Visual electrophysiology 
 
 Visual electrophysiology aims to objectively test the function of several components of 
the human visual system. Several tests are available, of which only full-field flash and pattern 
electroretinography (ERG) will be discussed briefly. All tests were performed in accordance with 
standards and/or guidelines suggested by the International Society for Clinical Electrophysiology 
of Vision (ISCEV) [296, 297]. 
 
  a/ neuroretinal anatomy 
 
 The neurosensory retina, evaluated by the techniques below, consists of three types of 
neurons: the photoreceptors, bipolar cells and ganglion cells (Figure 17).  
  
The photoreceptors are divided in two distinct classes, the rods and the cones. So 
named because of their different morphology, these cells, responsible for the translation of light 
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energy into an electrical signal, are also very different in the way they function. The rods are very 
sensitive to light and therefore responsible for night vision (scotopic). Cones require higher 
amounts of ambient light (photopic) to be activated and mediate high spatial resolution and colour 
vision.  
 
 Rods and cones synapse with the second order neuron in the retina, the bipolar cells, 
which form a relay with the retinal ganglion cells (or third order neurons). Via their axons, 
information is conveyed through the optic nerve to the occipital visual cortex. 
 
       
Figure 17 
Schematic representation of the neuroretinal anatomy 
 
b/ full-field flash ERG  
 
 The full-field flash ERG records a mass electrical response generated by both the neural 
and nonneural retinal cells of the whole retina, upon stimulation of the eye with a flash of light. It 
therefore provides an objective measure of retinal function without the need for too much 
cooperation by the patient.  
  
After the patient is dark-adapted for a minimum of 20 minutes, a whole field stimulator is 
applied to stimulate the whole retina through dilated pupils. As such, 5 different standard 
responses are generated: 
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1/ ERG to weak flash from the dark-adapted eye, elicited by the rod photoreceptors; 
2/ ERG to a strong flash from the dark-adapted eye, arising from the rod and cone 
photoreceptors; 
3/ Oscillatory potentials, arising from the inner retina. 
 
After ten minutes of light adaptation, the remaining two responses are generated: 
 
4/ ERG to a strong flash in the light-adapted eye, arising from the cone photoreceptors; 
5/ ERG to a rapidly repeating stimulus (30Hz), arising from the cones. 
 
 Gold foil electrodes, recording electrical activity of the retina, are placed onto the cornea. 
Final traces are usually averaged to minimize interference by artefacts. 
 
 The classic ERG trace has two distinct components, generated by different cell layers of 
the retina (Figure 18). An initial negative deflection is called the a-wave, which is followed by a 
positive b-wave. The a-wave is generated at least partially by the photoreceptors, the b-wave 
reflects activity of bipolar and Müller cells (supportive cells of the retina). Several characteristics 
which can be evaluated include the amplitude and latency of the a-wave and the amplitude and 
implicit time (from stimulus onset to peak) of the b-wave. Abnormalities in any of the former allow 
better characterisation of a clinical phenotype. The standard ERG protocol thus allows us to make 
a distinction between the response of the rods and that of the cones and between involvement of 
the outer retina (a-wave) versus that of the inner retina (b-wave). 
 
 
Figure 18 
Normal full-field flash electroretinographical trace. The waveforms are exemplary only, and are not intended to indicate 
minimum, maximum or even average values. Large arrowheads indicate the stimulus flash. Dotted arrows exemplify how 
to measure time-to-peak (t, implicit time), a-wave amplitude and b-wave amplitude. 
Adopted from Marmor et al. [297] 
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  c/ pattern ERG (PERG) 
 
 PERG is a retinal response elicited from the macular area of the retina, traditionally 
using a transient pattern reversal checkerboard stimulus. It is measured in photopic conditions 
with optimal refraction and undilated pupils. Electrode positions are similar to those for full-field 
ERG. A typical PERG response consists of an initial small component at 35 ms of stimulus onset 
(N35), a positive deflection at 50 ms from stimulus onset (P50) and a subsequent negative 
component at 95 ms (N95) (Figure 19).  
Whereas the full field ERG does not convey any information on the retinal ganglion cell 
layer, the PERG does so. Therefore, the combined use of full field ERG and pattern ERG 
explores the response of all retinal cell layers. 
  
 
Figure 19 
Normal pattern ERG trace 
Adopted from Marmor et al. [297] 
 
 2.2.1.3 Autofluorescence imaging 
 
 Besides white light digital photography, fundus imaging was performed using fundus 
autofluorescence (AF), red free and infrared monochromatic images. These novel techniques 
offer new ways of identifying various manifestations of retinal disease. Using a confocal scanning 
laser ophthalmoscope (cSLO), AF shows the distribution of lipofuscin in the RPE in vivo. This 
pigment accumulates in the RPE with aging as a result of incomplete photoreceptor degradation. 
Because of its suggested role in senescence, the detection of lipofuscin has been considered a 
noninvasive marker for monitoring the status of the RPE [298].   
 After pupillary dilatation with tropicamide 1%, autofluorescent images were recorded 
using argon blue laser light for excitation and a barrier filter with a cut off at 500 nm to record 
fundus autofluorescence and red free imaging. For near infrared imaging, wavelengths are 787 
nm for excitation and a barrier filter allowing light passage above 810 nm. Full-emission spectra 
are recorded via a polarization filter to obtain red-free and infrared images. Before acquisition of 
the autofluorescence sequence, illumination and focus level are adjusted to individual 
requirements at the infrared mode of the device, in order to generate high quality images.  
Infrared, autofluorescence and red free images, in series of approximately 50 single pictures per 
eye, are generated using a 30-degree field-overview mode. The images encompassed the entire 
macular area, retinal midperiphery and periphery. After automated alignment and averaging to 
improve signal to noise ratio by image analysis software (Heidelberg Eye Explorer, Heidelberg 
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engineering, Dossenheim, Germany) mean images are used for further analysis. Finally, HRA 2® 
software can be applied on selected individual and mean images of excellent quality to generate 
a seamless montage of the entire fundus in AF, RF and IR mode. 
 
2.2.2  Molecular methods and techniques 
 
 2.2.2.1 Amplification of DNA sequences 
 
 In order to analyse a DNA sequence of interest, molecular techniques require an amount 
of DNA that is usually not readily available from patients. To make a high number of copies of the 
sequence  of  interest  in  the  patient’s  DNA,  the polymerase chain reaction (PCR) was used. 
Routine PCR can amplify fragments sized up to 5 kb; because of the presence of ABCC6 
pseudogenes, larger fragments needed to be amplified to exclude these pseudogenes. To this 
end a long-range PCR method was used. A PCR or long-range PCR reaction consists of 30 to 40 
fully automated cycles of three basic steps (Figure 20):  
 
 1/ heating to melting temperature (95°) to obtain single-strand DNA; 
 
 2/ annealing of forward and reverse sequence-specific primers;  
 
3/ primer extension, using nucleotides and based on the sequence of the DNA template 
obtained after step 1. 
  
 A final elongation step after the last cycle at 72° ensures proper completion of the 
structure of all molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 
Schematic representation of the polymerase chain reaction 
 
 
 46 
 2.2.2.2 Mutation detection 
 
 To determine whether a mutation is present in a fragment of DNA, its sequence can be 
determined using sequencing. The sequencing technique is based on enzymatic single strand 
DNA synthesis with base-specific dideoxynucleotides, serving as chain terminators (Figure 21). 
 
 
Figure 21 
The principle of direct DNA sequencing. Single strand DNA is obtained and amplified using a PCR reaction (panel A). 
Panel B and C display the mixture of ss-DNA molecules, varying in length by one base and terminated with a fluorescent 
dideoxynucleotide. Panel D shows the output, an electropherogram, after passing through a scanning system. 
 
A single-stranded fragment of patient DNA acts as a template to form a mixture of single-
stranded DNA molecules, all varying in length by one base. Each molecule is terminated with one 
dideoxynucleotide with a base-specific fluorescent signal. The latter is picked up by a laser-based 
scanning system and is translated into a base sequence for the particular fragment. The graphical 
representation, obtained by the sequencing software, is called an electropherogram and depicts 
the two alleles of the gene of interest. As both are identical in physiological circumstances, the 
alleles are superimposed and only one peak is observed for every nucleotide. In case of a 
heterozygous mutation, a double peak can be observed while homozygous mutations give rise to 
a single peak of the incorrect nucleotide.   
 
 High throughput facilities have made direct sequencing more efficient and economic than 
before. At the beginning of this project, the technique was however still laborious and a less 
arduous screening procedure, denaturing high-performance liquid chromatography (dHPLC) 
was applied (Figure 22). During the last two years of this project, the technique has been 
abandoned in the advent of high throughput analysis techniques.   
 
 First, the DNA fragments under study are denatured and then reannealed with single-
stranded wild-type DNA fragments to form either homo- (when no sequence change is present) or 
heteroduplexes (in the presence of a sequence change). dHPLC is based on the differential 
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retention of these homo- and heteroduplexes in the liquid chromatography column. Variations in 
temperature and chemical composition of the elution buffer were standardised for each exon of a 
specific gene. The generated data are interpreted in a graphical way; samples displaying an 
altered curve compared to the wild type are further investigated through sequencing.  
 
 
Figure 22 
The dHPLC principle, based on the detection of heteroduplexes 
 
 One of the major challenges in mutation analysis is the substantiation of causality of a 
given base pair change. In the event of deletions, insertions, frameshifts or when a premature 
termination codon is introduced – when a nonsense mutation occurs – causality is easily 
assumed. For missense mutations, causality is often not straight forward and a series of criteria 
can be used to predict whether a change may be pathologic. These include conservation of the 
affected amino acid between different species (or orthologs) and/or between different members of 
the same protein family (or paralogs). Also a change in biochemical characteristics of the mutated 
amino acid can suggest causality. Next, several in silico analysis techniques are available to 
predict the pathologic nature of a sequence variation. Finally, if a base pair change is not found in 
200 control alleles, this increases chances of it being a causal mutation.  
 
2.2.3  Biochemical methods and techniques 
 
 For the detection of various antigens in tissues, serum or plasma, we applied 
immunohistochemical and Enzyme-Linked Immunosorbent Assays (ELISA) using antibodies 
provided by VitaK®, a spin-off of the University of Maastricht (The Netherlands). Both techniques 
are basically analogous, if not that they use test samples of different origin. The technical details 
of these experiments are explained in chapter 3; here, only the general principles of these 
techniques will be discussed.  
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  a/ general principles and terminology 
 
 The techniques described below are based on one of the basic concepts of immunology, 
namely the specific immune response or the production of an antibody to a particular antigen. 
 
 An antibody is a plasma molecule that binds specifically to particular proteins; in innate 
immunity these are able to bind and neutralize pathogens while in the immunological techniques 
described here they are used to capture, measure and/or visualize a protein of interest. For this 
reason, antibodies can be manufactured in vitro.  Monoclonal antibodies are produced by a 
single clone of cells, while polyclonal antibodies result from several clones, often from more than 
one species. 
 
 An antigen is a molecule that reacts with an antibody and named for their ability to 
generate antibodies. However, not all antigens – such as those described in this thesis – 
necessarily elicit such antibody production. 
 
  b/ immunohistochemistry 
 
 Immunohistochemistry is a method to detect a protein on tissue sections in which the 
antibody is chemically coupled to an enzyme that converts a colourless substrate into a colored 
reaction product whose deposition can be directly observed under a light microscope.  
 
  c/ enzyme-linked immunosorbent assays (ELISA) 
 
 For an antigen (e.g. a protein of interest) to be detected, a purified antibody specific for 
this antigen is linked to an enzyme. The samples (plasma or serum) to be tested are coated onto 
the surface of plastic wells to which they bind non-specifically. The labelled antibody is then 
added to these wells under conditions where non-specific binding is prevented, so that only 
binding to the targeted antigen causes the labelled antibody to be retained on the surface. 
Unbound labelled antibody is removed from all wells by washing, and bound antibody is detected 
by an enzyme-dependent colour-change reaction, using spectrometers.  
 
 This basic serological assay has been modified to measure directly the amount of antigen 
or antibody in a sample of unknown composition, by using competitive inhibition or sandwich 
assay (Figure 23). 
 
a/ with a competitive ELISA the presence and amount of a particular antigen in an 
unknown sample is determined by its ability to compete with a labelled reference antigen 
for binding to an antibody attached to a plastic well. By adding varying amounts of a 
known, unlabeled standard preparation, a standard curve is constructed and the assay 
can then measure the amount of antigen in unknown samples by comparison to the 
standard. This assay can also be used for measuring antibody in a sample of unknown 
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composition by attaching the appropriate antigen to the plate and measuring the ability of 
the test sample to inhibit the binding of a labelled specific antibody.  
 
b/ in a sandwich or capture ELISA, the antigen of interest in characterized by its ability 
to bridge between two monoclonal antibodies reacting with different epitopes (or site on 
an antigen recognized by an antibody) on the antigen. The first, unlabeled antibody is 
attached to the plastic well and then the test sample is added. After washing, bound 
antigen is detected by binding a second, labelled antibody directed at a different epitope. 
This assay is highly specific because antigens that cross-react with one antibody are very 
unlikely to cross-react with the other.  
 
 
Figure 23 
Sandwich ELISA versus competitive ELISA. The analyte is represented by the oval, while the antibodies marked by a star 
have fluorescent characteristics 
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Chapter 3 
Results                                                       o                                
      
“Une  accumulation  de  faits  n’est  pas  plus  une  science  qu’un 
tas de pierres n’est une maison” 
    
                      Henri Poincarré (La science et l’hypothèse) 
 
 As the attentive reader will perceive, papers are not always given here in their original 
order of publication. Rather than merely presenting a cumulative data set, it has been attempted 
to order the papers into three major topics – molecular studies, phenotypical papers and studies 
on the PXE-like disorder and its implications for the pathogenesis of PXE. In doing so, this 
chapter already attempts to integrate all data accumulated in the past four years, which will be 
further clarified in the discussion chapter.  
 
3.1 ABCC6 mutational spectrum and 
genotype-phenotype studies 
 
Publication 1  
Novel clinico-molecular insights in Pseudoxanthoma Elasticum 
provide an efficient molecular screening method and a 
comprehensive diagnostic flowchart. 
 
Olivier M. Vanakker, Bart P. Leroy, Paul Coucke, Petra Van Acker, Dirk Matthys, 
Bart Loeys, Anne De Paepe. 
 
Human Mutation 2008;29:205 
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In this paper, a comprehensive clinical and molecular study of 38 Belgian PXE probands 
and 21 relatives (4 affected and 17 carriers) is described. An extensive clinical evaluation 
protocol, described in chapter 2, was implemented and molecular analysis of the ABCC6 gene 
performed.  
The objective of this study was to itemize the clinical characteristics in both patients and 
carriers in a thorough and systematic way, with serial assessments over time and correlate them 
to the molecular data observed in this cohort. As such, this study has contributed to: 
 
a/ a more clear delineation of the “classic clinical features” of PXE;   
  
 b/ the recognition of stroke as a major complication in PXE patients; 
  
c/ formulating easy-to-use diagnostic flow-charts; 
  
d/ the expansion of the ABCC6 mutation spectrum; 
 
 e/ the unequivocal proof of the autosomal recessive inheritance of PXE; 
 
 f/ a more efficient screening method for the ABCC6 gene; 
 
 g/ the awareness of complex disease modifying mechanisms being present. 
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MUTATION IN BRIEF 
© 2007 WILEY-LISS, INC. 
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Novel Clinico-molecular Insights in Pseudoxanthoma 
Elasticum Provide an Efficient Molecular Screening 
Method and a Comprehensive Diagnostic Flowchart  
Olivier M. Vanakker1,8, Bart P. Leroy1,2, Paul Coucke1, Lionel G. Bercovitch3, Jouni Uitto4, 
Dennis Viljoen5, Sharon F. Terry6, Petra Van Acker1, Dirk Matthys7, Bart Loeys1, and  
Anne De Paepe1*
1 Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; 2 Department of Ophthalmology, Ghent 
University Hospital, Ghent, Belgium; 3Department of Dermatology, Brown Medical School, Providence, RI, USA; 
4Department of Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, Pennsylvania, 
USA; 5University of Witwatersrand, South Africa; 6PXE International, Washington, DC, USA; 7 Department of 
Paediatrics, Ghent University Hospital, Ghent, Belgium; 8 Research assistant for the Fund for Scientific Research 
Flanders (Belgium) 
*Correspondence to: Anne De Paepe, MD, PhD, Center for Medical Genetics, Ghent University Hospital, De 
Pintelaan 185, B-9000 Ghent (Belgium); Tel.: 0032 9 2403602; Fax: 0032 9 2404970; E-mail: 
anne.depaepe@ugent.be 
 
Communicated by Peter Byers 
Pseudoxanthoma elasticum (PXE) is a heritable connective tissue disorder characterized by 
ocular, cutaneous and cardiovascular manifestations. It is caused by mutations in the 
ABCC6 gene (chr. 16p13.1), encoding a transmembrane transporter protein, the substrate 
and biological function of which are currently unknown. A comprehensive clinical and 
molecular study of 38 Belgian PXE probands and 21 relatives (4 affected and 17 carriers) 
was performed. An extensive clinical evaluation protocol was implemented with serial 
fundus, skin and cardiovascular evaluation. We report on 14 novel mutations in the ABCC6 
gene. We observed extensive variability in severity of both cutaneous and ocular lesions. The 
type of skin lesion however usually remained identical throughout the evolution of the 
disorder, while ophthalmological progression was mainly due to functional decline. 
Peripheral artery disease (53%) and stroke (15%) were significantly more prevalent than in 
the general population (10-30% and 0.3-0.5% respectively). Interestingly, we also observed a 
relatively high incidence of subclinical peripheral artery disease (41%) in our carrier 
population. We highlight the significance of peripheral artery disease and stroke in PXE 
patients as well as the subclinical manifestations in carriers. Through follow-up data we 
gained insight into the natural history of PXE. We propose a cost- and time-efficient two-
step method of ABCC6 analysis which can be used in different populations. Additionally, we 
created a diagnostic flowchart and attempted to define the role of molecular analysis of 
ABCC6 in the work-up of a PXE patient.  © 2007 Wiley-Liss, Inc. 
KEY WORDS: pseudoxanthoma elasticum; ABCC6; natural history; diagnostic flowchart 
INTRODUCTION 
Pseudoxanthoma elasticum (PXE; MIM# 264800) is an autosomal recessive systemic disorder characterized by 
abnormalities of the skin (papular lesions and increased laxity in flexural areas), the ocular system (peau d’orange 
and/or angioid streaks with subretinal neovascularisation, haemorrhage and loss of central vision) and the 
DOI: 10.1002/humu.9514 
 
 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Vanakker et al. 
cardiovascular system (accelerated atherosclerosis) [Neldner, 1988; De Paepe et al., 1991; Hu et al., 2003]. Its 
prevalence is estimated to be 1:75000 [Hu et al., 2003].  
A clinical diagnosis of PXE is traditionally confirmed by demonstrating fragmentation and calcification of 
elastic fibres in a lesional skin biopsy, using appropriate staining methods. Although the elastolysis is 
characteristic, additional abnormal morphology or distribution of other extracellular matrix components (collagen, 
fibrillins, proteoglycans) is also observed [Lebwohl et al., 1993; Baccarani-Contri et al., 1994]. 
In 2000, ABCC6 (ATP-binding Cassette C6 - MIM# 603234) was identified as the defective gene in PXE 
[Bergen et al., 2000; Le Saux et al., 2001]. The gene sequence consists of 31 exons, spanning ~ 73 kb of DNA. 
ABCC6 encodes an ATP-dependent transmembrane transporter, the biological substrate of which is as yet 
unknown. Similarly, the relationship between aberrant ABCC6 activity and extracellular matrix changes in PXE 
remains to be elucidated. ABCC6 is mostly found at the basolateral cell membrane in liver and kidneys and to a 
lesser extent in the tissues affected by PXE [Scheffer et al., 2002]. Its cellular location suggests that ABCC6 
transports a substrate important for connective tissue homeostasis into the blood, suggesting that PXE may be 
considered a metabolic disease.  
To date, more than 150 mutations in ABCC6 have been reported [Bergen et al., 2000; Le Saux et al., 2000; 
Ringpfeil et al., 2000; Struk et al., 2000; Le Saux et al., 2001; Cai et al., 2001; Meloni et al., 2001; Ringpfeil et al., 
2001; Le Saux et al., 2002; Hu et al., 2003b; Chassaing et al., 2004; Gheduzzi et al., 2004; Noji et al., 2004; 
Chassaing et al., 2005; Hendig et al., 2005; Katona et al., 2005; Miksch et al., 2005; Schulz et al. 2005 ; Schulz et 
al. 2005; Schulz et al. 2006; Kiéc-Wilk et al., 2007]. Most mutations are located at the 3’ end of the gene between 
exons 24 and 30. Two distinct mutations occur more frequently than others. One is the nonsense mutation 
c.3421C>T (p.R1141X), which, in a homozygous state, leads to complete loss of ABCC6 function and is more 
frequent among the European population [Chassaing et al., 2005]. The second is a large deletion spanning exons 
23 through 29 and is more prevalent in the United States [Le Saux et al., 2001]. Presently, no clear genotype-
phenotype correlations have been established.  
Some authors have suggested that peripheral and coronary artery disease can be present in heterozygous carriers 
[Trip et al., 2002], although no skin and ocular characteristics have been described so far in such individuals [van 
Soest et al., 1997; Sherer et al., 2001; Trip et al., 2002; Hu et al., 2003; Wegman et al., 2005]. Hence, it remains 
unclear what the exact nature of (sub)clinical manifestations in carriers, let alone their clinical relevance might be.  
In this study we present extensive clinical and molecular data on 42 Belgian PXE patients (38 probands and 4 
affected siblings) and 17 carriers.   
PATIENTS AND METHODS 
Patient group 
Clinical evaluation and analysis of the ABCC6 gene was performed in a cohort of 38 clinically proven PXE 
probands, 4 affected siblings, as well as 17 carriers. In 37 probands, a clinical diagnosis of PXE patient was based 
on the presence of both of the following criteria: 
1) ophthalmological manifestations including at least retinal peau d’orange lesions and/or angioid streaks;   
2) skin involvement: macroscopic skin lesions including yellowish papules and/or plaques of the skin in the  
neck, and other flexural areas (armpits, elbows, knees) and/or microscopic skin lesions on full thickness skin  
biopsy independent of whether or not these were accompanied by macroscopically visible lesions. 
One additional proband (pat 30-001) was included based on the presence of angioid streaks, peau d’orange and 
subretinal neovascularisation with macular degeneration. In addition he suffered from cardiovascular disease 
(recurrent strokes, myocardial infarction). Family members were considered affected when one of the two previous 
criteria was present. 
The patient population consisted of 17 men and 25 women. Ages ranged from 18 to 81 years (average age of 52 
years). The carrier cohort consisted of 11 men and 6 women, with ages ranging from 16 to 76 years (average age of 
39 years). Informed consent was obtained from all patients and carriers and the study was approved by the Ethical 
Committee of the Ghent University Hospital.    
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Clinical evaluation protocol 
All patients were examined by at least one of the authors (OMV, BPL, ADP). Serial fundus, skin and 
cardiovascular evaluation allowed objective evaluation of progression of disease in 34 patients.  
Skin biopsies were taken either in lesional skin or at the back of the neck when no lesion was clinically 
apparent. Histological confirmation of PXE was obtained with haematoxylin & eosin, Van Giesson and von Kossa 
stains [Neldner, 1988]. In order to establish potential genotype-phenotype correlations, the dermatological 
manifestations of patients were scored as follows (adapted from [Gheduzzi et al., 2004]). For macroscopical 
lesions: S0: No typical skin lesions; S1: Yellow papules; S2: Plaques of coalesced papules; S3: Laxity and 
redundancy of skin.  
Best-corrected visual acuity measurements were combined with dilated fundoscopy and fundus photography to 
evaluate the retinopathy. The ocular manifestations were scored as following: E0: No abnormalities; E1: Peau 
d’orange; E2: Angioid streaks; E3: Subretinal neovascularisation with retinal haemorrhages; E4: Macular 
degeneration with scarring. 
With respect to the cardiovascular history, information on intermittent claudication (pain or weakness when 
walking that is relieved with rest) [Aronow, 2005], vascular occlusion requiring surgery, angor pectoris or 
myocardial infarction was obtained. Physical exam specifically screened for presence of weak or absent pulses and 
hypertension (defined as diastolic blood pressure ! 90 mmHg and/or systolic blood pressure ! 140 mmHg 
[O’Brien et al., 2005].  Echocardiography looked for the presence of mitral valve prolapse [Hayek et al., 2005], 
mild valvular regurgitation (grade I/II) or severe valvular regurgitation (grade III/IV) [Singh et al., 1999]. Finally, 
Doppler examinations of the carotid and femoral arteries were performed. 
Levels of serum calcium and phosphorus, kidney and liver tests and serum lipids (cholesterol [LDL – HDL], 
triglycerides) were also determined. 
Seventeen patients (4 male and 13 female) underwent ultrasonography of the abdomen and testicles. Also, a 
history of gastro-intestinal bleeding was documented.   
A similar protocol was used for the clinical evaluation of obligate carriers. In siblings of patients, molecular 
analysis was performed to identify carriers prior to a clinical re-evaluation.  
Molecular analysis 
Genomic DNA was isolated from whole blood (QIAamp blood kit, Qiagen®) according to an established 
procedure.  
The ABCC6 coding region was amplified using previously described PCR primers [Wang et al., 2001]. To 
obtain better amplification we changed the original primer sequence for exons 15, 25, 26 and 29. In order to 
distinguish between ABCC6 and its two pseudogenes, ABCC6-"1 and ABCC6-"2, a long-range PCR was 
performed of exons 1 through 10 [Pulkkinen et al., 2001]. Subsequently, PCR reactions for the separate exons were 
performed on the long-range amplicon. For the detection of the exon 23-29 deletion, primers described by Le Saux 
et al. were used [Le Saux et al., 2001].  
The coding region and intron/exon boundaries of ABCC6 were analysed with dHPLC (denaturing High 
Performance Liquid Chromatography) using the WAVE® System (Transgenomic® Inc., San Jose, United States) 
and subsequent direct sequencing of abnormal peaks using an Applied Biosystems 3100 Sequencer®, with ABI 
PRISM BigDye Terminator Cycle Sequencing Kit (Applied Biosystems®, Foster City, United States).  
All primers and dHPLC parameters are available upon request from the corresponding author. Unreported 
sequence variants were defined as causative using the criteria as reported by Cotton and Scriver, 1998. Nucleotide 
numbers are derived from cDNA ABCC6 sequences (GenBank accession no. NM_001171.2) For cDNA 
numbering +1 corresponds to the A of the ATG translation initiation codon. 
RESULTS  
Molecular data 
The ABCC6 gene was analysed in 38 PXE probands. Additionally, in 4 affected siblings of 3 different families, 
sequencing demonstrated the presence of the same mutations as those identified in the probands and as such 
confirms the autosomal recessive inheritance in PXE.   
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A total of 70 mutations were identified in 76 different disease alleles corresponding to a mutation detection rate 
of 92% (Table 1). Nine probands were homozygous (24%), twenty-three were compound heterozygous (60%) and 
in 6 patients only 1 mutation was identified. Of the 70 mutations, 36 were unique and included 3 nonsense 
mutations, 25 missense mutations, 6 deletions and 2 frame-shift mutations. Fourteen mutations were novel. All 
missense mutations altered amino acids that are highly conserved among orthologs (Mus musculus, Rattus 
norvegicus, Danio rerio and Fugu rubripes) and rather conserved in paralogs.  
Fifty-nine of the mutations (84%) were located in the 3’ half of the gene (exon 15 and beyond). Mutations were 
most frequently located in exons 24 (47%), mainly due to the p.R1141X mutation, 18 (8%), 28 (7%) and 29 (5%). 
Five new missense mutations were located in the functionally important first Nucleotide Binding Fold (NBF1) and 
five were located in exons coding for the second Nucleotide Binding Fold (NBF2). The nonsense mutation 
c.3421C>T (p.R1141X) in exon 24 was most frequently found (31/76 alleles or 41%), both in homozygous (52%) 
and compound heterozygous (43%) state. The Del23-29 mutation accounted for three out of seventy-six alleles 
(4%). 
 
Table 1. Genotype and Phenotype of 42 Belgian PXE Patients 
 
Patient 
 
S
e
x 
Age/Clinical score at  
initial presentation 
Age/Clinical score at  
most recent follow-up 
Mutations* 
Allele 1                                       Allele 2 
01-001 F 52 - S0, E2 65 – S0, E3, HT p.R1141X c.3421C>T p.R760Q c.2279G>A 
02-001 M 18 – S1, E2, VR-I 18 – S1, E2, VR-I p.R1141X c.3421C>T p.R1141X c.3421C>T 
03-001 F 59 – S1, E4 75 – S1, E4, HT, IC, VR-I p.R1141X c.3421C>T p.N793L c.2379C>G 
04-001 F 36 – S3, E2 36 – S3, E2 p.N466Y c.1396A>T p.R1339H c.4016G>A 
05-001 F 26 – S1, E4 43 – S3, E4, VR-I p.R1141X c.3421C>T p.T364M c.1091C>T 
06-001 F 36 – S2, E4 44 – S2, E4, P p.A1303P c.3907G>C None found - 
07-001 M 48 – S1, E2, HT 58 – S1, E4, HT p.R1141X c.3421C>T p.R1141X c.3421C>T 
08-001 F 26 – S1, E0 44 – S2, E2 p.R1141X c.3421C>T p.R760Q c.2279G>A 
09-001 M 49 – S0, E3, P, GIB 65 – S2, E4, P, HT, VR-I, GIB p.A1303P c.3907G>C None found - 
10-001 F 46 – S1, E2 63 – S3, E4, HT, AP,VR-I p.R1141X c.3421C>T p.R1141X c.3421C>T 
11-001 M 25 – S1, E2, GIB 37 – S1, E3, GIB p.R1141X c.3421C>T None found - 
12-001 F 52 – S1, E4, CI, HT, VR-I 52 – S1, E4, IC, HT, VR-I p.R1141X c.3421C>T p.R1141X c.3421C>T 
12-002 F 40 – S1, E2, HT, MVP, VR-I 40 – S1, E2, HT, MVP, VR-I  p.R1141X c.3421C>T p.R1141X c.3421C>T 
13-001 F 65 – S0, E2 80 – S0, E2, P, VR-I p.R1141X c.3421C>T p.R1141X c.3421C>T 
13-002 F 57 – S3, E4 73 – S3, E4, HT, CI, VR-I p.R1141X c.3421C>T p.R1141X c.3421C>T 
14-001 F 23 – S1, E2 27 – S1, E2 p.S398R c.1194C>G - c.3364delT 
15-001 F 27 – S1, E2 27 – S1, E2 p.R1138W c.3412C>T p.R1221H c.3662G>A 
16-001 M 51 – S2, E2 54 – S2, E2 p.R1141X c.3421C>T p.R1141X c.3421C>T 
17-001 M 42 – S1, E3, IC 58 – S1, E3, IC Del23-29 - p.R518Q c.1553G>A 
18-001 M 63 -  S1, E4 63 – S1, E4 p.E1400K c.4198G>A None found - 
19-001 F 34 – S2, E2 50 – S2, E2 p.A1303P c.3907G>C p.R1398X c.4192C>T 
20-001 F 52 – S2, E2, HT, IC, GIB 68 – S2, E4, HT, IC, GIB p.R1141X c.3421C>T None found - 
21-001 M 20 – S1, E2 26 – S1, E2 p.R1141X c.3421C>T p.R1141X c.3421C>T 
22-001 M 53 – S2, E2, IC, AP 69 – S2, E2, HT, IC, AP p.M751K c.2252T>A p.R1164Q c.3491G>A 
23-001 F 20 – S1, E2 27 – S1, E2, P, VR-I p.G666V c.1996G>T - c.1868-5T>G 
24-001 M 54 – S1, E2 57 – S1, E2 p.T500P c.1498A>C p.E521D c.1563G>C 
25-001 F 50 – S1, E3, HT, MI 57 – S2, E3, HT, MI p.R1141X c.3421C>T p.R1141X c.3421C>T 
26-001 M 52 – S2, E4, HT 68 – S2, E4, HT, CI p.M751K c.2252T>A Del23-29 - 
27-001 F 61 – S3, E4 68 – S3, E4, P, CI, AP p.R1141X c.3421C>T - c.4104delC 
Allele 2 
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28-001 F 31 – S1, E2 32 – S1, E2 - c.1674DelC p.R765W c.2293C>T 
Patient S
e
x 
Age/Clinical score at  
initial presentation 
Age/Clinical score at  
most recent follow-up 
Mutations* 
Allele 1                                 Allele 2 
29-001 M 30 – S1, E3 32 – S1, E3 p.E125K c.373G>A p.L1025P c.3074T>C 
30-001 M 65 – S0, E2, HT, CI, MI 66 – S0, E2, HT, CI, MI p.G1405S c.4213G>A None found - 
31-001 F 38 – S1, E4 39 – S1, E4 p.R1141X c.3421C>T Del23-29 - 
32-001 M 22 – S1, E2 36 – S1, E2 p.R1141X c.3421C>T p.R518Q c.1553G>A 
33-001 F 45 – S2, E3, P 61 – S2, E3, P, VR-II p.R1141X c.3421C>T p.R1141X c.3421C>T 
34-001 F 65 – S1, E4, HT 81 – S1, E4, HT, AP p.R1141X c.3421C>T p.T1301I c.3902C>T 
35-001 F 62 – S2, E2 78 – S2, E2, HT - c.175_179del p.G1354R c.4060G>C 
35-002 F 58 – S2, E2 74 – S2, E4 - c.175_179del p.G1354R c.4060G>C 
35-003 M 67 – S2, E2 79 – S2, E3, HT, VR-I - c.175_179del p.G1354R c.4060G>C 
36-001 M 53 – S1, E4 59 – S1, E4, HT, AP p.R1114H c.3341G>A p.Q1237X c.3709C>T 
37-001 M 18 – S3, E2 18 – S3, E2 p.Q981H c.2943G>T - c.3507-3C>A
38-001 F 27 – S1, E2 27 – S1, E2 p.G1263R c.3787G>A - c.4182delG 
Table 1 represents the sex of all patients (M = male; F= female) and the age (in years – italics), respectively at initial 
presentation and last follow-up. Patients are identified by a code: 01 = family number; 001 = subject number. The 
oculocutaneous phenotype is shown as a clinical score where S = cutaneous manifestations and E = ocular manifestations. 
Cardiovascular and gastrointestinal complications are abbreviated as: P = weak or absent pulsations; HT = hypertension; IC = 
intermittent claudication;  MVP = mitral valve prolapse; VR-I = mild valvular regurgitation; VR-II: severe valvular 
regurgitation; AP = angor pectoris; MI = myocardial infarction; GIB = gastro-intestinal bleeding. Mutations found in both 
alleles of ABCC6 are shown; novel mutations are marked in bold.  
* GenBank accession no. NM_001171.2. For cDNA numbering +1 corresponds to the A of the ATG translation initiation 
codon. 
 
 
Clinical characteristics of patients 
At initial presentation, typical PXE skin and mucosal lesions, such as yellowish papules, peau d’orange or a 
yellow reticular pattern of the inner lip mucosa (Fig. 1A and E), were observed in 90% of all patients (38/42). All 
patients but two (13-001; 30-001) had characteristic microscopic skin lesions on van Giesson and von Kossa stains. 
The dermatological manifestations are summarized in Table 2A. 
At initial presentation, all but one patient had angioid streaks (Fig. 1F). Fifty percent suffered from moderate 
(2/10-6/10) to severe (# 1/10) decrease in visual acuity. Detailed ophthalmologic findings, both at initial 
presentation and last consultation, are shown in Table 2B. 
An increased prevalence (15%) of neurovascular manifestations (ischaemic stroke) was found in our study 
population (Table 3). Cardiovascular examination further revealed a high prevalence of peripheral artery disease 
(PAD). Fifty-three percent of all patients (22/42 – average 53 years; range 26-75 years) had abnormal Doppler 
examinations (atherosclerotic plaques or stenosis), most frequently of the lower extremities. Of these, 41% (9/22) 
had a clinical history of intermittent claudication. Cardiac ultrasound only revealed haemodynamically 
insignificant valvulopathies (Table 3). Only one patient had a haemodynamically significant mitral valve prolapse 
(MVP).  
Abdominal ultrasounds revealed calcifications in kidneys, liver and/or spleen in 10 out of 17 examined patients 
and testicular microlithiasis in all four male patients examined [Vanakker et al., 2006]. Only three patients (7,5%) 
experienced gastro-intestinal bleeding. However, these were always recurrent (up to six events), requiring surgery 
in at least one patient (09-001).  
Plasma levels of calcium and phosphorus, kidney and liver tests revealed no significant abnormalities, 
irrespective of either age or presence of visceral calcifications. 
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Figure 1. Oculocutaneous characteristics of family 12. The elder patient (12-001; 52 yrs.) has mild skin lesions (A-B) 
with characteristic histological changes, a typical PXE retinopathy with angioid streaks, subretinal bleeding and 
macular degeneration (C) leading to severe decrease of central vision since age 18. Patient has complaints of 
intermittent claudication since age 16. Her sister (12-003; 40 yrs.) has typical coalesced plaques in flexural areas of 
body and mucosal lesions on inner lip (D-E), a fundus with uncomplicated angioid streaks (F) and normal visual 
acuity. Patient has no cardiovascular complaints. 
Natural history of PXE 
We studied the natural history of the ocular, cutaneous and cardiovascular symptoms in a subcohort of 34 
patients (ages ranged from 20 to 67 years - average age 45 years). Mean period of follow-up was 11 years (range 
1-20 years).  
Despite that most patients did subjectively note an enlargement of existing skin lesions, we observed 
progression of dermatological signs (evolving from papules to plaques or increased skin laxity) in only a limited 
number of patients (5/34 or 14.5%), usually starting in the fourth decade. In four of these, papular lesions 
coalesced into plaques (n=2) or evolved towards increased skin laxity (n=2). One patient without macroscopical 
skin lesions at age 49 developed plaques of coalesced papules at 65 years.  
From an ophthalmologic perspective, anatomical progression (angioid streaks evolving to neovascularisation, 
exudation and/or haemorrhage) occurred in 9 patients (26,5%), usually starting in the sixth decade or later. 
However, functional decline, observed as a decrease in visual acuity was noted in 41% of patients. The mean 
decrease observed was 5 lines (5/10). If present, visual loss was usually binocular, albeit often consecutive. In 6 
patients (17,5%), an evolution towards total loss of central vision (<1/20) ensued. Although this occurred most 
often in only one eye (5/6), the other eye was always severely affected (< 3/10), resulting in a considerable visual 
handicap.  
Cardiovascular complications, most frequently hypertension, were more prominent with aging, starting from the 
fifth decade of life (17/25 patients or 68%). Coronary artery disease was less frequently seen in this age group 
(7/25). From the sixth decade on, intermittent claudication also became more apparent (8/18 patients or 44%). 
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Table 2. Prevalence of the Cutaneous (A) and Ocular (B) Manifestations of PXE in This Study at Initial   
Presentation and at Last Consultation 
 Initial presentation Last consultation 
A. Dermatological manifestations n = 42 % n = 42 % 
No macroscopical skin lesions 4 9 3 7 
Typical or mild macroscopical skin lesions present 38 90 39 93 
     Papular peau d’orange 35 83 35 83 
     Yellow reticular rash 4 9 4 9 
     Plaques of coalescent papules 10 24 13 31 
     Laxity and redundancy of skin 4 9 6 14 
     Buccal mucous membrane involvement 8 19 8 19 
B. Ocular manifestations n = 42 % n = 42     % 
Visual acuity 
       7/10 – 10/10 
       2/10 – 6/10 
       1/10 or less 
 
21 
14 
7              
 
50 
33 
17 
                
18 
10 
14 
 
43 
24 
33           
Peau d’orange  27 64 27 64 
Angioid streaks 41 98 42 100 
Retinal haemorrhage 5 12 10 24 
Macular degeneration 11 26 16 35 
Comets with or without comet-like tails NA NA 7 16.5 
Table 2: NA: Not available. 
 
 
Table 3. Prevalence of the Cardiovascular Manifestations of PXE in This Study 
 
Cardiovascular manifestations    Patients 
n=42        % 
      Carriers 
 n=17         % 
GP 
% 
Cerebrovascular accident 6 15 2 12 0.3-0.5a
(A)symptomatic PAD (abnormal Doppler result)  
       Total 
       !55 yrs, $ 
       !55 yrs, % 
 
22 
4/10 
8/12 
 
53 
40 
66 
 
7 
5/6 
0 
 
41 
34 
0 
 
10-30b 
16.9c
20.5 
Hypertension 17 41 5 34 27d
Intermittent claudication 9 22 1 6 1-4.6e
Angina pectoris 5 12 1 6  
Myocardial infarction  2 5 1 6  
Mitral valve prolapse 1 2.5 0 0  
Mitral valve insufficiency 
       Grade 1 – 2 
       Grade 3 – 4 
 
11 
1 
 
26 
2.5 
 
8 
1 
 
47 
6 
 
90f 
 
Tricuspid valve insufficiency 16 38 0 0 17f
Pulmonary valve insufficiency 5 12 0 0 5g
Gastro-intestinal haemorrhages 3 7 0 0  
Table 3: GP = general population; a = [Sudlow et al., 1997]; b = [ Criqui, 2001]; c = [Meijer et al., 1998]; d =   
[O’Brien et al., 2005]; e = [Aronow, 2005] ; f = [Singh et al., 1999] ; g = [Choong et al., 1989].  
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Clinical characteristics of carriers 
In the carrier population (n=17) neither macroscopic skin lesions nor fundus peau d’orange or angioid streaks 
were observed. In two carriers, comets with comet tails were observed. Most carriers (16/17) presented no 
significant valvular dysfunction (Table 3).  However, seven male individuals (average age 57 years) had peripheral 
atherosclerosis on Doppler examination, two of whom were symptomatic: one suffered from intermittent 
claudication at age 29 and one needed a carotid artery endarterectomy (age 56). The prevalence of (a)symptomatic 
PAD in European males older than 55 years is estimated to be 16.9% [Meijer et al. 1998]. Of the 6 carriers 
fulfilling these criteria, 5 suffered PAD (83%). Visceral calcifications were identified by abdominal ultrasound in 3 
of the carriers, while 2 carrier males were found to have focal calcifications of the testicular capsule [Vanakker et 
al., 2006]. Blood tests showed no significant alterations.  
Genotype-phenotype correlations 
Table 1 summarizes the clinical manifestations of patients as a clinical score. No significant genotype-
phenotype correlations emerged from this study. Especially in patients homozygous for the p.R1141X mutation – 
previously associated with a more severe phenotype [Hu et al., 2003]–, no significant difference with patients with 
either one or no nonsense mutation was observed.  
 
DISCUSSION 
Fourteen novel ABCC6 mutations were identified in this study, bringing the total number of reported mutations 
at 165 [Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil et al., 2000; Struk et al., 2000; Le Saux et al., 2001; Cai 
et al., 2001; Meloni et al., 2001; Ringpfeil et al., 2001; Le Saux et al., 2002; Hu et al., 2003b; Chassaing et al., 
2004; Gheduzzi et al., 2004; Noji et al., 2004; Chassaing et al., 2005; Hendig et al., 2005; Katona et al., 2005; 
Miksch et al., 2005; Schulz et al. 2005 ; Schulz et al. 2005; Schulz et al. 2006; Kiéc-Wilk et al., 2007]. Exons 18, 
24, 28 and 29 harbour about seventy percent of all mutations, which confirms findings of previous studies that 
most mutations occur either inside or downstream of exon 18. Based on these finding we propose a two-step 
molecular screening procedure. An initial analysis can be limited to the latter four exons (including p.R1141X) and 
the Del23-29 with a direct sequencing based approach. In the Belgian population, this approach would allow to 
detect more than 70 % of all PXE mutations. Subsequently, samples with no or only one mutation can be screened 
for all other exons starting at the 3’ side, using direct sequencing. In our population this second step was only 
necessary in 50% of the PXE patients. In a minority of patients, analysis of the ABCC6 promotor and scanning for 
deletions can be relevant. Such a screening strategy could be applied in other populations, provided it is adapted to 
the mutational spectrum of that particular population.  
A large inter- and intrafamilial variability in clinical severity was noted. In some, the cutaneous manifestations 
were very mild or even completely absent. Others (7/40) were severely affected with increased skin laxity and 
redundant skin folds. A nice example of intrafamilial variability is shown in Figure 1. Our observations suggest 
that the type of skin lesion usually remains identical throughout the evolution of the disorder. In a minority of PXE 
patients, skin lesions evolve towards large coalesced plaques of papules and/or moderate to severe laxity of the 
skin. Especially the latter can cause considerable esthetical and psychological problems. On the other hand, three 
patients (7%) had no apparent macroscopic skin lesions.  As such, a negative skin inspection can not exclude the 
diagnosis of PXE.   
The presence of angioid streaks in all patients in this study is not surprising, since ours is a somewhat older 
population. In our experience all PXE patients develop angioid streaks in their second or third decade. Therefore 
we feel that at the age of 30 years, angioid streaks are mandatory to make a diagnosis of PXE. In younger 
individuals, streaks are often preceded by peau d’orange which should suffice as an ophthalmologic sign [Neldner 
and Struk, 2002; Hu et al., 2003]. The fact that only 64% of our patients had peau d’orange fundus lesions is also 
related to the high average age of our study population, since peau d’orange regresses with age [Neldner and Struk, 
2002]. Comets and comet tails have been described as a pathognomonic and early sign of PXE [Gass, 2003; 
Wegman et al., 2005]. We found these white, punched-out fundus lesions in some of the patients (7/42) but, more 
surprisingly, also in carriers (2/17). Given the presence of disseminated foci of visceral and testicular 
hypercalcification of both patients and carriers [Vanakker et al., 2006], the comets and comet tails may equally 
represent areas of hypercalcification of the Bruch membrane and chorioretina. This hypothesis is indirectly 
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substantiated by the concurrent presence of abdominal and/or testicular calcifications in 5 out of 6 patients and 1 
out of 2 carriers who underwent extensive systemic ultrasound evaluation, and presented with comets and/or comet 
tails in the fundus.  
Cerebrovascular manifestations were remarkable in that there was a considerably higher prevalence of 
ischaemic stroke in our patient cohort (6/42 or 15%) than in the general population (0.3-0.5%) [Sudlow and 
Warlop, 1997]. Our observations confirm the association between PXE and stroke described in several case reports 
[McKusick, 1966; Neldner, 1988; Schievink et al., 1994; van den Berg et al., 2000]. It usually does not occur until 
the fifth or sixth decade in PXE [Pieczuro et al., 1981; Schievink et al., 1994].  
Further cardiovascular work-up revealed an increased incidence of PAD on Doppler examination. However, 
59% of these were completely asymptomatic. In the latter, subclinical atherosclerotic plaques were mostly detected 
in the femoral arteries. This suggests that in PXE patients, Doppler evaluation of the vessels in the lower 
extremities may be equally important as that of the carotid arteries.  Identification of a significant MVP in only one 
patient in this study reflects the overdiagnosis of prolapse before revision of valvular anatomy and diagnostic 
criteria in the late 1980s [Hayek et al., 2005]. Although often severe and recurrent, gastro-intestinal haemorrhages 
only occurred in 3 patients, which suggests that this is a less frequent complication than reported previously 
[Neldner, 1988]. However, since gastro-intestinal haemorrhaging is a serious complication, secondary prevention 
after stroke with anti-platelet drugs poses a therapeutic dilemma [Aessopos et al., 1997].  
Some of the findings in carriers were also unusual (Table 3). The increased incidence of (a)symptomatic PAD, 
suggests that heterozygosity for an ABCC6 mutation may be a risk factor for common diseases such as 
atherosclerosis or hypertension. The presence of small calcifications in the abdominal organs and testicles, as well 
as comets and comet tails in fundo subscribes to the hypothesis of subclinical manifestations in carriers. They are 
however, most probably of little clinical significance.  
In light of the current clinical and molecular knowledge, we have attempted to develop a diagnostic flowchart, 
defining the role of skin biopsy and molecular analysis within a diagnostic work-up of a patient thought to suffer 
from PXE (Fig. 2). Our initial inclusion criteria (typical ophthalmological and skin manifestations, a positive skin 
biopsy) were very strict and derived from the criteria of Lebwohl et al., 1994. In clinic, patients either present first 
with cutaneous or with ocular manifestations. Of these, cutaneous changes are most often the first sign noticed by 
either patient or physician. Indeed, visual complaints only occur later during the course of the disease, as a 
complication of subretinal neovascularisation. In order to make a clinical diagnosis of PXE the combination of 
dermatological inspection and fundoscopy remains essential.  
The clinical diagnosis is certain when both skin (papular lesions, plaques) and fundus findings (peau d’orange, 
angioid streaks) are typical of PXE, provided that the phenocopy associated with haemoglobinopathies has been 
excluded in Mediterranean and African countries [Aessopos et al., 1997].  In these cases, ABCC6 analysis may 
confirm the clinical diagnosis, which may obliviate the need for an initial skin biopsy.  
ABCC6 analysis can also be useful when either the skin or fundus lesions are the only clinical findings. Even in 
absence of a positive family history, PXE remains the most probable diagnosis in cases where typical skin or 
fundus manifestations are present, making the use of molecular testing an efficient alternative for skin biopsy or an 
added value for screening the family. A skin biopsy remains essential in cases where clinical evidence for PXE is 
very limited (normal fundus and very mild papules).  
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Figure 2. Diagnostic flowchart for Pseudoxanthoma elasticum. AS = angioid streaks; Pd’O= peau d’orange; C(T) = comets or 
comet tails; FH = family history; typical skin lesions = yellowish papules, peau d’orange, yellow reticular pattern of lip; mild 
skin lesions = papular or reticular pattern suggestive of PXE. “ABCC6” = molecular analysis of the ABCC6 gene. Based on the 
clinical findings during skin and fundus evaluation, a diagnosis of PXE can either be definite or probable. A positive family 
history can in some cases add to degree of certainty of diagnosis. When having definitive clinical diagnosis of PXE, ABCC6 
analysis is sufficient for confirmation. 
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 This study arose from an international joint effort of PXE International – the US patient 
advocacy group – together with the Ghent group and the South African PXE group. It aimed to 
evaluate the efficacy of molecular analysis of the ABCC6 gene and genotype-phenotype 
correlations in a large –so far the largest – case series of PXE patients.  
 ABCC6 was analysed using dHPLC and direct sequencing in 270 patients (239 
probands, 31 affected family members), of which clinical data was obtained using a detailed 
questionnaire.  
 Not only does this study contribute to the description and expansion of the ABCC6 
mutation spectrum with 39 novel mutations, but – due to its magnitude – unambiguously 
demonstrates that no distinct clinical correlate can be delineated from the patients’ mutations. It 
emphasizes that phenotypic variability in PXE must be due to other mechanisms besides ABCC6 
mutation characteristics (type, location or functional effect), such as modifier genes or epigenetic 
modifications. 
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Background: Pseudoxanthoma elasticum (PXE), an autosomal recessive disorder with considerable
phenotypic variability, mainly affects the eyes, skin and cardiovascular system, characterised by dystrophic
mineralization of connective tissues. It is caused by mutations in the ABCC6 (ATP binding cassette family C
member 6) gene, which encodes MRP6 (multidrug resistance-associated protein 6).
Objective: To investigate the mutation spectrum of ABCC6 and possible genotype–phenotype correlations.
Methods: Mutation data were collected on an international case series of 270 patients with PXE (239
probands, 31 affected family members). A denaturing high-performance liquid chromatography-based
assay was developed to screen for mutations in all 31 exons, eliminating pseudogene coamplification. In 134
patients with a known phenotype and both mutations identified, genotype–phenotype correlations were
assessed.
Results: In total, 316 mutant alleles in ABCC6, including 39 novel mutations, were identified in 239
probands. Mutations were found to cluster in exons 24 and 28, corresponding to the second nucleotide-
binding fold and the last intracellular domain of the protein. Together with the recurrent R1141X and del23–
29 mutations, these mutations accounted for 71.5% of the total individual mutations identified. Genotype–
phenotype analysis failed to reveal a significant correlation between the types of mutations identified or their
predicted effect on the expression of the protein and the age of onset and severity of the disease.
Conclusions: This study emphasises the principal role of ABCC6 mutations in the pathogenesis of PXE, but the
reasons for phenotypic variability remain to be explored.
P
seudoxanthoma elasticum (PXE) is an inherited disorder
in which mutations in the ABCC6 (ATP-binding cassette
family C member 6) gene lead to dystrophic mineralization
and fragmentation of connective tissues.1–4 Multiple organs are
affected, including the skin, eyes and cardiovascular system,
and the pathogenic changes include lax and inelastic skin,
angioid streaks in the retina and mineralization of the internal
elastic lamina of midsized arteries, including the cerebral,
coronary, gastrointestinal and peripheral vasculature. Onset is
often in late childhood or adolescence, when yellowish
cutaneous papules may be noted, most commonly on the neck,
axillae and antecubital fossae. However, in many cases angioid
streaks in the ocular fundus are the initial physical finding,
which correspond to breaks in the elastin-rich Bruch’s
membrane of the choroid. As the disease progresses, fragile
new vessels may grow through the angioid streaks and
hemorrhage, leading to central vision loss. The cardiovascular
system may also be affected, leading to hypertension, inter-
mittent claudication, gastrointestinal bleeding, ministrokes and
rarely, myocardial infarction. Early identification of the disease
and increased surveillance for its sequelae might improve the
quality and length of life of those affected. Not only would early
detection of mutations in the ABCC6 gene in at-risk people
facilitate diagnosis, but elucidation of possible genotype–
phenotype correlations might enable the prediction of disease
severity and development of early intervention strategies.
Inheritance of PXE is autosomal recessive; although a few
families have been reported in which two generations are
affected, pathogenetic mutations in both ABCC6 alleles of
affected people were present indicating pseudodominance.2 5 6
Mineralization and fragmentation of elastic fibers, the
hallmark of PXE, results from altered function of multidrug
resistance-associated protein 6 (MRP6), the gene product
encoded by ABCC6. The ABCC6 gene is located at chromosome
16p13.17 8 along with two closely related but nonfunctional 59
pseudogenes, ABCC6-Y1 and ABCC6-Y2, corresponding to
exons 1–9 and 1–4, respectively.9 The close sequence similarity
of the two pseudogenes to the actual coding gene complicates
mutation detection and sequencing, although coding gene-
specific primer sets can be designed for each exon without
interference from the pseudogene sequences.9 The ABCC6 gene
is encoded in 31 exons spanning approximately 75 kb of the
human genome and is transcribed into an mRNA of,5 kb and
translated into a 165 kDa protein of 1503 amino acids.7 It is
expressed primarily in the liver and functions as a putative
efflux transporter of currently unknown substrate specificity,
although recent studies have shown that it can function as a
transmembrane transporter of polyanionic, glutathione con-
jugated molecules in vitro.10–13 In addition to high levels of
ABCC6 expression in the liver, clearly measurable levels of
Abbreviations: ABCC6, ATP-binding cassette family C member 6; dHPLC,
denaturing high-performance liquid chromatography; IC, intracellular
domain; MRP6, multidrug resistance-associated protein 6; NBF, nucleotide-
binding fold; PTC, premature termination codon; PXE, pseudoxanthoma
elasticum; TM, transmembrane domain
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expression are detected in the proximal tubules of kidneys, and
lower, barely detectable levels are found in the skin, retina and
blood vessels, tissues most severely affected by PXE.14–16
MRP6 has three hydrophobic membrane-spanning domains
containing a total of 17 transmembrane helices and two
intracellular nucleotide-binding folds (NBFs), comprising 3
highly conserved Walker motifs, and is critical for the putative
function of the protein in transmembrane transport driven by
the energy from ATP hydrolysis. To date, .150 distinct
mutations in the ABCC6 gene have been described in the
literature including missense and nonsense mutations in 27 of
the 31 exons and deletions spanning the entire coding
region.2 15 17–38 Clustering of missense mutations to exons
corresponding to the nucleotide-binding folds and a few
intracellular segments connecting two transmembrane
domains have been noted. Two recurrent mutations, R1141X
and a large deletion of exons 23–29 (del23–29,
p.A999_S1403del) have been described in a significant propor-
tion of patients, leading to a mutation-detection strategy that
first identifies the recurrent mutations by restriction-enzyme
digestion, followed by sequencing of the remaining exons.39
In this study, we collected genotype data on 270 patients
with PXE from 239 families and were able to characterise the
phenotype in 198 of these patients to improve diagnosis,
identify genotype–phenotype associations and facilitate genetic
counselling of people at risk for PXE.
METHODS
Informed consent was obtained from all patients and the study
was approved by the institutional review board of Good
Samaritan Medical Center, Brockton, Massachusetts and the
Genetic Alliance BioBank Institutional Review Board.
Donors and samples
Blood samples were collected from 270 patients with PXE (239
probands and 31 affected family members) from the USA,
Canada, Europe, Australia and South Africa. None of these
families was previously used in other mutation analysis
datasets. A detailed questionnaire was used, covering demo-
graphic information, family history, and dermatological,
ophthalmological, gastrointestinal, cardiac, vascular, neurolo-
gical, orthopaedic, gynaecological and nutritional histories and
physical findings, which was used to ascertain the phenotype of
the patients for genotype–phenotype correlations. The pheno-
typic characteristics were summarised according to organ
system and severity (Phenodex PXE International; see
table 1). In all index cases, the diagnosis of PXE was made
according to the consensus criteria of Lebwohl et al3 and
confirmed by skin biopsy specimens stained with H&E and/or
von Kossa stain. People with a positive family history (ie
confirmed PXE in a first-degree relative and either eye or skin
signs), were also considered to be affected.
Mutation detection
Genomic DNA was isolated from peripheral blood samples
(Puregene DNA Isolation Kit; Gentra Systems, Minneapolis,
Minnesota, USA). Control genomic DNA was obtained from the
human lymphoblastoid cell line K562 (American Type Culture
Collection, Manassas, Virginia, USA). All DNA samples were
adjusted with water to a concentration of 10 ng/mL.
Our mutation-detection strategy was based on: (1) identifi-
cation of the recurrent mutations R1141X and del23–29 by
restriction-enzyme digestion; (2) optimised denaturing high-
performance liquid chromatography (dHPLC) scanning of PCR
products corresponding to all exons in subjects in whom the
two recurrent mutations were not identified on both alleles,
followed by (3) sequencing of exons with altered dHPLC
patterns; and (4) confirmation of novel mutations by restric-
tion-enzyme digestion or resequencing.
Screening for the recurrent mutations R1141X and del23–29
was performed as previously described.30 31 Conditions and
primers for generating PCR products spanning all exons of the
coding regions and flanking intronic sequences of the ABCC6
gene were identified for optimum dHPLC screening (supple-
mentary table 1; available at http://jmg.bmj.com/supplemental).
These primers were designed to exclude the pseudogenes
homologous to exons 1–4 and 1–931 and to anneal within ,50
bases of the 59 and 39 ends of the exon and to exclude known
intronic polymorphisms where possible. In many cases, the
primers originally designed for exons 10–31 were not suitable for
sequencing, and new primers corresponding to sequences
situated .50 bases from the intron–exon boundaries were
designed to improve sequencing results. PCR for dHPLC analysis
was performed using 1.5 U Taq polymerase (Qiagen Inc.,
Valencia, California, USA) mixed with 5 U Optimase Taq
polymerase (Transgenomic, Gaithersburg, Maryland, USA) and
Q buffer (Qiagen), according to the manufacturer’ instructions.
PCR reactions contained 200 ng DNA as template and 20 ng of
each primer in a final volume of 50 ml. Cycling conditions for all
primer pairs were 94˚ C for 5 min, followed by 41 cycles of 94˚ C
for 1 min, annealing temperature for a particular primer pair
(range 55–60˚ C) for 1 min and 72 C˚ for 1 min, with a final step at
72˚ C for 5 min.
The PCR products generated using patients with PXE DNA as
template were allowed to form heteroduplexes with an equal
volume of a PCR product of the same exon amplified from
template DNA of the lymphoblastoid control cell line K562. For
this purpose, the PCR products were mixed in a 1:1 ratio and
denatured at 94 C˚ for 10 min, followed by reannealing at 65 C˚
for 15 min and 37 C˚ for 15 min. The PCR products were
screened by dHPLC (WAVE; Transgenomic, Gaithersburg,
Maryland, USA) using methods designed to enhance partial
denaturation of the PCR products containing mismatched bases
(supplementary table 1; available at http://jmg.bmj.com/supple-
mental). PCR products showing pattern shifts were sequenced
in both directions in most cases. DNA sequencing was
performed on an automated sequencer (ABI Prism 377 or ABI
Table 1 Phenodex assignment of patients with PXE to
different phenotypic categories based on clinical findings in
five organ systems
System Findings
Skin
S0 No sign
S1 Papules/bumps
S2 Plaques of coalesced papules
S3 Lax and redundant skin
Eye
E0 No sign
E1 Peau d’orange
E2 Angioid streaks
E3 Bleeding and/or scarring
GI
G0 No sign
G1 GI bleeding as related to PXE
Vascular
V0 No sign
V1 Weak or absent pulses
V2 Intermittent claudication
V3 Vascular surgery
Cardiac
C0 No sign
C1 Chest pain/angina/abnormal ECG or abnormal stress
test with no symptoms
C2 Heart attack
ECG, electrocardiogram; GI, gastrointestinal.
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3100; Perkin-Elmer-Cetus, Foster City, California, USA).
Putative mutations were confirmed by restriction-enzyme
digestion followed by agarose-gel electrophoresis or by rese-
quencing of a new PCR product when a suitable restriction
enzyme was not available. Novel amino acid substitution
mutations that affected conserved residues and were not found
in 200 control alleles were considered causal.40
Genotype–phenotype correlation analyses
Only patients who filled out the complete clinical questionnaire
and in whom the mutations in both alleles had been
characterised were included in the genotype–phenotype corre-
lation analysis. Of an original cohort of 270 patients, 134
fulfilled both these criteria. These were 94% Caucasian (all of
European descent: 80% USA, 8% Canada, 7% South Africa, 2%
UK, 2% Australia, 1% other European countries), 4% Native
Americans, 1% Hispanic, 0.5% African American and 0.5%
Pacific Islander. Medical records for .10% of the respondents
were compared with the questionnaire responses to determine
whether the results were representative. Two epidemiologists
(SH, MM) analysed the data, using SASH version 9.1 (Cary,
NC).
For the purposes of the genotype–phenotype correlation
study, the symptoms and signs were scored as presented in
table 1. The data gathered indicated that PXE primarily affected
five main clinical areas: skin (S), eyes (E), gastrointestinal
system (G), heart (C) and vasculature (V). The data also
indicated that for each of these areas there were between two
and four grades of severity.
The genotype–phenotype analysis consisted of two parts.
First, subjects were grouped by the probable effect of their
mutation on protein function: (1) no functional protein,
including premature termination codon causing mutations
and out-of-frame insertions and deletions; (2) some functional
protein, such as in-frame deletions or insertions and missense
mutations; and (3) those where it was not possible to predict
whether functional protein would be made, such as splicing
mutations.
In the second part of the analysis, subjects with PXE were
grouped according to the location of their mutations along the
putative MRP6 protein (ie, intracellular domains, transmem-
brane domains, or other).
For each approach, groups were compared using the Fisher
exact test.
RESULTS
Mutation detection
Mutation detection was performed on 270 samples from 239
families. The mean (SD) age of the patients was 45 (15.9) years
( range 3–81) and 72% were female (n=173). Of the 239 index
cases, 31 (31/240, 12.9%) had no identifiable mutations.
Collectively, 316 mutant alleles were identified, yielding an
overall detection rate of 66% (316/478) (all mutations and
combinations are listed in supplementary table 2; available at
http://jmg.bmj.com/supplemental).
In total, 82 distinct mutations were identified in this case
series (table 2). The two most common mutations were R1141X
(29.3%, 92/316) and del23–29 (18%, 57/316). In all, 23 subjects
(9.6%) were homozygous for either the R1141X (n=11) or
del23–29 (n=2) or compound heterozygous (n=10) for these
two mutations. All other mutations were found in ,10 subjects
(table 2). A total of 51 mutations occurred only once. Two
subjects carried three mutations, with two PXE mutations on
one allele, although haplotype phase could not be determined
because of lack of parental samples. No mutations were
identified in 161 alleles and there was an insufficient quantity
of one patient’s DNA for complete genotyping.
Further dHPLC screening of the ABCC6 gene resulted in the
identification of recurrent but less common mutations. Of
these, R1339C, R1164X and 2787+1gRc represented 5.0%, 4.7%
and 2.8%, respectively, of the 316 alleles identified. R1339C was
common in the South African Afrikaner population (15 of 40
alleles, 37.5%) and rare in the European/American case series
(1/238 alleles). The high incidence of R1339C in the South
African population is probably due to a founder effect.26
Conversely, R1164X (0/40 alleles) and 2787+1gRc (0 of 40
alleles) were absent in the South African case series but were
prevalent in the European and American patient populations.
Novel mutations
In all, 38 novel, previously unreported mutations were
identified in 61 patients in this study (table 2, figs 1 and 2).
Most were missense mutations (23 of 39), but there were also
four splicing mutations, four insertions, three deletions and five
nonsense mutations that had not been previously reported.
Prevalence of mutations by exon
Assignment of all of the mutations in this multi-national case
series by exon showed that most point mutations occurred in
exons 24 (133/316, 42%) and 28 (36/316, 11%) with a smaller
number in exons 9 (14/316, 4.4%) and 18 (10/316, 3%) of the
ABCC6 gene (table 2, fig 1). Collectively, the mutations in exons
24 and 28, including the common mutations R1141X and del
23–29, accounted for 71.5% of all the 316 mutations identified
in this study (table 2), and the 11 most prevalent mutations
(R1141X, del23–29, R1339C, R1164X, 2787+1GRT, G1302R,
R1138Q, R1138W, Q378X, R1314W, R518Q) accounted for 70%
(223 of 316) of the mutant alleles identified (table 2).
Missense mutations cluster in certain domains
Of the 82 distinct mutations detected in this study, 48 (48/82,
58.5%) were missense mutations and were found to cluster in
certain domains of the MRP6 protein (table 2, fig 2). The NBFs
were found to harbour a large proportion of missense
mutations (NBF1 10/49, 20.4%, NBF2 10/49, 20.4%), apparently
reflecting the biological importance of these regions in the
binding and hydrolysis of ATP and their critical role in the
function of the MRP6 protein. Similarly, other cytoplasmic,
intracellular domains (IC) were found to harbour a relatively
large proportion of missense mutations (19/49, 38.7%) but
these clustered in a number of domains, with the majority
found in IC8 (7/49, 14.2%), again reflecting the potential
importance of this domain in terms of the function of the
protein. Notably, certain transmembrane domains (TM) were
completely devoid of missense mutations (TM 3–5, 8, 14–17).
Phenotyping of index cases
Of the 197 patients with full phenotypic data, the character-
istics were distributed as follows: 193 people (98%) had some
skin signs, 176 (89%) had eye signs, 136 (69%) had vascular
signs or symptoms, 50 (25%) had cardiac signs or symptoms
and 16 (8%) had gastrointestinal signs (supplementary table 2;
available at http://jmg.bmj.com/supplemental). To examine
these distributions by age, these patients were categorised into
three age categories: (1) ,40, (2) 40–54 and (3) .55 years. The
mean skin score was 2.2 in all three age categories, the mean
scores for eye, vascular and cardiac symptoms increased with
age, and the mean gastrointestinal score was nearly 0 in those
aged ,40 and was 0.1 in the other two age categories.
Genotype–phenotype correlations
The comparison of subjects whose mutations would probably
have resulted in no functional protein with those whose
mutations would probably have resulted in some functional
ABCC6 mutations in pseudoxanthoma elasticum 623
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Table 2 Distinct mutations identified in the international case series of 271 patients with PXE
Nucleotide change*! Predicted consequence!
Frequency
(alleles)
Exon–intron
location
Domain
affected`
Mutant
alleles (%) References1
c.105delA p.S37fsX80 2 2 0.6 28
c.177–185del9 p.R60_Y62del 1 2 0.3 9, 28
c.179del12ins3 p. R60_W64del L60_R61ins 1 2 0.3
c.220-1gRc SJ 1 IVS 2 0.3
c.724gRt p.E242X 1 7 0.3
c.938insT FS 1 8 0.3 25
c.998+2delT SJ 1 IVS 8 0.3 2, 21
c.998+2del2 SJ 1 IVS 8 0.3 18
c.951cRg p.S317R 2 9 TM6 0.6 28
c.1087cRt p.Q363X 1 9 0.3
c.1091gRa p.T364R 1 9 TM7 0.3 9, 19, 21, 28
c.1132cRt p.Q378X 4 9 1.2 9, 17–19, 28, 37
c.1144cRt p.R382W 2 9 IC4 0.6
c.1171aRg p.R391G 3 9 IC4 0.9 9, 18, 28, 37
c.1176gRc p.K392N 1 9 IC4 0.3
c.1388tRa p.L463H 1 11 TM9 0.3
c.1484tRa p.L495H 1 12 IC5 0.3 28
c.1552cRt p.R518X 2 12 0.6 18, 19, 27, 28, 37
c.1553gRa p.R518Q 4 12 IC5 1.2 18, 19, 24, 28, 31
c.1603tRc p.S535P 1 12 TM10 0.3
c.1703tRc p.F568S 1 13 TM11 0.3 24
c.1798cRt p.R600C 1 14 TM11 0.3
c.1857insC FS 1 14 0.3
c.1987gRt p.G663C 1 16 NBF1 0.3
c.1999delG FS 1 16 0.3
c.2070+5GRA SJ 2 IVS 16 0.6
c.2093aRc p.Q698P 2 17 NBF1 0.6
c.2097gRt p.E699D 1 17 NBF1 0.3
c.2177tRc p.L726P 1 17 NBF1 0.3
c.2237ins10 FS 2 17 0.6
c.2252tRa p.M751K 1 18 NBF1 0.3 20, 37
c.2263gRa p.G755R 2 18 NBF1 0.6
c.2278cRt p.R760W 3 18 NBF1 0.9 20, 28, 32, 37
c.2294gRa p.R765Q 2 18 NBF1 0.6 20-22, 25, 28, 32, 37
c.2329gRa p.D777N 1 18 NBF1 0.3
c.2359gRt p.V787I 1 18 NBF1 0.3
c.2432cRt p.T811M 1 19 IC6 0.3 6
c.2643gRt p.R881S 1 20 IC6 0.3
c.2787+1GRT SJ 9 IVS 21 2.8 17, 20, 24, 28, 31, 37
c.2814cRg p.Y938X 1 22 0.3
c.2820insC FS 1 22 0.3
c.2831cRt p.T944I 1 22 TM12 0.3
c.2848gRa p.A950T 1 22 TM12 0.3
c.2974gRc p.G992R 1 22 TM13 0.3 2, 42
c.3340cRt p.R1114C 2 24 IC8 0.6 19, 28, 32, 37, 41
c.3389cRt p.T1130M 3 24 IC8 0.9 18, 19, 21, 22, 28, 30, 32, 37, 41
c.3398gRc p.G1133A 1 24 IC8 0.3
c.3412gRa p.R1138W 7 24 IC8 2.2 28, 30, 37
c.3413cRt p.R1138Q 7 24 IC8 2.2 18, 19, 24, 25, 28, 30, 32, 37, 41
c.3415gRa p.A1139T 2 24 IC8 0.6
c.3415gRa &
c.2070+5GRA*
p.A1139T & SJ 1 24, IVS 16 IC8 0.3
c.3415gRa &
c.4335delG*
p.A1139T & FS 1 24, 30 IC8 0.3
c.3421cRt p.R1141X 92 24 29.3 5, 9, 15,18, 19, 21, 22, 24, 28, 30–32,
33, 37, 41
c.3427cRt p.Q1143X 1 24 0.3
c.3490cRt p.R1164X 15 24 4.7 18, 27, 28, 31, 33
c.3491gRa p.R1164Q 1 24 IC8 0.3 28
c.3661cRt p.R1221C 1 26 IC9 0.3 21, 22, 28, 29
c.3662gRa p.R1221H 2 26 IC9 0.6 40
c.3676cRa p.L1226I 1 26 IC9 0.3
c.3722gRa p.W1241X 2 26 0.6
c.3774insC FS 2 27 0.6
c.3775delT p.G1259fsX1272 3 27 0.9 15, 25, 28, 41
c.3880-3882del p.K1294del 1 27 0.3
c.3883-5GRA SJ 1 IVS 27 0.3
c.3892gRt p.V1298F 1 28 NBF2 0.3 25
c.3904gRa p.G1302R 7 28 NBF2 2.2 21, 22, 25, 28
c.3907gRc p.A1303P 1 28 NBF2 0.3 21, 22, 25, 28
c.3912delG FS 1 28 0.3 28
c.3940cRt p.R1314W 4 28 NBF2 1.2 24, 25, 32, 36
c.3941gRa p.R1314Q 1 28 NBF2 0.3 25, 28, 32, 36, 41
c.4004tRa p.L1335Q 1 28 NBF2 0.3
c.4015cRt p.R1339C 16 28 NBF2 5.0 19, 25, 28, 33
c.4016gRa p.R1339H 2 28 NBF2 0.6
c.4025tRc p.I1342T 1 28 NBF2 0.3
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protein did not yield significant differences. Secondly, subjects
with PXE and with missense mutations on one or both alleles
were grouped according to the location of their mutation (NBF,
IC, TM). Each group was compared with the other three groups
but no significant differences were obtained (data not shown).
Subjects who had mutations in two different locations (n=8)
were assigned initially to the first location, and the analysis
then repeated with these subjects assigned to the second
mutation location. Again, no significant differences were found
in these analyses.
Although there is no evidence to support the assumption that
protein function can be revealed by type of mutation in the
absence of functional data, we attempted to confirm the finding
of Schulz et al,32 that the age of PXE diagnosis and the number
of organ systems affected is significantly different between
patients with predicted non-functional protein compared with
those with some potentially functional protein. The classifica-
tions were made according to predicted consequences to the
protein; missense mutations were predicted to result in some
protein that may be functional, whereas nonsense, insertion
and deletion mutations were predicted to result in non-
functional protein. The consequence of splicing mutations
could not be predicted. Unfortunately, the number of patients
in whom a definite age of diagnosis was known was limited to
50 patients. The mean age at diagnosis of patients with a non-
functional protein in this study was 28.5 (n=19), and that of
patients with some protein function was 28.8 (n=31). These
differences were not significant (p=0.95). When the analysis
was repeated for reported age of onset of symptoms regardless
of age of diagnosis, presuming that age at onset is younger than
age at diagnosis, again no significant differences were found.
DISCUSSION
This study identified a number of novel and recurrent
mutations in the ABCC6 gene in a large multinational case
series of patients with PXE. In all, 82 distinct mutations, of
which 39 were novel, previously unreported, were identified in
239 probands. The detection rate of 66% is less than that
reported by other groups, and potentially reflects (1) the lower
detection rate when using dHPLC for screening,41 42 (2) the
inability of the methods used to detect large deletions including
heterozygous loss of entire exons or the entire ABCC6 gene, and
(3) presence of mutations in regions such as the 59 regulatory
elements, 39 untranslated region and central intronic sequences
of ABCC6, which were not analysed in this study. Finally, there
is the possibility that mutations in genes other than ABCC6 can
Nucleotide change*! Predicted consequence!
Frequency
(alleles)
Exon–intron
location
Domain
affected`
Mutant
alleles (%) References1
c.4041gRc p.Q1347H 1 28 NBF2 0.3 25
c.4104delC FS 1 29 0.3 25
c.4192cRt p.R1398X 2 29 0.6 25
c.4335delG FS 1 30 0.3
c.4441gRa p.G1481S 1 31 NBF2 0.3
c.4501gRa p.G1501S 1 31 NBF2 0.3
Ex23_29del p.A999_S1403del 57 23–29 18.0 15, 18, 21, 25, 27, 28, 31, 32, 37, 44, 45
FS, frameshift; IC, intracellular domain; IVS, intron; NBF, nucleotide binding fold; SJ, splice junction; TM, transmembrane domain.
*The numbering system corresponds to ABCC6 cDNA (GenBank accession number NM00171.2), the adenosine residue in translation initiation codon ATG being +1.
The combination of mutations indicated by an asterisk were identified on one allele of the same patient.
!Mutations in bold are novel.
`In cases of missense mutations, the affected protein domain is indicated.
1In cases of previously published mutations, the corresponding references are listed.
Figure 1 The positions of nonsense, splice junction, insertion and deletion mutations identified in the ABCC6 gene in patients with pseudoxanthoma
elasticum (PXE). Vertical blue boxes represent the 31 exons, and every fifth exon is numbered. Splicing, small insertion and deletion mutations are shown
above the line, and nonsense mutations below, with the position of the recurrent del23–29 mutation. Dark blue boxes, nucleotide-binding fold domains;
bold, recurrent mutations; red, novel mutations.
Table 2 Continued
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result in a PXE phenotype, although no concrete evidence for
this possibility currently exists. The recurrent mutations
R1141X and del23–29 were the most prevalent, consistent with
previous reports. In our international case series, mutations in
exons 24 and 28 together with del23–29 accounted for the
majority of the mutations detected (71.5%) in the ABCC6 gene.
Several other recurrent mutations were also identified and
comprised around 20% of the total number of mutations.
The NBF domains of the MRP6 protein harboured a large
number of missense mutations (22/49), reflecting the strong
amino acid sequence conservation in this region, necessary to
maintain the function of the protein (fig 2). In addition,
intracellular domain 8 harboured several missense mutations
(8/49), suggesting the importance of sequence conservation in
this region of the protein and perhaps a function that has yet to
be identified.
Genotype–phenotype analysis of the 134 patients for whom
both ABCC6 mutations and full phenotypic data were available
failed to reveal any definitive correlations. The correlation of
age of PXE diagnosis with the predicted consequence of the
mutation (protein or no protein), as reported by Schulz et al,32
could not be confirmed. As there is no empirical confirmation
of whether there is functional MRP6 protein as a result of each
of the mutations, the accuracy of this conclusion rests on the
validity of the presumption that the mutation either does or
does not lead to functional MRP6 protein. Molecular studies of
three different MRP6 missense mutations (V1298F, G1302R
and G1321S) performed in vitro found that none of these three
mutations resulted in ATP-dependent substrate transport
although ATP binding was normal.11 Although these in vitro
data do not address whether the proteins bearing these
missense mutations are actually formed in the cell and inserted
properly into the membrane, it confirms the hypothesis that a
missense mutation in a critical portion of the molecule can
completely ablate the function of the protein and result in a
phenotype as severe as if no protein was present at all.
Finding no genotype–phenotype correlations in complex
mendelian disorders, such as metabolic diseases, is not
uncommon.43 44 This lack of association suggests that no simple
relationship exists between the type and position of mutations,
the mutations themselves and the severity of disease. Thus, it is
not possible from these data to predict the type or severity of
phenotypic manifestations from mutation studies themselves.
Because the type of phenotypic outcome and its severity cannot
be predicted from genotype data, all patients with PXE should
be screened regularly for potential serious and possibly life-
threatening complications regardless of their genotype.
An interesting observation was the absence of macroscopic
skin lesions in four patients (9, 58, 131 and 171), although skin
biopsy revealed typical histological characteristics of PXE.
Patient 9 had significant ophthalmological complications,
suggesting that this patient was not a carrier. In three of these
patients, a complete genotype was determined, confirming the
clinical diagnosis and emphasising that skin features, although
present in the majority of patients with PXE, are not always
mandatory for the diagnosis.
This study is limited by possible selection bias: participants
volunteered and were contacted through the support group.
Thus, it is skewed towards people who seek support, which
might select for people with a more severe phenotype. In
addition, more women than men responded, although that
gender ratio is reflective of the PXE population in general.
Furthermore, the phenotypic data were obtained through self-
reports, making their accuracy somewhat questionable, even
Figure 2 Schematic representation of the MRP6 protein and the positions of missense mutations identified in patients with pseudoxanthoma elasticum (PXE).
Vertical blocks are the 17 transmembrane domains of the MRP6 protein; dotted lines, nucleotide-binding fold; bold, recurrent missense mutations; red, novel
mutations.
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though matching with medical records in a subgroup yielded a
high correlation. Nonetheless, the results of this study, along
with results of all previous genotype–phenotype correlation
studies, indicate strongly that a straightforward and clinically
usable correlation does not exist, as could be expected from the
nature of this disorder. However, because of the significant
clinical relevance, further work is needed to determine if there
are subcellular phenotypes that correlate with genotypes in
PXE.42 Although mutation detection in PXE has not been
shown to have prognostic value, presymptomatic testing in
families with history of PXE can provide early diagnosis and
may be of value in surveillance for development of disease. In
addition, it will probably prove to be of value in genetic
counselling as well as in diagnosis of atypical cases or apparent
phenocopies.
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 In 2004, a report in the Journal of Urology described a fourteen-year old PXE patient in 
whom coincidentally bilateral testicular microlithiasis was discovered. A possible association of 
these widespread hyperechogenic foci throughout the testicular parenchyma was suggested, as 
some previous cases of breast or kidney calcifications in PXE patients were published. 
Confirmation of such a relationship could have significant clinical implications, as an important 
number of retrospective studies proposed these lesions as a risk factor for developing testicular 
cancer.   
 
 This study describes the ultrasonographical findings, both abdominal and testicular, in 17 
PXE patients and 17 heterozygous carriers, confirming visceral and testicular calcifications to be 
part of the PXE phenotype in both patients and carriers. Although no abnormalities of abdominal 
organ function or history of testicular cancer could be beheld, natural history of these lesions is 
largely unknown. As such, a cautious attitude and regular follow-up should be advised. 
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Visceral and testicular calcifications as part of the phenotype in
pseudoxanthoma elasticum: ultrasound findings in Belgian
patients and healthy carriers
1O M VANAKKER, MD, 2D VOET, MD, PhD, 2M PETROVIC, MD, PhD, 3F VAN ROBAEYS, MD, 1B P LEROY,
MD, 1P COUCKE, PhD and 1A DE PAEPE, MD, PhD
1Center for Medical Genetics , 2Department of Sonography and 3Department of Radiology and
Medical Imaging, Ghent University, Hospital, De Pintelaan 185, 9000 Ghent, Belgium
ABSTRACT. Occasionally calcifications in abdominal organs, breasts and testicles have
been reported in pseudoxanthoma elasticum (PXE) patients. In the present study, an
ultrasound evaluation was performed of the abdomen and – in male patients – of the
testicles in 17 PXE patients and 17 heterozygous carriers. Blood samples were taken to
evaluate calcium load, liver and kidney function. Calcifications in liver, kidneys and
spleen were detected in 59% of the patients and in 23.5% of healthy carriers.
Parameters of kidney and liver function were normal in both groups, suggesting that
the calcifications have no direct effect on organ function. Testicular ultrasound
revealed parenchymous calcifications in all males investigated. Widespread, small
hyperechogenic foci resembling testicular microlithiasis were seen. In some carriers,
focal calcifications were identified. The current data suggest that visceral and testicular
calcifications are part of the phenotype of PXE patients. Their presence in some of the
healthy carriers are suggestive of subclinical manifestations in these relatives. The
natural history and long-term effects of the parenchymal calcifications remain to be
elucidated. As testicular microlithiasis may be associated with a higher risk for
malignancy, regular clinical and ultrasound follow-up seems indicated in these
patients.
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Pseudoxanthoma elasticum (PXE – OMIM [Online
Mendelian Inheritance in Man]# 264800) is an autosomal
recessive connective tissue disorder with multiple
systemic manifestations. The phenotype consists of a
triad of papular lesions and increased skin laxity in the
flexural areas of the body, angioid streaks in the ocular
fundus with eventually retinal haemorrhages and loss of
central vision, and accelerated atherosclerosis leading to
cardiovascular complications [1–5]. The incidence of this
rare disease has recently been estimated to be 1:75 000
[6], although this may be an underestimation due to the
high variability of the phenotype. Clinical manifestations
of the disease are attributed to alterations of elastic fibres
within the extracellular matrix of the affected organs.
These fibres undergo progressive fragmentation and
mineralization, which is the histopathological hallmark
of the disease [2]. Nevertheless, other components of the
extracellular matrix, such as collagen, fibrillins and
proteoglycans have either an abnormal morphology or
distribution [7, 8].
The gene responsible for PXE (ABCC6 - MIM# 603234)
is located on chromosome 16p13.1. It encodes an
ATP-dependent transporter the substrate of which is
as yet unknown. The relationship between this protein
and the phenotype also remains to be elucidated
[9–11].
It has been shown that healthy carriers of PXE have
similar cutaneous abnormalities at the ultrastructural
level, suggesting that a mild phenotype may be seen in
these individuals [12]. Although a higher incidence of
cardiovascular disease has been reported, carriers do not
develop other manifestations of PXE such as cutaneous
and/or retinal disease [12–14].
Occasionally, PXE patients have been reported in which
calcifications in several organs, including kidney, pancreas,
spleen and breasts have been observed [15–21].
Additionally, one case report has described the presence
of multiple calcifications in the testicles of a
14-year-old PXE-patient [22]. These reports suggest a
possible association of organ calcifications and PXE. To our
knowledge, no systematic screening of patients nor of
healthy carriers has been performed. We present a
comprehensive ultrasound study of 17 PXE patients in
whom the association between visceral and/or testicular
calcifications and PXE was established. Furthermore, 17
heterozygous relatives were screened to detect whether
similar lesions could be found.
Patients and methods
Sixteen patients with clinical, molecular and biopsy-
proven PXE were examined. Informed consent was
Address correspondence to: Anne De Paepe, Center for Medical
Genetics, Ghent University Hospital, De Pintelaan 185, B-9000
Ghent, Belgium.
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obtained from all patients and the study was approved
by the Ethical Committee of the Faculty of Medicine of
the Ghent University Hospital. Our patient population
consisted of 5 men and 12 women. Ages ranged from
18 years to 80 years with an average of 54 years.
The group of 17 heterozygous carriers included
offspring as well as parents of patients (obligate carriers).
Additionally, siblings of patients proven to be hetero-
zygous carriers of an ABCC6 mutation were included.
The carrier group consisted of 11 men and 6 women.
Ages ranged from 16 years to 76 years with an average
age of 39 years.
All index-patients and carriers were personally exam-
ined at the PXE clinic of the Center for Medical Genetics
at the Ghent University Hospital. Thorough patient
histories were recorded in all individuals with special
consideration for signs and symptoms indicating hepatic,
renal or splenic dysfunction.
The full clinical protocol used at the PXE clinic of the
Center for Medical Genetics at the Ghent University
Hospital, including careful dermatological, ophthalmo-
logical and cardiovascular examinations and ultrasound
of the abdomen and testicles, was applied in both
groups. Ultrasound examinations were performed at
the Department of Sonography using a HDI 5000 system
(Philips, Brussels, Belgium) with a C5-2 and a L12-5
scanhead for the examination of the abdomen and
scrotum, respectively. To minimize interobserver varia-
tion three ultrasonographers performed the examina-
tions were blinded to patient information. Serum
analysis was performed to evaluate calcium load, liver
and kidney function in order to exclude other aetiologies
of parenchymal calcifications and to assess the possible
functional effect of the lesions. Parameters measured in
all individuals included serum concentrations of aspar-
tate amino transferase (AST), amino alanine transferase
(ALT), alkaline phosphatase (AF), gamma-glutamyl
transpeptidase (cGT), creatinine, urea, calcium and
phosphorus.
Skin biopsies were taken either in an affected skin area
or at the back of the neck when no lesion was
macroscopically apparent. Histological confirmation of
PXE was obtained with haematoxylin and eosin, van
Giesson and Von Kossa stains to detect the typical
anomalies of the elastic fibre.
Molecular screening of the ABCC6 gene was per-
formed using dHPLC (denaturing high performance
liquid chromatography) (Transgenomics, Cheshire, UK)
and subsequent sequencing of all ABCC6 exons in those
that showed abnormal dHPLC-patterns.
Results
Abdominal ultrasounds
Abdominal ultrasound revealed calcifications scat-
tered throughout the parenchyma of the kidneys (8
patients), liver (4 patients) or spleen (3 patients) in 10/17
(59%) of PXE patients (Figure 1a–d). In those with
visceral calcifications, kidneys were most frequently
affected (80%). In 3 out of 10 (30%) patients, two or
more organs were involved. The number of calcified
lesions ranged from a few in the spleen to widely
disseminated in the liver parenchyma. Calcifications
were seen as hyperechogenic foci with acoustic shadow-
ing, measuring 2–3 mm in diameter. Renal calcifications
were localized in the corticomedullary junction, but also
within the cortical tissue. Similar lesions could be
observed in 4 out of 17 healthy carriers. Two of those
had kidney calcifications while the others had lesions in
the liver. Other ultrasound findings included hepatic
haemangiomas and steatosis.
Serum tests to evaluate kidney and liver function were
performed in all patients and carriers examined. No
abnormalities of either liver enzymes nor serum creati-
nine and urea were observed. Calcium levels were
always within normal limits. None of the individuals
in this study had signs or symptoms indicative of
abnormal function of the liver, spleen or kidneys.
Testicular ultrasounds
Ultrasound of the scrotum was performed in four PXE
patients. In three multiple widespread, small hyperecho-
genic foci resembling a ‘‘heaven full of stars’’ were
identified throughout the parenchyma of both testicles
(Figure 2). This appearance matches the criteria of
classical testicular microlithiasis as described by
Dell’Acqua et al [23]. One patient had only few of these
lesions, compatible with limited testicular microlithiasis.
However, no histological confirmation of this diag-
nosis was obtained since none of the patients had any
complaint warranting a biopsy. No testicular tumours
were detected during the examination.
In two out of 11 healthy carriers examined, focal
calcifications of the testicular capsule or parenchyma
were observed. The parenchymatous calcification was a
small unilateral focus without acoustic shadowing. These
individuals were asymptomatic. Two carriers were
found to have a hyperechogenic mediastinum testis,
which can be considered a normal variant.
Discussion
PXE is a rare autosomal recessive disease character-
ized by fragmentation and calcification of the elastic
fibres. Clinical manifestations mainly consist of cuta-
neous, ophthalmological and cardiovascular lesions.
Case reports have mentioned the occurrence of calcifica-
tions in the visceral organs, breasts and testicles in some
individuals [15–21]. In this study, a standardized
examination protocol comprising abdominal and testi-
cular ultrasounds was used in 17 PXE patients to observe
whether calcified lesions in these organs could be
detected.
Due to the autosomal recessive inheritance of PXE,
parents and children of probands are obligate carriers of
one mutation in the ABCC6 gene. Previous ultrastruc-
tural studies in relatives of PXE patients have revealed
cutaneous morphologic alterations similar to those seen
in patients, although less severe in nature [12]. Trip et al
described a higher risk of coronary artery disease in
carriers of the frequent R1141X nonsense mutation [13].
These observations indicate that heterozygous carriers
may have mild PXE manifestations, albeit without
O M Vanakker, D Voet, M Petrovic et al
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obvious cutaneous or ophthalmological symptoms.
Therefore, ultrasound evidence of subclinical manifesta-
tions was sought in mutation carriers.
Abdominal ultrasound
The data presented suggest that visceral calcifications
in the kidneys, liver and spleen are indeed part of the
phenotype of PXE patients. Interestingly, similar lesions
were found to be present in some of the healthy carriers,
although less frequently and to a lesser extent.
All ages were represented in patients and carriers with
visceral calcifications, making our findings unlikely to be
attributed solely to the age of the individuals. Calcium
and phosphorus load were normal in all individuals,
excluding other aetiologies of visceral calcifications such
as chronic granulomatous diseases (e.g. sarcoidosis),
renal failure, hyper(para)thyroidism, pheochromocy-
toma, adrenal insufficiency or malignancy.
Figure 1. Ultrasound images of calcified foci in several abdominal organs: (a) frontal cross-section through the abdomen with
multiple calcifications in the liver of a pseudoxanthoma elasticum (PXE) patient; (b) subcostal transverse cross-section of the liver
of a heterozygous carrier in which two calcifications with acoustic shadowing are seen; (c,d) frontal cross-section through the
abdomen with view of multiple hyperechogenic foci in (c) the right kidney and (d) spleen of PXE patients.
Figure 2. Longitudinal cross-section of the testicle with
scattered parenchymatous calcifications in the right testicle
of a pseudoxanthoma elasticum (PXE) patient as a typical
example of testicular microlithiasis.
Visceral and testicular calcifications in PXE
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As serum tests for liver and kidney function revealed
no abnormalities and none of the individuals examined
suffered from any disturbances of renal, hepatic or
splenic function, the calcified foci probably do not
interfere with liver, kidney or splenic function.
However, their natural history and long-term effects
remain to be elucidated.
Therefore an abdominal ultrasound at the time of
diagnosis may be indicated. Furthermore, regular
re-evaluation with serum tests and ultrasound are
advisable.
It has been previously reported that both abdominal
plain radiographs and CT are unable to visualize these
lesions [18]. In the only patient with renal foci in whom
abdominal radiographs were performed in this study, no
calcifications were visible. We did not perform CT
imaging in our population and can therefore not rule
out that, due to technical improvements and new
developments, these lesions can now be visualized.
However, since ultrasound proved to give sufficient
data and comparing the costs and radiation load of both
examinations, we feel that at present CT is not an added
value in the work-up of a PXE patient in a clinical setting.
In a research setting, however, it would be interesting to
find out if these lesions are indeed visible with modern
CT techniques and to evaluate their extent and char-
acteristics in comparison with ultrasound findings. Thus,
in view of all known aspects, ultrasound should be
considered the investigation of first choice for detection
of these calcifications on a routine basis.
Testicular ultrasounds
Testicular parenchymal calcifications were identified
in all male patients so far examined. These lesions,
described as bilateral, small, hyperechogenic foci, meet
the ultrasound criteria of testicular microlithiasis (TM).
The TM pattern is defined as usually bilateral hyper-
echogenic multiple small foci without acoustic shadow
and with complete or partial extension to the paren-
chyma. Cases in which five or more foci can be
demonstrated are defined as classical TM [24–27].
Cases that do not meet this criterion are designated as
limited TM. The imaging diagnosis can be confirmed by
showing intratubular microliths on biopsy [24–27]. Since
none of our patients had either complaints or fertility
problems testicular biopsies were considered unethical.
TM is of special interest due to its reported association
with testicular malignancy [29–36]. Nevertheless, it
remains unclear whether primary testicular tumours
actually occur more frequently in patients with pre-
existing TM. Large prospective studies are needed to
further clarify this issue. Until further data are available,
it seems cautious to consider patients with a TM-like
ultrasound image as having a potentially increased risk
of developing a testicular malignancy and to offer
regular ultrasound screening [28–34, 36].
The findings in healthy carriers were different from
those in patients in their extent and/or location within
the testicle. Multiple hyperechogenic foci confined to
the capsule or the mediastinum testis were detected,
the latter probably being a normal variant. Although
anatomically this could also be compatible with
calcifications in the rete testis [37], we cannot be sure
of this without a biopsy which is unjustifiable in these
patients.
In another carrier, we observed one parenchymatous
calcification which could be considered as limited TM.
The remaining parenchyma, however, was completely
normal and we cannot exclude that these findings are
fortuitous. Since they have, to our knowledge, not
previously been described in PXE, further study on a
larger group of carriers would be of interest.
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 In this study, four unrelated PXE patients presenting with unexplained vision loss – i.c. 
decreased visual acuity in the absence of retinal haemorrhages – were investigated thoroughly 
via electrophysiological examinations to assess retinal and macular function.  
 
 Three distinct types of retinal dysfunction could be delineated, suggesting that such 
malfunction is not uncommon in PXE patients, particularly when no obvious anatomical corruption 
can be detected. In addition, molecular analysis in these patients revealed a novel ABCC6 
nonsense mutation.   
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Pseudoxanthoma Elasticum with Generalized Retinal
Dysfunction, a Common Finding?
Isabelle Audo,1,2,3,4 Olivier M. Vanakker,4,5,6 Alaric Smith,7 Bart P. Leroy,5,8
Anthony G. Robson,2 Sharon A. Jenkins,2 Paul J. Coucke,5 Alan C. Bird,2 Anne De Paepe,5
Graham E. Holder,2 and Andrew R. Webster2,3
PURPOSE. Pseudoxanthoma elasticum (PXE; [MIM 264800]) is
an autosomal recessive systemic disorder characterized by pro-
gressive degeneration and calcification of elastic fibers in con-
nective tissue. The phenotype is variable, with cutaneous,
vascular, and ophthalmic abnormalities. The disorder is a con-
sequence of mutations in the ABCC6 gene. Visual impairment
is mainly due to neovascular complications, and retinal func-
tion is usually assumed to be normal. The purpose of this study
was the objective assessment of macular and generalized reti-
nal function in unrelated patients with clinical and/or genetic
features of PXE.
METHODS. Four unrelated patients carrying a clinical diagnosis
of PXE presented with unexplained visual loss. After ophthal-
mic examination, retinal and macular function was assessed by
full-field electroretinogram (ERG) and pattern ERG, respec-
tively, according to ISCEV (International Society for Clinical
Electrophysiology of Vision) recommendations. Molecular
analysis of the ABCC6 gene was performed in three patients by
dHPLC (denaturing high-performance liquid chromatography)
and direct sequencing.
RESULTS. Full-field ERG revealed significant reduction of cone
and rod responses in all four patients. Funduscopic appear-
ances varied. Three patients were found to carry ABCC6 mu-
tations. In case 1, a novel nonsense mutation (p.L1474X) was
detected in exon 31 paired with a splice-site mutation. Muta-
tion analyses in cases 3 and 4 revealed previously reported
ABCC6 mutations.
CONCLUSIONS. These findings suggest that retinal dysfunction in
PXE may not be uncommon. The mechanism underlying retinal
dysfunction is unknown but may result from metabolic distur-
bance leading to retinal toxicity with a possible role of modi-
fying genetic or environmental factors rather than specific
ABCC6 mutations. (Invest Ophthalmol Vis Sci. 2007;48:
4250–4256) DOI:10.1167/iovs.05-1604
Pseudoxanthoma elasticum (PXE, MIM [Mendelian Inheri-tance in Man] 264800) is a systemic disorder characterized
by progressive degeneration and calcification of elastic fibers.
The phenotype of the disease is highly variable, partially de-
pending on the age of the patient, and includes mainly skin,
ocular, and cardiovascular abnormalities (see Ref. 1 for re-
view). The prevalence of the disease is estimated between 1 in
70,000 and 1 in 100,000.2,3 In the past, both autosomal reces-
sive and dominant transmission have been described. How-
ever, recent evidence suggests that most, if not all, familial
cases are recessive forms. Previously described dominant ped-
igrees can be explained by the presence of pseudodominance
due to a high carrier rate or consanguinity.3,4 Several groups
have identified ABCC6 as the defective gene,5–8 which causes
a loss of function resulting in the PXE phenotype. It is a
member of the ATP-binding cassette transmembrane trans-
porter family, also assigned to the subfamily of multidrug re-
sistant proteins (MRPs).9 It is highly expressed in human and
mouse liver, to a lesser degree in kidneys,10–12 but at only very
low levels in the tissues that are clinically most affected.5,10
The precise function of ABCC6 remains unclear, although its
location at the basolateral side of the cellular membrane sug-
gests a role in transporting substances involved in connective
tissue homeostasis, normally extruded from liver and kidney.
Hence, PXE could be considered a metabolic disease.13,14
The cutaneous phenotype typically consists of discolored
(yellowish) papules and plaques on the neck and Moroccan
leatherlike skin lesions with redundant folds in flexural areas.
Cardiovascular complications that may be associated with the
disease are mainly due to accelerated atherosclerosis (e.g.,
peripheral and coronary artery disease, stroke).1
The ocular phenotype is variable. A “peau d’orange” fundus
appearance can be present in childhood as the earliest oph-
thalmic sign, but it tends to become less distinct with age. This
unusual mottled feature corresponds with yellowish lesions of
the retinal pigment epithelium (RPE), typically in the midpe-
riphery and particularly on the temporal side. Angioid streaks
radiating from the optic disc are commonly reported, and other
signs may include optic nerve head drusen and reticular pig-
mentary dystrophy of the macula. Crystalline bodies may be
present in the midperiphery and juxtapapillary area with vari-
able degrees of underlying RPE atrophy. These lesions are
referred to as “comets” and may be associated with streaks of
RPE thinning in a cometlike tail pattern extending toward the
posterior pole.15,16 These focal abnormalities may be the only
lesions typical of PXE, according to Gass.15
Visual impairment in patients with PXE can occur because
of macular atrophy, choroidal rupture, or choroidal neovascu-
larization, with or without choroidal hemorrhage from angioid
streaks, and theoretically from complications of optic nerve
head drusen. Visual function is poorly documented in the
literature: Franc¸ois and De Rouck17 described mild amplitude
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reduction in electroretinograms (ERGs) in 46% of cases, mostly
in eyes with advanced disciform macular degeneration suggest-
ing that retinal dysfunction is not an unusual abnormality in
PXE. Holz et al.18 failed to detect any functional changes
associated with the peau d’orange retinal appearance.
In this study, four patients with PXE are reported who had
generalized retinal dysfunction involving both cones and rods.
METHODS
Electrophysiology was performed with gold foil recording electrodes
according to ISCEV (International Society for Clinical Electrophysiol-
ogy of Vision) standards.19,20 Molecular analysis was performed in
three patients. The ABCC6 gene was amplified by using polymerase
chain reaction primers previously described by Wang et al.21 and Le
Saux et al.22 For the detection of the common exon 23 to 29 deletion,
a PCR-based method with primers described by Le Saux et al.22 was
performed on all samples. In this assay, PCR amplification will be
observed only in the presence of a multiexon deletion. The coding
region and intron–exon boundaries of the whole ABCC6 gene were
analyzed with dHPLC (denaturing high performance liquid chromatog-
raphy; Wave System; Transgenomics, Inc., Omaha, NB) and direct
sequencing (model 3100 sequencer with PRISM BigDye Terminator
Cycle Sequencing Kit; Applied Biosystems, Inc., Foster City, CA).
The protocols used to performed this study adhered to the tenets of
the Declaration of Helsinki and were approved by the local Ethics
Committee.
RESULTS
Case 1
A 16-year-old Turkish boy had a history of night blindness since
the age of 2. Although fit and well at presentation, he had been
treated for non-Hodgkin malignant lymphoma at the age of 2
years with chemotherapy, including systemic treatment with
endoxan, oncovin, ara-C, methotrexate, and 6-mercaptopurin
and intrathecal methotrexate, prednisolone, and alexan. He
reported poor color discrimination, worsening of visual acuity,
and progressive visual field constriction over a 3-year period.
There was no family history of visual problems or systemic
diseases. His dizygotic twin brother was asymptomatic with
normal vision, and his parents were first cousins (Fig. 1a). At
the time of his first visit, his vision was 6/12 in both eyes with
an optical correction of !4(!1.75)20° in the right eye and
!3.75(!2.25)165° in the left. He had been wearing spectacles
since the age of 5. Static perimetry (Fig. 2) showed diffuse loss
of sensitivity worse in the central field. On slit lamp examina-
tion, his anterior segments were unremarkable, and, in partic-
ular, there was no evidence of crystalline deposits in the
corneal limbus. Fundus examination (Fig. 3a) revealed bilateral
angioid streaks, a peau d’orange aspect on the temporal side of
the macula of both eyes and some macular RPE atrophy. In-
traretinal crystalline bodies were disseminated over the poste-
rior pole and midperiphery and associated with underlying RPE
atrophy. Some of the larger crystalline lesions were associated
with a punched-out appearance. Fundus autofluorescence ex-
amination (Fig. 3b) showed areas of low density consistent
with RPE atrophy associated with the crystals, angioid streaks,
and fovea. The punched-out lesions had a distinct autofluores-
cent appearance with a high-density center surrounded by a
hypoautofluorescent ring. Angioid streaks and the crystalline
lesions showed areas of window defect on fluorescein angiog-
raphy congruent with the underlying RPE atrophy (Fig. 3c). On
indocyanine green angiography, punched-out lesions corre-
spond to hypofluorescent areas (Fig. 3d). Examination with
optical coherence tomography (Fig. 3e) revealed the presence
of crystalline bodies at the level of the inner retinal layers.
Color contrast sensitivity was assessed along the protan, deu-
tan, and tritan axes. All thresholds were grossly elevated (data
not shown). The patient underwent electrophysiology (Fig.
4a). Pattern ERG was markedly reduced in the right eye and
undetectable in the left. The rod-specific ERG was markedly
subnormal in both eyes. The maximum responses showed
reduced amplitude for both a- and b-waves. The 30-Hz flicker
and single flash cone ERGs showed profound delay and pro-
found reduction in amplitude. The findings are those of severe
generalized retinal dysfunction involving the cone more than
the rod systems, with pattern ERG evidence of macular involve-
ment, worse on the left than the right. Other tests results,
including full blood count, ionogram, creatinine level and he-
moglobin electrophoresis, were normal. No sickle cell trait was
detectable. A dermatologic examination showed no evidence
of the skin lesions in the flexural areas, and the patient de-
clined a skin biopsy. Visual acuity dropped to 6/24 bilaterally
32 months after presentation but the fundus appearance was
unchanged.
Molecular analysis of the ABCC6 gene revealed two base-
changes: a 3507(–3)C3T transition at the splice acceptor site
of intron 24 and a p.L1474X nonsense mutation (c.4420 A3T,
exon 31; Figs. 5a, 5b).
Case 2
This 45-year-old Moroccan man presented with a 2-year history
of gradual visual loss in both eyes and photophobia. He also
reported difficulties seeing in the dark and especially adjusting
from light to dark. Six years earlier, he had been given a
diagnosis of PXE based on typical skin lesions and fundus
abnormalities. There was no family history of visual problems
or systemic disorders. His parents were first cousins (Fig. 1b).
His visual acuity at the time of the referral was hand move-
ments with "1(!1.50)90° on the right and 6/18 to 2 with
"0.50(!1.25)90° on the left. Visual fields to confrontation
FIGURE 1. Family pedigrees. (a) Case 1: there was no family history of ocular disorder or PXE. Parents
were first cousins. The patient had an unaffected dizygotic twin. (b) Case 2: no family history of ocular
disorder or PXE. Parents were first cousins and the patient married one of his first cousins. (c) Case 4: the
patient had three affected siblings with variable PXE manifestations as well as an affected mother, maternal
aunt, and a cousin, which raised the suspicion of pseudodominant PXE.
IOVS, September 2007, Vol. 48, No. 9 Pseudoxanthoma Elasticum with Generalized Retinal Dysfunction 4251
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showed residual perception in the superior and temporal field
of both eyes. A fundus examination (Fig. 3f) showed healthy
optic discs, narrow vessels, angioid streaks, and bilateral pig-
mented fibrovascular scars in the macula, probable sequelae of
bilateral choroidal neovascularization. A peripheral examina-
tion showed atrophy of the RPE outside the arcade, with
pigment migration at the level of the retina.
Electrophysiology was performed (Fig. 4). No pattern ERG
was detectable. A full-field ERG showed no rod-specific re-
sponse, severely subnormal maximal rod–cone responses and
markedly delayed and reduced 30-Hz flicker ERG. The findings
were consistent with severe generalized retinal dysfunction
affecting both rod and cone systems, with severe bilateral
macular involvement. These results suggest advanced photore-
ceptor dystrophy and cannot be explained on the basis of
fibroglial scars present on fundus examination. He was re-
viewed in the clinic 6 months later and showed a decline in his
vision-to-hand movement in the right eye and 6/36 in the left.
Two years after presentation, his vision was hand motion in the
right eye and 6/60 with !1.50("1.50)85° in the left. The
fundus appearance was unchanged. The patient declined fur-
ther testing and was unwilling to provide a blood sample for
genotype analysis.
Case 3
This 37-year-old white woman with a diagnosis of PXE was
referred in May 2003 for follow-up of her retinal status. She
reported night blindness and peripheral visual field constric-
tion. She had received a diagnosis of PXE in her early 20s,
based on characteristic fundus abnormalities and typical skin
lesions. There was no family history of ocular disease or sys-
temic disorder and there was no parental consanguinity. Her
visual acuity was 6/9 in the right eye with "1.50 D and 6/24
with "1 D in the left eye. Visual fields showed concentric
constriction in her right eye and diffuse loss of sensitivity in the
left eye. Fundus examination (Fig. 3g) revealed multiple an-
gioid streaks, a temporal appearance of peau d’orange,
punched-out lesions in the midperiphery, and RPE atrophy in
the periphery with pigment migration into the neural retina.
There was no evidence of choroidal neovascularization. One of
the angioid streaks passed through the foveola in the left eye,
with additional RPE atrophy explaining the poor left visual
acuity. Pattern ERG and full-field ERG abnormalities were se-
vere bilaterally, in keeping with generalized retinal dysfunction
affecting rod more than cone photoreceptors with evidence of
severe bilateral macular involvement (Fig. 4). Her vision re-
mained stable, and her fundus appearance was unchanged at
the 1-year follow-up.
On mutation analysis, this patient was homozygous for the
p.R1141X nonsense mutation (c.3421C3T) in exon 24 (Fig.
5c).
Case 4
This white man was first seen at the age of 26. He carried a
diagnosis of PXE based on fundus changes (angioid streaks and
peau d’orange), typical skin lesions, and a history of digestive
complications with gastrointestinal hemorrhage. The diagnosis
was confirmed by skin biopsy, which showed degeneration
and calcification of the elastic fibers.
He had visual field loss that initially had been attributed to
bilateral complicated optic nerve head drusen. He also had
three affected siblings with variable manifestations of PXE as
well as an affected mother, maternal aunt, and a cousin. There
was a possible low degree of consanguinity in the family,
which raised the suspicion of pseudodominant PXE (Fig. 1c).
His vision at the time of the first referral was 6/18 in the
right eye and 6/9 in the left. Over the course of follow-up, his
visual acuity gradually deteriorated consequent to choroidal
FIGURE 2. Case 1: static visual field tests: note the diffuse loss of sensitivity worse in the central field.
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neovascularization in the right eye, which resulted in a disci-
form scar, and atrophic changes in the left eye, in addition to
the optic nerve drusen. By the age of 55, his vision was hand
movements in the right eye and 1/60 in the left eye. Fundus
examination (Fig. 3h) showed a waxy appearance of both optic
nerves with nerve head drusen, angioid streaks, a fibroglial scar
on the right macula and an area of geographic atrophy on the
left. The severity of visual impairment was unusual for PXE and
electrodiagnostic tests were performed to distinguish between
optic nerve and retinal dysfunction (Fig. 4). No pattern ERG
was detectable, indicating severe macular dysfunction bilater-
ally. Rod specific ERG was subnormal. Maximum ERGs, 30-Hz
flicker, and transient photopic ERGs were mildly subnormal
bilaterally. These findings were consistent with severe bilateral
macular dysfunction with evidence of mild generalized retinal
involvement affecting the rod more than the cone system.
The patient was found to be compound heterozygous for
the known p.R1114P missense mutation (c.3341G3C) in
exon 24 and a multiexon deletion of exons 23 through 29
(Figs. 5d, 5e).
DISCUSSION
The present study characterizes the molecular and clinical
features of a heterogeneous group of four patients with PXE
who underwent comprehensive assessment of generalized ret-
inal function. Full-field ERG revealed three functional pheno-
a
b
c
d
e
(l)(r)
(l)
(r)
(1) (2) (3) (4)
(l)(r)
f
h
g
FIGURE 3. (a) Case 1: fundus color photographs from the right (r) and left eye (l). Note the presence of bilateral angioid streaks, peau d’orange
in the temporal sector of both eyes, some amount of macular retinal pigment epithelium atrophy, atypical intraretinal crystalloid deposits
disseminated over the posterior pole and midperiphery, cometlike tail aspect with underlying retinal pigment epithelium atrophy. Some of the
larger crystalline lesions have a punched-out appearance. (b) Fundus autofluorescence. Note the areas of low-density consistent with RPE atrophy
associated with the crystals, angioid streaks, and fovea. The punched-out lesions have a distinct autofluorescence appearance with a high-density
center surrounded by a hypoautofluorescent ring. (c) Fluorescein angiography from the right eye (54s (1) and 5m36s (2)) and from the left eye
(16s (3) and 3m40s (4)). Note the hyperfluorescent area associated with the angioid streaks, the crystals and the punched-out lesions by window
defect reflecting the underlying RPE atrophy. (d) Indocyanine green angiography: hypofluorescent spots corresponding to the punched-out lesions.
(e) Optical coherence tomography: note the presence of crystals in the inner retinal layers. (f) Case 2: healthy optic discs, narrow blood vessels,
angioid streaks, and bilateral pigmented fibrovascular scars in the macula, probable sequelae of bilateral choroidal neovascularization. A peripheral
examination showed atrophy of the retinal pigment epithelium outside the arcade with pigment migration at the level of the retina, a sign of
photoreceptor loss. (g) Case 3: multiple angioid streaks including one that passes through the foveola in the left eye and additional atrophy of the
retinal pigment epithelium, explaining the low vision in the left eye; no evidence of choroidal neovascularization; a temporal appearance of peau
d’orange; punched-out lesions in the midperiphery; RPE atrophy in the periphery with pigment migration and bone spicules at the retinal level.
(h) Case 4: waxy appearance of both optic nerve heads and drusen, angioid streaks, a fibroglial scar on the right macula, and an area of geographic
atrophy on the left.
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FIGURE 4. Electrophysiology (a) Case 1: scotopic rod-specific ERGs are markedly subnormal from both eyes. The maximum responses show
reduced amplitude for both a- and b-waves. Both 30-Hz flicker and single flash cone ERGs show profound delay and profound reduction in
amplitude. Pattern ERG is markedly reduced in the right eye (RE) and undetectable in the left (LE). The findings are those of severe generalized
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types; cone–rod dystrophy (case 1), rod–cone dystrophy
(cases 3 and 4), and severe photoreceptor dystrophy involving
rods and cones equally (case 2). Uniquely in PXE, pattern ERGs
were recorded, allowing objective assessment of macular func-
tion.23
Funduscopic appearances also varied. Diffuse changes ex-
tending beyond the arcades were seen (cases 1 and 2) with
numerous intraretinal crystals in case 1. One possibility is that
the crystalline retinopathy is due to the chemotherapeutic
agents used during his childhood illness, although there is no
precedent for this with any of the agents listed. Alternatively,
this appearance has been reported in the retinas of persons
affected with PXE,1,15 whereas no association between the
chemotherapeutic drugs taken by the subject and crystals can
be found in the literature. In case 1, a novel nonsense mutation
(p.L1474X) was detected in exon 31. A further base change
was detected, 3507(!3)C3T, which is predicted to affect
splicing and has been detected previously in PXE patients
(Olivier Vanakker, personal communication, 2005). Mutation
analysis in cases 3 and 4 revealed known mutations in exon 24
and a multiexon deletion which is frequently observed in PXE.
There have been few reports in the literature describing
retinal function in PXE. Franc¸ois and De Rouck17 described 15
patients. Slightly subnormal dark adaptation was present in 18
eyes. Nonstandard ERG recordings suggested mild retinal dys-
function in 14 eyes that involved only the cone system (2
cases), only the rod system (4 cases), or both rod and cone
systems (8 cases). Most of these patients had advanced disci-
form degeneration, although normal ERGs were also recorded
in cases of terminal macular degeneration. These findings sug-
gest that moderate retinal dysfunction, similar to that in case 4
(Fig. 4d) may commonly be present and could explain the
night vision difficulties reported frequently by PXE patients in
our experience.
Yoshida et al.24 described an association between PXE and
severe retinal dysfunction in a single Japanese pedigree.24 The
proband was homozygous for a novel mutation in ABCC6
(nonsense mutation in exon 5), and his two affected daughters
were heterozygous for this mutation with clinical signs of PXE
and ERG evidence of rod–cone dystrophy (RP). The authors
suggested either a coincidental association or the possibility of
a combination of ABCC6 alleles, which can give rise either to
PXE or PXE and RP. ABCC6 may also behave like a modifier
gene contributing to the pathogenesis of RP.24
A coincidental association between PXE and retinal dystro-
phy in the current series could occur, with co-inheritance of
the ABCC6 mutations with those in an as yet unknown gene
with a role in retinal function. This scenario would be more
likely in cases 1 and 2, for whom parental consanguinity the-
oretically increases the likelihood of an association of two
separate and independent recessive disorders. The generalized
retinal dysfunction seen in these four patients may have been
due to the effect of specific alleles of the ABCC6 gene. How-
ever, the genetic analysis of three patients suggests not. Five of
the six mutant alleles are known to contribute to PXE in other
studies and are considered to represent null alleles. The one
novel mutation detected in this study, p.L1474X, would cause
a premature-truncating codon and would be likely to succumb
to nonsense-mediated decay and hence also to be null. It is
more likely therefore that the determination of whether PXE
will be accompanied by generalized retinal dysfunction will
depend on modifying factors, either environmental or genetic,
that affect the way retinal tissue tolerates the metabolic abnor-
malities of the disorder.
Why retinal tissue should be affected at all by ABCC6 dis-
ruption is not clear. Only low levels of ABCC6 mRNA have
been detected in frequently affected tissues,5,10,12 although
conflicting results have been reported in the literature regard-
ing immunohistochemical analysis of the ABCC6 pro-
tein.5,9,12,13 Conversely, high levels of ABCC6 mRNA and pro-
tein were found in liver, which is unaffected in PXE.5,10–13
Gorgels et al.13 observed a decrease in HDL cholesterol levels
in Abcc6!/! mice and suggested that alteration of plasma lipid
composition may be implicated in the systemic changes ob-
served in PXE. Retinal toxicity could be secondary to changes
in Bruch’s membrane precluding proper nutrient supply to
photoreceptors leading to their secondary dysfunction and
degeneration. The further investigation of Abcc6!/! mice
might give insights into the mechanisms that lead to the patho-
logic changes observed in PXE.13
retinal cone–rod system dysfunction with macular dysfunction worse on the left than on the right. (b) Case 2: full-field ERGs show an undetectable
rod-specific response, severely subnormal maximum responses and markedly delayed and reduced-flicker ERG. No definite pattern ERG is
detectable. The findings are those of severe generalized retinal dysfunction, affecting both rod and cone photoreceptors with severe bilateral
macular involvement. (c) Case 3: the scotopic rod-specific ERG was severely reduced bilaterally. Maximum responses are markedly subnormal. The
30-Hz flicker is delayed and subnormal in amplitude as is the photopic single-flash ERG. Pattern ERG is bilaterally undetectable. The findings are
consistent with a moderately severe photoreceptor dysfunction affecting the rods more than the cones with severe bilateral macular involvement.
(d) Case 4: scotopic rod-specific ERGs are subnormal. The 30-Hz flicker and transient photopic ERGs were mildly subnormal bilaterally. No pattern
ERG was detectable. The findings are consistent with generalized rod dysfunction with mild cone system involvement and with bilateral macular
dysfunction. (e) Example of normal responses. Maximum ERGs were recorded to a stimulus 0.6 log units stronger than the ISCEV standard flash,
as a better demonstration of the ERG a-wave.19
FIGURE 5. Electropherograms of the sense strand of genomic DNA
from the patients investigated (a–d) and an agarose gel electrophoresis
picture of patient 4 (e). A heterozygous splice-site mutation
(a, 3507(!3)C3T) and heterozygous nonsense mutation (b,
c.4420A3T) in case 1, a homozygous nonsense mutation c,
c.3421C3T) in case 3, and a heterozygous missense mutation
(d, c.3341G3C) in case 4. Note that only the undeleted allele ampli-
fied. The presence of a multiexon deletion (e, del23-29) with specific
primers with positive controls is shown in case 4. Arrows: position of
the mutation.
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When considering the influence of ABCC6 mutations on
retinal function, electrophysiological assessment provides im-
portant insight into the underlying causes of visual failure and
most accurately describes the functional phenotype. It should
probably be considered more often, although it would nor-
mally be indicated if any discrepancy exists between the pa-
tient’s visual complaints, visual acuity, and clinical examina-
tion.
In conclusion, the present study highlights an underre-
ported but disabling association of PXE—generalized retinal
dysfunction—and describes the detailed phenotype of these
patients. It appears that this specific complication of PXE is not
due to the inheritance of specific alleles, which suggests the
action of modifiers. It is possible that the generalized retinal
dysfunction in PXE is more common than is recognized.
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Successful medical care for PXE patients is strongly depending on the age of diagnosis; 
early disease recognition implies a better prognosis. This is particularly true for the 
ophthalmological complications, for which several therapeutic options nowadays exist. From this 
perspective, novel techniques became available – often for other, more common disorders – 
which can be of potential interest for PXE families.  
 
 In this study three innovative fundus visualization methods – infrared, redfree and 
autofluorescence imaging – are evaluated for their capacity to depict the PXE retinopathy in 22 
PXE patients and 25 obligate carriers. These techniques emerged as standard imaging 
instruments in age-related macular degeneration and several other retinal dystrophies. 
Particularly the wet form of ARMD, characterized by neovessel formation, reveals great similarity 
with the PXE retinopathy and triggered the hypothesis of better visualizing early onset ocular 
disease in PXE. Indeed, these techniques were shown to be more sensitive than white light 
funduscopy in visualizing early retinal changes in PXE, as well as appreciating their extent. It is 
concluded that they should be considered part of the standard work-up of PXE families.        
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Abstract  
Purpose: Pseudoxanthoma Elasticum (PXE) is an autosomal recessive disorder caused 
by mutations in the ABCC6 gene, and primarily affects the oculocutaneous and cardiovascular 
systems. However, the phenotype, including the ophthalmological manifestations, varies in 
severity. The present study aims to evaluate the added value of novel fundoscopic imaging 
techniques, such as infrared, red-free and autofluorescence imaging in PXE.  
Methods: In 22 molecularly proven PXE patients and 25 obligate carriers with one 
ABCC6 mutation, PXE retinopathy was evaluated using funduscopy, white light, red-free, infrared 
and autofluorescence imaging. 
Results: At least one characteristic of PXE retinopathy was evident on fundoscopy of all 
eyes. Angioid streaks could be subdivided in those with (brick red) or without (feathered) adjacent 
RPE alterations. Infrared imaging showed the brick red coloured streaks as well-demarcated dark 
fissures, even when these passed unnoticed on funduscopy. Feathered types were detected as 
triangular areas of hypo-autofluorescence. The peau d’orange was much better visible and much 
more widespread on infrared imaging, with extension from the posterior pole towards the whole 
midperiphery. Comets and comet tails, were best seen with red-free imaging. 
Conclusions: Infrared, red-free and autofluorescence imaging are more sensitive than 
white light funduscopy and imaging in visualizing early retinal signs of PXE. In addition, this 
specialised imaging allows better appreciation of the extent of lesions. Hence, such imaging 
increases the chances of making a correct diagnosis early, and aids in the accurate evaluation of 
evolution of disease in the ophthalmic follow-up of PXE patients. 
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Introduction  
Pseudoxanthoma elasticum (PXE; OMIM# 264800) is an autosomal recessive 
multisystem disorder, mainly affecting the oculocutaneous and cardiovascular systems1,2,3. It is 
caused by mutations in the ABCC6 gene (chrom. 16p13.1; OMIM# 603234), encoding a 
transmembrane transporter of which the substrate remains as yet unknown4,5. The histology of 
PXE is characterized by ectopic mineralization and fragmentation of elastic fibres in the reticular 
dermis, Bruch membrane (BM) and the elastic laminae of blood vessels1,2. 
Skin symptoms manifest first in childhood as yellowish discoloured papules or increased 
skin laxity in flexural areas, although there is significant variability in clinical severity1,2,3. 
Cardiovascular complications are those of accelerated atherosclerosis with occlusive vascular 
disease1,2,3. The PXE retinopathy is characterized by a mottled aspect of the retinal midperiphery 
(called peau d'orange) most prominent temporal to the macula, and ruptures in BM known as 
angioid streaks. The latter often, if not invariably, lead to subretinal neovascularisation with a risk 
for spontaneous and/or post-traumatic haemorrhage with subsequent loss of visual acuity1,2,3. 
Additionally, comets and comet tails, crystalline bodies in the retinal midperiphery and juxta-
papillary area with a variable degree of retinal pigment epithelium (RPE) atrophy have been 
reported. Although not known to impair visual function, they have been described as the only 
lesions pathognomonic for PXE6. The clinical heterogeneity of PXE is also reflected in the retinal 
phenotype: although invariably present, the retinopathy remains rather limited and uncomplicated 
in young patients, making an early diagnosis more difficult. Additionally, very similar 
ophthalmological characteristics have been observed in PXE phenocopies, such as those 
associated with either beta-thalassaemia or the PXE-like syndrome (OMIM# 610842) 8,9. 
However, ocular signs and symptoms are less severe and uncomplicated in the latter9.  
Dilated fundus photography using white light, whether or not combined with fluorescein 
angiography, has proven to be a useful technique to evaluate the retinal phenotype. More 
recently, novel non-invasive imaging techniques, such as infrared imaging (IRI) and 
autofluorescence imaging (AFI), have emerged10-15. The former allows evaluation of the integrity 
and health of the RPE and the underlying choroidal structures. Infrared light penetrates more 
easily through the optical media and has a reduced absorption and increased reflection both by 
melanin and haemoglobins when compared to light of wavelengths shorter than 585 nm. Since at 
787 nm near infrared light is barely visible, the technique is very patient friendly. The 
chromophore of AFI is lipofuscin, excessive accumulation of which in lysosomes of RPE cells is a 
common finding in a variety of hereditary and degenerative retinal disorders10,11,12. RPE-lipofuscin 
seems to derive predominantly from incomplete digestion of photoreceptor outer segments and 
there is accumulating evidence suggesting an important role of lipofuscin in RPE cell dysfunction 
and cell loss16-24. Both techniques are now often used in a whole range of retinal diseases, 
including inherited retinal dystrophies, both to detect early signs of disease as well as better and 
detailed description of the phenotype 10-15. 
We provide data on twenty-two molecularly proven PXE patients and twenty-five PXE 
carriers, which illustrate that infrared and autofluorescence imaging are more sensitive than white 
light funduscopy and imaging in visualising both early and more evolved signs of PXE 
retinopathy. These techniques thus represent an important additional tool in the diagnosis and 
ophthalmic follow-up of PXE families. 
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Patients and Methods 
Twenty-two patients with a clinically (dermatological and ophthalmological examination, 
skin biopsy) and molecularly (ABCC6 analysis) confirmed diagnosis of PXE, and twenty-five 
obligate carriers with one proven ABCC6 mutation were studied. As such, phenocopies of PXE 
associated with beta-thalassaemia and PXE-like syndrome with identical retinal characteristics 
compared with classic PXE were excluded 8,9. The respective age of patients and carriers ranged 
from 11 to 68 years (mean 43 years) and 15 to 76 years (mean 44 years). All underwent a 
complete ophthalmic examination, including assessment of best-corrected visual acuity (BCVA), 
slitlamp examination, fundoscopy and extensive fundus imaging. Fluorescein and indocyanin 
green angiography and optical coherence tomography (Stratus OCT, Carl Zeiss Meditec Inc, 
Dublin, California, USA) were performed when and where required. Ocular ultrasonography (OTI 
scan Ophthalmic Ultrasound, Ophthalmic Technologies, Toronto, Canada) was used to evaluate 
(potential) optic disc drusen. Fundus imaging consisted of white light digital photography with a 
Topcon TRC-50EX fundus camera (Topcon Corporation, Tokyo, Japan). Fundus 
autofluorescence, red free and infrared monochromatic images were obtained using a confocal 
scanning laser ophthalmoscope (cSLO; Heidelberg Retina Angiograph HRA2; Heidelberg 
Engineering, Dossenheim, Germany), the optical and technical principles of which have been 
described previously10-15. The HRA2 cSLO has a small pinhole aperture, suppressing light 
originating from outside the focal plane to enhance image contrast compared with nonconfocal 
images. It uses an argon blue laser light with a wavelength of 488 nm for excitation and a barrier 
filter with a cut off at 500 nm to record fundus autofluorescence and red free imaging. For near 
infrared imaging, the excitation wavelengths is 787 nm and a barrier filter allows light passage 
above 810 nm. Full-emission spectra are recorded via a polarization filter to obtain red-free and 
infrared images. Before acquisition of the autofluorescence sequence, illumination and focus level 
were adjusted to individual requirements at the infrared mode of the device, in order to generate 
high quality images.  Infrared, autofluorescence and red free images, in series of approximately 
50 single pictures per eye, were generated using a 30-degree field-overview mode. The images 
encompassed the entire macular area, retinal midperiphery and periphery. Following acquisition, 
any images containing eye movements, blinks or uneven illumination were discarded. After 
automated alignment and averaging to improve signal to noise ratio by image analysis software 
(Heidelberg Eye Explorer, Heidelberg engineering, Dossenheim, Germany) mean images were 
used for further analysis10. Finally, HRA 2® software was applied on selected individual and 
mean images of excellent quality to generate a seamless montage of the entire fundus in AF, RF 
and IR mode. 
All images were analysed for various ocular manifestations of PXE, including angioid 
streaks, peau d'orange, comets, comet tails and optic disc drusen, in both early, neovascular and 
advanced atrophic stages of the disease. Autofluorescence and infrared images were compared 
with the colour pictures. AF was defined as low (hypo-autofluorescence; AF signal lower than 
background), high (hyperautofluorescence; AF signal higher than background) or unchanged 
compared to normal background autofluorescence. On infrared images the choroidal vessel 
contrast is usually negative (dark vessels on light fundus background), the retinal vessels and the 
optic disc rim appear dark or have dark borders with respect to the surrounding fundus14. 
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Informed consent was obtained from all patients and carriers and all procedures were in 
accordance with the Declaration of Helsinki protocol. The study was approved by the Ethical 
Committee of the Ghent University Hospital. 
Results  
Eight male and fifteen female PXE patients were included in this study. BCVA ranged 
from 12/10 to 1/300. All patient fundi examined revealed at least one characteristic of the PXE 
retinopathy, which was always present in both eyes of each individual (table 1). 
All patients except the youngest patient, a boy of 11 years old, had angioid streaks in 
both eyes, which could be visualised with colour imaging, RFI, AFI and IRI.  
On standard digital colour imaging, streaks could be divided in those with or without adjacent 
RPE alterations. Streaks lacking bordering RPE abnormalities were seen as the typical brick red 
coloured streaks, presenting as irregular and jagged lines radiating from a concentric peripapillary 
ring towards the equator of the eye. In some patients, these were limited to a few almost 
imperceptible lines (fig. 1) whilst in other patients they presented as thick jagged lines (fig. 2) with 
an at times complex interlacing network (fig. 3). Angioid streaks were always most prominent at 
the posterior pole and typically tapered and faded whilst approaching the equator of the eye, with 
an arborescent pattern of progressively smaller branches. In rare cases (2/22) they continued 
beyond the equator as irregular, white and depigmented lines, possibly representing calcium 
deposition in and around the streak (fig. 4). 
With infrared imaging, angioid streaks appeared as uniform, well-demarcated dark fissures 
against a lighter background, even when they passed unnoticed on colour imaging. This classic 
type of streaks had no visually obvious correlate on AFI, although traces could sometimes be 
discovered when comparing with IRI (figs. 1 & 6). However, autofluorescence imaging sometimes 
showed a reticular pattern of hyperautofluorescence in the macular area, remeniscent of 
patterned hypercalcification of the Bruch membrane in the posterior pole (Fig 1c). Only the 
youngest of 22 patients did not have angioid streaks (fig. 8). 
In all fundi, RPE alterations, mostly loss of pigment and more rarely hyperpigmentation, were 
observed adjacent to some of the streaks. 
RPE hypopigmentation, seen in 26 fundi of 13 patients, yielded a “feathered” appearance to the 
streak on colour imaging (fig. 5). With AFI, the feathered streaks and surrounding area depleted 
of pigment, appeared as a triangular area of hypo-autofluorescence, with the base of the triangle 
oriented towards the optic disc. IR imaging depicted these feathered streaks in a similar way as 
colour photography did. In older and larger streaks, small islands of normal autofluorescence 
could be observed within the streak. Such islands in the older, larger streaks are better visible in 
IRI than on colour pictures. (figs. 7 & 11). 
Hyperpigmented RPE alterations were seen as dark brown, round or oval zones of variable size 
along areas of streaks or in atrophic macular scars in 4 patients. Equal in aspect to atrophic 
areas, on AFI these appear as hypo-autofluorescent lesions with the same size (Fig. 9). On IRI, a 
limited hyperintensity was noticed compared to the background was detected. However, this 
would pass unnoticed on the basis of IR evaluation alone (fig. 9). 
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Peau d'orange, which, according to some investigators, represents a widespread and 
patchy increase of pigment in the RPE cells1,2, could potentially also be due to changes in BM 
architecture. Indeed, calcification and fragmentation of elastic fibers, which lead to dermal peau 
d’orange lesions, may also underlie the fundus lesions. The speckled or mottled appearance from 
the macula to the midperiphery, was seen in 36 (change number after inclusion of new patients) 
fundi. On colour pictures, this fine mottling was visible in the nasal retina and temporal fundus 
between the macula and the equator of the eye. On AFI, no difference in autofluorescence was 
observed in regions of peau d'orange. However, IR imaging always revealed a diffuse speckled 
pattern of peau d'orange, extending beyond the temporal midperiphery (fig. 8). In 55% of fundi 
(24/44), the peau d’orange area covered the entire midperiphery to the equator and the posterior 
pole, including the entire macula. Extensive macular atrophy and/or scarring precluded evaluation 
of  peau  d’orange  in  10  fundi.  The  overall  extent  of  peau  d’orange,  was  best  appreciated  on 
composite infrared images of the fundus, with often a far larger area considered affected than that 
visible on white light digital fundus images. 
Comets and/or comet tails were observed as solitary, subretinal, nodular, white bodies 
with a tapered white tail of RPE atrophy extending posterior to the body on colour images in 90% 
(38/42) of the examined fundi. The body may have some pigmentation at its margin. AFI showed 
small, punctiform hyperautofluorescent lesions but could not detect all comets individually. IR 
imaging was able to visualize several comets, which went undetected on colour, as small white 
hyperintensities. However, the most sensitive technique in detecting those pathognomonic 
lesions was RFI. With the latter all of these were seen as whitish flecks on a gray background (fig. 
10). In some fundi, a spray of comets and comet tails was observed, creating an aspect of “comet 
rain” (fig. 10).  
 Optic disc drusen, thought to be composed of hyalin-like calcific material within the 
substance of the optic nerve head, were seen binocularly in 2 patients and uniocularly in 1 patient 
using colour imaging and AFI. On standard ophthalmoscopy, buried drusen could be suspected 
due to an elevated disc with a scalloped margin and without a physiological cup. Surface drusen 
of the disc appear as waxy pearl-like irregularities. Drusen on the surface of the optic nerve head 
may be visible with autofluorescence, but if they lie deeper, i.e. on the nerve fibers, the optic disc 
may look normal. In such cases ultrasonography is indispensable. On AFI, superficial drusen 
were visualized unambiguously in all examined fundi because of the hyperautofluorescence of 
the optic disc without attenuation of the signal by overlying tissue (fig. 11). On confirmation B-
scan ultrasonography, the drusen were recognized by their high acoustic reflectivity. Optic disc 
drusen could be suspected on IR imaging and RF imaging afterwards, albeit that they did not 
stand out in these images. 
Fibrovascular scars following choroidal neovascularisation in the macular area were 
observed in 17 eyes. Autofluorescence in these end-stage fundi was very low in areas of atrophy 
and high in the junctional zone separating atrophic zones from surrounding, more normal retina. 
In 5 patients, additional lobular hypo-autofluorescent lesions were noted on AFI, adjacent to but 
separated from the fibrovascular scars. In 2 patients, previously treated with photodynamic 
therapy, a paler zone was observed around the area of choroidal neovascularisation on colour 
imaging (Fig 3). On AFI the borders of a uniform hypo-autofluorescent zone correlate with the 
borders of the paler zone found around the fibrovascular scar on colour pictures. These paler 
zones appeared as an atrophic area on IR imaging. 
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In eight of the twenty-five carriers (3 males and 5 females) examined, comets and comet 
tails were observed. In 3 carriers the appearance of the comets were similar to those seen in PXE 
patients. However, in 5 carriers comets were limited to small white dots with neither 
hyperpigmented borders nor comet tails. No other abnormalities of fundus autofluorescence or 
infrared imaging, such as limited peau d'orange or angioid streaks were observed. 
Case Age, sex Eye BCVA AS Pd’O C(T) ODD NV PDT Anti-VEGF ABCC6 mutations 
1 61, F OD 2/10 + + + - + + - p.R1459C/- 
  OS 9/10 + + + - + + -  
2 43, F OD 12/10 + + + - - - - p.R1141X/p.R1141X 
  OS 12/10 + + + - - - -  
3 35, M OD 11/10 + + + - - - - p.E125K/p.L1025P 
  OS 1/300 + + + - + + +  
4 21, M OD 10/10 + + + - - - - p.R1141X/p.R1141X 
  OS 10/10 + + + + - - -  
5 11, M OD 10/10 - + + - - - - c.3506+2T>C/- 
3506+2T>C 
 
  OS 10/10 - + + - - - -  
6 55, F OD 1/20 + + + - + - - p.R1141X/p.R1141X 
  OS 1.5/10 + + + - + - -  
7 40, M OD 4/10 + + + - + + - p.R265G/p.R1141X 
  OS 1/10 + + + - + + -  
8 22, F OD 10/10 + + + - - - - p.R1141X/p.R1141X 
  OS 10/10 + + + - - - -  
9 29, F OD 10/10 + + + - - - - p.G1263R/c.4182delGG 
  OS 10/10 + + + - - - -  
10 20, M OD 10/10 + + + + - - - c.3507-3C>A/p.T944I 
  OS 10/10 + + + + - - -  
11 37, F OD 10/10 + + + + - - - p.Q154R/- 
  OS 9/10 + + + + - - -  
12 66, F OD 1/20 + - - - + - - p.R1141X/p.R1141X 
  OS 1/10 + - - - + - -  
13 68, F OD 10/10 + - - - - - - p.R760Q/p.R1141X 
  OS 10/10 + - - - - - -  
14 68, M OD 2/10 + - + - + - - p.A1303P/p.L946I 
  OS CF + - + - + - -  
15 58, F OD 7/10 + + + - + - + p.R1141X/c.4103delC 
  OS CF + + + - + + -  
16 62,M OD 1/20 + + + - + - + p.R1141X/p.Q1237X 
  OS CF + + + - + - -  
17 47, F OD 10/10 + - - - - - - c.3506+2T>C/- 
   OS 10/10 + - 
- 
- - - - -  
18 54, F OD 10/10 + + + - + - + p.R1141X/p.A1303P 
  OS 10/10 + + + - - - -  
19 30, F OD 10/10 + + + - - - - p.S398R/c.3364delT 
  OS 10/10 + + + - - - -  
20 39, F OD 12/10 + + + - - - - p.R1141X/- 
  OS 10/10 + + + - - - -  
21 30, F OD 10/10 + + + - - - - p.G666R/c.1868-5T>G 
  OS 10/10 + + + + - - -  
22 34, M OD 12/10 + + + - - - - c.3364delT/p.R518X 
  OS 12/10 + + + - - - -  
Table 1 
Ophthalmologic characteristics of patients in the present study. BCVA: Best Corrected Visual Acuity, CF: Counting 
Fingers;  AS:  Angioid  Streaks;  Pd’O:  Peau  d’Orange,  C(T):  Comet  (tails);  ODD:  Optic  Disc  Drusen;  NV: 
Neovascularisation; MD: Macular Degeneration; PDT: Photodynamic Therapy; anti-VEGF: anti-Vascular Endothelial 
Growth Factor antibodies 
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Discussion  
Visualizing the PXE retinopathy with AF and IR imaging  
Pseudoxanthoma elasticum manifests with cutaneous, ophthalmological and 
cardiovascular symptoms, with considerable morbidity1,2,3. Because of significant intra- and 
interfamilial variability in phenotypic severity, making a correct clinical diagnosis of PXE is often 
difficult, with consequent delay of a potentially essential, early intervention. 
This study aimed to evaluate whether novel imaging techniques, such as monochromatic 
infrared and autofluorescence imaging with cSLO, are able to better visualize the PXE 
retinopathy compared to standard digital colour fundus pictures, thereby facilitating early 
diagnosis. 
Angioid streaks were observed in all but one fundi, as expected, and could be classified 
into two types, based on whether or not they were accompanied by surrounding RPE alterations. 
All eyes contained a mixture of both types. In the absence of RPE alterations, AFI was not able to 
visualize the streaks - even with multiple contrast settings. In contrast, angioid streaks were very 
distinct on IR imaging compared to colour fundus photography, and are visible as well-
demarcated, dark fissures with high contrast to surrounding tissues. Hence, streaks either absent 
or initially unnoticed on colour pictures were detected with IRI. Streaks with concomitant RPE 
alterations showed a feathering pattern, pigmented borders and/or deposits in the middle of the 
streaks. On AFI, the overall autofluorescence intensity of these feathered streaks appeared 
lower, which might be explained by loss of lipofuscin in the RPE cells adjacent to the streaks. The 
pathological substrate of this finding could be absence of photoreceptors, RPE atrophy, RPE 
proliferation with hyperpigmentation, a decrease of outer segment phagocytosis by RPE cells, or 
a combination of several of these. Since none of the patients suffered from scotomas in the areas 
of streaks, which would be expected in case of absent photoreceptors or RPE atrophy, the latter 
three possibilities seem the most plausible25. The hyperpigmented borders appeared as uniform 
dark hypo-autofluorescent zones with the same size compared to those in the colour images. The 
decreased autofluorescence could indeed be due to proliferation of the RPE cells at the borders 
which block AF and to attenuation due to dysfunction of RPE cells overlying the streak which lose 
their lipofuscin17. The presence of dotted areas of normal autofluorescence within longstanding 
angioid streaks visualised on AF pictures, may represent normal zones of RPE and potentially 
BM in the center of streaks, due to fragmentation of the main body of the RPE at the streak 
margin. For these streaks associated with RPE alterations, IR imaging did not reveal any 
significant difference compared to colour photography. 
Media opacities including lens opacification may result in AF images that are of insufficient quality 
if at all they can be obtained. Such opacities do not hamper IR imaging, due to better penetration 
of long-wavelength light. 
Together, these observations suggest that a combination of AF and IR imaging is essential for 
optimal visualisation of the different types of angioid streaks and as such is superior to colour 
imaging for the early detection and follow-up of angioid streaks. 
It has been suggested that angioid streaks could disappear in patients with longstanding PXE26. 
We observed streaks becoming obscured by extensive chorioretinal scarring and accompanying 
proliferation of the retinal pigment epithelium. However, on colour, AF and IR imaging, distinctive 
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remnants of streaks persisted at the periphery of such lesions, suggesting that angioid streaks 
are persistent throughout the natural history of the disorder. 
Although peau d'orange has previously been described as granular stippling on AFI26, the 
pigment alterations seen on colour imaging did not yield any significant difference in fundus 
autofluorescence in the present study. On infrared imaging, we observed the peau d'orange to be 
more widespread than originally described, and present throughout the posterior pole and the 
whole midperiphery. This might be due to pure technical reasons, since IR imaging is less 
compromised by macular lutein and zeaxanthin pigment. This observation further strengthened 
our belief that this technique has a significant higher sensitivity in detecting changes of the outer 
retinal layers compared to colour fundus imaging. 
We found IR imaging to be also superior in visualising comets and comet tails in 
combination with RF imaging. Even comets barely visible or absent on colour pictures could be 
seen with IRI and RFI. In contrast, on AFI not all comets were recognised. If comets and comet 
tails indeed are the only pathognomonic ocular characteristic of PXE7, they are of significant 
diagnostic value, especially in young patients in whom angioid streaks are often not yet present 
(fig. 14). Since they can also occur in carriers, a thorough skin evaluation and molecular analysis 
of the ABCC6 gene is indicated when such lesions are detected. 
Drusen of the optic disc seem to be more common in PXE than in the general 
population27. AFI proved to be efficient in detecting these optic disc drusen which were confirmed 
on ultrasound. It may be assumed that a common process of abnormal mineralisation might be 
the predisposing factor both for drusen of the optic nerve head and for comets and comet tails. 
In end-stage fundi, increased autofluorescence in the junctional zone around atrophic 
areas may represent areas of future RPE atrophy11. However, these findings are of limited 
predictive value. The standard examinations to detect subretinal neovascularisation in such 
patients remain fluorescein and indocyanine green angiography. 
Conclusion  
Because of extensive variability in clinical severity, the diagnosis of PXE is often delayed 
until ophthalmological complications occur. Since novel ophthalmic therapeutic agents, such as 
different agents with anti-VEGF action, have become available, the need for an early diagnosis 
has become even more important. The present study showed that infrared, red-free and 
autofluorescent imaging are of significant clinical relevance in PXE, as they contribute to 
improved imaging quality and hence early diagnosis and more adequate follow-up. Serial, 
prospective investigations of patients with these techniques can give us important clues as to the 
natural history of this complex disorder. As such, we consider them part of the standard 
evaluation of novel and known PXE patients and their family members. 
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Figure 1 
From left to right and top to bottom: 
 
Fig 1: RE of female patient 18, with angioid streaks limited to a few almost imperceptible lines on fundus image radiating 
from a concentric peripapillary ring towards the equator (a); fine streaks better visible on IRI (b) but not on AFI (c); 
however, AFI shows reticular pattern of hyperautofluorescence in macular area, reminiscent of patterned 
hypercalcification of Bruch membrane in posterior pole 
 
Fig 2: RE of female patient 2 with angioid streaks showing as thick jagged lines 
 
Fig 3: Angioid streaks in LE of male patient 3 form complex interlacing network; in addition, atrophy and scar of subretinal 
neovascular membrane after consecutive treatment with photodynamic therapy and intravitreal bevacizumab are visible in 
macular area; white lesions around some angioid streaks may represent chorioretinal calcification 
 
Fig 4: Angioid streaks in periphery may become (partially) calcified with whitish aspect as seen in nasal periphery of LE of 
female patient 6 
 
Fig 5: Aspect of feathered type of angioid streaks in RE of young female patient 8 on white light (a), infrared (b), 
autofluorescence (c) and red-free imaging (d); note better visibility of the streaks as whitish areas on IRI and RFI than on 
white light fundus imaging; streaks appear as dark areas on AFI 
 
Fig 6: Parallel white light, infrared and autofluorescence images of infrapapillar angioid streak in LE of female patient 15: 
whereas streak is better visible on IRI (b) than on fundus image (a), it is hard to see on AFI (c) 
 
Fig 7: RE of female patient 20: small islands of normal retinal tissue within older, broader streaks showed normal 
autofluorescence, but are better visible in IRI (b) than on colour pictures (a) or AFI (c) or RFI (not shown) 
 
Fig 8: Peau d’orange much more extensively visible on IRI (b) than on colour fundus image (a) in 11-year old male patient 
5; note extension of peau d’orange changes around the whole posterior pole on IRI; no angioid streaks present at this 
early age, although comets and comet tails are visible 
 
Fig 9: Hyperpigmentation due to RPE hyperplasia in macular scar after PDT treatment (a); hyperpigmentation and atrophy 
appear as dark areas on AFI (c); hyperpigmentation appears as a light zone on IRI (b), and black on RFI (d) 
 
Fig 10: A burst of comets and comet tails inferior to optic disc of female patient 19; note that the comets are best visible 
on RFI (d) compared to colour fundus imaging (A), IRI (b) and AFI (c); in addition, broad angioid streaks emanating from 
the optic disc are best seen on IRI (b) and colour fundus image (a) 
 
Fig 11: Superficial optic drusen in LE of patient 11 (a) visualised unambiguously on AFI because of 
hyperautofluorescence of optic disc (c); disc drusen could be suspected on IRI imaging (b) and RFI imaging (d) albeit that 
they did not stand out; note areas of normal retinal tissue within broad angioid streaks inferotemporal of fovea 
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Publication 6 
Heterozygous ABCC6 mutations in ischemic stroke patients: 
initial experience 
 
Olivier M. Vanakker, Paul J. Coucke, Bart P. Leroy, Julie De Zaeytijd, Jacques 
De Reuck, Anne De Paepe. 
 
Submitted to Neurogenetics  
 
 
 In this pilot study, 206 patients admitted to the Stroke Unit of the Department of 
Neurology of the Ghent University Hospital because of ischemic stroke were examined both 
clinically and molecularly in order to detect any previously unnoticed PXE patients or 
heterozygous mutation carriers. The protocol consisted of:  
 
 1/ a careful dermatological examination; 
 
 2/ a funduscopic evaluation of the retina using white light;  
 
3/ and molecular analysis of the recurrently mutated ABCC6 exons (exon 18, 24, 28 and   
    29), as defined in paper 1. 
 
 Although no novel PXE patients could be identified in this stroke population, we were 
able to show heterozygous ABCC6 mutations to be significantly associated with ischemic stroke. 
This exploratory pilot study suggests limited value of systematic clinical evaluation of stroke 
patients for PXE. Data are however promising in implicating heterozygous ABCC6 mutations to 
be associated with sporadic ischemic stroke.  
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Abstract 
 
Evidence is emerging that ischemic stroke results from the complex interplay between 
environmental and genetic risk factors. One method to identify genetic factors, is a candidate 
gene approach. Because of the increased incidence of ischemic stroke in pseudoxanthoma 
elasticum – an autosomal recessive disease caused by mutations in the ABCC6 gene – and the 
higher cardiovascular risk in carriers of one ABCC6 mutation, we investigated whether 
heterozygous ABCC6 mutations are more frequent in ischemic stroke patients compared to the 
general population.  
 
In 206 consecutive ischemic stroke patients, clinical evaluation could not reveal features 
of PXE, while ABCC6 hotspot analysis identified 12 carriers of one ABCC6 mutation in the stroke 
group compared to two carriers in a control group of 197 individuals. The calculated Odds Ratio 
was 6.062 (p =0.012; 95% CI 1.4-24.4). 
   
This exploratory pilot study suggests limited value of systematic clinical evaluation of 
stroke patients for PXE. Data are however promising in implicating heterozygous ABCC6 
mutations to be associated with sporadic ischemic stroke.  
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Introduction 
 
Stroke, one of the leading causes of death and long-term disability worldwide, is known to 
have a heterogeneous etiology. In ischemic stroke – which is the most common form of stroke 
accounting for over 80% of stroke events – known risk factors (arterial hypertension, 
dyslipidaemias, diabetes mellitus, cigarette smoking, peripheral artery and cardiac disease) are 
insufficient to explain stroke risk, making it likely that other causal risk factors and pathways are 
involved [1,2]. Studies in twins, families and animal models provide substantial evidence for a 
genetic contribution to ischemic stroke [1]. In recent years, it has become clear that stroke can 
either occur in the context of monogenic disorders or, more frequently, result from the interplay 
between modifiable risk factors and genetic susceptibility [2]. Several association studies have 
described DNA variants, mostly polymorphisms, to be associated with an increased or decreased 
risk for stroke, while linkage studies identified a number of gene loci possibly involved in stroke 
[3-12].  
One of the monogenic disorders occasionally associated with stroke is pseudoxanthoma 
elasticum (PXE; OMIM# 264800). This autosomal recessive disorder is characterized by 
mineralization and fragmentation of elastic fibers and is caused by mutations in the ABCC6 gene 
(ATP-binding cassette C6 - OMIM# 603234), encoding an ATP-dependent transmembrane 
transporter [13]. PXE affects the skin (coalescent yellowish papules in flexural areas of the body), 
the eyes (retinopathy with angioid streaks, leading to vision loss) and the cardiovascular system 
(occlusive arterial disease) [14,15]. We have observed a significant increase in the prevalence of 
ischemic stroke in PXE patients, suggesting that a disabled ABCC6 pathway may play an 
important role in stroke pathophysiology [15]. Furthermore, heterozygous carriers of one ABCC6 
mutation (e.g. parents and children of a PXE patient) have been shown to be at a higher risk for 
coronary and peripheral artery disease, although they do not develop skin features or ocular 
problems [15,16,17]. Little is known however about a possible association between heterozygous 
ABCC6 mutations and sporadic ischemic stroke, although we previously noted PXE carriers to be 
prone to ischemic stroke [15]. As the carrier frequency of one ABCC6 mutation in the general 
population has been estimated to be ~1%, an association with disease could be important for 
public health [18].  
To examine the feasibility and potential relevance of clinical examination for presence of 
PXE features and molecular analysis of the ABCC6 gene in ischemic stroke patients, an 
exploratory pilot study was designed, involving 206 consecutive patients with confirmed ischemic 
stroke who were admitted to the Stroke Unit of the Ghent University Hospital. While not being 
able to detect true PXE patients in this cohort, we demonstrated heterozygosity for ABCC6 
mutations to be more prevalent in an ischemic stroke population, compared to the general 
population.  
 
Patients and Methods 
 
Patient selection 
Two-hundred and six consecutive patients admitted to the Stroke Unit of the Ghent 
University Hospital between March 2004 and August 2007 with a proven diagnosis of ischemic 
stroke were approached for written consent to participate in the study. In case of will inaptitude, 
the closest relatives gave informed consent. Patients with cerebral haemorrhage or cerebral 
venous thrombosis were not included.  
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Baseline demographic data (age, sex) and history of conventional risk factors (hypertension, 
diabetes, hypercholesterolaemia, current smoker, peripheral and coronary vascular disease, 
valvular disease) were obtained (table 1).  
 
 Cases (n=206) Controls 
(n=197) 
p-value 
Mean age (± SD) 69 (± 11,5) 67 (± 11,5) 0,08 
Sex (M:F ratio) 1,45 1,01 0,07 
Hypertension (%)*,‡ 150 (73) 0 <0,0001 
Diabetes Mellitus (%) 49 (23) 34 (17) 0,11 
Dyslipidaemia (%)‡ 72 (35) 18 (9) 0,17 
Smoking (%) 18 (7) 10 (5) 0,015 
Heart valve disease‡ 7 (3) 0 <0,0001 
Coronary disease‡ 56 (27) 0 <0,0001 
Peripheral vascular disease‡ 35 (17) 0 <0.0001 
Table 1 
Demographic characteristics of cases and controls. *Hypertension defined as bloodpressure > 160/90 or history of 
hypertension or hypertensive treatment ; † History of diabetes or confirmed laboratory diagnosis; ‡ Significant differences 
(p<0.05) between cases and controls 
 
On admission for their stroke a detailed medical history, including vascular risk factors 
and previous treatments, was obtained in all patients. All patients had a complete clinical 
evaluation and underwent a full cardiovascular examination, including ECG, chest X-ray and 
routine blood analyses, Doppler sonography of the extracranial arteries, 24-h electrocardiogram 
monitoring and transthoracic echography of the heart. CT scan of the brain was performed on 
admission after stroke and repeated within 2 weeks. Transoesophageal echocardiography, 
cerebral MRI and MR angiography and/or conventional angiography were carried out at the 
discretion of the clinician. The stroke types were classified according to the Trial of ORG 10172 in 
Acute Stroke Treatment (TOAST) criteria (table 2) [19]. All patients underwent thorough skin 
inspection of the flexural areas and lip mucosa to assess possible skin and/or mucosal lesions 
and funduscopy to evaluate the presence of a PXE retinopathy.  
The control population consisted of a group of 197 Belgian individuals, age-matched with the 
study group, undergoing a routine check-up and presenting without known cardiovascular events. 
A blood sample was obtained from patients and controls for molecular analysis of the ABCC6 
gene. 
This study was approved by the Ethical Committee of the Ghent University Hospital and 
the Declaration of Helsinki Principles was followed. 
 
Molecular analysis of the ABCC6 gene 
Molecular analysis of the ABCC6 gene was limited to the most prevalent mutations, i.e. 
the p.R1141X nonsense mutation (c.3421C>T), the multi-exon deletion spanning exons 23-29, as 
well as four previously defined recurrently mutated exons (exon 18, 24, 28 and 29) [15]. We 
showed previously that this detection strategy allows to identify 75% of all ABCC6 mutations in a 
Belgian population, thus being representative for the whole ABCC6 mutation spectrum [15].  
Genomic DNA was isolated from whole blood (QIAamp blood kit, Qiagen®) according to an 
established procedure. The ABCC6 coding region was amplified using previously described PCR 
primers [20].  
For the detection of the exon 23-29 deletion, primers were used as described by Le Saux et al. 
[13].  
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The coding region and intron/exon boundaries of ABCC6 were analyzed through direct 
sequencing using an Applied Biosystems 3730xl Sequencer®, with ABI PRISM BigDye 
Terminator Cycle Sequencing Kit (Applied Biosystems®). Unreported sequence variants were 
defined as causative according to criteria reported by Cotton and Scriver, 1998. Nucleotide 
numbers are derived from gDNA ABCC6 sequences (GenBank accession no. NM_001171) 
 
Statistical analysis 
Differences in allelic frequencies between patients and controls were examined using the 
two-tailed  Fisher’s Exact  test.  Logistic  regression  analysis  was  used  to  assess modification  of 
mutation-stroke interaction by cardiovascular risk factors (hypertension, dyslipidaemia, diabetes 
mellitus, and smoking). Results were expressed as odds ratios (OR) and their 95% confidence 
intervals (CI). An OR of<1 corresponds to a reduced risk of disease; an OR of >1 with an 
increased risk. The significant level was set at α=0.05 two-tailed. 
 
Results 
 
The study group consisted of 206 consecutive unrelated patients admitted with ischemic 
stroke (122 men, 84 women; mean age 69 ± 11.5 years) and 197 control individuals (99 men, 98 
women, mean age 67 ± 11.5 years). Distribution of subtypes of stroke is presented in table 2. 
Most cases were due to large vessel disease or cardio-embolic strokes.  
 
Subtype All stroke samples 
 Number % 
Large Vessel Disease (LVD) 96 47 
Small Vessel Disease (SVD) 41 20 
Cardio-embolic Stroke 49 23 
Other/Unclear 20 10 
TOTAL 206 100 
Table 2 
Different stroke subtypes based on TOAST classification 
 
Thorough skin and ophthalmological evaluation was not able to reveal characteristic skin 
lesions or features of the PXE retinopathy in any of the examined patients. Subsequently, we 
analyzed the previously identified recurrently mutated exons and evaluated the presence of the 
multi-exon deletion spanning exons 23 through 29. A total of 12 mutations was identified, all of 
which were in the heterozygous state. Two mutations were recurrent, i.e. the frequent p.R1141X 
nonsense mutation was found in 2 patients, and the multi-exon 23-29 deletion was present in 3 
patients (table 3). The other mutations were unique and included 1 previously reported splice site 
mutation, 1 deletion and 5 missense mutations, 2 of which were novel (p.E1376A, p.I1345T). All 
missense mutations altered amino acids that are highly conserved among orthologs (Mus 
musculus, Rattus norvegicus, Danio rerio and Fugu rubripes) and conserved in paralogs. They 
were not found in a panel of 200 control individuals. In the stroke population, seven mutations 
were located within exon 29 or caused deletion of this exon. The remainder were located in exon 
24 (p.R1141X) or 28 (p.I1345T). No mutations were detected in exon 18. 
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Pat. S 
E 
X 
Current 
age (yrs) 
Stroke 
Type 
N Age at first 
Event (yrs) 
Cardiovascular risk factors F 
H 
Mutation* 
005 F 71 SVD 2 ? - - c.4208+9G>A - 
006 F 61 SVD 1 61 Hyperhomocysteïnaemia + Del23-29 - 
026 M 74 LVD 2 74 HCh (R/) - c.4104delC - 
035 M 67 CE 1 67 HCh (R/) - c.3421C>T p.R1141X 
037 F 79 LVD 1 79 AHT (R/), DM (R/) + c.4127A>C p.E1376A 
065 F 43 LVD M ? - + c.4127A>G p.E1376G 
088 M 64 LVD 1 64 - - Del23-29 - 
098 M 78 SVD M ? AHT (R/); HCh (R/), tabagism - c.4168G>A p.E1400K 
135 F 63 LVD 1 63 - - c.3421C>T p.R1141X 
143 F 53 LVD 1 53 DM, HCh (R/) - c.4082A>G p.D1361G 
146 F 74 CE 2 59 DM (R/) - c.4043T>C p.I1345T 
166 M 71 CE 1 71 AHT, tabagism - Del23-29 - 
Table 3 
Clinico-molecular characteristics of the 12 stroke patients carrying an ABCC6 mutation. N: Number of stroke events; FH: 
Familial history; SVD: Small vessel disease; LVD: Large vessel disease; CE: Cardio-embolic stroke; M: Multiple; HCh: 
Hypercholesterolaemia; R/: Adequately treated; AHT: Arterial hypertension; DM: Diabetes mellitus *GenBank accession 
no. NM_001171.2. For cDNA numbering +1 corresponds to the A of the ATG translation initiation codon 
 
Molecular analysis of the control population revealed a mutation (p.R1141X) in only two 
individuals (aged 52 and 64). The calculated OR for the presence of an ABCC6 mutation was 
6.062 (p=0.012; 95% CI 1.4-24.4). Logistic regression analysis for cardiovascular risk factors 
(arterial hypertension, dyslipidaemia, diabetes mellitus, smoking, peripheral artery and cardiac 
disease) as modifiers of the interaction between the detected mutations and stroke did not yield 
significant results. 
Besides these causal mutations, several ABCC6 polymorphisms were detected, most of 
which were intronic and were predicted not to affect splicing. Of the exonic polymorphic variants, 
p.Q1390E (c.4168C>G; exon 29) was found in 3 patients.  
The clinical characteristics of the stroke patients in which a heterozygous ABCC6 
mutation was found are listed in table 3. The mean age of these patients (7 female and 5 male) 
was 66 years (range 43-79 years). Six patients (50%) presented with large vessel disease. The 
remaining patients suffered from small vessel disease (25%) of cardio-embolic stroke (25%). 
About half of the patients had a history of one or more previous cerebrovascular disease 
episodes. A positive familial history of stroke was found in only 3 patients. 
  
Discussion 
 
Ischemic stroke is observed in a number of monogenic disorders, one of which is PXE. 
However, the majority of strokes have a multifactorial etiology. Strong evidence from 
epidemiological and animal studies have implicated genetic influences in the pathogenesis of 
ischemic stroke. The identification of individual causative mutations is difficult, in part because 
genetic influences are likely to be of polygenic nature. In the present study, we have used a 
candidate gene approach to investigate the contribution of genetic factors in ischemic stroke. 
Indeed, we observed a remarkable increase in ischemic stroke incidence in Belgian PXE patients 
compared to the general population [15]. As heterozygous carriers of 1 ABCC6 mutation have 
been suggested to have an increased risk for cardiovascular events, we investigated whether the 
incidence of PXE patients with a mild phenotype or heterozygous carriers of PXE is increased in 
an ischemic stroke population.  
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Despite thorough dermatological and ophthalmological screening of all 206 patients, we 
were not able to detect mild or previously unnoted PXE features. Previously, four young PXE 
patients have been described in whom the presenting complaints were cardiovascular 
complications [23]. Although the mean age in this study population is significantly higher, our 
findings do not demonstrate an increase of (homozygous) PXE patients with a mild phenotype 
among the  cerebrovascular patient cohort. Nevertheless, it remains of interest to perform a brief 
and inexpensive skin and fundoscopic examination, particularly in (young) individuals suffering 
from ischemic stroke without other predisposing vascular risk factors. 
However, molecular analysis of the ABCC6 gene revealed a heterozygous mutation in 12 
patients (6 %). As the estimated carrier frequency of ABCC6 mutations in the general population 
is approximately 1%, this result indicates that heterozygosity for an ABCC6 mutation is a risk 
factor for ischemic stroke with an odds ratio of 6.023. Other risk factors, such as smoking, 
hypertension, diabetes mellitus or dyslipidaemia, did not significantly modify the interaction 
between the mutations and the stroke episode. Considering that the detection rate of mutations 
with our molecular protocol is 75%, it can be postulated that approximately one quarter more 
mutations (i.c. 3 mutations) would have been found if the whole gene would have been 
sequenced. This would increase the proportion of ABCC6 carriers  to 7,2% (OR = 7.6; p=0.002; 
95%CI: 1.9-30.5). One recurrent polymorphism was found in three stroke patients. Although this 
polymorphism resides within the coding sequence of the second nucleotide binding fold (NBF2), 
known to be critical for ATP-binding there is no evidence to suggest that this base pair variant 
would have a functional effect on ABCC6 transport function. 
The stroke phenotypes which are associated with these ABCC6 mutations are diverse, 
including mostly large vessel disease but also small vessel disease and cardio-embolic stroke. 
This distribution – with large vessel disease being the main stroke type – concurs with our 
previous observations in PXE patients [15]. This heterogeneity of stroke phenotypes found to be 
associated with ABCC6 mutations, renders it difficult to delineate a specific subgroup of ischemic 
stroke patients whom might be prone to ABCC6 mutations. Thus, applying this molecular analysis 
in routine diagnostics is precocious at this time. Importantly, a negative familial history should not 
lead to the conclusion that a genetic influence is unlikely. Several of the patients studied had 
additional vascular risk factors for stroke, underscoring that stroke is a multifactorial disorder, in 
which an ABCC6 mutation may act as a genetic susceptibility factor.   
Our findings concur with the previously suggested increased cardiovascular risk in 
heterozygous carriers of ABCC6 mutations and implicate yet another member of the superfamily 
of ABC transporters in the diseased brain. Besides the role of these ATP-dependent proteins in 
drug resistance (e.g. in intractable epilepsy), certain members have been described in relation to 
ischemic stroke [24-26]. ABCB1 expression was found to be elevated after stroke, having a 
deleterious effect on neuroprotective agents [25]. Conversely, two polymorphisms in ABCA1 – the 
causal gene for Tangier disease – were found to be associated with a decreased risk for ischemic 
stroke [26].  
The pilot nature of this study has some limitations. First, the study was done with a 
relatively small sample size, among others because of the intensive character of the physical 
examinations. This sample size may attribute for the large 95% confidence interval which is 
observed. Second, analysis of recurrent mutations as an initial screening method for the ABCC6 
gene, leaves the issue of whether more mutations can be found by performing the full analysis of 
the coding region. These study limitations not withstanding, our data strongly suggest that it is not 
useful to routinely perform physical evaluation of ischemic stroke patients for PXE. Our findings 
appear to be promising in implicating heterozygous ABCC6 mutations in non-syndromic stroke, 
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providing a basis for future studies to validate these results. Such studies should investigate the 
whole coding region of the ABCC6 gene – combining direct sequencing and techniques focussed 
on detecting deletions such as MLPA – in large study cohorts, preferentially combining different 
ethnic backgrounds. 
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3.3 Identification and etiopathogenetic study 
of a PXE related disorder: unravelling a 
common final pathway with PXE  
 
Publication 7 
Pseudoxanthoma elasticum-like phenotype with cutis laxa and 
multiple coagulation factor deficiency represents a separate 
entity. 
 
Olivier M. Vanakker, Ludovic Martin, Dealba Gheduzzi, Bart P. Leroy, Bart Loeys, 
Veronica I.Guerci, Dirk Matthys, Sharon F. Terry, Paul J. Coucke, Ivonne 
Pasquali-Ronchetti, Anne De Paepe. 
 
J Invest Dermatol 2007;127:581-587   
 
This papers gives a detailed account of the identification of a novel disorder in which 
patients initially present with symptoms and signs typical for PXE. During the course of the 
disorder, a generalized increase of inelastic skin folds is observed, resembling cutis laxa and 
hence highly atypical for PXE. The clinical differences with PXE – among which are a mild 
retinopathy and the consistent presence of a clotting deficiency – are discussed, as well as the 
particular electronmicroscopical features of this disease.  
 
 Through a candidate gene approach, we were able to identify the causal gene for this 
disorder as the GGCX gene, coding for an important enzyme in the vitamin K-cycle. These data 
gave important insights in the pathogenesis of this PXE-like disorder – implicating vitamin K-
dependent inhibitors of calcification – and would prove to be of great value to gain insights in the 
final pathway leading to PXE (publication 8).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pseudoxanthoma Elasticum-Like Phenotype with
Cutis Laxa and Multiple Coagulation Factor
Deficiency Represents a Separate Genetic Entity
Olivier M. Vanakker1,2,3, Ludovic Martin4, Dealba Gheduzzi5, Bart P. Leroy1,6, Bart L. Loeys1,
Veronica I. Guerci7, Dirk Matthys3, Sharon F. Terry8, Paul J. Coucke1, Ivonne Pasquali-Ronchetti5
and Anne De Paepe1
Data on six patients with a Pseudoxanthoma Elasticum (PXE)-like phenotype, characterized by excessive skin
folding (resembling cutis laxa) and a deficiency of the vitamin K-dependent clotting factors (II, VII, IX, and X) are
presented. A comparison is made between the clinical, ultrastructural, and molecular findings in these patients
and those seen in classic PXE and cutis laxa, respectively. Clinical overlap with PXE is obvious from the skin
manifestations of yellowish papules or leathery plaques with dot-like depressions at presentation, angioid
streaks and/or ocular peau d’orange, and fragmentation and calcification of elastic fibers in the dermis.
Important phenotypic differences with PXE include much more severe skin laxity with spreading toward the
trunk and limbs with thick, leathery skin folds rather than confinement to flexural areas, and no decrease in
visual acuity. Moreover, detailed electron microscopic analyses revealed that alterations of elastic fibers as well
as their mineralization were slightly different from those in classic PXE. Molecular analysis revealed neither
causal mutations in the ABCC6 gene (ATP-binding cassette subfamily C member 6), which is responsible for PXE,
nor in VKORC1 (vitamin K 2,3 epoxide reductase), known to be involved in vitamin K-dependent factor
deficiency. However, the GGCX gene (gamma-glutamyl carboxylase), encoding an enzyme important for
g-carboxylation of gla-proteins, harbored mutations in six out of seven patients analyzed. These findings all
support the hypothesis that the disorder indeed represents a separate clinical and genetic entity, the molecular
background of which remains to be unraveled.
Journal of Investigative Dermatology advance online publication, 16 November 2006; doi:10.1038/sj.jid.5700610
INTRODUCTION
Pseudoxanthoma Elasticum (PXE – OMIM no. 264800) is an
autosomal-recessive multisystem disease, affecting mainly
the eyes (peau d’orange (Pd’O), angioid streaks (AS), loss of
central vision owing to neovascularization and subsequent
exudation, and hemorrhage), the skin (yellowish papules or
plaques of coalesced papules on the neck and in flexural
areas), and the cardiovascular system (diffuse occlusive
arterial disease). In some patients, the skin lesions can be
progressive, evolving toward excessive skin folding in the
flexural areas (McKusick, 1966; Neldner, 1988; Hu et al.,
2003; Chassaing et al., 2005). Histologically, it is character-
ized by fragmentation and mineralization of the elastic fibers
in the reticular dermis.
PXE is caused by mutations in the ABCC6 gene (ATP-
binding cassette subfamily C member 6 – chromosome
16p13.1) encoding an ATP-dependent transmembrane trans-
porter whose substrate and pathophysiological role remain to
be elucidated (Bergen et al., 2000; Le Saux et al., 2000;
Ringpfeil et al., 2000; Struk et al., 2000).
Cutis laxa (OMIM nos. 123700; 219100) is a hetero-
geneous group of acquired or inherited (autosomal-recessive
or -dominant) disorders, characterized by loose, sagging, and
redundant skin. The clinical findings can be limited to the
skin, although extracutaneous manifestations (pulmonary
emphysema, hernias, intestinal diverticuli, ocular anterior
segment abnormalities) have also been described (Lewis
et al., 2004; Ringpfeil, 2005).
The histopathology of cutis laxa, using van Giesson stains,
can reveal both loss and fragmentation of elastic fibers in the
reticular dermis (Lewis et al., 2004; Ringpfeil, 2005).
Although the molecular background of cutis laxa is largely
& 2006 The Society for Investigative Dermatology www.jidonline.org 1
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unknown, causal mutations have been reported in the elastin
gene (ELN on chromosome 7q11.2) and in the fibulin-5 gene
(FBLN5 on chromosome 14q32.1) (Tassabehji et al., 1998;
Loeys et al., 2002; Markova et al., 2003).
We describe six patients in whom a clinical diagnosis of
PXE was initially made and subsequently supported by light
microscopy on skin biopsy. However, these patients progres-
sively developed excessive skin folds which, although
initially confined to the flexural areas, spread both toward
the abdomen and limbs. Moreover, all six patients were also
found to have a deficiency of the vitamin K-dependent
coagulation factors (factors II, VII, IX, X). Two patients had a
history of or suggestive of cerebral aneurysms.
This phenotype has been previously described in a few
case reports (MacMillan and Vickers, 1971; Rongioletti et al.,
1989; Le Corvaisier-Pieto et al., 1996) but to our knowledge,
no molecular data are available.
We have undertaken a detailed electron microscopy study
of the ultrastructural characteristics of the dermis of these
patients. Additionally, a molecular study of the ABCC6 gene
was performed as well as an initial candidate gene screening
for the clotting disorder.
Based on the clinical, structural, and molecular findings
on these six novel patients, we hypothesize that their
condition represents a separate genetic entity.
RESULTS
Clinical description
Six Caucasian patients with initial signs of typical yellowish
papules that coalesce and form plaques with regularly
depressed dots, sometimes referred to as cutaneous
‘‘Pd’O’’ (Figure 1b), developed an increasing number
of excessive, leathery skin folds, which gradually spread
beyond the flexural areas of the body (Figure 1c–f).
The papular and leathery skin lesions with dot-like
depressions, however, remained stable. Fundoscopy
revealed only limited AS and/or Pd’O without comets
temporal to the macula in patients 1 through 4 and normal
visual acuity in all patients (Figure 1a). During follow-up,
both fundus appearance and visual acuity remained un-
changed.
Cardiovascular investigations, including clinical examina-
tion, electrocardiography, and ultrasonography, showed
subclinical atherosclerotic plaques in the lower limbs in
two patients and vascular occlusion with intermittent claudi-
cation in one patient. In patient 1, two cerebral aneurysms
were subsequently discovered at age 36 and 46 years and
successfully treated.
Routine blood coagulation tests revealed a
prolonged prothrombin time with decreased levels of the
vitamin K-dependent clotting factors (Table 1). Clinical
manifestations were present in only two patients. Patient 3
suffered three meningeal hemorrhages over a period of 20
years. Further bleeding events include a postpartum hemo-
rrhage after delivery of her only child and one episode of
unexplained hematemesis. Patient 5 had a history of
epistaxis, spontaneous gingival bleeding, and severe vaginal
hemorrhages.
Details on the individual phenotypes can be found in
Table 2.
a
c
b d e
f
Figure 1. Clinical characteristics of the presented phenotype in several patients. Note (a) a mild retinopathy, (b) skin lesions featuring yellowish papules that
coalesce and form plaques with regularly depressed dots, and (c–f) generalized excessive and leathery skin folds.
2 Journal of Investigative Dermatology
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Ultrastructural findings
By light microscopy, the overall appearance of the dermis
was identical to that typical of PXE. The reticular dermis
presented areas in which elastic fibers were polymorphous,
fragmented, and mineralized, as shown by Von Kossa
staining.
At the ultrastructural level, the alterations of the
elastic fibers could be better analyzed and compared
with those of PXE and revealed peculiar features. Although
the two classical types of mineral precipitates, fine granular
and bulky calcifications, were present, elastic fibers
had a more fragmented and mottled appearance compared
to those typical of PXE. In longitudinal sections, elastic
fibers appeared to be made of loose, thin strands of
polymorphous elastin material. Moreover, very often miner-
alization occupied only a limited area within huge
elastic fibers and was organized as peculiar small
electron-dense crystal-like precipitates. Several collagen
fibrils were fused forming the so-called ‘‘collagen flowers’’
(Figure 2).
Table 1. Biochemical analysis results of the PT and vitamin K-dependent coagulation factor activity levels
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Normal
PT (INR) 1.81 1.84 1.97 2.19 1.7 1.9 0.8–1.2
Factor II (% nl)1 66 61 38 38 20 18 100 (90–150)
Factor VII (% nl) 26 39 50 62 74 88 100 (90–150)
Factor IX (% nl) 70 71 103 90 48 56 100 (90–150)
Factor X (% nl) 15 40 20 17 20 18 100 (90–150)
PT, prothrombin time; INR, International Normalized Ratio.
1Percentage of normal activity.
Table 2. Comparison of the phenotypical, histopathological, and molecular characteristics of the six presented
patients (1–6) and the four previously reported cases (7–10)
1 2 3 4 5 6 7 8 9 10
Sex F F F F F M M M F F
Age1 46 47 67 32 46 44 40 33 24 24
Age of onset skin symptoms1 18 13 3 18 NA NA 16 Puberty Puberty Puberty
Positive familial history ! ! ! ! NA NA ! ! + +
Generalized skin folds/laxity + + + + + + + + + +
Yellowish papules ! + + + + + NA NA ! !
Dot-like depressions + + + + + + NA NA ! !
Yellow mucosal pattern ! + + ! NA NA NA NA NA NA
Esthetic surgery performed ! + + + NA NA NA NA NA NA
Positive calcium stain + + + + + + + + + +
AS + + + + ! ! ! ! ! !
Ocular Pd’O ! + ! + ! ! NA ! ! !
Decreased visual acuity ! ! ! ! ! ! ! ! ! !
Clotting deficiency + + + + + + + + + +
Abnormal bleeding tendency ! ! + ! + ! + ! + +
Subclinical atherosclerosis ! + + ! + ! ! ! + +
Weak peripheral pulsations ! ! ! + ! ! NA NA NA NA
Cerebral aneurysms + ! ? ! NA NA ! ! ! !
ABCC6 mutations ! ! ! ! NA NA ! NA NA NA
VKORC1 mutations ! ! ! ! ! ! ! NA NA NA
AS, angioid streaks; F, female; M, male; NA, not available; Pd’O, peau d’orange.
1In years.
Case 7: Le Corvaisier-Pieto et al., 1996; case 8: Rongioletti et al., 1989; cases 9 and 10: MacMillan and Vickers, 1971.
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Molecular results
Molecular analysis of the ABCC6 gene, responsible for PXE,
failed to identify mutations in all six patients, and in one
patient reported earlier (Le Corvaisier-Pieto et al., 1996).
Sequencing of the VKORC1 gene (vitamin K 2,3 epoxide
reductase), responsible for vitamin K recycling, did not reveal
any mutation. Analysis of the second gene involved in the
clotting disorder, GGCX (gamma-glutamyl carboxylase),
revealed six novel missense mutations and one novel
nonsense mutation in the seven patients, including the
patient reported earlier (Table 3). Mutations occurred in
homozygous or compound heterozygous form in four
patients. In two other patients, only one mutation could
be detected. These mutations affected amino acids which
were fully or almost fully conserved in Mus musculus,
Rattus norvegicus, Fugu rubripes, Anopheles, and Drosophi-
la. None of these mutations were found in 200 control
chromosomes of unrelated healthy Europeans.
DISCUSSION
The six patients described show clinical overlap with PXE,
hence the initial diagnosis of a severe form of that disorder.
All initially manifested skin manifestations considered typical
of PXE, such as yellowish papules and/or plaques with
dot-like depressions characterized by light microscopy as
fragmentation and calcification of elastic fibers in the
reticular dermis. Moreover, the observed retinopathy (AS
originating from the optic disc, Pd’O lesions temporal to the
macula) in these patients was anatomically similar if not
identical to that seen in PXE.
However, clinical, ultrastructural, and molecular differ-
ences allow us to discriminate the phenotype of these
patients from PXE and from cutis laxa (Table 4).
First, these patients are remarkable for the severity of their
skin involvement. Increased skin laxity and excessive skin
folding can be seen in PXE, but usually these features remain
confined to the flexural areas of the body (McKusick, 1966;
Neldner, 1988; Hu et al., 2003; Chassaing et al., 2005). In
contrast, in these patients, the leathery skin folds extended
toward the limbs and abdomen leaving only the face, hands,
and feet unaffected. Interestingly, the speed of evolution of
the skin laxity was quite different between patients. Whereas
progression over several years in patients 1 and 4 led to the
very severe skin phenotype in their early thirties, patient 3
already suffered from severe skin laxity during her childhood,
and patient 2 manifested rapid progression during puberty.
Secondly, the fundus examination revealed only limited
AS and/or mild Pd’O. Moreover, visual acuity remained
stable in all four patients during follow-up. In contrast, in
PXE, up to 60% of patients suffer from considerable loss of
central vision. Although sample size is small, this suggests
that in this PXE-like phenotype, the retinopathy is milder and
has a more benign prognosis.
Third, electron microscopy revealed that dermis altera-
tions, especially those of elastic fibers, were similar, but not
identical, to those in PXE. Similarities with PXE were that
(i) changes occurred in the same areas of the dermis; (ii) not
a
c
e f
d
b
Figure 2. Ultrastructural characteristics of the presented phenotype. At low
magnification electron microscopy, dermal alterations are mainly located
in the reticular dermis and appear very similar to those in PXE. The great
majority of elastic fibers are polymorphous, fragmented, and mineralized and
are surrounded by rather thick and compact collagen bundles (a and b).
Both the fine granular (a and b, asterisks) and the bulky types (a and b, arrows)
of elastic fiber mineralization, always described in PXE, are present.
However, different from classical PXE, the great majority of the apparently
normal elastic fibers are organized as rather thin and polymorphous strands
of elastin material connected into a loose network (c and d, arrows).
Moreover, calcification affects often the marginal areas of elastic fibers
(d–f, arrowheads), whereas in PXE mineralized fine deposits are always
in the core of elastic fibers. Similar to PXE, collagen fibrils can be fused
forming the so called ‘‘collagen flowers’’ (f, inset, arrows). Bar¼1 mm.
Table 3. Mutations found in the six presented cases
(1–6) and one earlier reported case (7)
Patient Allele 1 Exon Allele 2 Exon
1 p.W493S c.1506G4C 12 p.W493S c.1506G4C 12
2 — — — — — —
3 p.R476C c.1454C4T 10 — — —
4 p.R476H c.1455G4A 10 — — —
5 p.Q374X c.1149C4T 8 p.G537Y c.1339G4T 12
6 p.Q374X c.1149C4T 8 p.G537Y c.1339G4T 12
7 p.F299S c.924T4C 8 p.G558R c.1700G4A 12
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all elastic fibers were mineralized, but in those that were, the
two types of mineralization already described in PXE were
present; (iii) fibroblasts had huge cisternae of the endoplas-
mic reticulum; (iv) lateral fusion of collagen fibrils were
observed in one patient. However, elastic fibers, either
mineralized or not, were different from that typical of PXE.
In patients 1, 2, and 3, they were often made of aggregates of
distinct strands of elastin and mineralization was mostly
confined to the periphery of the fibers (case 1) or was
associated to the most compact areas of the fibers (cases 2
and 3). In contrast, in patient 4 elastic fibers were huge and
compact and mineralization was very severe. Moreover,
electron-dense crystal-like bodies, never observed in PXE,
were present in all patients in the central core of finely
mineralized elastic fibers.
Finally, molecular analysis of the ABCC6 gene, respon-
sible for PXE, failed to identify mutations in all of the patients,
including the one reported earlier.
Classical cutis laxa syndromes could also be excluded
because neither the retinopathy nor mineralization of elastic
fibers is seen in those disorders (Krill and Archer, 1972; Lewis
et al., 2004).
A second feature of the phenotype is a deficiency of the
clotting factors II, VII, IX, and X, which are synthesized in the
liver and depend on vitamin K for their function. Such
deficiency can either be acquired or congenital (Oldenburg
et al., 2000; Sadler, 2004; Zhang and Ginsburg, 2004).
However, in our patients there was no evidence for an
acquired form, as they did not exhibit any hepatic disease or
malabsorption.
Congenital deficiency of the vitamin K-dependent factors
(VKCFD) is a very rare autosomal-recessive disorder. It is
caused either by mutations in the GGCX gene (VKCFD1 –
OMIM no. 277450) on chromosome 2p12, or in the VKORC1
gene (VKCFD2 – OMIM no. 607473) on chromosome
16p11.2. These genes encode a vitamin K-dependent
carboxylase and vitamin K 2,3 epoxide reductase, respec-
tively (Oldenburg et al., 2000; Li et al., 2004; Rost et al.,
2004a, b; Zhang and Ginsburg, 2004). Both enzymes are
essential for post-translational g-carboxylation of clotting
factors, enabling them to attach to the phospholipid bilayer of
membranes as an essential prerequisite for blood coagulation
(Zhang and Ginsburg, 2004). The clinical features of VKCFD1
and -2 are highly variable and may include epistaxis,
(neonatal) intracranial hemorrhage, hemarthrosis, etc.,
although several patients remain asymptomatic (Zhang and
Ginsburg, 2004). Significant bleeding diathesis was observed
in cases 3 and 5, although it remains uncertain whether this
was due to the mild to moderate clotting factor deficiency. It
is interesting though that two cerebral aneurysms were
detected in case 1. Taken together with the potentially
subarachnoid hemorrhages in case 3, this may indicate that
patients with this disorder might have an increased risk for
cerebral aneurysms. By contrast, in PXE, cerebrovascular
complications are mostly ischemic (stroke).
In order to elucidate the molecular pathogenesis of this
phenotype, we initially focused on the VKORC1 gene, as it is
also located on chromosome 16p, albeit 15Mb away from
ABCC6. However, sequencing of the whole coding region
did not reveal any causal mutation. In contrast, analysis of the
second gene involved in the clotting disorder, GGCX, has
revealed seven different mutations in six patients. Of these,
p.Q374X, p.W493S, p.R476C, and p.R476H are located in
the propeptide binding site of the g-carboxylase, important
for binding of the substrates. This site has been mapped to
amino acids 50–225, 349–500, and 425–513 (Yamada et al.,
1995; Wu et al., 1997; Lin et al., 2002). Thus, they could
result in a shorter residence time of the substrate on the
g-carboxylase with formation of poorly carboxylated, less
active proteins (Mutucumarana et al., 2000).
Site-directed mutagenesis demonstrated that regions
around residues 234, 406, and 503 partly define the
propeptide binding sites (Sugiura et al., 1996). The p.F299S,
p.G537Y, and p.G558S mutations may therefore also
influence the affinity of the g–carboxylase for its substrates.
Further bio- and immunohistochemical analysis of the
Table 4. Clinical, ultrastructural, and molecular characteristics of the PXE-like syndrome with a coagulation
disorder versus PXE and cutis laxa
PXE-like PXE Cutis laxa
Generalized skin folds/laxity Always present Not present Often present
Positive Von Kossa stain of the dermis Present Present Not present
Electron microscopy of the dermis Mineralized elastic fibers Mineralized elastic fibers Scarce and mottled elastic fibers
Retinopathy (AS/Pd’O) Present but mild Present and often severe Not present
Decreased visual acuity Not present 60% Infrequent
Clotting deficiency Always present Not described Not described
Atherosclerosis Subclinical in 50% (Sub)clinical in 55% Infrequent
Cerebral aneurysms Present Infrequent Infrequent
Abnormal bleeding tendency Present (50%) Infrequent (10%) Not described
ABCC6 mutations Not present Present (DR=96%) Not present
AS/Pd’O, angioid streaks/peau d’orange; DR, detection ratio; PXE, Pseudoxanthoma Elasticum.
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functional effects of these mutations is currently ongoing. It is
worthwhile mentioning that the vitamin K-dependent en-
zymes responsible for carboxylation of clotting factors are
also involved in modulating bone mineralization and in
preventing calcium precipitation in soft tissues (Price and
Williamson, 1985; Price et al., 1998). Our molecular results
are remarkable in that mutations in this phenotype seem to
occur typically in exons 8, 10, and 12. Mutations in these
exons have not been described so far in patients with the
hereditary coagulation disorder without the cutaneous
phenotype. It is our hypothesis that these exons are of critical
importance in domains that are essential in the activating role
of the GGCX enzyme in the coagulation cascade, but also for
the activation of other gla-proteins such as, for example,
matrix gla protein or osteocalcin. The latter are known
inhibitors of calcification. Hence, a decreased or
absent activation of such proteins can explain the calcifica-
tion and subsequent fragmentation of the elastic fibers. The
severity of the skin lesions might be due to the additive effect
of decreased or absent activity of multiple calcification
inhibitors.
A second theoretical possibility would be digenic
inheritance, in which a second, as yet unknown gene, is
responsible for the cutaneous phenotype. Linkage
analysis was possible in only one family without known
mutations; unfortunately, we were unable to obtain DNA
from a sib of the proband, essential for the interpretation of
the results.
Furthermore, apart from gene defects, the correct carboxy-
lation of clotting factors and of modulators of mineralization
in bone and soft tissues may depend on post-translational
maturation of enzymes (Wajih et al., 2004) as well as on cell
metabolic alterations affecting, for instance, the structural
organization of membranes of the endoplasmic reticulum
where carboxylating enzymes are located (Wallin et al.,
1999). Therefore, the problem is rather complex and the
involvement of vitamin K-dependent processes in miner-
alization of connective tissues and of elastic fibers in
particular is under investigation.
At present 10 cases with this peculiar phenotype have
been reported (Table 4). In the literature, the fundus
examination has always been considered normal. However,
owing to the very mild aspect of the retinopathy, it is possible
that small AS were missed. The fact that visual acuity has
always been reported as normal is yet another indicator of the
rather mild nature of the ocular features.
Bleeding tendency was very variable, as can be expected
from the hereditary form of VKCFD.
In conclusion, as (i) the fundus findings and the elastic
fiber mineralization in the skin of patients exclude any known
form of cutis laxa, and (ii) the distinct clinical manifestations
and severity of cutaneous and retinal symptoms, as well as
the slightly different ultrastructural features and the absence
of ABCC6 mutations in patients seem to exclude PXE, data
support the hypothesis that these patients suffer from a new
disorder. The molecular background of this peculiar pheno-
type, and more specifically the role of the GGCX gene, is
currently under investigation.
MATERIALS AND METHODS
Patients
The patients were clinically examined (skin evaluation, fundoscopy,
and cardiovascular work-up) at the Ghent University Hospital
(Belgium) (case 1), l’Hoˆpital Porte Madeleine, Orle´ans (France)
(cases 2 and 3), the University of Modena and Reggio Emilia,
Modena (Italy) (case 4). Patients 5 and 6 who reside in the United
States were not personally evaluated by the authors, but clinical data
were obtained from their medical specialists. The first four patients
had a full thickness skin biopsy taken in a skin lesion suggestive for
PXE. Biopsies were evaluated with light microscopy using hematox-
ylin and eosin, van Giesson (elastin), and Von Kossa (calcium) stains.
For electron microscopy, skin biopsy fragments were immedi-
ately fixed in 3% glutaraldehyde in Tyrode’s saline pH 7.2 for
2–4 hours at room temperature, washed in saline, post-fixed in 1%
osmium tetroxide in the same buffer for 1 hour, dehydrated in
ethanol and propylene oxide, and embedded in spurr resin. Semithin
sections were stained with 1% toluidine blue and observed by light
microscopy. Thin sections were stained with 1% uranyl acetate in
50% ethanol and lead citrate and observed in a Jeol EM1200
electron microscope. Skin biopsy fragments from patients 2 and 3
were first fixed in formalin and embedded in paraffin and then
rescued and embedded in spurr resin.
Coagulation assays were performed on citrated blood samples.
The activities of factors II, VII, IX, and X were measured in one-stage
clotting assays using Diagnostica Stago (Asnie`res sur Seine, France)
reagents. The prothrombin time was performed using the STA-
Neoplastin CI plus kit (Diagnostica Stago, France).
Informed consent was obtained from all patients and the
Declaration of Helsinki Principles was followed. This study was
approved by the Ethical Committee of the Ghent University Hospital.
Molecular analysis
Molecular analysis of the ABCC6 gene was performed in all six
patients and one additional, already reported, patient (Le Corvaisier-
Pieto et al., 1996), using PCR primers described by Wang et al.
(2001). In order to distinguish between ABCC6 and its two
pseudogenes a long-range PCR was performed of exons 1 through
10. The following primers were used: forward primer: 50-ATA CTC
AGT ATC AGC CAG GAT GTT-30 and reverse primer: 50-GGG ACT
CCG TTC AAA TCC CG-30. Subsequently, PCR reactions for the
separate exons were performed on the long-range amplicon. For the
detection of the deletion of exons 23–29, the primers described by le
Saux et al. (2001) were used.
The VKORC1 coding region was analyzed using following
primers: exon 1: forward primer 50-CTC CGT GGC TGG TTT TCT
C-30and reverse primer 50-CCG ATC CCA GAC TCC AGA AT-30;
exon 2: forward primer 50-ATG GGA GGT CGG GGA ACA-30 and
reverse primer 50-TGA GCA GCT AGC TGG CTG-30; exon 3:
forward primer 50-TCT GCC CTG GAG CCT CTT-30 and reverse
primer 50-CAC ATC TAG GGC CTT CTA G-30.
The GGCX coding region was analyzed using primers and PCR
conditions described by Oldenburg et al. (2000).
The whole coding region and intron/exon boundaries of ABCC6,
VKORC1, and GGCX were analyzed with direct sequencing using
an Applied Biosystems 3100 Sequencer, with ABI PRISM Big Dye
Terminator Cycle Sequencing Kit (Applied Biosystems, Lennik,
Belgium).
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Nucleotide numbers are derived from cDNA GGCX sequences
(GenBank accession no. BC013979). For cDNA numbering, þ 1
corresponds to the A of the ATG translation initiation codon.
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Low serum vitamin K in PXE patients results in defective 
carboxylation of mineralization inhibitors similar to the 
consequences of GGCX mutations in the PXE-like syndrome. 
 
Olivier M. Vanakker*, Ludovic Martin*, Leon J. Schurgers, Daniela Quaglino, 
Cees Vermeer, Ivonne Pasquali-Ronchetti, Paul J. Coucke, Anne De Paepe. 
(* joint first author) 
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In this paper, immunohistochemical and ELISA experiments were applied on skin tissues, 
serum and plasma samples of PXE-like and PXE patients to determine the pattern of active 
(carboxylated) and inactive (uncarboxylated) Gla-proteins and associated inhibitors of 
calcification. Further, the vitamin K (VK) serum concentration was measured in PXE-like and PXE 
samples using HPLC, to evaluate the VK status.  
  
 Significant disturbances in mineralization inhibitor activation are demonstrated in the 
circulation and the dermis of PXE-like syndrome patients, with an accumulation of uncarboxylated 
matrix gla protein (ucMGP) and osteocalcin (ucOC). Serum levels of VK were normal in these 
patients. In PXE patients, we found similar, although not identical results for the Gla-proteins in 
the circulation and local dermal tissue. However, the VK serum concentration in PXE patients 
was significantly decreased compared to controls.  
 
 This study confirms the pathomechanistic hypothesis formulated in publication 7 on the 
PXE-like syndrome and allows us to conclude that ectopic mineralization in the PXE-like 
syndrome and in PXE results from a deficient protein carboxylation of VK-dependent inhibitors of 
calcification. While in PXE-like patients this is due to mutations in the GGCX gene, a deficiency of 
the carboxylation co-factor VK is at the basis of the decreased activity of calcification inhibitors in 
PXE. 
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Abstract 
 
Soft-tissue mineralization is a tightly regulated process relying on the activity of systemic 
and tissue-specific inhibitors and promotors of calcium precipitation. Many of these, such as 
matrix gla protein (MGP) and osteocalcin (OC), need to undergo carboxylation to become active. 
This posttranslational modification is catalyzed by the gammaglutamyl carboxylase GGCX and 
requires vitamin K (VK) as an essential co-factor. Recently, we described a novel phenotype 
characterized by ectopic mineralization of the elastic fibers resulting from mutations in GGCX. 
Because of the resemblance with pseudoxanthoma elasticum (PXE), a prototype disorder of 
elastic fiber mineralization, it was coined the PXE-like syndrome. As mutations in GGCX 
negatively affect protein carboxylation, it is likely that inactive inhibitors of calcification contribute 
to ectopic mineralization in PXE-like syndrome. Because of the remarkable resemblance with 
PXE, we performed a comparative study of various forms of VK-dependent proteins in serum, 
plasma (using ELISA) and dermal tissues (using immunohistochemistry) of PXE-like and PXE 
patients using innovative, conformation-specific antibodies. Furthermore, we measured VK serum 
concentrations (using HPLC) in PXE-like and PXE samples to evaluate the VK status.  
In PXE-like patients we noted an accumulation of uncarboxylated Gla-proteins, MGP and 
OC, in plasma, serum and in the dermis. Serum levels of VK were normal in these patients. In 
PXE patients, we found similar, although not identical results for the Gla-proteins in the circulation 
and local dermal tissue. However, the VK serum concentration in PXE patients was significantly 
decreased compared to controls.  
Our findings allow us to conclude that ectopic mineralization in the PXE-like syndrome 
and in PXE results from a deficient protein carboxylation of VK-dependent inhibitors of 
calcification. While in PXE-like patients this is due to mutations in the GGCX gene, a deficiency of 
the carboxylation co-factor VK is at the basis of the decreased activity of calcification inhibitors in 
PXE.  
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Introduction 
 
 Soft-tissue calcification is a highly regulated process relying on both systemic and tissue-
specific balances of inhibitors and promotors of calcium precipitation. Fetuin-A  (α2-Schmid-
Herremans glycoprotein), a member of the cystatin family of protease inhibitors produced 
predominantly by the liver, is considered an important circulating inhibitory factor of soft tissue 
mineralization (1). Among local regulators, matrix gla protein (MGP), osteopontin (OPN) and bone 
morphogenetic protein-2 (BMP-2) are associated with tissue mineralization in vivo (2,3,4).  
Proteins primarily involved in the regulation of bone mineralization, such as osteocalcin (OC) or 
osteonectin (ON), have also been linked to local extraosseous regulation of calcium homeostasis 
(5).  
Among all, MGP is considered the key physiological inhibitor of soft tissue calcification, 
acting as a direct inhibitor of calcium crystal formation as MGP deficient mice suffer from 
spontaneous and ultimately fatal calcification of arteries and cartilage (6). Together with OC and 
the clotting factors II, VII, IX and X, MGP needs to undergo carboxylation of glutamate (Glu) into 
gamma-carboxyglutamate (Gla) residues to become active. Carboxylation catalyzed by the 
endoplasmic gammaglutamyl carboxylase (GGCX) to form Gla-residues in all these proteins 
requires vitamin K (VK) as a co-factor, hence  the  terms  “VK-dependent" or "Gla"-proteins (7). 
MGP, unique among the Gla-proteins, also has the tandemly repeated Ser-X-Glu sequence at the 
N-terminus end, which is a recognition motif for serine phosphorylation. Phosphorylation is 
thought to be carried out by the Golgi casein kinase (8,9). It has been previously suggested that - 
next to being carboxylated - MGP must be fully phosphorylated at each target serine residue to 
have its optimal inhibitory activity on soft tissue calcification (9).  
Besides the gamma-carboxylase, the metabolic VK-cycle also involves the reductase 
enzyme VKORC1. Mutations in the GGCX or VKORC1 genes are associated with a hereditary 
deficiency of the VK-dependent clotting factors as well as a clinically relevant dosing dependency 
of anti-coagulants [(10,11). Besides these enzymatic defects, a deficiency of VK has been 
described in association with coagulation, bone (osteoporosis, osteoarthritis) and vascular 
(atherosclerosis) disorders resulting from insufficient carboxylation of Gla-proteins (12,13). 
We recently described an additional phenotype resulting from sequence changes in the 
GGCX gene (chrom. 2p12; OMIM#137167). This novel autosomal recessive disorder was 
characterized by a generalized deficiency of the VK-dependent clotting factors as well as 
mineralization and fragmentation of elastic fibers leading to thickened, inelastic skin and limited 
retinopathy (14). This disease was coined the “PXE-like syndrome” (OMIM#610842) because of 
its remarkable clinical and histological resemblance with pseudoxanthoma elasticum (PXE, 
OMIM#264800), a prototype disorder of elastic fiber mineralization (15,16). PXE is caused by 
mutations in the ABCC6 gene (chrom. 16p13.1; OMIM#603234), coding for an ATP-dependent 
transmembrane transporter, which is most abundant in liver and kidney (17,18). Neither the 
substrate of ABCC6 nor its relation to ectopic mineralization or elastic fiber changes observed in 
PXE is presently known. 
As GGCX mutations in the PXE-like syndrome negatively affect protein carboxylation, we 
and others hypothesized that elastic fiber mineralization results from deficient VK-dependent 
inhibitors of calcification, such as MGP and OC. Recently reported findings already point towards 
a role of MGP in classic PXE, but neither the involvement of other Gla-proteins nor the 
mechanism for such involvement have been studied yet (19-22). Because of the remarkable 
phenotypical similarities of the PXE-like syndrome and PXE and the absence in PXE of GGCX or 
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VKORC1 mutations – which both have the potential of disrupting the VK-cycle -, we wondered 
whether the VK-cycle could also be disturbed by another mechanism in PXE. More precisely, we 
hypothesized that disturbances in Gla-proteins in PXE patients could be linked to VK, the cofactor 
in the VK-cycle and an essential mediator of Gla-protein carboxylation.   
We aimed to evaluate these hypotheses by studying the various forms of Gla-proteins in serum 
and tissues of PXE-like syndrome and PXE patients by using innovative antibodies. The latter 
were designed to specifically measure and differentiate between carboxylated and 
uncarboxylated forms of the proteins in immunohistochemistry (IHC) as well as in ELISA assays. 
Furthermore, we evaluated the VK status in PXE-like and PXE patients by HPLC measurement of 
VK serum concentrations. 
 
Materials and methods 
 
Patients  
PXE and PXE-like patients were clinically evaluated in the Department of Genetics of the 
Ghent University Hospital (Belgium), the Department of Dermatology of the Orleans Hospital 
(France), and the Department of Biomedical Sciences, University of Modena and Reggio Emilia 
(Italy). Informed consent was obtained from all patients and the Declaration of Helsinki protocols 
were followed. This study was approved by the Ethical Committee of the Ghent University 
Hospital. 
 
Biochemical measurements 
 Serum was prepared by incubating the samples for 20 minutes at RT and subsequent 
centrifugation (10 min, 3000xg); plasma was prepared in citrate tubes. All samples were frozen 
within 2h after blood collection.  
 Mineralization inhibitor levels were quantified in serum and citrate plasma of 4 PXE-like 
and 16 PXE patients using the ELISA technique. For measurement of the total fraction of 
uncarboxylated MGP (ucMGP), a competitive ELISA assay was applied (23,24).  
 Two additional sandwich ELISAs were developed at VitaK BV, Maastricht, The 
Netherlands, to determine the respective plasma levels of desphospho carboxylated (dp-cMGP) 
or desphospho uncarboxylated (dp-ucMGP) MGP. In brief, monoclonal anti-dpMGP was coated 
to the microtiter plate. After blocking, either patient plasma or standards were incubated. The 
standard peptide was synthetic MGP, based on the non-phosphorylated 3–15aa sequence and 
either the non-carboxylated 35–54aa sequence or carboxylated 35-54aa sequence, linked with a 
hydrophilic spacer (Pepscan, Lelystad, the Netherlands). After incubation and washing, the 
standard or sample was detected using a biotinylated monoclonal ucMGP antibody or biotinylated 
cMGP antibody. 
 For measurements of uncarboxylated (ucOC) and carboxylated (cOC) osteocalcin we 
used conformation-specific sandwich ELISAs (Takara Shuzo Co Ltd., Shiga, Japan). Results 
were compared with serum levels obtained in a previously described sex- and age-matched 
control population of 55 individuals (25). 
 Vitamin K1 serum concentrations were assessed in 4 PXE-like and in 30 PXE patients 
using an HPLC technique with post-column reduction and fluorescence detection, as previously 
described (26). None of the patients were taking VK supplements or coumarins at the time of 
measurement. Serum VK1 levels in patients were compared with those of a sex- and age-
matched reference population of 384 healthy men and women.  
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Immunohistochemistry 
 IHC was performed on skin biopsy specimens from 3 female patients with the PXE-like 
syndrome reported in a previous study (14), and on skin samples from 9 patients (1 male and 8 
females) with a clinical, histological and molecular diagnosis of PXE. Normal age- and sex-
matched skin biopsy samples from 7 individuals and lesional skin from 3 patients with solar 
elastosis or elastofibroma were used as controls. 
Light microscopy was performed on tissues embedded in paraffin. Antibodies against cMGP, 
ucMGP, fetuin-A, ON, BMP-2, gas-6 and OC were provided by VitaK (Maastricht, the 
Netherlands) [Schurgers et al, 2005]. The mAb against OC and polyclonal antibodies against 
gas6, fetuin, OPN, ON and BMP-2 stained total protein (27). After deparaffinization, sections 
were heated in 0.2% citric acid at pH 6.0, washed with phosphate-buffered saline and incubated 
with the primary antibody. For the polyclonal antibodies, citric acid treatment was not added. All 
antibodies were diluted in blocking reagent (Roche Diagnostics, Mannheim, Germany). Negative 
controls were performed by omitting the primary antibody. Biotinylated sheep anti-mouse IgG 
(monoclonal antibodies - Amersham Biosciences, Little Chalfont, UK), swine anti-Rabbit IgG 
(polyclonal antibodies - Dako, Golstrup, Denmark) or anti-goat IgG (BMP-2 - Dako, Golstrup, 
Denmark) were used as a second antibody (1h at RT), followed by incubation with the avidin-
linked alkaline phosphatase complex (Dako, Golstrup, Denmark); staining was performed by the 
AEC revelation kit (brown stain; Dako). Sections were counterstained with haematoxylin and 
mounted with cover slips. All labellings were performed and evaluated independently by OMV 
and LM to assess reproducibility. The intensity of the staining was qualified in each section as 
‘absent’ (0), ‘light’ (+), ‘moderate’ (++) or ‘heavy’ (+++).  
Electron microscopy was performed on skin biopsies which were fixed in 2.5% glutaraldehyde in 
Tyrode’s saline pH 7.2 (16-20h at 4°C), post-fixed in 1% osmium tetroxide (Fluka AG Chem) in 
the same buffer for 2h at RT, dehydrated in ethanol and propylene oxide and embedded in Spurr 
resin (Polysciences Inc., Warrington, PA). Some specimens were rescued from formalin fixed and 
paraffin embedded biopsies. Ultrathin sections were collected on nickel grids and processed for 
immunocytochemistry as already described (28). Unspecific epitopes were neutralized by 
incubating sections on 0.5% bovine serum albumin in buffer. Monoclonal antibodies towards 
uncarboxylated and carboxylated species of MGP and towards carboxylated MGP were used in 
parallel in all experiments where controls and patient samples had to be compared. 
Immunoreactions were revealed by secondary antibodies conjugated with 10 nm gold particles 
(E.Y. Laboratories, San Mateo, CA). Controls were performed by omitting the primary antibody or 
by incubating sections with non-immune sera instead of the primary antibody. Sections were then 
stained with uranyl acetate and lead citrate and observed by transmission electron microscopy 
(Jeol, EM1200, Tokyo, Japan).  
 The intensity of immunostaining was evaluated by counting the number of gold particles 
per unit area. More than 20 different and randomly selected areas were analyzed and mean 
values and standard deviations were calculated. Since the reactivity of the two antibodies is 
different, comparison was made only between samples processed in parallel with the same 
antibody. 
 
Statistical analysis 
All data given are means of duplicate measurements. Error bars represent standard deviation. 
Differences between groups were compared using the two-tailed  Student’s  t-test and were 
considered significant at p <0.05.  
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Results 
 
A. PXE-like syndrome patients 
Biochemical measurements 
 Serum and plasma concentrations of OC and MGP (Figure 1). The total amount of 
OC was significantly higher in the circulation of patients compared to controls, being 17 ng/ml and 
8,5 ng/ml, respectively. Elevated levels of circulating ucOC were demonstrated (a), whilst cOC 
levels were diminished (b), resulting in significantly higher ucOC/cOC ratio compared to the 
reference population (c). For MGP, both the sandwich and competitive ELISA assays were used. 
An increase of the dp-ucMGP isoform (d) with a very high uc/cMGP ratio compared to controls (f) 
was shown. Competitive ELISA measurement of total ucMGP revealed significantly decreased 
serum levels (g).  
 Serum concentration of vitamin K. The serum VK concentration in PXE-like patients 
was normal compared to a control population (0.58 ng/ml vs. 0.60 ng/ml in the reference 
population; p>0.1).  
 
 Pathology findings 
Light microscopy. Labelling for cMGP and ucMGP was strongly positive in the mid-
dermal elastorrhexis area (Figure 2A & B) and absent in elastorrhexis-free areas and in control 
samples (Figure 2E & F). Labelling for OC was weakly to moderately positive in the epidermis 
and elastorrhexis zone compared to controls (Figure 3A). OC was the only protein that also 
stained weakly positive in fibroblasts, compared to moderate staining in controls. Fetuin-A stained 
heavily in the area of elastorrhexis as well as subepidermally - in the upper papillary dermis 
(Figure 3B). Both OPN and BMP2 stained strongly in the elastorrhexis zone, compared to very 
weak or no staining in controls (data not shown). 
Electron microscopy. In the dermis of PXE-like patients and controls, fibroblasts were 
almost negative for ucMGP. By contrast, fibroblasts were slightly positive for cMGP in controls 
and almost negative in patients (data not shown). In the extracellular space, elastic fibers were 
the only matrix constituent positive for both forms of MGP in PXE-like patients and in controls. 
The evaluation of the number of gold particles per 1 µm2 on the apparently normal elastic fibers 
revealed that ucMGP was more abundant within the fibers of PXE-like patients compared to 
controls, the number of gold particles being 48±24 / µm2 in patients and 27±8 / µm2 in controls 
(p<0.001) (Figure 4A & 5B). The antibody recognizing ucMGP reacted with epitopes abundantly 
present in bulky calcium precipitates (data not shown) and in the core of calcified elastic fibers 
(Figure 5B). By contrast, the antibody recognizing cMGP primarily localized at the border of the 
finely mineralized areas within elastic fibers (Figure 5D). 
 
B. PXE patients 
Biochemical measurements 
Serum and plasma concentrations of OC and MGP (Figure 1). The total amount of 
OC was slightly lower in PXE than in control sera, being 7,5 ng/ml in patients and 9,0 ng/ml in 
controls. No significant abnormalities were noted in levels of cOC, ucOC, dp-cMGP and dp-
ucMGP, nor in their respective uc/c ratios using sandwich ELISA compared to control samples (h-
m). The competitive assay for total ucMGP however showed decreased serum levels, similar to 
PXE-like patients (n). Evaluation of the phosphorylation status of MGP revealed a significantly 
increased level of phosphorylated over non-phosphorylated MGP. 
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Serum concentration of vitamin K. Median serum VK concentration in PXE patients 
was 0.12 ng/ml. In the reference population, the median concentration was 0.60 ng/ml (p< 0.05).  
 
Pathology findings 
Light microscopy. Findings similar to those of PXE-like elastorrhexis areas and 
fibroblasts were obtained for cMGP, OC, OPN and BMP2 (Figure 2C). Although ucMGP stained 
somewhat less intense in the elastorrhectic fibers compared to those in PXE-like syndrome, it 
was still significantly more prominent compared to controls (Figure 2D). Fetuin-A also stained 
significantly in the elastorrhexis zone while the sub-epidermal labelling was less prominent 
compared to PXE-like tissues.  
Electron microscopy. As previously reported (20), in the dermis, control fibroblasts were 
slightly positive for both ucMGP and cMGP, and PXE fibroblasts were less positive for cMGP 
compared to controls (not shown). The immunolocalization of cMGP and ucMGP gave results 
almost identical to those in the dermis of patients with the PXE.like syndrome (Figure 5A & C).  
Irrespective of the calcification degree, elastic fibers were the only extracellular matrix component 
positive for both antibodies. The immunoreaction for ucMGP, the inactive form of MGP, was 
always more intense in PXE compared to control elastic fibers. Moreover, as already reported 
(20), it was confirmed that ucMGP antibodies were associated with either bulky and finely 
dispersed mineral precipitates inside elastic fibers (Figure 5A), whereas cMGP antibodies nicely 
and precisely localised at the border of the mineralised areas of calcified elastic fibers  (Figure 
5C).      
  
C. Control experiments 
In both PXE-like and PXE patients, Gla-proteins which are not involved in calcium 
homeostasis, such as gas-6, did not stain the elastorrhexic fibers (data not shown). MGP, OC 
and fetuin-A labellings did not yield a positive stain in solar elastosis or elastofibroma samples 
used as controls of skin conditions with dystrophic but non-mineralized elastic fibers (data not 
shown) 
 
Discussion  
 
 The present study confirms that inactive VK-dependent Gla-proteins are present both in 
the circulation and locally in dermal tissue of PXE and PXE-like patients. While in PXE-like 
patients this is likely due to the GGCX mutations, PXE patients tend to present decreased serum 
levels of VK, the essential co-factor of the VK-cycle, necessary for gamma-carboxylase activity. 
 
A. VK-dependent proteins in PXE-like patients 
In this study we first evaluated the hypothesis that low levels of carboxylated species of 
MGP and OC results in elastic fiber mineralization in PXE-like patients affected by GGCX 
mutations. We noted a significant accumulation of uncarboxylated MGP in dermal elastorrhexis. 
Quantitative analysis at the ultrastructural level confirmed the abundance of uncarboxylated MGP 
and unusually low amounts of carboxylated protein compared to controls. Sandwich ELISA 
assays in serum and plasma of PXE-like patients revealed decreased levels of carboxylated 
forms of MGP and OC while the levels of immature forms, respectively uncarboxylated 
unphosphorylated MGP and the total fraction of uncarboxylated OC, were dramatically increased. 
As a result, carboxylated/uncarboxylated ratios of both MGP and OC were decreased. Indeed, all 
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these findings are the direct consequences of GGCX deficiency and are factors likely to favour 
calcium precipitation in tissues such as the skin.  
Two findings need further interpretation. First, competitive ELISA experiments, 
specifically measuring total uncarboxylated MGP (dp-ucMGP and p-ucMGP), showed 
unexpectedly decreased serum levels. This may be explained by the high affinity of the 
phosphorylated ucMGP fraction (the most abundant form) for calcium in contrast to the 
unphosphorylated ucMGP. Hence the former may accumulate in the calcified tissues resulting in 
low serum levels. Secondly, labelling for cMGP and cOC was clearly positive in all PXE-like skin 
samples. Interestingly, cMGP and ucMGP localised in different areas of mineralised elastic fibers 
in patients. Similarly to what observed in the dermis of PXE patients (20), cMGP was at the 
border of mineralization, whereas ucMGP was heavily associated with mineral precipitates 
(Figure 4). The presence of carboxylated species in lesional skin and plasma indicates that the 
VK-metabolism was not completely abolished. Yet, the amount of cMGP and cOC accumulating 
at sites of calcium precipitation appear to be far below the critical threshold necessary to limit the 
calcification process. In a single pedigree displaying PXE-like features, Li et al. recently reported 
that dermal elastorrhexis only weakly expressed carboxylated MGP (22). In the latter paper both 
mutations detected in the GGCX gene were associated with different reduction in gamma-
carboxylase activity. We did not measure the gamma-carboxylase activity in our own patients but 
it seems likely that they keep a significant enzyme activity, since about 30% of carboxylated MGP 
and OC was still present in the circulation, although not sufficient to avoid connective tissue 
calcification.  
The intensity of OC labelling in middermal elastorrhexis suggests an additional local role 
for this Gla-protein, albeit more limited. Even though the lack of conformation-specific antibodies 
does not allow us to demonstrate that most OC in lesional skin is uncarboxylated, our finding of 
increased serum and plasma levels of uncarboxylated OC in PXE-like patients corroborates with 
this possibility. 
Besides the local calcification inhibitors MGP and OC, we observed strong staining of the 
potent systemic inhibitor of calcification fetuin-A in PXE-like patient’s dermis. This serum protein 
carries calcium phosphate and has been shown to play a major role in preventing pathological 
calcification (29-31). The extent of the protective mechanism by fetuin-A however appears to be 
less than that exerted by MGP, as fetuin-A deficient mice only develop minor calcified lesions 
compared to the extensive calcifications in Mgp -/- mice (30). However, fetuin-A is closely related 
to the extracellular transport of MGP. Price et al. have shown that cMGP, but not ucMGP, is 
carried by fetuin-A in plasma (8). This suggests that VK-dependent post-translational 
carboxylation of MGP is essential for fetuin-A binding and transport, and therefore could influence 
calcium deposition in the PXE-like syndrome resulting in a two hit mechanism for the promotion of 
calcification via MGP.  
 Measurement of VK in serum of PXE-like patients revealed normal concentrations. This 
confirms the hypothesis that in PXE-like syndrome ectopic mineralization is primarily the result of 
the GGCX mutations causing inactive Gla-proteins.  
 
B. VK-dependent proteins in PXE patients 
The identification of the PXE-like syndrome opened an interesting avenue of comparative 
research in PXE, because of the resemblance of both phenotypes. We therefore evaluated the 
involvement of MGP, OC and fetuin-A in PXE skin samples and observed similar IHC results as 
in PXE-like tissues. Biochemical measurements also revealed a decrease of serum and plasma 
total ucMGP, but - in contrast to PXE-like patients - normal concentrations of dp-ucMGP were 
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found. Unlike PXE-like samples, PXE samples were noted to present an increased ratio of 
phosphorylated over non-phosphorylated MGP suggesting a difference in MGP phosphorylation 
pattern to be an important discriminator between PXE and the PXE-like syndrome.  
Contrary to PXE-like patients, none of the PXE patients had mutations or functionally 
relevant polymorphisms in the GGCX gene, which could explain a possible dysregulation of the 
VK-cycle. We therefore also evaluated serum concentrations of VK, the essential co-factor of this 
metabolic cycle. We observed a poor vitamin K1 status in PXE patients with median serum 
concentrations much lower than these measured in the reference population (0.12 ng/ml vs 0.60 
ng/ml, SD= 0.31, p<0.05) or in other disorders associated with Gla-protein-related abnormal 
mineralization such as Crohn’s disease or osteoarthritis (13,32). In some patients (n=5), the VK 
concentration was below the detection limit, as observed in disorders with malabsorption of fat-
soluble vitamins such as cystic fibrosis (33).  
These low VK serum concentrations would suggest that gamma-carboxylation of OC is 
also negatively affected in PXE. Surprisingly, we did not detect abnormal OC levels in PXE serum 
samples, despite the IHC resemblance of labellings for OC with PXE-like syndrome, in which 
highly disturbed OC serum levels were noted. Osteoblasts, the cell type most expressing OC, 
have however a high level of low-density lipoprotein receptor-related protein 1 (LRP1) on their 
surface. LRP1 allows efficient uptake of the apoprotein E-containing chylomicron remnants that 
carry the bulk of the diet-derived VK. Therefore, it is plausible to assume osteoblasts to be more 
efficient in acquiring their share of the inadequate amounts of circulating VK in PXE patients than 
e.g. vascular smooth muscle cells in arteries or fibroblasts in skin (34).  
 The observation of such poor VK status in PXE patients supports the recently suggested 
hypothesis of VK as a candidate substrate of the ABCC6 transporter, which could provide a link 
between mutations in the ABCC6 gene, deficient protein carboxylation and resulting 
mineralization of elastic fibers (35). As VK has been described as an enhancer of kinase function, 
increased intracellular VK concentrations could also explain the increased phosphorylation of 
MGP observed in PXE patients (36).  
  
The increased expression of OPN, a mineral-binding phosphoprotein abundant in several 
mineralized tissues, in both PXE and PXE-like can be considered a rescue response to MGP 
dysfunction (37). OPN upregulation in mineralized aorta of Mgp -/- mice has previously been 
proposed to act as a secondary, inducible, calcification inhibitor which limits further mineralization 
(3). In Mgp -/- mice, OPN initiates removal of the mineral by macrophages (38). Of note, 
macrophages have also been found to be abundant near calcified areas in PXE dermis (39). 
MGP has been shown to negatively regulate BMP2, a known osteoinductive protein (40). The 
observed upregulation of BMP2 may likewise be due to MGP dysfunction. 
By immunoelectron microscopy it has been confirmed that ucMGP is specifically 
associated with calcification in both disorders and that the scarce cMGP present in the dermis of 
patients is precisely localised at the boundary separating calcified from normal elastin so 
appearing to inhibit/limit mineralization. Previous IHC reports on ectopic mineralization, showing 
involvement of various glycoproteins such as vitronectin or bone sialoprotein were hampered by 
the low specificity of these findings (41). In the present study, samples of disorders with 
dystrophic elastic fibers but no mineralization, such as elastosis or elastofibroma, did not yield 
any MGP, OC or fetuin labellings, suggesting that our observations are highly specific for PXE 
and the PXE-like syndrome. Similarly, labelling for Gla-proteins not involved in calcium 
homeostasis, such as gas-6, were negative. 
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From our findings, we can conclude that ectopic mineralization in the PXE-like syndrome 
and in PXE results from a deficient carboxylation of VK-dependent inhibitors of calcification. In the 
PXE-like syndrome, this deficiency results directly from mutations in the gamma-carboxylase 
gene. In PXE, deficiency of the carboxylation co-factor VK is at the basis of the decreased activity 
of calcification inhibitors. In both disorders MGP has a critical place. Whether VK is indeed the 
substrate of ABCC6 needs further study. However, our observations are promising towards 
therapeutic interventions in PXE, a disorder with no treatment to date. It has been shown in other 
disorders  with  poor  VK  status  that  exogenous  VK  supplementation  enhances  the  level  of  γ-
glutamyl-carboxylation, increasing the levels of carboxylated Gla-proteins, and as such (partially) 
inhibiting calcium precipitation. In animal models with deficient VK-dependent calcification 
inhibitors, ectopic calcification could be partially rescued with high doses of VK (25). As it is 
possible that other inhibitory pathways of calcification, such as the Ank-pathway in the Abcc6-/- 
mice (42), or other genes are also involved in clinical manifestations of human PXE and PXE-like 
syndrome, the extent of the VK supplementation effect remains to be determined in a clinical 
setting. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Sandwich ELISA and competitive ELISA (g&n) measurement results in PXE-like and PXE patients, compared to controls. 
uc: uncarboxylated; c: carboxylated; p: phosphorylated; dp: dephosphorylated; OC: osteocalcin; MGP: matrix gla protein;  
*: p< 0.05 
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Figure 2  
IHC staining results for carboxylated MGP (cMGP) and uncarboxylated MGP (ucMGP),  respectively in PXE-like patients 
(a-b), PXE patients (c-d) and controls (e-f) 
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Figure 3 
 IHC staining for osteocalcin and fetuin-A in PXE-like patients. In PXE, similar labeling was observed 
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Figure 4  
Transmission electron microscopy of elastic fibers in the skin of  control subjects. Gold particles represent epitopes 
positive to anti-ucMGP (a) and anti-cMGP (b) antibodies. Bars: 1µm and 0.5µm (inserts) 
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Figure  5  
Transmission electron microscopy of mineralized elastic fibers in the skin of  PXE (a,c) and PXE-like (b,d) patients. Gold 
particles represent epitopes positive to anti-ucMGP (a,b) and anti-cMGP (c,d) antibodies. Bars: 1µm and 0.5µm (inserts) 
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Publication 9 
 
An atypical case of pseudoxanthoma elasticum with abdominal 
cutis laxa: evidence for a clinical disease spectrum 
 
Olivier M. Vanakker, Bart P. Leroy, Leon J. Schurgers Paul J. Coucke, Anne De 
Paepe. 
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In this case report, a patient is presented with a severe cutis laxa of the abdomen. 
Several biochemical and molecular tests, including biochemistry of the collagens and sequencing 
of the fibulin-5 and elastin gene failed to endorse the diagnosis of a classic type of cutis laxa. 
Incidental ultrasonographical discovery of renal calcifications during his general work-up 
suggested a possible diagnosis of PXE.  
 
A thorough clinical examination revealed a minimal yellowish reticular pattern in the 
anterior neck region. Skin biopsy and ophthalmological examination confirmed the diagnosis of 
classic PXE, albeit that on ultrastructural evaluation also calcium deposits in the periphery of 
elastic fibres – typical for the PXE-like syndrome - were noted. Clinically, this patient presented 
characteristics of both classic PXE (retinopathy, renal calcifications) and the PXE-like syndrome 
(cutis laxa beyond the flexural areas).  
 
Immunohistochemical experiments and ELISA tests for various inhibitors of calcification 
exhibited results which were partly reminiscent of both PXE and the PXE-like syndrome. It is to 
be expected that this patient, and to a further extent, the PXE-like syndrome, is merely the tip of 
the iceberg of ectopic calcification disorders which are clinically, pathogenetically or both ways 
related to PXE.  
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Abstract 
 
In this case report, a patient is presented with a severe cutis laxa of the abdomen. 
Several biochemical and molecular tests, including biochemistry of the collagens and sequencing 
of the fibulin-5 and elastin gene failed to endorse the diagnosis of a classic type of cutis laxa. 
Incidental ultrasonographical discovery of renal calcifications during his general work-up 
suggested a possible diagnosis of PXE.  
 
A thorough clinical examination revealed a minimal yellowish reticular pattern in the 
anterior neck region. Skin biopsy and ophthalmological examination confirmed the diagnosis of 
classic PXE, albeit that on ultrastructural evaluation also calcium deposits in the periphery of 
elastic fibres – typical for the PXE-like syndrome - were noted. Clinically, this patient presented 
characteristics of both classic PXE (retinopathy, renal calcifications) and the PXE-like syndrome 
(cutis laxa beyond the flexural areas).  
 
Immunohistochemical experiments and ELISA tests for various inhibitors of calcification 
exhibited results which were partly reminiscent of both PXE and the PXE-like syndrome. It is to 
be expected that this patient, and to a further extent, the PXE-like syndrome, is merely the tip of 
the iceberg of ectopic calcification disorders which are clinically, pathogenetically or both ways 
related to PXE.  
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Introduction  
 
Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder, characterized by 
abnormalities of the skin (yellowish papules  in  flexural  areas),  eyes  (peau  d’orange,  angioid 
streaks and retinal haemorrhage) and cardiovascular system (occlusive artery disease) (1,2). The 
histological hallmark of the disease is calcification and fragmentation of elastic fibres. PXE is 
caused by mutations in the ABCC6 gene, coding for an ATP-dependent transmembrane 
transporter, the substrate and pathophysiological role of which remains to be elucidated (1-3). 
Recently we described a novel PXE-like syndrome, in which patients develop generalized 
redundant skin folds beyond the flexural areas, associated with a mild retinopathy and a 
coagulation defect of the vitamin K (VK)-dependent clotting factors (4). Although 
lightmicroscopically identical to PXE, subtle differences in elastic fibre mineralization – which 
occurred in the periphery of the fibre rather than the fibre core – could be observed 
ultrastructurally. This disorder is caused by mutations in the GGCX gene, encoding a gamma-
carboxylase. By carboxylating the glutamyl-residues of VK-dependent proteins, this enzyme is 
responsible for an essential posttranslational modification to make these proteins active (5). For 
this enzymatic reaction, vitamin K is an essential co-factor.  
Both in PXE and the PXE-like syndrome, an accumulation of uncarboxylated VK-
dependent calcification inhibitors – such as matrix gla protein (MGP) and osteocalcin (OC) was 
observed, resulting in elastic fiber mineralization (6). While in the PXE-like syndrome this was due 
to the GGCX mutations, low serum levels of VK in PXE patients were thought to be responsible 
for the inadequate activation of calcification inhibitors in PXE (6).  
     We report on a patient who presented with clinical, histological, biochemical and 
molecular features of both PXE and the PXE-like syndrome and as such uniquely illustrates that 
PXE and the PXE-like syndrome represent a spectrum of diseases. 
 
Materials and methods  
 
Clinical work-up of the patient was performed as described earlier (1). Skin biopsies were 
taken from the lateral neck and the abdominal region and were evaluated with light microscopy 
using Haematoxylin & Eosin, van Giesson (elastin) and Von Kossa (calcium) stains. Preparation 
of skin biopsy fragments for electron microscopy was done as described by Gheduzzi et al. (7). 
Immunohistochemistry with antibodies against cMGP, ucMGP and OC, provided by VitaK BV 
(Maastricht, The Netherlands) were performed as previously described (6).     
Molecular analysis of the ABCC6 and GGCX genes was performed as previously 
described (1,4). For biochemical measurements of mineralization inhibitors, serum was prepared 
by incubating samples for 20 minutes at room temperature and subsequent centrifigation. Plasma 
was prepared in citrate tubes. For measurement of the total fraction of ucMGP, a competitive 
ELISA assay was applied (8). Two additional sandwich ELISAs were developed at VitaK BV to 
determine the respective plasma levels of dp-cMGP and dp-ucMGP. For measurements of ucOC 
and cOC we used conformation-specific sandwich ELISAs (Takara Shuzo Co Ltd., Shiga, Japan). 
Vitamin K1 serum concentrations were assessed using an HPLC technique with post-column 
reduction and fluorescence detection, as previously described (9).   
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Case report and discussion  
 
A Caucasian male, born in 1987 from non-consanguineous, healthy parents, was first 
seen in our department at age 18 because of suspected cutis laxa. At age 10, his mother first 
noticed excessive skin folds, predominantly on the abdomen. The skin was loose and reduced in 
elasticity with relatively gross skin folds. Progressively, this cutis laxa-like aspect became also 
apparent in the axillae, upper arms and elbows (Figure 1). History revealed that prior to the 
occurrence of these skin folds, the skin had a reddish, inflamed aspect. This inflammatory 
process disappeared spontaneously leaving only the residual skin laxity. At the time of 
consultation, a similar rash was observed on the thorax. The lower limbs and the face were never 
affected. Despite the history of inflammation prior to the occurrence of cutis laxa, the aspect of 
the skin was not suggestive for acquired, post-inflammatory cutis laxa (10). Hence, the first 
diagnostic tests aimed to evaluate the connective tissue by means of a biochemical analysis of 
the collagens and molecular analysis of the elastin (ELN) and fibulin-5 (FBLN5) genes, 
responsible for hereditary cutis laxa (11,12). Neither abnormalities in the collagens nor mutations 
in the ELN and FBLN5 gene were observed. 
Our suspicion was first raised towards PXE when an abdominal ultrasound during a 
routine check-up revealed several small renal hyperintensities. Renal microcalcifications have 
previously been described as a common finding in PXE patients (13). Rigorous inspection of the 
skin, one year after the initial examination, revealed a very mild yellowish reticular rash in the 
frontal neck. No other skin characteristics compatible with PXE – in particular peau d’orange or 
papular lesions – were noted at that time. Further work-up of this patient included an 
ophthalmological evaluation, revealing a best corrected visual acuity of 12/20 with correction. In 
fundo,  peripapillar  angioid  streaks  and  peau  d’orange  in  the midperiphery  were  noted  in  both 
eyes. In the left eye, angioid streaks were also present in the macula (Figure 2).  
 
Skin biopsies were taken from the lateral neck and from the abdominal laxe skin folds. 
Lightmicroscopical evaluation revealed calcification and fragmentation of elastic fibres in the 
reticular dermis of both biopsies. No inflammatory signs were noted. On ultrastructural evaluation, 
the presence of fragmented elastic fibres with mineralization in the core of the fibres, typical for 
PXE, was confirmed (14). Also, huge fibroblasts with polymorphous nuclei and aggregates of 
matrix constituents, often seen in PXE, were present (14). Interestingly, also calcium deposits in 
the periphery of elastic fibres were observed, characteristic for the PXE-like syndrome (4) (Figure 
2). Together with the abdominal cutis laxa, an atypical localisation for classic PXE but often seen 
in PXE-like patients, this patient was further evaluated for characteristics of PXE and the PXE-like 
syndrome by means of immunohistochemistry, biochemical and molecular analysis. 
 
Immunohistochemical stainings of the affected skin, both in the neck and the abdomen of 
the patient, revealed marked staining of ucMGP and OC, as previously observed in both PXE and 
PXE-like patients (6). Interestingly, the distribution of the labelling was not confined to the 
middermis – as in PXE - but rather resembled the findings in PXE-like patients where ucMGP is 
observed throughout the whole dermis (Figure 3). Similarly, stainings for fetuin-A were of note 
because of the occurrence of a strong subepidermal labelling, a feature typically seen in PXE-like 
patients but absent in classic PXE (6).  
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Biochemical blood analysis, including calcium, phosphorus, kidney, liver and blood 
coagulation tests (PT, aPTT) were within normal limits, ruling out the co-existence of a deficiency 
of the vitamin K-dependent clotting factors. Measurement of circulating levels of carboxylated and 
uncarboxylated OC and MGP revealed elevated levels of ucOC, while cOC levels were 
diminished, resulting in significantly higher ucOC/cOC ratio compared to the reference population 
(Table 1). Such an elevated ucOC/cOC ratio was previously demonstrated in PXE-like patients 
(albeit even much higher than in the presented case) while PXE patients exhibit a normal 
ucOC/cOC ratio (6). As in PXE patients, circulating levels of dp-cMGP and dp-ucMGP were within 
normal limits, as well as the dp-c/dp-ucMGP ratio (6). Vitamin K circulating levels were found to 
be severely decreased in this patient compared to the reference population (0.15 ng/ml compared 
to 0.60 ng/ml in the reference population (p<0,05).   
 
Gla-protein / vitamin K Patient PXE* PXE-like* Controls* 
ucOC (ng/ml) 13,90 3 15 4 
cOC (ng/ml) 4,35 5 2 6 
ucOC/cOC 3,2 0,8 60 <0,8 
dp-ucMGP (%) 44,26 50 220 65 
dp-cMGP (%) 55,14 62 35 85 
dp-c/dp-ucMGP 0,80 0,4 9 0,76 
vitamin K (ng/ml) 0.15 0.12 0.58 0.60 
Table 1 
Plasma and serum measurements of circulating Gla-proteins and vitamin K. *Median values  
 
Molecular analysis of the ABCC6 gene revealed the patient to be compound 
heterozygous for the p.T941I (exon 22) and c.3507-3C>A (exon 25) mutations. Because of the 
clinical resemblance with the PXE-like syndrome, we also analysed the GGCX gene; although 
this analysis did did not reveal any GGCX mutations, the previously described p.R325Q 
(c.974G>A; exon 8) polymorphism was found in a heterozygous state. Surprisingly, this base pair 
change has been reported to have a gain-of-function effect on the gamma-carboxylase (15). 
Hence, we can hypothesize this variant to have a beneficial effect on gamma-carboxylation of 
Gla-proteins and hence the phenotype. However, because of the poor vitamin K status of our 
patient, it is plausible that this variant does not suffice to overrule the negative effect of vitamin K 
depletion on gamma-carboxylation.  
 
In conclusion, we report on a patient who presented to the clinic with phenotypical 
characteristics overlapping PXE (the yellowish reticular pattern in the neck, the retinopathy and  
the absence of a clotting factor deficiency) and the PXE-like syndrome (the gross laxe skin folds 
beyond the flexural areas). The overlapping nature of this peculiar phenotype was further 
strenghthened by the occurrence of central (PXE) and peripheral (PXE-like) calcium deposits in 
the elastis fibres, by the immunohistochemical labelling revealing an accumulation of inactive 
inhibitors of calcification throughout the whole dermis (as in PXE-like), by the increased ratio of 
ucOC/cOC serum concentrations (PXE-like) in contrast to the normal dp-cMGP/dp-ucMGP ratio 
in serum (PXE) and finally by the poor vitamin K status as is seen in PXE patients.  
 
At this point, molecular analysis in this patient, identifying two ABCC6 mutations and one 
gain-of-function polymorphism in GGCX does not suffice to explain these overlapping symptoms. 
It is likely that mutations or functional polymorphisms in one or more genes involved in calcium 
homeostasis play an additional role. While it has been previously suggested that in some PXE-
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like patients – presenting with extensive cutis laxa and a clotting factor deficiency – a digenic 
inheritance, characterized by two GGCX mutations and one heterozygous ABCC6 mutation might 
occur (16), the patient presented here uniquely emphasizes that not only the molecular features 
but also the clinical, immunohistochemical and biochemical characteristics of PXE and the PXE-
like syndrome may occur together in a single patient. These observations further expand the 
spectrum of PXE-like phenotypes and – in the absence of GGCX mutations – suggests a role for 
multiple genetic factors in soft tissue mineralization in general.  
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Figures 
 
 
Figure 1  
Phenotypic characteristics of the propositus with predominantly abdominal skin laxity (a,b), a mild yellowish reticular 
pattern in the frontal neck region (c), renal calcifications (d) and testicular microlithiasis (e) 
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Figure 2  
Ophthalmologic features with peau d’orange (a, circle), angioid streaks (b, arrowed) and 1 comet (b, circle). On 
ultrastructural analysis, fragmentation and calcification of the elastic fibre core (c, arrow) and periphery (d, asterisk) is 
observed. Bar = 1 μm 
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Figure 3 
Immunohistochemical staining of ucMGP is significantly positive in the middermis (a) and the deeper zones of the reticular 
(b) dermis 
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Chapter 4 
Discussion and future perspectives       o 
 
″I  hate  discussions. They sometimes make you change your 
mind.″         
 
″Whenever  people  agree  with  me,  I  always  feel  I  must  be 
wrong.″ 
 
      Oscar Wilde (Thoughts & Lady Windermere’s Fan) 
 
 The incentive for this thesis was to contribute to a better understanding of the 
mechanisms leading to PXE, as its pathogenesis remained basically unknown even more than 
100 years after it was first described. To achieve this objective, we made use of clinical studies, 
molecular techniques as well as basic science experiments. From the very beginning – my 
early steps in the wonder world of PXE – it became clear to me that, besides the enigmatic 
pathogenesis, also the knowledge on clinical aspects and natural history of the disease lacked 
comprehensiveness. Indeed, disorders such as PXE – described in another century and topic of 
numerous publications – are  easily  considered  as  ″sufficiently  characterised  from  a  clinical 
perspective″. Over the years, the day to day patient care – their history, questions and concerns – 
has convinced me that still a large number of clinical characteristics and finesses await 
uncovering. As systematic unravelment of the pathogenesis of a disease undoubtfully requires 
sufficient knowledge of all aspects of clinical symptoms and signs, a number of clinical studies 
were undertaken, providing novel insights in known and unknown organ systems affected by 
PXE. Because of its relevance for diagnosis and family screening, studies were undertaken to 
optimize molecular analysis of the ABCC6 gene and to explore the mutation spectrum and 
genotype-phenotype correlations.  Finally,  the  famous  adagio  of  translational  research,  “from 
bedside to bench to bedside”,  is put  into practice by  identifying a novel, fascinating disorder, 
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the etiopathogenesis of which lead to the establishment of a spectrum of PXE-like disorders and 
the perspective of an innovative therapeutic approach for such diseases. 
 
4.1 ABCC6 mutational spectrum and 
genotype-phenotype studies 
 
4.1.1  Molecular analysis of the ABCC6 gene 
 
 The kick-off project of this thesis comprised a thorough characterization – both clinically 
(see 4.2) and molecularly – of PXE patients followed at the Ghent Center for Medical Genetics. 
Using dHPLC and direct screening, we were able to expand the mutational spectrum of the 
ABCC6 gene with 17 novel mutations and reported a mutation detection rate of 96% (the highest 
detection rate reported so far (publication 1). The high efficacy of the molecular strategy applied 
in this particular study – a strategy which can be extrapolated to all future molecular studies in 
PXE – certainly complements the thorough clinical characterisation which is offered to each 
patient seen in our PXE clinic. These comprehensive protocols provide the patient with the most 
optimal health care focussed on his particular disease and gives the physician sufficient certitude 
on the accuracy of the clinical diagnosis. To date, more than four years after their compilation, 
these protocols still form the basis of a diagnostic or follow-up consultation in the Ghent PXE 
clinic.  
The main modification in the molecular protocols over the past four years concerned the 
replacement of the dHPLC technique by direct sequencing analysis. Introduced in 2002 as an 
efficient, fast and reliable technique for molecular screening, experience and technological 
evolution turned against this method. The read-out of the chromatogram was certainly not always 
straight forward and required a considerable expertise (Figure 24). Although dHPLC is without 
question still less expensive per se compared to a high throughput sequencing facility, we noticed 
that in some patients mutations could be missed either because the chromatogram was 
interpreted incorrectly as normal or because it did in fact yield a normal result. As such, the 
speed, sample turn-over and efficacy of current partially or fully automated sequencing facilities 
made it a valuable substitute for dHPLC. Hence, high tech molecular genetics has evolved – in 
only four to five years time – from sequencing methods to screening methods to again direct 
sequencing of the appropriate gene.   
  
 
Figure 24 
dHPLC chromatograms 
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Panel A exemplifies the p.R1141X mutation (bottom arrow), while the open arrow suggests a basepair change but actually 
was a normal variation. Panel B exemplifies a suggestive change, identified as the p. G755R polymorphism. Finally, panel 
C shows a subtle shift of the bottom curve, compatible with the c.2820-2821insC frameshift mutation. 
 
 Foremost the main shortcoming of molecular studies of the ABCC6 gene – including our 
own 2007 study – is the limited number of patients in the evaluated cohort. To evade this hurdle, 
we worked closely together with PXE International and the South-African PXE research group in 
a collaborative molecular study of 270 patients. Although the study design – based on self-
reporting through clinical questionnaires – made clinical characterization of the study population 
less extensive than our own cohort, the large number of patients enabled us to present a very 
comprehensive study of the ABCC6 mutation spectrum (publication 2). 
 Certainly, in both studies some ABCC6 mutations remained unidentified. This was due to 
the study design and limitations of the applied techniques. The recently identified genomic 
aberrations involving ABCC6 have e.g. not been investigated. In the cohort studied by 
Chassaing et al., these account for 28% of unidentified alleles following direct sequencing of the 
gene [239]. Secondly, direct sequencing has been shown to fail in detecting middle-sized 
deletions or duplications, making further optimization of the ABCC6 analysis strategy 
imperative.  
 The hypothesis of a second gene being involved in classic PXE seems unlikely in view of 
our high mutation detection rates.   
 
A traditional topic of debate, originating from the first classification by Michael Pope, 
beheld the existence of one or more dominant forms of PXE [27]. Despite a growing number of 
authors refuting this classification, the occasional report describing a dominant pedigree of 
phenotypes designated to be classic PXE still occurred [30, 32, 33, 299, 300]. Our molecular and 
phenotypical studies in the Belgian PXE population as well as in a more global PXE cohort, 
unequivocably showed autosomal recessive inheritance to be the only modus applicable for PXE. 
Dominant pedigrees should first be thoroughly evaluated at the molecular level to exclude 
pseudo-dominance. In those families with a compound heterozygous genotype, all family 
members should be examined for both mutations known in the family. Hence, the whole ABCC6 
gene should be analysed in an effort to identify two causal mutations. Indeed, it can not be 
excluded a priori that an individual designated as obligate carrier in the pedigree is in fact a 
patient with a mild(er) phenotype. The observation of phenotypical features in carriers, together 
with the lack of cutaneous signs in some patients, has rendered it difficult to exclude 
pseudodominance based on clinical examination. Hence, an “obligate carrier“ cannot be excluded 
to be a patient in a pseudodominant pedigree. Secondly, in those families where a single ABCC6 
base pair change is inherited from one generation to the next, the causality of this change should 
be critically evaluated. Indeed, it remains ever so difficult to predict the causal or functional effect 
of an aminoacid change, despite the standard criteria by Cotton and Scriver [301]. Finally, in the 
advent of increasing awareness for distinct PXE-like disorders, often with striking clinical 
similarities, phenotypes with undisputable autosomal dominant inheritance may represent novel 
disorders related to PXE.  
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4.1.2  Genotype-phenotype correlation studies 
 
 One of the most frequently asked questions by patients, who get the diagnosis of PXE, 
is what they should prepare themselves for in the future. How will their skin lesions evolve? Will 
these become an aesthetical burden? Will their eyesight deteriorate rapidly, condemning them to 
unilateral or bilateral (legal) blindness? Will the atherosclerotic or gastro-intestinal complications 
of the disease shorten their life span? What will be the effect of PXE on their quality of life in 
future years? The honest answer that every physician taking care of PXE families – when 
withholding from speculation – must give is also the most annoying and most difficult one – not in 
the least as it highlights our ignorance on some of the most vital aspects of this disease: “I do not 
know”. The need for clear answers was a driving force behind several small genotype-phenotype 
correlation studies – including our own – which were not able to detect any significant association 
between the type or position of a given mutation and the clinical characteristics of the patient 
(publication 1). Despite the observation of intrafamilial variability – two or more family members 
with identical mutations but a completely different, sometimes opposite phenotype – a “spark of 
hope” remained as the studied cohorts were possibly too small to obtain significant results. This 
critique was however not applicable to the large study we performed together with our 
collaborative partners; even in a cohort of more than 200 patients, a straightforward genotype-
phenotype correlation could not be delineated (publication 2).  
  
 Although these results are disappointing, they are by far not unexpected nor should they 
cause us to lose hope. Indeed, an extensive list of metabolic disorders exists, in which genotype-
phenotype correlations were not  identifiable  (mitochondrial  disorders,  Wilson’s  disease, 
arteriopathies, skeletal disorders, storage disorders, ...) [302-305]. The high variability in clinical 
severity of the PXE phenotype suggests that an important role – both from the pathomechanistic 
and clinical point of view – is set aside for other genetic factors, such as modifier genes and/or 
epigenetic modifications. The modifiers identified so far though seem to have little or no clinical 
significance, implicating this subject as a crucial area for future research [241, 242, 306, 307]. 
 
4.2 Innovative clinical aspects of PXE 
 
4.2.1  Soft tissue mineralization occurring in 
the skin and viscera 
 
   4.2.1.1 Dermatological characteristics 
 
The skin manifestations of PXE have been an established clinical sign, leading to the 
diagnosis of this disorder in many patients. Indeed, as the early retinopathy is asymptomatic and 
cardiovascular complications usually occur in adulthood, the yellowish papules and plaques 
are often the first to be recognized by patients and physicians. During our study of the Belgian 
PXE population, it came to our attention that some patients had not developed typical 
macroscopic skin lesions at the age of diagnosis. Although some of these individuals tended to 
exhibit papules later in life, it was concluded that a negative skin inspection does not 
automatically rule out the possibility of PXE. Due to this particular subgroup of patients, the 
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discussion of sampling error – when a skin biopsy is taken blindly – arose. In the event that the 
biopsy is considered normal, this could merely indicate that the sample was taken adjacent to a 
microscopic lesion. In such cases, the molecular analysis of the ABCC6 gene could have a 
genuine diagnostic purpose and replace the skin biopsy. Together with our excellent mutation 
uptake, this observation has significantly influenced the diagnostic flowchart described in 
publication 1.  
 
In our efforts to study the natural history of the PXE phenotype – yet another territory 
which had hardly been cultivated – we noted most patients to suffer expansion of their skin 
lesions: plaques became larger or inelastic skin folds turned out to be more prominent. However, 
the gradual change of skin lesion type – from papules to plaques to inelastic dermal folds – 
was rarely observed. Although this is by far a general truth for all patients, it can bring 
reassurance for patients who are often very pre-occupied with the aesthetic consequences of 
their disease.  
 
   4.2.1.2 Visceral calcifications 
 
Although occasional reports of organ calcifications – in kidney, pancreas, spleen and 
breasts – could be found, no systematic screening of PXE patients or healthy carriers had been 
performed. Following up on a 2004 case report of testicular microlithiasis in a fourteen-year old 
boy with PXE – in itself not an unusual finding in young children – we decided not to limit our 
study to the visceral organs but also perform ultrasounds of the testicles [172]. A remarkably high 
number of patients appeared to have hyperechogenic foci in one or more abdominal organs 
(publication 3). Such calcifications are themselves certainly not pathognomonic for PXE; several 
disorders are associated with metastatic mineralization (table 2); however, all of these involve 
abnormalities in the calcium-phosphorus balance, which are not present in PXE. As other 
disorders of dystrophic mineralization (scleroderma, dermatomyositis) could be clinically excluded 
in our patients, our observations are most likely part of the PXE phenotype. Indirectly, this is 
substantiated by the apparent concordance between visceral and ocular mineralization (comets 
and/or comet tails). Our recent observations in an increasing number of patients confirm these 
original findings. Neither in the original study cohort nor in the present patient population, 
significant abnormalities of kidney, liver or spleen function could be established, suggesting these 
lesions to be benign. In several patients, a progressive increase of the number of these calcified 
foci can be seen, indicating the need for a longer period of follow-up before drawing any definite 
conclusions. Publication 9 emphasizes the usefulness of an ultrasonographical screening 
examination of the abdomen in patients suspected to have a connective tissue and/or metabolic 
disease; when visceral calcifications are found to be associated with a normal ionogram, PXE 
should take a prominent place in the differential diagnosis. 
 
Widely spread hyperechogenic foci in the testicular parenchyma, so-called testicular 
microlithiasis (TM), were observed in all male patients of the original study cohort [308-310]. 
The cut-off between limited and classic TM has been established on 5 calcifications. Our current 
clinical expertise confirms that every male patient followed suffers from the classical form of 
metastatic testicular calcification. Also Bercovitch et al. observed TM in all examined male 
patients [311]. Strictly speaking, TM is a histopathological diagnosis, in which small calcified 
lesions, so-called microliths, can be observed within the seminiferous tubules (Figure 25). A 
testicular biopsy for these purposes is not justifiable in our patients, because of the risks of such a 
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procedure. Unfortunately, the histopathological study of Gheduzzi et al. on a deceased male PXE 
patient analysed nearly all tissues except… the testicles [36]. It remains sufficient to say that the 
ultrasonographical image – often referred to as  a  “snowstorm”  or  “heaven  full  of  stars”  – is 
characteristic for TM, even without histological confirmation.  
 
 
Figure 25 
Histopathological image (haematoxylin-eosin stain, x8) of testicular microlithiasis (Panel A). Microliths are arrowed. Panel 
B demonstrates the ultrasonographical characteristics of classical  testicular microlithiasis in a transverse cross-section of 
the testicles. 
Panel A adopted from Woodward et al. [312] 
 
Although TM is a known paediatric entity, often found in young boys and usually 
regressing with age, there are an increasing number of reports linking (pre-existing?) TM in adults 
to the occurrence of testicular tumours [313-353]. It must be noted that none of these reported 
associations were observed in a prospective study but were usually the subject of case reports or 
retrospective data. Hence, it remains unclear outside the field of PXE whether this presumed 
association is genuine or merely founded on coincidental observations. Little is known about the 
pathogenesis of TM or how it would contribute to the development of malignancy [308]. The fact 
that several other tumour types have metastatic calcifications as a secondary effect, may be an 
argument for a post hoc phenomenon. For PXE patients, the uncontrolled dystrophic calcification 
in various tissues could be explicatory enough for the parenchymatous mineralization of the 
testicles. This would imply that – even if isolated TM is linked to an increased risk for testicular 
cancer – the calcifications in PXE occur due to disturbance of other, probably not carcinogenic 
pathways. Indeed, no increase of tumours of any kind has been reported in PXE. However, until 
further prospective data – both on isolated TM and on testicular lesions in PXE – become 
available, we recommend a yearly ultrasonographical evaluation of the testicles and regular 
self-examination, as these methods have sufficiently proven their efficacy to detect testicular 
tumours in an early stage [354-356]. 
 
4.2.2  Ocular findings: a comet’s tale...  
 
From the ophthalmological side, there was a need for better characterization of the 
functional aspects of the PXE retinopathy as well as optimization of mild fundus lesion 
detection. Our studies have indicated the ophthalmological phenotype of PXE to be composed of 
both anatomical and electrophysiological dysregulation of the retina. Optimal visualization of the 
anatomical features is achieved combining IRI, RFI and AFI. 
 
 
 171 
   4.2.2.1 Anatomical fundus injuries 
 
Although fundus aberrations largely remained unchanged since their first description by 
Grönblad, the advent of novel imaging techniques made apparent that some of these lesions 
were underestimated or even overlooked when only white light funduscopy was applied. Infrared, 
red-free and autofluorescent imaging of the fundus are currently emerging as the standard in 
visualizing the damage due to ARMD and other retinal dystrophies and stand out because of their 
accuracy and high detection yield of limited early onset lesions [357-363]. Particularly the wet 
form of AMD, associated with development of abnormal neovasculature, is highly resemblant of 
the PXE retinopathy (Figure 26). When used to visualize PXE fundi, it was noticed that combining 
these novel methods lead to an earlier and more extensive visualization of both AS and peau 
d’orange (publication 5).   
 
 
Figure 26 
Pathogenesis of wet AMD. The growth of new vessels from the choriocapillaries (CC) through Bruch’s membrane (BM) 
results in neovasculature – choroidal new vessels – both above and below the RPE. IS/OS: inner segment, respectively 
outer segment of the photoreceptors; ONL: outer nuclear layer.  
Adopted from Tezel et al. [364] 
 
Angioid streaks could be classified into two types, based on whether or not they were 
accompanied by surrounding RPE alterations. In the absence of such RPE changes, AFI was not 
able to visualize the streaks, while they were very distinct on IR imaging compared to 
conventional colour fundus photography. Indeed, streaks either absent or initially unnoticed on 
colour pictures were detected with IRI. This lead us to conclude that a combination of AF and IR 
imaging is essential for optimal visualization of the different types of AS and is as such superior 
to colour imaging for the early detection and follow-up of AS. Although several potential 
pathogenetic mechanisms could be proposed based on the autofluorescence patterns of the 
different types of streaks, no definite pathologic substrate could be delineated so far to explain 
what is actually happening in the PXE retina at the cellular level. Our data suggests decreased 
outer segment phagocytosis by RPE cells to result in loss of intracellular lipofuscin in the RPE 
cells adjacent to the streaks, while at the borders of the AS, proliferation and dysfunction of RPE 
cells occurs. Hu et al. hypothesized ABCC6 deficiency to lead to aberrant transport mechanisms 
in the retina [24]. Our imaging findings may indeed point towards an influence of ABCC6 on the 
photoreceptor-RPE complex. As in AMD, the immune system might play a role in attacking the 
RPE, due to impaired recruitment of macrophages in the subretinal space. This might explain the 
accumulation of lipofuscin observed with AFI, while death of RPE cells could result in atrophy and 
dysfunctional RPE cells in expression of various growth factors such as VEGF. On the other 
hand, despite the extent of damage to the RPE, it remains intriguing that, even within 
longstanding AS, normal areas of RPE could be observed, suggesting a focal detriment. 
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Peau d’orange could be observed in more detail and to a greater extent throughout the 
retina using IRI (publication 5). In contrast to its earlier described restriction to the retinal 
periphery, the dotted pattern could be observed as far as the macular region in some patients. 
Despite the invasion of this highly fragile part of the RPE, this lesion – the nature of which 
presently still remains uncertain – did not bring about significant visual problems. Yet, when 
considering peau d’orange as a first indication of PXE retinopathy, preceding AS for many years, 
the value of these imaging modes for early recognition of the disorder is beyond question. 
Besides  peau  d’orange,  AS  and  the  neovascular  complications,  one  of  the  most 
underestimated fundus characteristics of PXE are comets or comet tails (CT). These punched 
out lesions – which were found to represent spots of calcification on ocular ultrasonography 
(Figure 27) – have been rarely cited in literature, yet were seen closely associated with PXE [24, 
119].  This could be confirmed in our studies, in which we also showed IR imaging of the fundus 
to be superior in detecting CT, even when they went unnoticed during standard fundus 
photography. As a result, in our current practice CT are used as an indicator for ABCC6 
dysregulation, although this does not imply both ABCC6 alleles to be mutated. Indeed, much to 
our surprise, we also found these distinct white dots in carriers of one ABCC6 mutation. So far, 
their occurrence in other retinal dystrophies or normal fundi has not been reported. Hence, the 
recognition of isolated CT should bring about suspicion of at least one mutation in the ABCC6 
gene, but does not automatically imply the patient to have PXE. Upon recognition, even by 
chance, a thorough skin evaluation and molecular analysis of ABCC6 is unquestionably indicated. 
 
Figure 27 
B-scan of a comet tail lesion, revealing a hyperechogenic spot (arrowed) with acoustic shadowing (asterisk), the typical 
hallmark of chalk on ultrasound.  
  
   4.2.2.2 Electrophysiological dysregulation 
Some PXE patients presenting with visual complaints do not have such considerable 
anatomical deterioration of the RPE – even after AFI examination –to justify their decreased 
visual acuity. Particularly in such patients, the presence of generalized retinal dysfunction should 
be considered. We have described three phenotypes – cone-rod dystrophy, rod-cone 
dystrophy and severe photoreceptor dystrophy – in four young individuals with severe visual 
handicap due to PXE (publication 4). Previous reports on retinal dysfunction are scarce and 
limited to older individuals with advanced disciform degeneration. The presence of such 
dysfunction in less deteriorated fundi may suggest it to be present in other PXE patients; this 
would certainly explain night vision and color discrimination problems often reported by patients. 
An accurate rate of occurrence of these electrophysiological problems in PXE patients remains, 
currently under investigation.  
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Because also in these individuals no correlation with the ABCC6 mutations could be 
noted, it seems most probable that modifier gene(s) determine whether or not PXE is 
accompanied by such generalized retinal dysfunction. Identification of such modifiers will be the 
topic of future research. 
 Natural history study of the PXE retinopathy (publication 1) revealed anatomical 
progression in a quarter of patients, while almost half presented with functional decline. It was 
particularly the latter which – due to binocular occurrence – resulted in significant visual handicap. 
Altogether, these data encourage further electrophysiological studies in PXE.  
 
 4.2.3  Cardio- and cerebrovascular features 
 
 I have always had the feeling that the cardiovascular symptoms or – if you will – 
complications of PXE were condemned to the backstage plan after the clinically obvious and 
diagnostically important skin lesions and the potentially handicapping ocular signs. It is in this 
respect probably no coincidence that the cardiovascular phenotype was historically the last to 
have been described and added to the triad of clinical signs and symptoms. Yet, although 
undoubtfully not as frequent as the oculocutaneous signs, the cardiac and vascular symptoms are 
the source of significant morbidity and – if not detected and treated timely – mortality. It was 
and is therefore my conviction that this part of the triad deserves thorough investigation.    
 
    4.2.3.1 Ischemic stroke in PXE 
 
 Although cerebrovascular complications of PXE were seldom emphasized in the past, we 
observed a considerable higher incidence of ischemic stroke in PXE patients, usually in the 
fifth or sixth decade of life. This observation in a consecutive cohort corroborated several case 
reports [85, 139, 365-371]. These results lead to the design of an exploratory pilot study in close 
collaboration with the Neurology department of the Ghent University Hospital to investigate in a 
cohort of consecutive ischemic stroke patients whether we could either find (subtle) signs of PXE, 
signifying stroke to be an eventual presenting complaint as was previously shown for acute 
myocardial infarction [159] or whether a higher frequency of mutations in the ABCC6 gene could 
be detected compared to the general population. While no novel PXE patients emerged from 
this pilot study, a significantly higher percentage of heterozygous ABCC6 mutations was 
found in the stroke population compared to controls (publication 6). The idea of an ABC-
transporter playing a role in the diseased brain is not novel, as several ATP-binding proteins have 
been implicated in drug resistance (e.g. in intractable epilepsy) as well as described in relation to 
ischemic stroke [372-377]. ABCB1 expression was found elevated after stroke, having a 
deleterious effect on neuroprotective agents [378]. Conversely, two polymorphisms in ABCA1 – 
the causal gene for Tangier disease – were found to be associated with a decreased risk for 
ischemic stroke [379, 380].  
 
The stroke patients in whom these heterozygous ABCC6 mutations were found, 
presented with clinical heterogeneity – in age, additional risk factors as well as stroke type – 
resulting in the impossibility of delineating particular subgroups of ischemic stroke in which 
ABCC6 mutations would occur more frequently. As such, the results of this pilot study do not offer 
guidelines for diagnostic testing of ABCC6 in stroke. Other limitations which are characteristic for 
a pilot study are the small sample size and, in this particular study, the use of hotspot analysis as 
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a tool for molecular screening. These limitations notwithstanding, the data from this study indicate 
that systematic physical examination in stroke patients to uncover subclinical PXE is not useful, 
although it remains a laudable habit to think about the disease when confronted with young 
patients lacking cardiovascular risk factors. On the other hand, our findings are promising in 
implicating ABCC6 mutations in ischemic stroke and provide a basis for future research, as 
detailed further. 
 
The association of these ABCC6 mutations – all of which were changes commonly 
detected in PXE families – with ischemic stroke is yet another indication that ABCC6 
heterozygosity can indeed be linked to a vascular phenotype. This is not without importance for 
the genetic counselling of PXE families: in obligate or potential carriers of an ABCC6 mutation, 
molecular analysis should be performed to confirm the mutation, which can be considered an 
additional cardiovascular risk factor. Although no direct intervention will affect this genetic 
susceptibility, the presence of this additional risk factor may serve as a catalysor for optimizing 
the additional preventive cardiovascular measurements. 
 
    4.2.3.2 Cardiovascular complications 
 
 Although not a frequent vascular complication, gastro-intestinal haemorrhages can be 
severe and debilitating. During a consultation, it remains frustrating to have to bring the message 
to a patient that a ten percent risk subsists of suffering such bleedings – plural, as in our 
experience one tends to be followed by several – but not being able to pinpoint which are the 
determinants of such haemorrhages. As no correlation with the ABCC6 genotype exists, one or 
more modifier genes are most probably involved although to date no genetic factors could be 
identified. Medical advice is restricted to the avoidance of systemic corticosteroids and non-
steroidal anti-inflammatory drugs, known to cause erosive mucosal lesions. The increased 
incidence of e.g. stroke in PXE patients sometimes creates a difficult therapeutic dilemma as the 
daily use of antiplatelet drugs for secondary prevention after cerebrovascular disease increases 
the risk for haemorrhages. No ideal solution exists for such quandaries but the enteric coated 
form of aspirin at the lowest effective dose (80 mg) is an adequate and safe intermediate solution 
[381]. 
 Other (cardio)vascular findings in our PXE patients, including the predominance of 
peripheral artery disease – in particular of the femoral arteries – and the limited incidence of 
mitral valve prolapse, have displaced the emphasis within the cardiovascular phenotype of PXE. 
The former stresses the importance of regular duplex examinations of the lower legs, which is 
often substituted by the easiness of carotid artery examination. Doppler examinations of both 
should be or remain a basic element of the routine follow-up examinations of every PXE patient.  
 Although high frequencies of mitral valve prolapse have been reported in other heritable 
disorders of connective tissue, such as Marfan syndrome or the Ehlers-Danlos syndrome [382], it 
does not appear to be an important clinical feature in PXE. Inevitably, the low incidence of this 
valvulopathy reflects the shift in the definition of prolapse [148]. Indeed, using echocardiography, 
MVP is categorized as “classic” MVP when valve leaflet thickening exceeds 5 mm, while a lesser 
degree of leaflet thickening is termed “non-classic” MVP. While the significance of classic MVP as 
a cause of serious complications (endocarditis, sudden cardiac death, CVA, ...) is beyond any 
doubt, the non-classic configuration could possibly be regarded as a benign variant [148, 383].    
    
 175 
4.2.4  Heterozygous carriers of 1 ABCC6 
mutation 
 
 For disorders with autosomal recessive inheritance, heterozygous carriers of one 
mutation – either obligate carriers such as parents and children of the affected proband or 
possible carriers such as the probands sibs – are generally assumed not to be affected by the 
disease. However, several examples can be summarised of disorders, the carriers of which 
present a partial (either mild or moderate) phenotype (Table 6).  
 
Disorder Clinical features in heterozygous carriers Ref. 
Hemochromatosis Porphyria cutanea tarda, acute myocardial infarction [384] 
Ataxia teleangiectasia Increased radiosensitivity and risk of cancer [385] 
Duchenne muscular dystrophy ERG abnormalities [386] 
Naxos disease 
Werner syndrome 
Whooly hair phenotype, mild RV dilatation 
Genetic instability 
[387] 
[388] 
Table 6 
Examples of autosomal recessive disorders with phenotypic expression in heterozygous carriers. RV: right ventricle 
 
 In PXE, the paradigm of the unaffected carrier has long been retained, despite the 
observation of elastic fibre degradation in macroscopically unaffected skin of carriers [197, 198]. 
The results of our phenotypical studies enabled us to question this principle. We noted carriers to 
exhibit soft tissue calcifications on ultrasonography of the abdomen, identical to but less 
frequent than in PXE patients (publication 3). As in patients, organ function remained apparently 
unaffected. Furthermore, some carriers were noted to exhibit hyperechogenic foci in the testicle, 
particularly in the capsula testis. Only one carrier was noted to have a parenchymatous 
calcifcation compatible with limited testicular microlithiasis. These findings suggest testicular 
calcifications – and hence the theoretical tumour risk – to be much less frequent compared to 
PXE patients.  
In addition to the abdominal and testicular mineralization, calcifications in fundo – so-called 
comets and/or comet tails – were also unveiled in carriers. Although these comets are highly 
specific for PXE, their presence in carriers make them not diagnostic for PXE patients but do 
suggest the presence of – one or two – mutations in the ABCC6 gene. When accompanied by 
other features of the PXE retinopathy, the diagnostic challenge is limited. The challenge lies in 
individuals – particularly young persons – in whom these comets are found as an isolated lesion. 
These individuals are not obliged to display peau d’orange or angioid streaks yet, even when their 
two ABCC6 alleles are mutated. Such an individual should be considered a PXE patient until 
proven otherwise and should be referred for complete work-up as stipulated above, molecular 
analysis of the ABCC6 gene included. Older individuals, beyond the third decade, who feature 
isolated calcifications in fundo, are less likely to exhibit PXE but are almost certainly carrier of one 
ABCC6 mutation. Also in these individuals, further work-up with ABCC6 sequencing and clinical 
follow-up may be useful for themselves and their family.  
For all calcifying lesions mentioned, it remains probable that they will never develop any 
clinical significance, although – especially for the viscera and testicles – follow-up is too limited to 
draw final conclusions. Comets and comet tails however do not compromise visual acuity. The 
importance of these calcified foci as minor diagnostic criteria remains – also in carriers – 
underrated. In contrast to the recent publication of Martin et al., in whom some carriers exhibited 
ophthalmological  complications, we  have never observed so much as ocular peau d’orange or 
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angioid streaks in carriers, although systematically searched for with highly sensitive detection 
methods (publication 5) [389].  
 
 Besides the diagnostic value of calcifications in carriers, our observation of a significantly 
increased incidence of peripheral artery disease (atherosclerosis) and ischemic stroke has 
important consequences for the follow-up of known PXE carriers and for genetic counselling of 
patients. Indeed, this observation unequivocally grants the coup de grâce to the principle of so-
called  “healthy  heterozygous  individuals”.  The  phenomenon  of  ABCC6 heterozygosity being 
associated with increased cardiovascular risk was further substantiated by our molecular 
studies in a case series of stroke patients, as discussed above. 
 
The presence of a (limited) phenotype in heterozygotes emphasizes the need for these 
individuals to be followed regularly in a specialised clinic. Also in the follow-up of these 
individuals, a detailed knowledge of which clinical features a heterozygous mutation can and 
cannot cause, must guide the type and frequency of the examinations the person undergoes. In 
our PXE clinic, all carriers are submitted to a thorough clinical work-up after the first visit – 
considered as a status praesens – including duplex ultrasound of the carotids and femoral 
arteries, ultrasonographic examination of the abdomen, testicles and heart and an 
ophthalmological examination. Depending on results, a plan for clinical follow-up is made up 
individually. The ophthalmological evaluation is performed only once if the patient is older than 25 
years, as it is our experience that features of the PXE retinopathy are always present after this 
age. When younger than age 25 at the first evaluation, the evaluation is repeated once beyond 
this age, with in the mean time annual intermediate controls.   
 
4.3 Identification and etiopathogenetic study 
of a PXE related disorder: unravelling a 
common final pathway with PXE  
 
4.3.1  Identification of a novel syndrome... 
 
 It was – and in retrospect still is – an indescribable vibe which went through the meeting 
room at a 2006 international research meeting in the Ghent Center for Medical Genetics. I had 
just presented a patient who for many years stood out in our cohort of PXE patients. Not only was 
she the only patient in whom we did not find any mutation in the ABCC6 gene – despite our rather 
high mutation uptake rate –, the extreme characteristics of her phenotype on many occasions 
made us wonder whether this was merely the more severe end of the PXE phenotypical spectrum 
or if this was something else? Although she presented to our clinic in her early twenties with 
typical papular skin lesions in the flexural areas and at first a diagnosis of PXE was confirmed by 
typical lightmicroscopical findings, the natural evolution of the skin lesions was unlike any other 
patient we had seen. Over a period of twenty years she developed gross, thick and leathery 
inelastic skin folds which were no longer confined to flexural areas but affected the whole body 
except the face. In addition, she only had minor angioid streaks next to a typical peau d’orange 
and this mild fundus aspect did not change over the years. Moreover, as a result of a pre-
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operative blood examination, a deficiency of the vitamin K-dependent clotting factors without 
clinical implications, was fortuitously noted. 
 
That morning in 2006, it became clear to us that there was something more to this 
phenotype. Our patient was no longer a single case since at least 7 other patients apparently 
presented with an identical phenotype, whom were followed in 3 different genetic centers. 
Although all these patients initially presented typical PXE skin lesions, the subsequent loss of skin 
elasticity did not remain confined to the flexural areas. Although the aspect of the lesions was 
very similar in all seven, the age of onset was diverse, with two of them having a cutis laxa-like 
phenotype already in childhood. Light microscopic evaluation showed middermal elastorrhexis 
as in PXE; thorough electron microscopic evaluation did however reveal subtle differences in the 
type and location of elastic fibre calcification and the structure of the elastic fibre meshwork 
compared to PXE, supporting our hypothesis that this might be a separate genetic entity.  
Besides these dramatic skin changes, all had the very mild retinopathy as in our patient with peau 
d’orange  (often  regressing  with age) and small angioid streaks, but lacking neovessel growth, 
haemorrhage and visual loss. Finally, all of these patients were found to have a deficiency of the 
vitamin K-dependent clotting factors – factor II, VII, IX, X – a clotting defect which in all but one 
patient – who suffered several hemorrhagic episodes – was a fortuitous, asymptomatic 
observation.  
 
As in none of these patients ABCC6 mutations were detected, a different gene was 
suspected and it was the associated coagulation defect that gave us insight into the pathway 
which harboured the causal gene of this novel disorder. A similar hereditary clotting disease had 
already been described in literature [390-392]. This autosomal recessive disorder was 
characterized by a clotting factor deficiency restricted to factor II, VII, IX and X – as in our patients 
– and was, again much like our patients, usually asymptomatic although occasionally it had been 
found to cause neonatal haemorrhage or menorrhagies. This genetic entity was caused by 
mutations in the VKORC1 gene or the GGCX gene, encoding two enzymes – respectively a 
reductase and a gamma-carboxylase – which play a crucial role in the vitamin K-cycle [390-393]. 
The VKORC1 gene is located on chromosome 16p, 15 MB from the ABCC6 gene. This relatively 
large distance made a chromosomal rearrangement affecting the two genes less likely while 
direct sequencing did not reveal any mutation in our patients. The second candidate gene, 
GGCX, was found to be mutated in all 7 patients. Missense and nonsense mutations were found 
in compound heterozygous or heterozygous state. Indeed, we have so far not been able to detect 
both mutations in all patients. This might be due to technical limitations, although it cannot be 
excluded that a digenic inheritance is applicable for this disorder. Indeed, patients with the 
GGCX-linked hereditary deficiency of vitamin K-dependent clotting factors do not present any 
skin symptoms. Ocular symptoms have also not been described in these individuals although it 
must be noted that in our PXE-like patients the retinopathy remained asymptomatic and will not 
be detected unless it is explicitly looked for. A possible hypothesis to explain this apparent 
discrepancy, besides digenic inheritance, is based on the observation that all GGCX mutations in 
our patients are confined to exons 8, 10 and 12, which have so far not been reported mutated in 
the isolated clotting deficiency patients [390-392]. It could therefore be assumed that these exons 
encode specific domains with particular binding partners (Figure 28). Aberrant binding of one or 
more of these proteins or transcription factors may induce the cutaneous and/or ophthalmological 
symptoms. Identifying these partners may as such be valuable for the pathogenesis of PXE itself, 
as  explained  in  the  “future  perspectives”  chapter.  The  identification  of  the GGCX gene as the 
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causal genetic factor in these patients confirmed our hypothesis that this was indeed a novel 
disorder, which we coined the PXE-like syndrome (OMIM# 610842). 
 
 
Figure 28 
Hypothesis of binding factors and domains. A specific binding factor (lightly coloured large cone) causes the clotting 
deficiency, while a second (darker large cone) causes the skin symptoms when not being able to bind to its binding site of 
the GGCX protein. 
 
 4.3.2  Impact of a novel OMIM entry 
 
The identification of this novel PXE-like disease has not been without importance for 
several reasons. First, it demonstrates the existence of a spectrum of hereditary disorders 
resembling PXE, although not an exact phenocopy such as the phenotype associated with 
haemoglobinopathies [266-271]. The concept of such a phenotypical spectrum was substantiated 
by the patient described in publication 9. This young man presented to the clinic several years 
ago at age 18 with a severe cutis laxa of the abdomen. Several biochemical and molecular tests, 
including biochemistry of the collagens and sequencing of the fibulin-5 and elastin gene failed to 
endorse the diagnosis of a classic type of cutis laxa. Only the incidental ultrasonographical 
discovery of renal calcifications during his general work-up suggested a possible diagnosis of 
PXE. A thorough clinical examination with these observations in mind revealed minimal papular 
lesions in the anterior neck region. Skin biopsy and ophthalmological examination confirmed the 
diagnosis. Clinically, this patient had characteristics of both classic PXE (retinopathy, renal 
calcifications) and the PXE-like syndrome (cutis laxa beyond the flexural areas). 
Immunohistochemical experiments and ELISA tests for various inhibitors of calcification exhibited 
results which were partly reminiscent of both PXE and the PXE-like syndrome. Thus, also at the 
basic science  level  this patients’ phenotype was situated  in between classic PXE and the PXE-
like syndrome. It is to be expected that this patient, and to a further extent, the PXE-like 
syndrome, are merely the tip of the iceberg of ectopic calcification disorders which are clinically, 
pathogenetically or both ways related to PXE.  
Second, the characterization of the PXE-like syndrome has opened a novel avenue for 
pathomechanistic research in the field of ectopic calcification disorders, implicating local and 
systemic (vitamin K-dependent) mineralization inhibitors to play a critical role in this spectrum of 
disorders. The considerable resemblance between three diseases – PXE, PXE-like syndrome 
and the intermediary phenotype found in one patient – created a unique opportunity for a 
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comparative research project. For this, we were fortunate to collaborate with VitaK, a spin-off 
company of the Maastricht University (The Netherlands) who is specialized in studies involving 
vitamin K and vitamin K-dependent proteins. It enabled us to apply state-of-the-art antibodies and 
ELISA techniques in gaining further insights as to how these regulatory proteins of mineralization 
might be involved in one or more of these phenotypes. The results, described in publication 8, 
were surprising.  
Since GGCX, the gene mutated in the PXE-like syndrome encoded an enzyme,  the γ-
carboxylase, known to play a critical role in the activation of vitamin K-dependent calcification 
inhibitors, clustering of the inactive conformation of these repressive proteins in soft tissues of 
these patients seemed a valid consequence. Providing evidence for this assumption would be a 
functional proof of the causality of the GGCX mutations we previously described. Indeed, a direct 
relation  exists  between  the  γ-carboxylase enzyme and the active Gla-proteins without the 
interference of any other enzymatic process. The posttranslational modification through 
carboxylation occurs by integrating a carboxyl (CO2) group onto a glutamate (or glu) residue, thus 
conceiving gamma-carboxyglutamate (or gla-) residues [393, 394]. Although an in vitro method 
exists to verify (residual) enzymatic function of GGCX, based on the incorporation of radioactively 
labelled CO2 in an artificial substrate containing glu residues, the technique is very laborious and 
– after some inquiries – had not been performed since many years. The use of confirmation-
specific antibodies, binding specifically to the carboxylated or uncarboxylated protein, and of 
ELISA tests, measuring the carboxylated or uncarboxylated levels of proteins in serum, would 
offer a valuable and much easier alternative [395]. 
 
The immunohistochemical labelling of PXE-like dermal tissues revealed the presence 
of both carboxylated (or active) and uncarboxylated (or inactive) MGP and osteocalcin in the 
dermis, indicating GGCX function not to be completely abolished. It did however substantiate that 
carboxylation was suboptimal, thus supporting the causality of the GGCX mutations we 
ascertained. In addition to these local mineralization inhibitors, also fetuin-A – a systemic 
calcification inhibitory protein – was found to play a role in the pathogenesis. Although this protein 
is not vitamin K-dependent per se – it does not need to be carboxylated to become functional – it 
has been shown to form complexes with MGP and calcium in the serum. As such, it was possible 
to bring back all our findings to the vitamin K-cycle. This was also legitimate for the remarked 
upregulation of bone-morphogenetic protein 2 (BMP-2) and osteopontin (OPN). Indeed, MGP is a 
known inhibitor of BMP-2; failure of this inhibitory impulse would lead to overexpression [67]. 
Similarly, the mgp-/- mouse was shown to display OPN overexpression as a secondary effect 
[55]. Only recently, another posttranslational modification step became signifying an important 
role in MGP maturation. Indeed, the MGP protein structure is unique among vitamin K-dependent 
molecules due to the presence of serine residues which endure phosphorylation [67, 396]. This 
enzymatic process has been proposed to be accomplished by an enzyme called the Golgi casein 
kinase. It was suggested that the phosphorylation of these serine residues is a second essential 
step for full activation of MGP, hence the relevance of the observed increased amount of 
unphosphorylated MGP in the dermis of PXE-like patients [396]. 
 
It was an exciting period when we decided to perform the same labelling experiments on 
the dermis of classic PXE patients, our hypothesis being that, considering the clinical similarities, 
the pathogenetic pathways behind these disorders would be related. Indeed, the 
immunohistochemical findings were close to identical, in that the labelling was confined to the 
middermis while in PXE-like patients the whole dermis was affected. We could also observe 
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subtle differences in fetuin-A staining, with a repetitive positive stain subepidermally in PXE 
patients, which remained absent in PXE-like tissues. Although at first glance these observations 
seem to concur with our initial hypothesis of a common pathway, it did remain puzzling how such 
high similarities, if not identical, lead to two clearly different clinical entities.  
 
We gained further insight into this intruiging ambiguity when performing biochemical 
measurements using ELISA. However, these results certainly did not simplify matters. As 
expected, the PXE-like serum showed perturbed ratios of active and inactive MGP and OC, the 
majority being the inactive form. This was a logical consequence of a mutated and less functional 
γ-carboxylase and was undeniably confirmed by both competitive and sandwich ELISA. In PXE 
patients, we noted a similar disturbance in the active/inactive ratio of MGP; however, a perfectly 
balanced ratio was found for OC. In addition, the competitive ELISA results for MGP failed to be 
confirmed by sandwich ELISA. Initially, we assumed technical error. As we obtained similar 
results in all consecutive patients tested, we considered the main differences between the two 
ELISA experiments. Besides the different technical approach, explained in chapter 2, sandwich 
ELISA was able to spot uncarboxylated unphosphorylated MGP. The competitive ELISA on 
the other hand was limited to detecting uncarboxylated phosphorylated MGP (Figure 29). 
These  subtle  changes  lead  us  to  conclude  that  besides  γ-carboxylation, also the other 
posttranslational modification process – phosphorylation of serine residues – is an important 
determinant for which disorder was to develop.  
 
 
Figure 29 
Specificity of the sandwich and competitive ELISA. Sandwich ELISA largely detects the uncarboxylated, unphospho-
rylated isoform of MGP and to a very limited extent the uncarboxylated phosphorylated isoform. Competitive ELISA only 
detects the uncarboxylated phosphorylated isoform of MGP.  
 
The apparent questions remaining after these experiments were:  
 
1/ which was or were the events leading to the accumulation of inactive VK-dependent 
proteins in PXE?  
 
 2/ how are these pathogenetic events related to the mutated ABCC6 transporter? 
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Indeed, in PXE patients no GGCX mutations or functionally relevant polymorphisms were 
found which could explain the dysregulation of VK-dependent inhibitors of calcification (Costrop et 
al., in preparation). For this reason, we looked first at the molecule serving as an essential co-
factor for the carboxylation process, VK. While serum concentrations of VK in PXE-like patients 
were – as expected – normal, a poor VK status was noted in PXE, with low serum levels of VK1 
compared to a reference population. Such significant VK deficiencies have been reported in a 
number of disorders, such as Crohn’s disease and cystic fibrosis (CF) (table 7). In some of these 
disorders, the poor VK status has been linked to deficient Gla-proteins. 
  
Disorder Ref. 
Crohn’s disease 
Cystic fibrosis 
Hemorrhagic disease of the newborn 
Osteoarthritis 
Renal insufficiency with haemodialysis 
[397] 
[398] 
[399-402] 
[403] 
[404] 
Table 7 
Disorders known to be caused or accompanied by poor vitamin K status 
 
In PXE patients, average serum levels were below the average level in Crohn’s disease 
and in some patients, unmeasurable as in CF patients. This profound VK deficiency in PXE could 
certainly be an adequate explanation for the accumulation of inactive Gla-proteins observed in 
the PXE dermis and serum. Nevertheless, some questions remain.  
 
1/ The issue of the normal activity of OC. It seems unlikely that the inability to detect 
uncarboxylated OC would be due to technical limitations, as the method applied was 
identical as that in PXE-like patients. OC is primarily expressed in osteoblasts. These 
cells have a high level of low-density lipoprotein receptor-related protein 1 (LRP1) on their 
surface and LRP1 allows efficient uptake of the apoprotein E-containing chylomicron 
remnants that carry the bulk of the diet-derived vitamin K1. Therefore, it is plausible to 
assume osteoblasts to be more efficient in acquiring their share of the inadequate 
amounts of circulating VK in PXE patients than e.g. vascular smooth muscle cells in 
arteries [405]. This hypothesis however needs further study.  
 
2/ Can disturbed Gla-protein carboxylation explain the other phenotypical 
characteristics of PXE, besides the skin lesions? Although further research is needed to 
confirm, literature study learns that it has been previously shown that Gla-proteins such 
as MGP are actively involved in vascular calcification related to common 
atherosclerosis, renal failure and diabetes vascular changes [60, 406-408]. The ocular 
expression of these proteins has not yet been studied extensively. Although MGP was 
shown to be present in the anterior segment of the eye, the retinal expression has not yet 
been investigated [409]. Gla-protein changes could also be responsible for ectopic 
calcification of other sites in classic PXE. We and others previously observed testicular 
microlithiasis to be often present in PXE patients [311, 410]; the testicles are known to 
produce an as yet uncharacterized Gla-protein [411]. In rats, OC has been shown to be 
expressed in male gonadal tissues, while renal calcifications could be due to dysfunction 
of Gla-proteins produced by kidney cells [412, 413]. So, it would indeed seem that all 
major clinical features of PXE could be explained by defects in Gla-protein function. 
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3/ Why are clotting abnormalities absent in PXE patients? It seems obvious to expect 
that, if a poor vitamin K status is present, clotting factors must also be affected. However, 
no clotting disorder – not even subclinically – has been found in PXE patients. The 
explanation for this apparent discrepancy lies in the observation of low VK levels in the 
blood; however – as there is no reason to assume malabsorption of any kind in PXE – the 
amount of VK1 transported via chylomicrons to the liver is normal. As clotting factors are 
produced and activated in the liver, enough VK1 is at hand to maintain this process. 
However, VK-dependent proteins involved in regulation of mineralization are local 
molecules, the activation of which occurs in peripheral tissues and hence is in need of 
peripheral VK1. The low blood levels reflect the low abundance of VK1 in these 
peripheral tissues.  
 
4/ The etiological background of the poor VK status in PXE remains speculative. It 
has been established that even within the general population VK status is suboptimal. As 
PXE patients as a group do not explicitly differ from the general population in food habits, 
differences in dietary intake cannot suffice as an explanation. The most attractive 
hypothesis so far appears to be the idea of ABCC6 as a transporter for vitamin K or one 
of its precursors and metabolites [414]. While vitamin K, and in particular VK1 is efficiently 
taken up by the liver in chylomicrons, it needs to be secreted back into the circulation to 
become available in peripheral tissues (Figure 30). 
 
 
Figure 30 
Vitamin K (VK) metabolism. From its dietary sources, VK1 is absorbed in the bowel and transported via chylomicrons 
towards the liver where it i) activates clotting factors and ii) is (partially) metabolized. VK itself and/or its metabolites are 
transported into the bloodstream towards peripheral tissues (smooth muscle, fibroblasts, …) where they function as a co-
factor for activation of inhibitors of calcification.  
 
How this secretion of VK by the liver is performed is not well known; so far, no VK 
transporters have been identified. Yet there is evidence of selectivity in secretion, 
suggesting the presence of such transport molecules. Additionally, the characteristics of 
the VK molecule – anionic properties, molecular weight – are compatible with those 
previously proposed for the ABCC6 substrate [414]. VK being a hydrophobic molecule 
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does not present an a priori problem, as presently no data can be found to refute an 
organic anion transporter having a hydrophobic substrate. Besides VK itself, the 
substrate of ABCC6 could also be one of the precursors or metabolites of VK. Two major 
compounds to consider are menaquinone-4 (MK-4) and glutathionyl-menadione (M-SG) 
[405]. VK1 is rapidly converted into MK-4 in the liver, which has cofactor activity in the 
carboxylation cycle, while M-SG – in itself not able to serve as cofactor – is turned into 
MK-4 in peripheral tissues [415]. Although this hypothesis seems attractive and could 
explain most, if not all of the PXE phenotype and pathogenesis, there are several snags 
to consider. In rats, M-SG is excreted in high rate into bile so that it remains to be seen 
whether the liver can also transport M-SG into blood [416]. One must also consider 
whether the rate of MK-4 formation in the liver is sufficient to provide VK to the periphery.  
 
The hypothesis of VK as substrate for the ABCC6 transporter would also address the 
increased phosphorylation of MGP we observed in PXE patients, while it was not present 
in PXE-like patients. VK has been reported to induce activity of kinase enzymes, e.g. in 
cancer cell lines. The increased amount of vitamin K present intracellularly in hepatocytes 
due to failing transport by ABCC6, may act as such a stimulus for the Golgi casein 
kinase. This ER kinase is membrane-bound and could be susceptible to cytoplasmic VK.  
  
Besides VK or one of its associated compounds, it remains possible that another cofactor 
of protein carboxylation serves as ABCC6 substrate. Although this would also explain the 
observed accumulation of uncarboxylated Gla-proteins in tissues and blood, it could not 
immediately explain the poor VK status in PXE patients.  
 
Whether VK is the substrate or not, our findings – including the influence on protein 
carboxylation and phosphorylation – implicate for the first time one or more distinct 
intracellular processes – next to the observation of oxidative stress, e.g. – being involved 
in PXE. It suggests a complex chain of intracellular events which finally leads to ectopic 
mineralization of elastic fibres. They also put further in perspective the exact order in 
which elastorrhexis tends to occur. As said previously, it has never been unambiguously 
shown whether calcification preceded fragmentation of elastic fibres or vice versa, as 
both mechanisms are theoretically plausible. The model presented above suggests the 
fragmentation to be a secondary effect of the primum movens, calcification of elastic 
fibres. Finally, our results have taken the attempts for designing therapeutic intervention 
trials in PXE to another level, by implicating this vitamin and the proteins depending on its 
activity for their function in PXE and PXE-like disorders.  
  
 As such, my work has reached the implementation of a research adagio which I have 
cherished from my early clinical and research aspirations on and which remains an important 
drive to me until present day: from bedside to bench to bedside. 
 
4.4 Future perspectives 
 
After describing what lies behind, it seems imperative to take a look at the close and 
more distant future of PXE research. From a clinical point of view it remains important to further 
characterize and refine the phenotype of classic PXE. For this, several studies are currently 
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ongoing or being designed for the near future. Questions to be answered concern the frequency 
and features of electrophysiological retinal disturbances in a larger cohort of consecutive patients 
as well as the genetic determinants making some patients more prone to these functional 
aberrations than others. Cardiovascular research should endeavour into the functional 
consequences of cardiac and vascular elastic fibre mineralization as well as involvement of 
endothelial dysfunction, so far unreported in PXE but known to be a significant actor in the 
atherosclerotic process [417]. The findings reported in our exploratory study on ischemic stroke 
should be validated in other studies, enrolling larger sample sizes as well as subgroups of 
patients depending on age, risk factors, stroke type and ethnic background.  
 
Reporting on natural history will also be of importance in the future. For some of the 
minor phenotypical features of PXE described in this thesis, such as abdominal and testicular 
calcifications, follow-up data are still limited. Careful prospective re-evaluation of these lesions 
over the next years will give us more insight into whether they are indeed rather innocent traits of 
PXE, useful in some cases for making the diagnosis but of no clinical significance, or whether 
they do influence organ function and/or cell differentiation, leading to organ dysfunction or 
tumorogenesis. 
 
Although we obtained a high mutation uptake through molecular ABCC6 analysis, it 
remains  unsatisfying  that  some  patients’  genotype  is  only  partially  or  not  at  all  characterized. 
Even though – in part – this most probably is due to technical limitations (despite our expectations 
for molecular genetics, no detection technique has proven to be flawless), other molecular basis 
should be excluded. So far, the work on the ABCC6 promotor has been limited, not in the least 
because of its complexity and high homology with the ABCC6 pseudogenes. Yet this fundamental 
element of the gene may harbour causal mutations in some of the patients. Secondly, direct 
sequencing of a gene has been known to fail in detecting middle-sized deletions and duplications. 
However, novel techniques have been developed to study this specific type of mutation. One 
such method, MLPA (multiplex ligand probe amplification) is currently being used by our research 
group with promising results (Costrop et al. manuscript in preparation). Although the hypothesis 
of a second gene involved in PXE seems unrealistic and far-fetched to me, it must be kept in 
mind that distant regulatory elements in cis or trans have been reported to harbour causal 
mutations in other diseases; at this time, a similar molecular basis in a limited number of patients 
cannot be excluded. Current knowledge on transcriptional regulation is scarce and mainly 
comprises the identification of HNF4  (Hepatic Nuclear Factor 4 Alfa) and NF-E2 (Nuclear Factor 
Erythroid 2) as enhancers of the murine Abcc6 gene promotor activity. Recently, also genes from 
the PLAG family of transcriptional factors have been put forward as regulators of ABCC6 [215]. 
The genes encoding these transcription factors may serve as useful candidates for further 
molecular testing.  
 
 Although PXE is widely known to be a disease with prominent clinical variability, this is 
often wrongfully interpreted as large variability in symptoms. Yet, the number of different clinical 
manifestations is rather limited; conversely, the severity by which patients are affected is 
significantly different between and within families. As we have ruled out the influence of the 
ABCC6 genotype on disease severity, it is likely that modifier genes play a crucial role. Although 
several reports were published regarding polymorphisms in genes encoding for MGP or OPN, the 
true influence of these base pair variants on the PXE phenotype is always doubtful, restricted and 
certainly not useful in a clinical setting. The search for clinically relevant modifiers proves to be 
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not as forthright as one might have imagined or hoped. This has become clear through our 
search for modifiers making some PXE patients more prone to gastro-intestinal haemorrhage 
(Costrop et al. manuscript in preparation). Yet, for clinicians and patients, the identification of 
modifying variants should be continued in future years.  
 
 With the implications of vitamin K-dependent proteins in PXE and the PXE-like syndrome, 
the possibility of vitamin K as a potential therapeutic approach became apparent. Because clinical 
trials using vitamin K supplements have been done before in patients with other disorders 
characterized by ectopic mineralization, such as renal dialysis patients, similar clinical trials in 
PXE should be feasible on short term [418]. Indeed, a large multicenter trial is currently being 
designed to test the hypothesis that vitamin K suppletion may have a biological and – in a second 
phase – clinically significant effect in PXE patients.  
 
 Finally, when looking back to the implications of the identification and etiopathogenetic 
unravellment of the PXE-like syndrome for the field, I am convinced that we should endeavour to 
identify and characterize both clinically and molecularly novel phenotypes within the PXE 
spectrum, as they can give valuable information, not only on the pathways involved in PXE and 
its related disorders but on elastic fibre homeostasis in general.  
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Summary                                                    o                          
o                                                 
“If others can see it as I have seen it, then it may be 
called a vision rather than a dream” 
 
 William Morris (News from Nowhere, 1892) 
 
      “Some states consider all visionaries to be madman” 
 
        William Blake (Laocoön, 1826-27) 
 
 
 Soft tissue calcification in the human body can be considered part of a process of 
continuous  degeneration  which  we  tend  to  designate  as  “aging”.  Being  an  example  of 
technological wit and superb bio-engineering second to none, even the decay of this corpus can 
hardly be considered a random or passive event. On the contrary, calcium precipitation is 
regulated quite tightly by an intruiging interplay between stimulatory proteins and inhibitory 
factors. Thus, it has been foreseen man not to be turned into a chalk pillar in his prime years, but 
rather to endure a much slower process of gradual mineralization. But when this brilliant 
regulatory opus starts failing, the reign of human pathology is entered, confronting the body with 
ectopic mineralization disorders.  
 
One of the archetypes of such disease is pseudoxanthoma elasticum or PXE, in which 
ectopic mineralization of elastic fibres causes skin, ocular and cardiovascular complications. 
Despite its identification more than two centuries ago, PXE has – as many genetic disorders – 
always been surrounded by a haze of mystery. It is the aim of this thesis to contribute to the 
clinical, molecular and histopathological characterization of this fascinating disease.  
 
Through careful characterization of the PXE patient cohort followed at the Ghent Center 
for Medical Genetics, we were able to emphasize important clinical features, such as stroke and 
peripheral artery disease, as well as identifying novel phenotypical features in patients and 
carriers, among which were abdominal calcifications and testicular microlithiasis. Also the 
question of a limited or subclinical phenotype in PXE carriers was addressed and we showed 
them to be more prone to cardiovascular disease, next to limited ophthalmological symptoms 
represented by comets and comet tails.  
In an exploratory pilot study among over 200 consecutive ischemic stroke patients, 
ABCC6 hotspot analysis yielded a significant increase in ABCC6 mutations compared to a 
healthy reference population. This signified another example of heterozygous carriers being 
prone to cardiovascular and/or cerebrovascular disease and introduced the ABCC6 gene in 
stroke research. 
In single and multi-center studies, this thesis contributed to the characterization and 
expansion of the ABCC6 mutation spectrum, as well as the exclusion of genotype-phenotype 
correlations. The applied molecular strategy for mutation analysis of the ABCC6 gene proved to 
be an efficient and cost-effective method, yielding the highest mutation detection rate so far. Also, 
the continuous discussion on the mode of inheritance and in particular the existence of an 
autosomal dominant form of PXE could be addressed constructively. 
Throughout the clinical follow-up of PXE patients, we applied novel fundus imaging 
techniques, such as autofluorescence and infrared imaging, with substantial improvement of the 
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diagnostic capacities of limited or subtle lesions in fundo. Through collaborative efforts, the 
importance of electrophysiological abnormalities – subdivided in three retinopathy phenotypes – 
was brought to attention. 
 
Within the span of this PhD thesis, a novel phenotype was identified and characterized 
both clinically and molecularly. This novel autosomal recessive disorder was coined the PXE-like 
syndrome, because of its resemblance with classic PXE, and was proven to be caused by 
mutations in the GGCX gene. Encoding the gamma-carboxylase, an enzyme important in the 
vitamin K (VK)-cycle, this observation implicated VK and proteins depending on this vitamin – 
among which are several inhibitors of mineralization – in the pathogenesis of the PXE-like 
syndrome and hence PXE. 
Through various immunohistochemical and ELISA methods, VK-dependent inhibitors of 
calcification were shown to be inactive or defective in these syndromes, leading to ectopic 
mineralization in the PXE-like syndrome but also in PXE patients. These observations could be 
attributed to the GGCX mutations in the PXE-like syndrome. The observation of extremely low VK 
serum levels – an essential co-factor for protein carboxylation in the VK-cycle –  in PXE patients  
explained why the VK-cycle is defective in PXE. The exact link with the impaired ABCC6 
transporter remains unclear, although it is tempting to think of VK or one of its associated 
molecules as the substrate of ABCC6. Also, these findings hold out the prospect of VK suppletion 
as a treatment for PXE. 
 
As such, the findings summarized in this thesis have elaborated the clinical and 
molecular knowledge of PXE and related disorders, and have opened novel avenues for further 
fundamental and applied research in the field of ectopic mineralization. Above all, they have 
benefitted patients and their family though a more efficient molecular diagnosis, a more to-the-
point follow-up and the prospect of a treatment for their burdensome disease. 
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Samenvatting                                            o  
 
“Dit Florentijnse patriciërsgeslacht degenereerde van 
generatie tot generatie en tenslotte werd kinderloos-
heid binnen de familie erfelijk.” 
 
J.G.A. Galeltti (Ich sehe viele, die nicht da sind, 1987) 
 
Mineralisatie of verkalking van de weke delen van het menselijk lichaam kan beschouwd 
worden als een onderdeel van een voortdurend degeneratief proces dat we doorgaans 
“veroudering”  noemen.  Als  een  voorbeeld van technologisch vernuft en uitmuntende bio-
engeneering zonder gelijke, kan zelfs de aftakeling van dit “corpus humanum” nauwelijks als een 
willekeurig of passief gebeuren beschouwd worden. Integendeel, de neerslag van calcium wordt 
zeer strikt geregeld door een intrigerend samenspel van neerslag-inducerende eiwitten en 
inhiberende factoren. Het is aldus zo geregeld dat we niet reeds tijdens onze jeugd veranderen in 
een krijtpilaar, maar dat we daarentegen een traag en geleidelijk proces van mineralisatie 
ondergaan. Doch wanneer dit brilliante regulerende opus niet meer optimaal werkt, worden we 
geconfronteerd met een bijzondere groep van ziektes: de ectopische mineralisatie-aandoeningen. 
 
  Eén van de archetypes van dergelijke aandoeningen is pseudoxanthoma elasticum of 
PXE, waarin ectopische verkalking van elastinevezels aanleiding geeft tot huid-, oog- en 
cardiovasculaire symptomen. Ondanks dat PXE ruim twee eeuwen geleden voor het eerst werd 
beschreven, blijft de ziekte – zoals dit het geval is voor vele genetische aandoeningen – omgeven 
door een sluier van mysterie. Het doel van deze thesis is dan ook een bijdrage te leveren tot de 
klinische, moleculaire en histopathologische karakterisatie van deze fascinerende aandoening.  
 Door zorgvuldige klinische karakterisatie van de groep van PXE patiënten gevolgd in het 
Gentse Centrum voor Medische Genetica, waren we in staat om het belang van bepaalde 
klinische kenmerken, zoals herseninfarcten en perifeer vaatlijden, te benadrukken. Daarnaast 
identificeerden we nieuwe fenotypische kenmerken in patiënten en heterozygote dragers, 
waaronder calcificaties van de buikorganen en testiculaire microlithiase. Ook het al dan niet 
aanwezig zijn van een beperkt of subklinisch fenotype in PXE dragers werd aangekaart en we 
toonden aan dat deze individuen een hoger cardiovasculair risico hebben, naast beperkte 
oftalmologische karakteristieken o.v.v. comets en comet tails.  
 In een pilootstudie in een groep van meer dan 200 patiënten met een herseninfarct werd 
d.m.v. ABCC6 hotspot-analyse een significant hoger aantal heterozygote ABCC6 mutaties 
terugevonden, in vergelijking met een controle groep. Dit betekent een bijkomend argument dat 
heterozygote dragers een hoger risico voor hart- en vaatziekten hebben; bovendien introduceert 
deze studie het ABCC6 gen in stroke onderzoek.  
Via lokale en multi-centerstudies draagt deze thesis ook bij tot de beschrijving en 
uitbreiding van het ABCC6 mutatiespectrum, alsook het uitsluiten van relevante genotype-
fenotypecorrelaties. Van de moleculaire strategie welke werd aangewend voor mutatie-analyse 
van het ABCC6 gen, werd aangetoond dat ze efficiënt is, met een uitstekende kosten-baten 
verhouding en een mutatie-detectieratio die tot dusver de hoogst gerapporteerde is. Ook de 
aanhoudende discussie omtrent de overervingsmodus van PXE, in het bijzonder het al dan niet 
voorkomen van een autosomaal dominante vorm, werd onderzocht.  
  Tijdens de opvolging van PXE patiënten hebben we gebruik gemaakt van nieuwe 
beeldvormingstechnieken van de oogfundus, zoals fundus autofluorescentie en infrarood 
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beeldvorming, die een duidelijke verbetering met zich meebrachten van de diagnostische 
mogelijkheden bij beperkte of subtiele letsels in fundo. In samenwerking met Moorsfield Eye 
Hospital te Londen brachten we ook het belang van electrofysiologische afwijkingen van de retina 
–  waarin drie verschillende fenotypes konden worden onderscheiden – onder de aandacht.  
 
 Tijdens dit doctoraatsonderzoek hadden we de mogelijkheid een nieuwe aandoening als 
aparte entiteit te identificeren en, zowel op klinisch als moleculair niveau, te karakteriseren. Deze 
nieuwe autosomaal recessieve ziekte werd het PXE-like syndroom genoemd, omwille van de vele 
gelijkenissen met klassieke PXE. We toonden aan dat de ziekte wordt veroorzaakt door mutaties 
in het GGCX-gen, dat codeert voor een gamma-carboxylase. Dit enzyme speelt een belangrijke 
rol in de vitamine K (VK)-cyclus. Aldus waren we in staat om VK en eiwitten die van dit vitamine 
afhankelijk zijn – waaronder verschillende inhibitoren van verkalking – te introduceren in de 
pathogenese van het PXE-like syndroom, doch ook van PXE.  
 Via verscheidene immunohistochemische en ELISA experimenten konden we aantonen 
dat verschillende VK-afhankelijke inhibitoren van calcificatie inactief of niet werkzaam waren in 
deze twee syndromen, hetgeen aanleiding gaf tot de ectopische verkalking. Deze bevindingen 
konden in het PXE-like syndroom teruggeleid worden tot de mutaties in het GGCX gen. In PXE 
werd de verklaring voor deze deficiënte eiwitten gevonden door het aantonen van zeer lage 
hoeveelheden VK – een essentiële co-factor voor de carboxylatie van eiwitten in de VK-cyclus – 
in het bloed van PXE patiënten. Hoe de gemuteerde ABCC6 transporter in relatie staat tot deze 
lage hoeveelheden VK is op dit ogenblik onduidelijk, hoewel het verleidelijk is te denken dat hetzij 
VK, hetzij één van zijn precursoren of metabolieten, door ABCC6 wordt getransporteerd. 
Bovendien bieden deze bevindingen het vooruitzicht van VK suppletie als behandeling voor PXE. 
 
 Zoals hierboven beschreven, hebben de resultaten van dit doctoraatsonderzoek geleid 
tot een uitbreiding van de klinische en moleculaire kennis over PXE en aanverwante 
aandoeningen. Er werden nieuwe wegen geopend voor verder fundamenteel en toegepast 
onderzoek binnen het gebied van ectopische mineralisatie. Boven alles zijn het de patiënten en 
hun familie die baat hebben bij onze resultaten, door een efficiëntere moleculaire diagnose, een 
to-the-point follow-up en het vooruitzicht van een behandeling voor hun belastende aandoening.  
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Résumé                                                      o  
 
“Le fils d’un eunuque eut mille enfants, cré tonnerre! 
Non, la stérilité n’est pas héréditaire” 
 
Alphonse Allais (Ibidem) 
 
“Voici le printemps, et mon arbre généalogique n’est 
pas encore en fleurs” 
 
         Erik Satie 
 
La minéralisation ou la calcification des parties molles du corps humain peut être 
considérée comme une partie d'un processus dégénératif permanent qu’on appelle généralement 
“le vieillissement". 
 Être un exemple de l'ingéniosité technologique et de bio-engeneering excellent sans 
égal, même le dépérissement de ce "corpus humanum “ ne peut guère être considéré comme un 
événement arbitraire ou passif. Au contraire, la précipitation du calcium est réglée très 
strictement par un jeu d'ensembles intriguant des facteurs induisants et des protéines inhibiteurs. 
Ainsi, il a été réglé que nous ne changeons pas lors de notre jeunesse en un pilier de craie, mais 
que par contre, nous subissons un processus lent et progressif de minéralisation. Mais quand ce 
opus régularisant brilliant ne fonctionne plus de façon optimale, nous sommes confrontés à un 
groupe de maladies particulières: les affections de minéralisation ectopique. 
 
Un des archétypes de ces affections est le pseudoxanthome élastique ou le PXE, dans 
lequel la calcification ectopique des fibres élastiques cause des symptômes des yeux, de la peau 
et cardio-vasculaires. Quoique le PXE ait été décrit pour la première fois il y a deux siècles, la 
maladie - comme c’est le cas pour beaucoup d'affections génétiques - reste entourée d’un voile 
mystérieux.  Le  but  de  cette  thèse  est  donc  d’apporter  une  contribution  aux  caractéristiques 
histopathologiques, cliniques et moléculaires de cette affection fascinante.  
Par  la  caractérisation  clinique  soigneuse  d’un  groupe  de  patients  ayant  le PXE,  suivis 
dans le Centre de Génétique Médicale Gantois, nous avons eu la possibilité d’accentuer l'intérêt 
de certaines caractéristiques cliniques, comme les infarctus cérébraux  et  l’athérosclérose.  En 
plus, nous avons identifié des caractéristiques phénotypiques nouvelles chez les patients et chez 
les porteurs/porteuses hétérozygotes, parmis lesquels les calcifications des organes du ventre et 
le microlithiase testiculaire. De  plus,  l’existence  d’un  phénotype  partiel  ou  indulgent  chez  les 
porteurs/porteuses du PXE a été abordé et nous avons démontré que ces individus courrent un 
risque cardio-vasculaire plus important, conjointement aux caractéristiques ophtalmologiques 
restreintes s.f.d. comets et comet tails.  
Dans  une  étude  pilote  d’un  groupe  de  plus  de  200  patients  ayant  eu  un  infarctus 
cérébral, nous avons retrouvé – en utilisant une analyse moléculaire des hotspots du gène 
ABCC6 – un nombre plus élevé de mutations hétérozygotes dans ce gène par rapport à un 
groupe de contrôle. Cet argument complémentaire confirme que les hétérozygotes ont un plus 
grand risque concernant les maladies cardio-vasculaires; de plus, cette étude introduit le gène 
ABCC6 dans la recherche étiologique des infarctus cérébraux.  
Par des études locales et multi-centres, cette thèse a aussi contribué à la description et à 
l'élargissement du spectre des mutations du gène ABCC6, de même que l'exclusion pertinente 
des corrélations entre le phénotype et le génotype. La stratégie d’analyse moléculaire, laquelle a 
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été utilisée jusqu'ici pour l'analyse du gène ABCC6, démontre son efficacité, avec un rapport 
excellent entre les coûts et les profits et un ratio de détection des mutations qui est le plus élevé 
ayant été rapporté dans la littérature récente. En plus, la discussion persistante concernant le 
mode d’hérédité du PXE et en particulier si une forme dominante existe, a été examiné.  
Pendant le suivi des patients ayant le PXE, nous avons utilisé des techniques nouvelles 
pour  examiner  le  fond  de  l’œil,  comme  l’auto-fluorescence et la lumière infrarouge qui nous 
permettent de créer une image plus claire, d’où une amélioration des possibilités diagnostiques 
lors des lésions ophtalmologiques subtiles. En collaboration avec Moorsfield Eye Hospital de 
Londres, nous avons abordé également l'intérêt sur des anormalités electrophysiologiques de la 
rétine, dans lequel ont pu discerner trois phénotypes différents.  
 
Au cours des recherches, nous avons eu la possibilité d'identifier une nouvelle affection 
comme une entité séparée et de la caractériser, aussi bien cliniquement qu'au niveau 
moléculaire. Cette nouvelle maladie récessive a été appelé le PXE-like syndrome, à cause des 
nombreuses similarités avec le PXE classique. Nous avons trouvé que la maladie est causée par 
des mutations dans le gène GGCX, qui code pour un gamma-carboxylase. Cet enzyme joue un 
rôle important dans le cycle métabolique de la vitamine K (VK). De cette façon, nous avons pu 
introduire la VK, mais aussi les protéines qui sont dépendantes de cette vitamine pour leur 
fonctionnement - comme différents inhibiteurs de calcification - dans la pathogénèse du PXE-like 
syndrome, mais aussi dans le PXE.  
En utilisant plusieures expériences immunohistochemiques et ELISA, nous avons pu 
démontrer que différents inhibiteurs de calcification étaient inactif ou non-actif dans ces deux 
syndromes, ce qui occasionne la calcification ectopique. Ces constatations sont valables 
jusqu’aux mutations dans le gène GGCX dans le PXE-like syndrome. Dans le PXE, l’explication 
pour ces protéines déficientes a été démontrée par des quantités très faibles de la VK - un 
facteur essentiel pour la carboxylation des protéines dans le cycle métabolique de la VK - dans le 
sang des patients avec le PXE. Bien que la relation entre le transporter muté ABCC6 et ces 
quantités faibles de la VK reste à présent imprécis, la séduisance reste de faire l’hypothèse que 
soit la VK, soit un de ses précurseurs ou métabolites associés, est transporté par le transporter 
ABCC6. En outre, ces constatations ouvrent de nouvelles perspectives pour la suppléance de la 
VK comme traitement pour le PXE.  
 
Comme décrit ci-dessus, les résultats de cette recherche ont permis un élargissement de 
la connaissance clinique et moléculaire du PXE et de ses affections apparentées. De nouvelles 
routes ont été ouvertes pour la recherche fondamentale et appliquée dans la branche de la 
minéralisation ectopique. Par dessus tout, ce sont les patients et leur famille qui profitent de nos 
résultats, grace à un diagnostic moléculaire plus efficace, un suivi ponctuel et la perspective d'un 
traitement pour leur affection contraignante. 
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Dankwoord                                                o 
 
        Waar is de weg ? Er is geen weg. 
Op naar het onbekende! 
 
Goethe (Faust) 
 
Beste lezer, sta mij toe mijn dankwoord te starten met een uitspraak van één van mijn grote 
voorbeelden – voor sommigen zal alles nu misschien duidelijk worden –, met name de 
Catalaanse surrealist Salvador Dalì. In 1963 sprak hij in een interview de onsterfelijke woorden: 
“There are some days when I think I'm going to die from an overdose of satisfaction." Welnu, een 
soortgelijk gevoel overvalt mij op het ogenblik van het schrijven van dit dankwoord. Het ei is 
gelegd, de laatste borstelstreken hebben het canvas beroerd. Perfectie bestaat niet, zoals mijn 
mentor mij altijd zei, maar je moet het altijd trachten na te streven. Bij deze, denk ik dan bij 
mezelf. Het resultaat van vier jaar bloed, zweet en tranen ligt nu in uw handen, klaar om 
doorbladerd te worden. En wees niet bang, laat u niet afschrikken om behalve de laatste 
bladzijden – het dankwoord, de samenvatting en het curriculum – ook de eerste vier 
hoofdstukken van dit werk door te nemen. Ze zijn voor u geschreven, met evenveel liefde en 
strevend naar verstaanbaarheid, als de laatste deeltjes van dit boek. Dat u de referentielijst niet 
van begin tot einde napluist, wil ik u gerust vergeven. 
 
Zoals u wellicht al gemerkt heeft of zal merken bij uw avond- en nachtelijke literatuur van dit werk, 
is het behalve de weergave van mijn academische activiteiten tot op heden ook gelardeerd met 
een aantal citaten, noem het intellectuele doordenkertjes, waar u ongetwijfeld nog uren genoegen 
zult aan beleven. Alle methodes zijn goed om meer mensen dan alleen de jury aan te zetten om 
het boek van voor naar achter uit te pluizen.     
 
Research, beste lezer, is vaak een moeilijke, maar altijd uitdagende opdracht, soms op de tast en 
vaak met vallen en opstaan. Goethe had misschien wel dit soort van professionele tijdsbesteding 
in zijn achterhoofd, want wetenschappelijk onderzoek pur sang is het verleggen van grenzen, het 
naast-de-betreden-paadjes-lopen, het zelf aanleggen van klinkerweggetjes doorheen het tot dan 
toe onbekende. Het is een vak dat velen tot de verbeelding spreekt, zeker als je interesses zich 
duidelijk manifesteren in de zogenaamd grote maatschappelijke problemen van deze tijd: AIDS, 
kanker, etc.  Wanneer je het in je hoofd haalt om een zeldzame ziekte, één van de “weeskindjes 
van de pathologie”, te bestuderen, pleegt de reactie hierop voornamelijk van de aard: “En hoe is 
het nog met de kinderen?” te zijn. Hoewel ik sinds kort al een wat zinniger antwoord kan geven 
op dergelijke vragen, blijft het moeilijk om anderen te overtuigen van het nut en de “added value”  
die de studie van zeldzame ziekten met zich meebrengt. Vandaar dat de niet-geringe gravitas 
van de taak - het ophouden van een al dan niet vakkundig geveinsde interesse - waarvan zij die 
mij doorheen dit werk hebben gesteund zich hebben gekweten, meer dan ooit een welgemeend 
dankjewel verdiend. 
 
Beste lezer, zo'n dankwoord brengt met zich mee dat enkele mensen - de happy few - speciale 
aandacht krijgen. Gedurende de voorbij jaren heb ik de eer gehad met heel veel leuke, 
sympathieke en – laat ons eerlijk zijn – soms ook minder sympathieke mensen samen te werken, 
te discussiëren, te lachen, etc. Vermoedelijk teveel om hier allemaal op te noemen en laat het die 
ene persoon die dit lijstje overloopt en zich vergeten voelt duidelijk zijn: het was niet mijn 
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bedoeling. Ongetwijfeld ben je tijdens het schrijven van dit werk vaak in mijn gedachten geweest 
en ik maak het goed tijdens de receptie door je een extra hors d’oeuvreke te schenken… 
 
Laat mij toe te starten met diegenen die voor de inhoud van dit werk onontbeerlijk zijn geweest. 
Die mensen die ik steeds bereid vond voor een nieuwe studie, een nieuw onderzoek, alwéér een 
bloedafname. “Mijn” PXE patiënten en hun familie. Weet dat zonder jullie input dit werk niet tot 
stand zou zijn gekomen. Ik dank jullie van ganser harte voor jullie bereidwilligheid en interesse. 
Pour mes patients francophones: un grand merci de tout mon coeur. For my overseas patients: 
my warmest feelings of gratitude for the many collaborations so far.  
 
Beginnen met doctoreren is zoals duiken van de hoogste springplank: je weet niet waar je aan 
begint als je er voor staat maar pas wanneer je op de rand balanceert, licht naar het water 
hellend, dan besef je: ik wil terug naar beneden. En zoals mijn befaamde driedubbele salto met 
halve draai en dubbele twist ook niet van in het begin volledig goed zat, zo zijn er ook voor een 
doctoraat mensen nodig om je salto’s, draaien en twists – in een wereld die niet de jouwe is -  te 
begeleiden en in goede banen te leiden. Ik ben in de eerste plaats enorm veel dank en erkenning 
verschuldigd aan mijn promotor, prof. dr. Anne De Paepe. Dank om in mij iemand te zien die 
deze opdracht tot een goed einde zou kunnen brengen en om mij toe te laten tot de 
getalenteerde en gedreven groep die het Centrum Medische Genetica in het algemeen en het 
bindweefselteam in het bijzonder is. Ik denk dat ik u zonder enige schroom mijn mentor kan 
noemen. Met vaste – en soms harde – hand hebt u mij weten te leiden rondom de hindernissen 
en valkuilen die inherent zijn aan elke vorm van wetenschappelijk onderzoek zodat de uitkomst 
niet werd gecompromitteerd. Geleidelijk aan – en vaak zonder ik er erg in had – hebt u mij laten 
kennis maken met alle facetten van research – onderzoek is meer dan enkel proefjes uitvoeren – 
en mij hierin meer verantwoordelijkheden gegeven. Als het goed is, is het goed en als het slecht 
is, is het slecht; een houding die ik tot op de dag van vandaag, in een wereld waar ik tot de 
ontdekking ben gekomen dat een eenduidige mentaliteit geen evidentie is, nog steeds enorm 
apprecieer.  
 
Daarnaast wens ik ook mijn co-promotor, prof. dr. Dirk Matthys, te danken om mij – als jonge 
assistent kindergeneeskunde – in de richting van genetica te leiden. In een zeer klinisch 
georiënteerde discipline als pediatrie is een combinatie met topresearch geen evidentie – een 
mentaliteit waar ik op dit ogenblik, tijdens het vervolledigen van mijn klinische opleiding, 
dagdagelijks mee wordt geconfronteerd – doch zijn enthousiasme heeft mij doen opteren mijn 
academische carrière te starten met dit doctoraat. 
 
Verder wil ik de overige hardcore leden van het bindweefselteam uitbundig danken. Prof. dr. Paul 
Coucke, beste Paul, voor het openzetten van de deuren van het bindweefsellabo, de begeleiding, 
de zomerse paëlla en de zwoele salsa (dit laatste niet als danspartner, welteverstaan). Dr. Bart 
Leroy, beste Bart, voor de bemoedigende woorden en opbouwende kritiek tijdens het schrijven 
van mijn eerste papers, de vakkundige introductie in de geheime kamers van de oftalmologie, 
voor het keuvelen, de ritjes in de Lotus (ik heb er nog hartkloppingen van) en bovenal de 
vriendschap. Jawel beste  lezer, samen met Bart en Paul  tijdens de paastijd om 1 uur  ’s nachts 
werken aan een paper, enkel gaande gehouden door het verorberen van chocoladen paaseieren: 
op zo’n momenten besef je wat vriendschap is...  
Dr. Bart Loeys, beste Bart 2 ;-), je kennis en expertise in de klinische en moleculaire genetica 
hebben me ongelooflijk veel geleerd. Dank voor het aangename gezelschap op congres, 
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alhoewel ik moet zeggen – ik heb je dit nog niet bekend – ik haat doughnuts en ik verafschuw om 
’s morgens op zoek te moeten gaan naar een ontbijt i.p.v. in het hotel te eten. Volgende keer kies 
ik dus het hotel! En dan de meiskes. Where does one begin... Sophie, Soppie voor de vrienden, 
je bent de animatie in het bindweefsellabo, de bindweefselstaf, de bindweefselcongressen en 
zoveel meer. Dankjewel voor de sfeer, de aangename babbel, de smoelentrekkerij op momenten 
dat het absoluut niet gepast was. Sofie, wie anders kon het zich veroorloven met een halve meter 
biochemie-dossiers ter nazicht af te komen en mij toch nog een glimlach te ontlokken.            
Marjolein, je bent één van de laatsten die in onze besloten kring is toegelaten. Het verwondert mij 
keer op keer hoe snel je je aan de anderen hebt aangepast. Hoe snel stijl kan plaats maken 
voor..., nu ja. In elk geval, verander niets, je past perfect binnen het profiel van een 
bindweefseler.  
Ik hoop, beste meisjes, dat we samen nog vele after-wetenschapsdag dinners mogen hebben, 
and we can feast like there is no tomorrow... 
 
Ongeveer een jaar geleden werd ik, na een lange zoektocht, bijgestaan door een jongedame die 
nu actief binnen de dagelijkse werking van de PXE research groep functioneert. Beste Laura, ik 
heb je eerder al verteld dat mijn eerste indruk van jou er één was van ”we gaan dit jonge veulen 
serieus in toom moeten houden”. De resultaten die je tot nog toe hebt behaald tonen – behalve 
de kwaliteit van de door mij ontworpen studies ;-) – aan dat we ons niet hebben vergist in jou. Je 
bent een aanwinst voor deze groep en ik dank je oprecht voor het vele werk dat je reeds hebt 
verzet en waardoor je meehelpt het onderzoek binnen ons domein in stand te houden.  
 
Tijdens mijn doctoraat ben ik ongeveer 7 maal van bureau veranderd, een record in onze dienst, 
maar het laatste anderhalf jaar had ik het geluk mijn dagdagelijkse beslommeringen te mogen 
delen met dr. Bert Callewaert en dr. Kristien Hoornaert. Beste Bert en Kristien, dank voor het 
gezelschap, de Delhaize-sfeer door de massa voedingswaren van Kristien en de sloten koffie van 
Bert. En Bert, coke rules!  
 
Mijn eerste schuchtere pasjes in het bindweefsellabo zouden een aaneenschakeling geweest zijn 
van (nog meer) uitschuivers en valpartijen, ware het niet voor de hulp, het begrip en het 
onvermoeibare enthousiasme van de talrijke laboranten. In een tijd waarin vechten voor een 
centrifuge in het toenmalige K5 labo nog werd aanzien als volwaardige topsport en sequeneren – 
wegens het toen nog hoge science fiction gehalte van een sequencing robot een ware marathon 
van pipetteerbewegingen – een grondige opwarming van de duimspieren vereiste, loodsten zij mij 
met engelengeduld doorheen het moeizame proces van mijn eerste PCR’s, dHPLC resultaten en 
sequenties. Ik herinner mij nog de warme gevoelens die mij overvielen bij het zien van mijn 
eerste PCR resultaat: een maagdelijk zwarte gelfoto, geen wit vlekje geamplificeerd DNA op te 
zien. Maar zie, jullie kundigheid is dan toch een beetje op mij afgestraald. Petra - de mater 
familias van het bindweefsellabo, die altijd alle producten weet staan in elk hoekje van welke 
diepvriezer ook te velde -, Renee, Karen, Inge, Chantal, Nilgul en alle anderen: ik ben jullie 
dankbaar voor het geduld, de  ondersteuning,  het  gekwebbel  (ik  zou  het  woord  ‘geroddel’  niet 
over mijn lippen kunnen krijgen ;-) en de vriendschap.  
 
Mijn klinische activiteiten in het CMGG brachten mij onherroepelijk ook in contact met de medici 
en paramedici die de genetische kliniek, vaak fluitend en niet gespeten van enige zwier, 
draaiende hielden en patiënten (en soms ook artsen en doctoraatsstudenten) psychologisch en 
organisatorisch met raad en daad bijstonden. Geert, Bruce, Sandra, Philippe, Ariane, Sylvia en 
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Virginie: het was telkens een verademing om op een open en constructieve manier met jullie te 
kunnen samenwerken; iets waarvan ik hoop dat het ook in de toekomst verder zal mogelijk zijn.   
Ook de mensen van het secretariaat, rotsen in de branding in dit chaotische wereldje, kan ik niet 
anders dan mijn eeuwige dank verschuldigd te zijn. Hoe zou het geweest zijn als jullie 
deskundigheid mij niet tussen de Scylla en Charybdis van dreigende vergeten afspraken en 
deadlines zou hebben geleid? Katia en Mieke, Isabelle, Leen, Nathalie en Liesbeth, dank voor de 
administratieve ondersteuning, dossierwerk, het telefonisch afschepen van (de natuurlijk totaal 
imaginaire) vervelende patiënten maar vooral ook de ondersteuning en vriendschap. 
  
Zijn voor de inhoud van dit werk de patiënten van een onschatbare waarde geweest, het 
welslagen van dit doctoraat zou nooit gelukt zijn zonder de onvoorwaardelijke steun en 
ondersteuning van het thuisfront. Paps en mams, zonder jullie zou er van geneeskunde nooit 
sprake geweest zijn. En zonder de regelmatige “en hoe zit het nu nog met het doctoraat?” vraag 
zou deze thesis nu misschien nog niet voor jullie liggen. Dank voor alle kansen die jullie mij 
hebben gegeven, het vertrouwen, de liefde en ondersteuning.  
 
Iets meer dan een jaar geleden hield ik een wezentje in mijn armen. Klein en onschuldig, nog niet 
goed gewassen en dus wat pluizig, met een grote open blik naar de wereld. Lieve Simon, kleine 
kabouter, jij hebt me de voorbije maanden op je eentje geleerd waar niemand tot dan ooit in was 
geslaagd: relativering. Je pretoogjes en guitige lach doen me glimlachen, je kan me de stress van 
het alledaagse doen vergeten en doen opgaan in die kleurrijke, sprookjesachtige wereld die jij 
thuis noemt. Ik hoop dat ik een stukje van jouw aanstekelijke spontaneïteit – zoals hameren op 
het toetsenbord terwijl papa’s grote boekdocument nog openstaat – kan bewaren, koesteren en 
uitstralen.  
 
De dagen tijdens en na een doctoraat zijn lang, de avonden – en soms ook de nachten – kort. De 
stress die gepaard gaat met voordrachten, deadlines, bepaalde niet-ideale werkomstandigheden, 
durven zich dan weleens meester maken van mijn anders zo vrolijke zonnetje-in-huis karakter. 
Liesbeth, mijn liefste, ik besef maar al te goed – zeker als ik zit te wachten tot je thuis komt van 
de volleyball ;-) – hoe vaak ik je heb laten wachten of alleen gelaten heb de voorbij jaren door 
overwerk, thuiswerk of ander gezwerk. Je onvoorwaardelijke steun, belangstelling en oppeppers 
wanneer nodig hebben de voorbije jaren - en in het bijzonder de laatste maanden -  gezorgd voor 
telkens dat ene lichtpuntje dat nodig was om er weer even tegenaan te kunnen. Hoewel ik je niet 
kan beloven dat alles vanaf nu rustiger wordt – je kent me, ook al kan een pak stress nu 
achterwege worden gelaten – neem ik me voor om ook in de toekomst maximaal te blijven 
genieten van ons gezinnetje...  
 
Zo, beste lezer, bent u aan het einde van “het grote boek” gekomen, een boek waarvan ik hoop 
dat ik er in de toekomst nog vele bladzijden mag aan toevoegen. Ik dank u voor uw aandacht, 
interesse (al dan niet geveinsd ;-) en bijbestellingen van bijkomende exemplaren. Until we meet 
again... 
         
 
        Gent, 26 december 2008 
        
 
 
